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Abstract 
Adult mammalian neurogenesis occurs throughout life within two discrete brain regions; 
subventricular zone (SVZ) and subgranular zone (SGZ). Acute insults to the brain are 
associated with spontaneous increases in neurogenesis. This has been observed in both 
the SVZ and SGZ, as well as non-neurogenic regions. In some cases, this spontaneous 
injury-induced neurogenic response has been linked to cognitive recovery, suggesting 
harnessing this innate potential for recovery could be a promising therapeutic target. 
Nevertheless, a direct functional relationship between injury-induced neurogenesis and 
cognitive recovery remains to be elucidated. The present work aimed to explore the 
functional relevance of spontaneous injury-induced neurogenesis in relation to recovery 
of hippocampal-dependent memory functions following acute brain injury.  
The kainic acid (KA) model of acute excitotoxic injury is a widely used model of acute 
neurodegeneration. Increases in SGZ neurogenesis have been well documented to occur 
following KA-induced injury, while evidence of neurogenesis occurring outside the SGZ 
is sparse. Prior work by our group had established the occurrence of neurogenesis in 
discrete non-neurogenic hippocampal regions; the CA1 and CA3. However, several 
questions have remained, such as where the newborn cells are initially generated and 
whether or not they functionally integrate into existing circuits.  
In our efforts to establish a reproducible model of KA-induced hippocampal 
neurodegeneration that facilitated subsequent neuronal repopulation, we investigated the 
impact of several variables that may have been affecting the inconsistencies we observed 
in our initial attempts to reproduce the model. We established the importance of surgical 
experience and validation of stereotaxic injection locations, and deduced the optimal KA 
concentration and stereotaxic injection co-ordinate for producing reproducible neuron 
loss and repopulation in the CA1 and CA3.  
In parallel, we investigated the origin and functional significance of the KA-induced 
neurogenic response previously observed by our group. Although numerous technical 
hurdles precluded firm conclusions from being drawn, we derived some useful 
methodological conclusions. Lastly, we undertook histopathological analyses of the 
APPswe/PS1ΔE9 mouse model of Alzheimer’s disease (AD), a neurodegenerative disease 
xvii 
where neurogenesis appears dysregulated, and established a baseline phenotype for future 
investigations into dysregulation of neurogenesis in AD. 
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Preface 
At the outset of this thesis, we began with the overarching aim to understand the 
functional relevance of spontaneous injury-induced neurogenesis to hippocampal-
dependent cognitive recovery following acute brain injury. Prior work conducted by our 
group had established sound evidence for the occurrence of substantial neurogenesis, in 
discrete hippocampal regions previously thought to be incapable of regeneration, 
following kainic acid (KA)-induced excitotoxic neurodegeneration (Figure 2.2; 
Abdipranoto-Cowley et al., 2009), providing a strong foundation for pursuing this 
research question. Furthermore, prior to the commencement of the work presented in this 
thesis, the KA model of injury had been well established and utilised as a reliable model 
of acute hippocampal neurodegeneration by us (Abdipranoto-Cowley et al., 2009) and 
others (Ferraguti et al., 2001; Gray & Sundstrom, 1998; Hattiangady et al., 2004; Lee et 
al., 2005; Nadler et al., 1978; Roe et al., 1998; Shetty & Turner, 1999; Tretter et al., 1996; 
Tretter et al., 2000). Thus, we anticipated it would be a relatively straightforward process 
to replicate the time-course of KA-induced neurodegeneration and neuron repopulation 
previously generated in our group and to subsequently commence investigations into the 
functional significance of the post-injury regenerative response (Chapter 3). What we 
discovered instead was the sensitivity and specificity of this discrete hippocampal 
regenerative response to a multitude of experimental variables. In Chapter 2 we detail the 
extensive efforts made to characterise the influence of many of these variables on our 
outcomes.  
Prior to the characterisation process, we had already begun developing the experimental 
tools necessary for the next steps of the project aiming to determine if there is any 
observable functional significance of the injury-induced neurogenic response we had 
previously observed. The development of these tools is detailed in Chapter 3 and the 
experiments presented were undertaken alongside those in Chapter 2. Throughout this 
process there were many technical hurdles, the significance of which is discussed in both 
Chapter 2 and Chapter 3 in the context of both our ongoing work and that of the wider 
field.  
One of the longer-term goals of this work was to translate any promising findings to a 
physiologically relevant in vivo model of chronic neurodegeneration. In particular, we 
were interested in understanding how dysfunctional neurogenesis in Alzheimer’s disease 
xxxi 
(AD), a chronic neurodegenerative disease where neurogenesis remains poorly 
understood, may be contributing to disease pathology and cognitive deficits. Another 
investigator in our group has previously characterised the behavioural phenotype of the 
APPswe/PS1ΔE9 transgenic mouse model of AD using a battery of cognitive assessments 
(a small subset of their unpublished behavioural findings are presented in Figure 4.2 and 
Appendix Figure 6.8). To supplement their behavioural characterisation findings, the 
author of this thesis undertook histopathological analysis of the APPswe/PS1ΔE9 mouse 
line, with the goal of establishing a baseline phenotype for future studies. These 
experiments are presented in Chapter 4. 
The author of the present thesis was the lead investigator for the projects represented in 
all three research chapters and as such was responsible for experimental design, execution 
and data analysis of all experiments described in these chapters, unless otherwise 
explicitly stated. Supervisory guidance was provided throughout by Lyndsey Konen and 
Dr Gary Morris, who were involved in concept formation, experimental design, data 
interpretation and manuscript edits. 
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“In the adult centers [sic], the nerve paths are something fixed, ended, and immutable. 
Everything may die, nothing may be regenerated…It is for the science of the future to 
change, if possible, this harsh decree.” 
-Ramón y Cajal Santiago, 1928 
 
1.1 Outline of the introduction 
Neurodegeneration resulting from both acute and chronic brain injuries is a prominent 
problem facing our society today. Degeneration of the central nervous system (CNS) 
resulting from these injuries can have devastating effects on the quality of life of affected 
individuals. At the societal level, they cause economical and sociological strain on society 
as they require intensive life-long care, especially when sustained by young adults 
(Chauhan, 2014). Furthermore, with the current exponential increase in our ageing 
population worldwide (http://www.who.int/ageing/about/facts/en/), the incidence of 
dementia and neurodegeneration-related disorders is projected to skyrocket, with an 
estimated 131 million people affected by dementia by 2050 (Alzheimer’s Disease 
International, 2016). Furthermore, there is currently no existing cure for 
neurodegenerative diseases, or successful treatments for brain injuries that will result in 
complete restoration of cognitive function. The limited regenerative capacity of the 
human CNS has driven many researchers to stimulate and investigate regeneration 
through exogenous treatments (Emsley et al., 2005; Jessberger, 2016; Lindvall & Kokaia, 
2011; Sohur et al., 2006). At the heart of this however, lies an eager interest for a deeper 
understanding of the mechanism underlying endogenous brain repair.   
This thesis focuses primarily on investigating the existence and functional relevance of 
spontaneous endogenous neurogenesis occurring in non-neurogenic brain regions 
following a controlled excitotoxic CNS injury. Excitotoxicity is a major contributing 
factor to cell death in a variety of neurodegenerative disorders, including (but not limited 
to) epilepsy, ischaemia, traumatic brain injury (TBI), spinal cord injury, multiple sclerosis, 
Alzheimer’s disease (AD), Parkinson’s disease, and Huntington’s disease (Dong et al., 
2009; Lai et al., 2014; Mehta et al., 2013; Prentice et al., 2015; Venugopal et al., 2017). 
This thesis has important implications for challenging the current theory that endogenous 
repair mechanisms are not possible, and opens up avenues for future research into 
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understanding why endogenous regeneration is possible under certain injury conditions 
and not others.  
In the following introduction, I provide a brief overview of the history of adult 
neurogenesis research, which involves the overturning of a century old dogma that the 
brain is unable to regenerate. I next describe the process of neurogenesis in two well-
accepted neurogenic regions of the adult mammalian brain under physiological conditions. 
Next, I outline the major experimental milestones in the investigation of injury-induced 
neurogenesis under pathological conditions, with a specific focus on acute CNS injuries, 
along with discussing their limitations. Finally, I discuss what questions remain to be 
elucidated within the field of injury-induced neurogenesis, and conclude with my thesis 
aims for attempting to address these questions. 
 
1.2 Overview of adult neurogenesis research 
Constitutive adult neurogenesis, throughout life, has by now been well characterised 
following the publication of landmark studies throughout the 20th century (Allen, 1912; 
Altman, 1963, 1966, 1969; Altman & Das, 1965; Bayer, 1982; Eriksson et al., 1998; 
Hamilton, 1901; Kaplan & Bell, 1984; Kaplan & Hinds, 1977; Kempermann et al., 1997; 
Kuhn et al., 1996; Sidman et al., 1959; Smart, 1961). It is evolutionarily conserved across 
species, from crustaceans (Harzsch & Dawirs, 1996), to birds (Goldman & Nottebohm, 
1983) and mammals (Altman & Das, 1965; Altman, 1963; Bonfanti & Peretto, 2011; 
Eriksson et al., 1998; Gould et al., 1999; Kornack & Rakic, 1999), with two notable 
exceptions; it has not been found in bats (Amrein et al., 2007) or cetaceans (Patzke et al., 
2015). Adult generated newborn neurons have been demonstrated to functionally 
contribute to existing neural circuits (for detailed reviews, see Braun & Jessberger, 2014; 
Deng et al., 2010; Sahay, Wilson, et al., 2011), illustrating potential important roles for 
newborn neurons in physiological cognitive functions. 
The process of neurogenesis, throughout life, takes place within a complex brain; multiple 
cells are dynamically interacting, sometimes transiently and in response to a variety of 
stimuli, and this is occurring within a sophisticated extracellular matrix and milieu 
(Morris et al., 2013). In concert, these dynamic interactions between neurons and other 
cells of the brain, including microglia, astrocytes and oligodendrocytes, give rise to 
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diverse cognitive functions, but how this occurs remains poorly understood. Neurons are 
clearly integral units in these cognitive functions, comprising just over half of all cells 
residing in the CNS (Azevedo et al., 2009; Herculano-Houzel, 2009; von Bartheld et al., 
2016). Despite their importance however, it was widely believed, until the late twentieth 
century, neuronal cell division and development was restricted to pre- and peri-natal 
periods and did not constitutively occur in the adult mammalian brain.  
Evidence challenging this dogma had in fact been gathering for some time. In 1901, 
Hamilton observed mitosis in rats 4 d postnatally (Hamilton, 1901), while Allen observed 
mitosis in the adult rat brain at least 120 d postnatally (Allen, 1912). However, technical 
limitations at the time prevented a conclusive determination of whether these mitotic cells 
were giving rise to new neurons or glia. In the late 1950s, a novel technique for identifying 
newborn cells was discovered which used autoradiography to detect tritium-labelled 
thymidine, which incorporates into the DNA of dividing cells during the S-phase of 
mitosis (Sidman et al., 1959). Subsequently, the first account of postnatally-generated 
neurons in three-day old mice was reported (Smart, 1961). Following on from this 
landmark study and again utilising autoradiography, Altman and colleagues reported 
‘neurogenesis’ in various regions of the post-natal and adult rat brain, including the 
dentate gyrus (DG) of the hippocampus (Altman & Das, 1965), the neocortex (Altman, 
1963, 1966) and olfactory bulb (Altman, 1969) as well as in the neocortex of cats (Altman, 
1963). Utilising a similar method, the work of Bayer, Kaplan and colleagues confirmed 
the existence of neurogenesis in rodents within both the DG and olfactory bulb (Bayer, 
1982; Kaplan & Bell, 1984; Kaplan & Hinds, 1977). 
The turning point in challenging the dogmatic view that neurogenesis is restricted to 
development came from the advance of 5-bromo-3’-deoxyuridine (BrdU; Gratzner, 1982; 
Miller & Nowakowski, 1988; Nowakowski et al., 1989) labelling. BrdU, a synthetic 
analogue of thymidine, marks dividing cells, allowing scientists to identify (Kuhn et al., 
1996) and quantify (Kempermann et al., 1997) newly generated cells using 
immunohistochemistry and stereology. The seminal study by Eriksson and colleagues in 
1998 was the first to demonstrate adult cell proliferation in the human brain using BrdU 
(Eriksson et al., 1998), laying to rest the long-held belief that neurogenesis does not occur 
in the adult human brain. In spite of the overwhelming evidence supporting the existence 
of adult neurogenesis, particularly derived from animal models, active debate remains 
among scientists regarding the extent of its prevalence and biological significance in 
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humans (Bergmann et al., 2012, 2015; Boldrini et al., 2018; Bonfanti, 2016; Dennis et al., 
2016; Kempermann et al., 2018; Sorrells et al., 2018). 
Under physiological conditions, we now recognise two well-defined niches in the adult 
mammalian brain where neurogenesis constitutively occurs: the subventricular zone 
(SVZ) and the subgranular zone (SGZ). These regions are thought to reside lineage-
specific precursor or progenitor cells, that is, cells with a restricted proliferative potential 
(Sohur et al., 2006). Throughout life, precursor cells residing in the SVZ proliferate and 
migrate to the olfactory bulb along the rostral migratory stream (RMS), eventually 
differentiating and maturing into granule or periglomerular interneurons (Doetsch & 
Alvarez-Buylla, 1996; Goldman, 1995; Lois & Alvarez-Buylla, 1993; Luskin, 1993). 
Precursor cells residing in the SGZ of the hippocampus provide new dentate granule 
neurons to the granule cell layer of the DG (Kempermann et al., 2015; Sohur et al., 2006). 
Many studies have also reported constitutive adult neurogenesis occurring in areas 
outside of these classically defined zones, including the cerebellum (Ponti et al., 2008), 
neocortex (Dayer et al., 2005; Fowler et al., 2002; Gould et al., 2001; Gould et al., 1999), 
striatum (Bédard et al., 2002; Collin et al., 2005; Luzzati et al., 2006), substantia nigra 
(Zhao et al., 2003), amygdala (Bernier et al., 2002; Fowler et al., 2002; Jhaveri et al., 
2017), hypothalamus (Fowler et al., 2002; Kokoeva et al., 2007), and cornu ammonis 
(CA)1 region of the hippocampus (Rietze et al., 2000). However, the origin of newborn 
cells populating these brains regions, whether they migrate from the SVZ, SGZ, or derive 
from within each region, remains to be determined (Wallace et al., 2017). 
 
1.3 Adult neurogenesis in the intact mammalian brain 
Adult neurogenesis is a complex process encompassing a myriad of features, including 
proliferation of the neural stem or progenitor cell, neuronal fate determination, 
differentiation of immature neurons, migration, survival, and finally functional 
integration into existing neuronal circuits (Abrous et al., 2005; Hagg, 2005; 
Kozorovitskiy & Gould, 2003; Ming & Song, 2005; Zhao et al., 2008). These processes 
are common to adult neurogenesis within both the SGZ and SVZ, albeit with subtle and 
distinct regional variations. In many ways, adult neurogenesis recapitulates the neuronal 
developmental processes observed in embryonic stages (Espósito et al., 2005; Laplagne 
et al., 2006). The entire process of adult neurogenesis, from cellular proliferation to 
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maturation and functional integration of newly generated cells requires approximately 4-
8 weeks in the adult rodent brain and varies according to the region investigated and the 
experimental methods used for detection and determination of a functionally integrated 
cell (Jessberger & Kempermann, 2003; Kempermann et al., 2004; van Praag et al., 2002; 
Zhao et al., 2008). Indeed, maturation has previously been observed to continue for up to 
4 months following proliferation (van Praag et al., 2002; Zhao et al., 2006), with newborn 
neurons increasing the density and complexity of their spines and arbours, respectively 
(Lledo et al., 2006). A detailed description of the discrete developmental trajectories of 
SGZ and SVZ neurogenesis in the adult mammalian brain will be described in the 
following section. 
 
1.3.1 Development and modulation of newborn neurons in the adult hippocampus 
With the exception of bats (Amrein et al., 2007) and cetaceans (Patzke et al., 2015), the 
maintenance of SGZ neurogenesis is a trait believed to be common across all mammalian 
species, including humans (Bonfanti & Peretto, 2011; Eriksson et al., 1998; Knoth et al., 
2010). Newborn neurons of the adult hippocampus are thought to arise from a neural stem 
cell pool residing in the SGZ of the DG. The entire process, from proliferation to 
maturation, is dependent on a complex interaction of signalling factors and neurotrophins. 
Newborn neurons migrate a short distance from the SGZ to the granule cell layer of the 
DG, where they mature and integrate into the surrounding circuitry, becoming seemingly 
indistinguishable from existing neurons born during embryonic development (Toni & 
Sultan, 2011). Furthermore, they are believed to only generate one type of neuron: granule 
cell neurons in the DG (Kempermann et al., 2015). 
In general, there are five well described stages a cell progresses through as it transitions 
from a multipotent stem cell to a post-mitotic neuron, and the expression of various 
molecular markers becomes either upregulated or downregulated at each developmental 
stage, with some overlap (Figure 1.1; Gonçalves et al., 2016; Kempermann et al., 2004; 
Ming & Song, 2011; Seri et al., 2004). During the first stage, multipotent radial glia-like 
stem cells (Type-1) proliferate, retaining the ability for asymmetrical division (Fukuda et 
al., 2003; Kempermann et al., 2004). In the second stage, these cells give rise to 
intermediate neural progenitor cells (Type- 2a and 2b), a population of highly 
proliferative cells constituting the largest fraction of proliferating cells within the adult 
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SGZ (Fukuda et al., 2003; Kronenberg et al., 2003). The primary distinction between a 
stem and progenitor cell lies in their capacity for self-renewal (Mckay, 1997; Weiss et al., 
1996). Specifically, a stem cell must retain the ability to self-renew and differentiate into 
other cells of the CNS and further, should retain their capacity for division in response to 
injury or disease (Weiss et al., 1996). The third stage, also referred to as the ‘migratory 
stage’, involves the migration of a cell from its place of origin to its final destination in 
the inner granule cell layer, permanently transitioning from potentially proliferative cells 
to post-mitotic immature neurons – neuroblasts (Type-3; Kempermann et al., 2004). 
During the fourth stage – the initial post-mitotic stage – axons and dendrites form on the 
immature granule cell (Type-4) and functional maturation occurs (Kempermann et al., 
2003). In the fifth and final stage, newly formed mature granule cells are integrated into 
the pre-existing circuitry (Jessberger & Kempermann, 2003). During this final stage the 
cell becomes resistant to cytotoxic stimuli, promoting cell survival through the secretion 
of various neurotrophic factors (van Praag et al., 2002). 
The entire process of development, from neural stem cell activation to differentiation and 
integration, is mediated by a complex interaction of intracellular factors along with 
extracellular factors from nearby neurons, glia, and epithelial cells (Lledo et al., 2006; 
Zhao et al., 2008). Factors such as noggin, a bone morphogenic protein antagonist, are 
involved in promoting cell proliferation within the SGZ (Fan et al., 2004), while brain-
derived neurotrophic factor (BDNF) is known to be involved in regulating cell survival 
(Zhao et al., 2008). Factors involved in the maturation and integration of adult-generated 
neurons include activity-dependent γ-aminobutyric acid (GABA) receptor activation (Ge 
et al., 2006), N-methyl-D-aspartate (NMDA) receptor activation (Tashiro et al., 2006), 
and hilar mossy cell activation (Marques-Mari et al., 2007). Neurotransmitters including 
dopamine, glutamate and serotonin are also believed to be involved in upregulating cell 
proliferation.  
In addition to biological factors, hippocampal neurogenesis is also modulated by exposure 
to external stimuli. Exposure to an enriched environment enhances neurogenesis (Brown 
et al., 2003; Kempermann et al., 1997, 1998; Kempermann et al., 2002; Nilsson et al., 
1999), as does voluntary exercise (Olson et al., 2006; Pereira et al., 2007; van Praag et al., 
1999, 2005), while factors such as stress negatively affect neurogenesis (Gould & Tanapat, 
1999; Levone et al., 2015).  
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Figure 1.1. Stages of adult neurogenesis in the rodent hippocampal dentate gyrus. Schematic diagram summarising 
the five developmental stages of adult neurogenesis in the rodent hippocampus. (1)  Activation and proliferation of 
multipotent radial glia-like stem cells (Type-1). (2) Proliferation of intermediate neural progenitor cells (Type-2a, 2b). 
(3) Generation of neuroblasts (Type-3) and migration from the subgranular zone (SGZ) to the inner granule cell layer 
(GCL). (4) The immature neuron (Type-4) commences integration into the surrounding circuitry, extending axons and 
dendrites to neighbouring cells. (5) Maturation of newly-generated dentate granule neuron. Also depicted are the 
approximate timeframe of adult hippocampal neurogenesis, expression of stage-specific molecular markers, and key 
processes governing each developmental stage. Abbreviations: CA1: cornu ammonis 1; CA3: cornu ammonis 3; DCX: 
doublecortin; DG: dentate gyrus; GFAP: glial fibrillary acidic protein; NeuN: neuronal nuclei; PSA-NCAM: 
polysialylated neuronal cell adhesion molecule; Sox2: (sex determining region Y)-box 2. Image adapted from Ming 
and Song (2011).  
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1.3.1.1 Function of adult hippocampal neurogenesis 
Although the functional significance of physiological adult hippocampal neurogenesis 
remained elusive for some time, surmounting evidence now suggests a key role in 
learning and memory processes (Oomen et al., 2014). Given the central role that the DG 
plays in supporting memory-based processes (Kesner, 2013), it is prudent to surmise that 
changes to this structure, through the addition or subtraction of new neurons, would lead 
to gross changes in network connectivity and cognitive processes. 
Rodent studies suggest that adult neurogenesis is necessary for various hippocampal-
dependent learning tasks. These include trace memory formation (Shors et al., 2001), 
spatial learning (Gould et al., 1999; Jessberger et al., 2009; Kee et al., 2007), pattern 
separation (Clelland et al., 2009; Sahay, Scobie, et al., 2011; Sahay, Wilson, et al., 2011), 
and fear memory retrieval (Kirby et al., 2012; Saxe et al., 2006). Additionally, increased 
adult neurogenesis was found to regulate forgetting during infancy and adulthood through 
disruption of existing hippocampus-dependent memory traces (Akers et al., 2014), while 
decreased neurogenesis has been implicated in the pathogenesis of anxiety and depressive 
disorders, with a critical role found for adult-born hippocampal neurons in regulating 
stress responding through mediating hippocampal endocrine activity (Snyder et al., 2011). 
It is clear from the previous studies that hippocampal neurogenesis plays a critical role in 
normal cognitive brain functioning. 
 
1.3.2 Development and modulation of newborn neurons in the adult olfactory bulb 
The SVZ is thought to comprise the largest germinal zone of the adult mammalian brain 
(Alvarez-Buylla & García-Verdugo, 2002). Similarly to the SGZ, adult neurogenesis 
derived from the SVZ also appears evolutionarily conserved across mammalian species, 
including humans (Bernier et al., 2000). In addition, this region is thought to contain the 
most abundant population of proliferating cells in the adult mammalian brain (Abrous et 
al., 2005).  Newborn interneurons of the adult olfactory bulb are thought to arise from the 
SVZ lining the walls of the lateral ventricles. Precursor cells residing in the anterior aspect 
of the SVZ proliferate and migrate to the olfactory bulb along the RMS, eventually 
differentiating into either of two classes of interneurons; inhibitory granule cells or 
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periglomerular cells (Doetsch & Alvarez-Buylla, 1996; Goldman, 1995; Lois & Alvarez-
Buylla, 1993; Luskin, 1993).  
Development of periglomerular cells is more diverse and comprises a smaller proportion 
of the newly generated cells from the SVZ (Lepousez et al., 2013); therefore, the vast 
majority of research has focused on the development and maturation of the more 
homogenous population of GABAergic granule neurons (Jin, 2016; Lledo & Valley, 
2016). Similar to the SGZ, generation of newborn neurons in the SVZ-olfactory bulb 
incorporates five well-described stages of neuronal development, with expression of 
various molecular markers either upregulated or downregulated at each developmental 
stage, with some overlap (Figure 1.2; Ming & Song, 2011; Petreanu & Alvarez-Buylla, 
2002). In the first stage, the population of quiescent radial glia-like cells in the SVZ of 
the lateral ventricles become activated (Doetsch et al., 1999; Garcia et al., 2004; Laywell 
et al., 2000), giving rise to the population of proliferating transient amplifying progenitor 
cells of the second stage. This population of highly proliferative cells are capable of 
generating neuroblasts, which subsequently migrate to the olfactory bulb via a process of 
chain migration, and facilitated by the RMS pathway (Lois et al., 1996). In the rodent 
brain, more than 30,000 neuroblasts are known to migrate daily to the olfactory bulb via 
the RMS (Alvarez-Buylla et al., 2001). Nevertheless, only a fraction survive to eventually 
become olfactory inhibitory neurons (Lois & Alvarez-Buylla, 1994). Upon reaching the 
olfactory bulb core, immature neurons detach from their migrating chains and commence 
radial migration towards their respective layers of the olfactory bulb, undergoing terminal 
differentiation into either granule or periglomerular neurons in either the granule cell 
layer or glomerular layer, respectively (Lledo et al., 2006). 
The developmental steps of SVZ-olfactory bulb neurogenesis are carried out in concert 
with a complex interaction of cell intrinsic programmes, and extracellular chemical 
signalling factors from the surrounding microenvironment (Jin, 2016; Lledo et al., 2006; 
Ming & Song, 2011). Cell intrinsic programmes include neurogenic, gliogenic and stem 
cell renewal factors from nearby neurons, glia, and epithelial cells, which in concert, help 
regulate the proliferative activity and cellular fate, and tangential migration of the 
newborn cells (Lledo et al., 2006). These processes are further modulated by extracellular 
factors such as neurotransmitters, hormones and growth factors from the surrounding 
microenvironment; factors which together, facilitate successful migration to the olfactory 
bulb.  
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Similar to the SGZ, survival of newborn SVZ-generated olfactory neurons is dependent 
upon a complex interaction of chemical signalling input, along with external sensory 
stimuli in the form of olfactory enrichment and exposure (Lledo et al., 2006; Wallace et 
al., 2017). Indeed, previous investigations have demonstrated the detrimental effect of 
sensory deprivation on cell survival. Sensory deprivation, mediated by transgenic 
mutation producing absence of electrical activity in the olfactory epithelium of mice, 
triggered a decrease in granule cell survival (Petreanu & Alvarez-Buylla, 2002). The loss 
of olfactory granule cells following odour deprivation may be mediated, in part, by 
reduced SVZ neurogenesis and increased apoptosis of newborn granule and 
periglomerular cells (Corotto et al., 1994; Mandairon et al., 2006), while odour 
enrichment facilitated generation of newborn olfactory bulb neurons and led to 
subsequent improvements in odour memory, an effect that was specific to olfactory 
neurons and did not affect hippocampal neurogenesis (Rochefort et al., 2002). 
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Figure 1.2. Stages of adult neurogenesis in the rodent subventricular zone/ olfactory bulb. Schematic diagram 
summarising the five developmental stages of adult neurogenesis in the rodent subventricular zone (SVZ)/ olfactory 
bulb. (1)  Activation and proliferation of quiescent radial glia-like stem cells in the SVZ of the lateral ventricle (LV). 
(2) Proliferation of transient amplifying progenitor cells. (3) Generation of neuroblasts. (4) Neuroblasts migrate to the 
olfactory bulb via chain migration along the rostral migratory stream (RMS). Within the olfactory bulb, immature 
neurons migrate radially towards their respective layers. (5) Maturation of periglomerular neurons (PN) in the 
glomerular layer (GL) and granule neurons (GN) in the granule cell layer (GCL) of the olfactory bulb. Also depicted 
are the approximate timeframe of adult SVZ/ olfactory bulb neurogenesis, expression of stage-specific molecular 
markers, and key processes governing each developmental stage. Abbreviations: DCX: doublecortin; GFAP: glial 
fibrillary acidic protein; NeuN: neuronal nuclei; PSA-NCAM: polysialylated neuronal cell adhesion molecule; Sox2: 
(sex determining region Y)-box 2. Image adapted from Ming and Song (2011).  
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1.3.2.1 Function of adult neurogenesis in the olfactory bulb 
Ongoing SVZ neurogenesis has been hypothesised to contribute to the functional integrity 
of the olfactory bulb circuit (Lledo & Valley, 2016; Sakamoto, Ieki, et al., 2014), along 
with increasing plasticity of the olfactory neuronal networks through optimising olfactory 
processing for certain olfactory-related behaviours (Malvaut & Saghatelyan, 2016; 
Mandairon et al., 2011; Moreno et al., 2009; Sakamoto et al., 2011; Sakamoto, Kageyama, 
et al., 2014). Survival of newborn neurons is increased following olfactory discrimination 
learning (Alonso et al., 2006), while reduction or ablation of SVZ neurogenesis was 
associated with deficits in perceptual learning and olfactory memory (Lazarini et al., 2009; 
Sultan et al., 2010). Furthermore, previous experimental manipulations involving sensory 
deprivation have not only demonstrated decreased population of newly generated 
olfactory neurons, but have also shown attenuation in density and length of spines and 
dendrites of the newly generated neurons, respectively (Kelsch et al., 2009; Saghatelyan 
et al., 2005). Together, these studies suggest a critical role for physiological SVZ 
neurogenesis in modulating olfactory processes (Lazarini & Lledo, 2011).  
 
1.4 Adult neurogenesis following acute brain injury 
In addition to its role in the intact brain, adult neurogenesis has also been suggested to 
play a critical role in the brain’s ability to recover from various insults. The dichotomous 
regulation of adult neurogenesis in acute versus chronic conditions has been well 
documented across both experimental animal models and human studies (Kaneko & 
Sawamoto, 2009). Furthermore, surmounting evidence from rodent models suggest 
neurogenesis may either be disrupted or impaired in chronic neurodegenerative disorders 
such as Parkinson’s disease and AD (Abdipranoto et al., 2008; Horgusluoglu et al., 2017; 
Winner & Winkler, 2015), despite contrasting evidence demonstrating upregulation of 
neurogenesis in select AD models (Ermini et al., 2008; Jin, Galvan, et al., 2004; López-
Toledano & Shelanski, 2007; Yu et al., 2009). Furthermore, reduced adult neurogenesis 
has been implicated in the etiopathology of psychiatric disorders such as depression (Hill 
et al., 2015) and schizophrenia (Reif et al., 2006). In stark contrast to chronic disease 
conditions, acute injury to the CNS, such as that which occurs following stroke, 
excitotoxic injury, and TBI, appears largely associated with upregulation in neural cell 
proliferation and neurogenesis. Although it remains inconclusive why, broadly speaking, 
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adult neurogenesis proceeds after acute injury but is impaired in chronic disease states, 
surmounting evidence suggests the differential neuroinflammatory response in acute 
versus chronic conditions (Whitney et al., 2009), specifically microglial activation 
(Ekdahl et al., 2009; Ekdahl et al., 2003; Monje et al., 2003), may be significant in 
mediating this dichotomy.  
Numerous studies have now demonstrated that acute insults to the brain can increase 
neurogenesis above physiological levels in the canonical neurogenic regions of the brain; 
the SVZ and SGZ. More excitingly however, accumulating evidence shows that 
following acute CNS injury, neurogenesis can also occur in regions outside of the 
canonical neurogenic regions. In the following sections, we outline the key findings 
which have defined the field of injury-induced neurogenesis research, focusing 
specifically on two commonly used models of acute injury for investigation of 
neurogenesis; excitotoxic injury/ experimentally-induced apoptosis and ischaemic injury. 
 
1.4.1 Excitotoxic injury/ experimentally-induced apoptosis 
1.4.1.1 Neurogenic regions 
Experimentally-induced excitotoxic and/or apoptotic injury are commonly used methods 
for studying neurogenesis following injury. In particular, seizure-induced injury, such as 
that mediated by administration of a convulsant agent such as kainic acid (KA) or 
pilocarpine, has been well established to stimulate increased proliferation and 
neurogenesis in the canonical neurogenic regions of the SGZ of the DG (Jessberger & 
Parent, 2015). Utilising markers of cell proliferation, such as BrdU or Ki67, has allowed 
researchers to visualise and quantify the dramatic increase in proliferative activity 
following seizure injury (Abdipranoto-Cowley et al., 2009; Bengzon et al., 1997; Gray et 
al., 2002; Gray & Sundstrom, 1998; Jessberger et al., 2005; Parent et al., 1997). 
Furthermore, a large proportion (~75-90%) of these newly generated cells appear to 
mature into dentate granule neurons, subsequently expressing markers characteristic of 
mature dentate granule neurons 4 weeks following seizure injury (Jessberger et al., 2005; 
Jessberger et al., 2007; Parent et al., 1997).  
Seizure-induced injury appears to affect the migration patterns of the newly generated 
cells in both the SGZ and SVZ. In the SGZ, a subset of the newly generated neurons 
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migrate ectopically to the hilus region, where they appear to become functionally 
integrated into the circuitry involved in spontaneous seizure generation (Parent et al., 
1997; Scharfman et al., 2002). In the SVZ, pilocarpine-induced seizure injury stimulated 
increased migration of newly-generated neuroblasts to the olfactory bulb (Parent et al., 
2002). Following prolonged seizures, a subset of the newly generated SVZ-derived 
neuroblasts were observed to exit the RMS prematurely, migrating ectopically towards 
the neocortical striatum. However, survival of ectopically migrated SVZ-derived neurons 
was low, with few newly-generated neurons observed in the cortical regions at 35 d post-
injury. 
The functional relevance of SGZ neurogenesis following seizure injury has been largely 
investigated in relation to its role in the etiopathology of epilepsy, with surmounting 
evidence pointing to the role of aberrant seizure-induced SGZ neurogenesis in 
perpetuating development of epilepsy symptomatology (Jessberger & Parent, 2015). 
Evidence in support of this theory comes from studies utilising retroviral-mediated 
approaches or genetic ablation techniques. Inhibition of SGZ neurogenesis, with the anti-
epileptic drug valproic acid, following KA-mediated injury was associated with improved 
performance in a hippocampus-dependant object recognition task, suggesting a functional 
neuroprotective effect of reduced neurogenesis (Jessberger, Zhao, et al., 2007). Similarly, 
genetic ablation of SGZ neurogenesis prior to pilocarpine-induced seizure injury was 
found to suppress both spontaneous seizure frequencies, along with improved 
performance in a hippocampus-dependent memory task (Cho et al., 2015). It is clear from 
the aforementioned studies that SGZ neurogenesis, at least in response to seizure injury, 
may not always lead to a beneficial outcome for the organism. 
 
1.4.1.2 Non-neurogenic regions 
Although the vast majority of studies describing experimentally-induced excitotoxic 
and/or apoptotic injury neurogenesis have focused on the canonical neurogenic regions 
of the SGZ and SVZ, evidence describing the occurrence of injury-induced neurogenesis 
outside of these regions has also been previously described. In their 2003 study, Dong 
and colleagues investigated the effects of KA-induced neurodegeneration on 
hippocampal neurogenesis in neonatal rats aged 7 d. Bilateral administration of KA 
intracerebroventricularly (ICV) was found to increase the number of BrdU-labelled cells 
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co-expressing class III β-tubulin and neuronal nuclei (NeuN), markers of immature and 
mature neurons, respectively, in the CA3 subfield approximately 5 weeks following 
injury (Dong et al., 2003). Furthermore, this was observed concurrently with the presence 
of ongoing degeneration, assessed through TUNEL-labelling, in the cornu ammonis 
(CA)3 region at 5 and 7.5 weeks following injury. Previous studies from our group also 
utilised KA-induced neurodegeneration to investigate spontaneous neurogenesis. 
Unilateral ICV administration of KA was found to enhance neurogenesis in the DG, CA1 
and CA3 regions 42 d following KA injury, assessed through co-expression of BrdU and 
NeuN (Abdipranoto-Cowley et al., 2009). Furthermore, stereological quantification of 
neuronal population revealed a spontaneous increase in total neuron population across 
both the CA1 and CA3 regions between 7 and 42 d post-injury. Although the functional 
relevance of the newly generated neurons was not investigated, these studies suggest that 
discrete regions of the hippocampus, in addition to the SGZ, may possess neurogenic 
capacities under certain injury conditions. 
Findings describing spontaneous neurogenesis in the neocortical regions have been more 
conflicting. The landmark study by Magavi and colleagues in 2000 was the first study to 
demonstrate that injury-induced neurogenesis was possible in non-neurogenic regions of 
the mammalian brain (Magavi et al., 2000). Utilising chromophore-targeted neuronal 
degeneration of layer VI corticothalamic neurons in the anterior neocortex, the authors 
observed newly-generated neurons in the injured regions of the cortex co-expressing 
BrdU and NeuN 28 weeks following injury. Furthermore, analysis of SVZ cell 
populations 2 weeks following injury revealed co-expression of BrdU with DCX, 
suggesting the newly generated neocortical neurons may have originated from the SVZ 
and migrated ectopically to the neocortex. The same group later extended their findings 
to show that corticospinal motor neurons could be induced to regenerate using the same 
protocol of chromophore-targeted neuronal degeneration (Chen et al., 2004). Furthermore, 
the newly generated neurons were capable of long-distance connections, projecting axons 
from the motor cortex down to the spinal cord, and persisted for up to 56 weeks, the 
longest survival time utilised in the study. In contrast, Diaz and colleagues (2013) 
investigated the regenerative potential of a population of glutamatergic neurons in the 
adult rodent neocortex following targeted apoptotic injury (Diaz et al., 2013). The authors 
utilised two separate transgenic mouse models with inducible expression of neuron-
specific Caspase-8 protein and inducible diphtheria toxin gene to produce targeted 
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apoptosis of glutamatergic neurons in the neocortical region. Their findings showed that 
targeted apoptosis of glutamatergic neocortical neurons did not result in increased 
generation of newly generated neurons, with the majority of DCX-expressing cells in the 
neocortex co-expressing the oligodendrocyte precursor protein Olig2. Together, these 
studies suggest that the regenerative potential in non-neurogenic regions of the brain may 
be dependent on both the inducing injury, and/or the population of neurons affected by 
the injury. 
 
1.4.2 Ischaemic injury 
1.4.2.1 Neurogenic regions 
Ischaemia is one of the most widely utilised methods used to investigate neurogenesis 
following experimentally-induced injury (Ohira, 2011). Similar to seizure-induced 
injuries, upregulation of neurogenesis has been established to occur in both the SGZ and 
SVZ following various models of experimentally-induced stroke (Arvidsson et al., 2001; 
Jin et al., 2001; Kee et al., 2001; Kernie & Parent, 2010; Liu et al., 1998; Yamashita et 
al., 2006). Utilising BrdU-immunoreactivity, increased cellular proliferation was 
observed in the SGZ following experimental ischaemia (Jin et al., 2001; Liu et al., 1998; 
Takagi et al., 1999). This increased cellular proliferation has been shown to persist for up 
to 2 weeks (Bingham et al., 2005; Kee et al., 2001), a process found to be modulated by 
several factors including NMDA receptor stimulation (Arvidsson et al., 2001; Bernabeu 
& Sharp, 2000; Kawai et al., 2004), mitogen and stress-activated protein kinases 
(Karelina et al., 2015), and stimulated by apoptosis (Salazar-Colocho et al., 2008). 
Although ischaemia increases SGZ proliferation bilaterally (Jin et al., 2001), proliferating 
cells contralateral to the side of injury experience reduced survival (Takasawa et al., 2002). 
The newly-generated cells have been observed to migrate into the granule cell layer of 
the DG, where they matured into granule neurons, persisting for at least 7 months 
following injury (Liu et al., 1998). 
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1.4.2.2 Non-neurogenic regions 
Neurogenesis following ischaemic injury has also been demonstrated in non-neurogenic 
regions of the mammalian brain, including the neocortex (Gu et al., 2000; Jiang et al., 
2001; Ohira et al., 2010), striatum (Arvidsson et al., 2002; Parent et al., 2002; Thored et 
al., 2006; Zhang et al., 2004; Zhao et al., 2003), and CA1 of the hippocampus (Bendel et 
al., 2005; Nakatomi et al., 2002; Salazar-Colocho et al., 2008; Schmidt & Reymann, 
2002).  
Although adult neurogenesis does not normally occur in the adult mammalian striatum 
under physiological conditions, ectopic migration of SVZ-derived cells into the post-
ischaemic striatum and peri-infarct cortical region has been well documented in the 
literature (Hou et al., 2008; Kreuzberg et al., 2010; Kuge et al., 2009; Liu et al., 2009; 
Ohab et al., 2006; Parent et al., 2002; Thored et al., 2006; Yamashita et al., 2006). 
Following ischaemic injury, SVZ-derived neuroblasts appear unconstrained to the 
migratory patterns followed under physiological conditions, migrating to the ischaemic 
striatum via multiple migratory routes and retaining the capacity for cell division during 
migration (Zhang et al., 2009). The neurogenic response following ischaemia appears to 
persist long after the initial injury event, with previous studies describing the continued 
generation of striatal neuroblasts up to one year post-ischaemia (Kokaia et al., 2006; 
Thored et al., 2006). Together, these studies suggest that neural progenitors may continue 
to play a role in brain plasticity long after the initial ischaemic injury event. 
A crucial question regarding ischaemia-induced neurogenesis is whether these newly-
generated neurons become functionally integrated in the existing circuitry, and 
specifically, whether these new neurons can contribute to recovery of cognitive deficits. 
The first evidence that ischaemia-induced neurogenesis could be contributing to 
functional recovery was described by Nakatomi and colleagues (2002). Following 
transient forebrain ischaemia, which induced selective degeneration of the hippocampal 
CA1 region, the authors observed a spontaneous increase of newly generated neurons in 
the CA1 pyramidal layer 28-56 d following injury (Nakatomi et al., 2002). These newly 
formed neurons were derived from the posterior periventricular area, caudal to the SVZ 
and adjacent to the CA1. This endogenous regenerative response was enhanced by 
exogenous administration of growth factors, such that fibroblast growth factor 2 and 
epidermal growth factor infusion produced recovery of the CA1 neuron population 
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equivalent to 40% of the original CA1 neuron population at 28 d post-injury. Furthermore, 
the newly-generated neurons were observed to persist up to 56 d post-injury, and this was 
associated with improved performance on a hippocampus-dependent spatial learning task, 
suggesting that the newly generated neurons may be contributing to functional recovery. 
Bendel and colleagues (2005) extended these findings, utilising ischaemic injury in the 
absence of exogenous stimulatory treatment to investigate the functional contribution of 
CA1 neurogenesis to cognitive recovery (Bendel et al., 2005). The authors firstly 
demonstrated a temporal correlation between ischaemia-induced degeneration of CA1 
neurons and deficits in spatial learning and memory functions assessed via Morris water 
maze testing (Bendel et al., 2005). Consequently, subsequent spontaneous regeneration 
of CA1 hippocampal neurons 90 d following ischaemic injury was associated with 
recovery of hippocampal-dependent spatial learning and memory deficits. Together, these 
studies demonstrate the inherent potential of endogenous neurogenesis to repair the brain 
following acute injury and contribute to functional recovery.  
 
1.4.3 Caveats to studies of spontaneous injury-induced neurogenesis 
It is clear from the aforementioned studies that, following acute CNS injury, upregulation 
of neurogenesis occurs in both neurogenic and non-neurogenic regions of the adult 
mammalian brain. However, in spite of the overwhelming evidence in support of 
unassisted neurogenesis following injury, the field remains sceptical about its biological 
relevance (Bonfanti, 2016; Sun, 2016; Yu et al., 2014). Chief among these concerns is 
related to the relatively low proportion of cells that survive beyond the initial post-injury 
proliferative phase (Arvidsson et al., 2002; Parent et al., 2002), with an estimated 80% of 
stroke-generated cells dying within the first 2 weeks (Arvidsson et al., 2002). This high 
attrition rate raises doubts regarding the robustness of the endogenous neurogenic 
response following injury, and leads to suggestions that the endogenous levels occurring 
may not be sufficient to affect functional recovery following injury. Furthermore, even in 
studies which have observed functional recovery coinciding with reappearance of CA1 
neurons ~90 d following ischaemic injury (Bendel et al., 2005), long-term follow-up 
studies revealed subsequent disappearance of these newly generated CA1 neurons ~125-
250 d post-injury (Bueters et al., 2008), calling into question the sustainability and long-
term functional relevance of the spontaneous neurogenic response to injury. Lastly, the 
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studies describing functional improvements have only described a temporal association 
between the behavioural improvements observed and increases in post-injury 
neurogenesis. Thus, the functional contribution of these newly-generated neurons to post-
injury recovery remains to be delineated. 
As a consequence, much of the research focus has been directed towards enhancing the 
endogenous injury-induced neurogenic response through various exogenous treatments 
at both the molecular and cellular level. These include growth factor treatments (Keiner 
et al., 2010; Kobayashi et al., 2006; Nakatomi et al., 2002; Schäbitz et al., 2000; 
Yoshimura et al., 2001, 2003), stem cell transplantation/therapy (Bliss et al., 2007; Daadi 
et al., 2008; Hicks et al., 2009; Jin et al., 2011; Lindvall & Kokaia, 2011; Mine et al., 
2013; Tatarishvili et al., 2014), cellular reprogramming/ trans-differentiation (Grande et 
al., 2013; Guo et al., 2014; Niu et al., 2013; Torper et al., 2013, 2015), and physiological 
stimulation through exercise and environmental enrichment (Bondi et al., 2014; Gorantla 
et al., 2016; Griesbach et al., 2009; Kato et al., 2014; Piao et al., 2013). Although some 
studies have described improvements in sensorimotor function and injury-related 
neurological deficits alongside the stimulated neurogenic response following injury 
(Griesbach et al., 2009; Hicks et al., 2009; Kato et al., 2014; Mine et al., 2013; Nakatomi 
et al., 2002; Piao et al., 2013; Schäbitz et al., 2000; Tatarishvili et al., 2014), the long-
term consequences remain to be determined, along with the persistence of the resulting 
regeneration and recovery observed.  
 
1.5 Adult neurogenesis under pathological disease conditions: 
Alzheimer’s disease 
1.5.1 Introduction to Alzheimer’s disease 
Clinically, AD presents primarily as an episodic memory impairment (Albert et al., 2011). 
The diagnosis of AD is confirmed either in vivo or post-mortem by the assessment of 
amyloid-β (Aβ) peptides and tau pathology (Hyman et al., 2012; Jack et al., 2018). In 
particular, the Aβ peptide can aggregate into both soluble oligomers and insoluble Aβ 
plaques, which are quantifiable (Jack et al., 2018). Similarly, the tau protein 
hyperphosphorylates and aggregates into quantifiable neurofibrillary intracellular tangles. 
Together, these two markers are the neuropathological hallmarks of AD and the presence 
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of both pathological markers, above specific thresholds, are required for the diagnosis of 
AD (Morris et al., 2018). 
The amyloid cascade hypothesis, the predominant theory of AD pathogenesis, posits that 
the deposition of Aβ plaques is a key trigger in the pathogenesis of AD (Morris et al., 
2014). This theory is supported by evidence that genetic mutations in the amyloid 
precursor protein (APP), from which Aβ peptide proteins are produced, are linked to a 
familial early-onset form of the disease (Selkoe & Hardy, 2016). Familial early-onset AD 
has additionally been linked to genetic mutations in presenilin-1 (PS1) and presenilin-2 
(PS2). These APP, PS1 and PS2 mutants are 100% penetrant as causes of early-onset AD 
(Bilkei-Gorzo, 2014; Elder et al., 2010). Importantly, the PS1 and PS2 proteins form part 
of an enzymatic secretase protein complex that is known to cleave the Aβ peptide from 
its parent APP (Small et al., 2010). The aberrant processing of APP leads to either 
increased Aβ levels, or increased production of the more aggregation prone Aβ1-42 peptide 
over the shorter Aβ1-40 peptide (Morris et al., 2014). These processes have been postulated 
to trigger the subsequent aggregation of Aβ into multi-peptide oligomeric structures and 
Aβ-containing plaques, hypothetically triggering the molecular processes leading to AD 
(Dimitrov et al., 2013; Selkoe & Hardy, 2016).  
Preclinical in vivo mouse models of AD have been designed to recapitulate the clinical 
and pathological features of the human condition. This has largely been achieved through 
the overexpression of APP, PS1 and/or PS2 proteins harbouring the mutations associated 
with early-onset human AD, in transgenic mice (Götz et al., 2018). Despite their 
limitations (Morris et al., 2014; Sasaguri et al., 2017), transgenic mouse models remain a 
critical tool by which scientists investigate the underlying early pathological processes of 
AD and they facilitate the development of novel therapeutic drugs (Bilkei-Gorzo, 2014; 
Elder et al., 2010).  
There are many transgenic AD mouse models, differing in the combination of genes 
expressed, the promoters utilised to drive gene expression, the genetic mutations present, 
and the background mouse strain utilised (Jankowsky & Zheng, 2017). As such, 
differences in the timing and degree of Aβ pathology occur. Additionally, the degree of 
tau phosphorylation, neuronal cell loss, as well as onset of cognitive alternations will vary 
across transgenic AD mouse models, with many models displaying only a subset of these 
phenotypes (Webster et al., 2014). Some of the most commonly utilised transgenic mouse 
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models used to study AD include Tg2576, APP23, APP/PS1, 3xtg AD, and 5xFAD 
(Bilkei-Gorzo, 2014; for an exhaustive overview of available transgenic mouse models 
of AD, see https://www.alzforum.org/research-models/alzheimers-disease).  
In the present study, we utilised APPswe/PS1ΔE9 mice carrying the familial AD-linked 
human APP with Swedish double mutation (APPswe), co-integrated with a familial AD-
linked loss of function mutation in PS1, which results in the deletion of exon 9 within the 
PS1 protein (PS1ΔE9; Jankowsky et al., 2004). The background on AD provided in this 
section is pertinent to the study presented in Chapter 4. For a more comprehensive 
overview and rationale of the transgenic AD mouse model utilised in the present study, 
see section 4.1. 
 
1.5.2 Neurogenesis and Alzheimer’s disease 
The progressive loss or degeneration of discrete neuronal populations, in the absence of 
regeneration, is a characteristic feature common to a broad range of neurodegenerative 
diseases (Winner & Winkler, 2015). In AD, the most common form of neurodegenerative 
disease worldwide (Horgusluoglu et al., 2017), regions such as the hippocampus are 
particularly vulnerable to neuronal degeneration early in disease progression (Dubois et 
al., 2007; Kaye et al., 1997). Furthermore, disturbances in memory and cognitive 
functions are among the earliest clinical manifestations of the disease (El Haj et al., 2015; 
Jahn, 2013). This has led to the view that within regions of enhanced cellular plasticity, 
such as the hippocampus, dysfunctions in neurogenesis-related processes may be 
contributing to the pathology of the disease, particularly in the early stages (Winner & 
Winkler, 2015). Thus, intense interest as to whether the neurogenic process is altered or 
dysfunctional in neurodegenerative diseases such as AD, has led some to postulate 
whether neurodegenerative diseases are actually a “failure of neuroregeneration” 
(Armstrong & Barker, 2001). Furthermore, a key question emerging within this field is 
whether stimulation of neurogenesis may be a viable therapeutic strategy for replacement 
of the neurons lost during disease progression, and whether this, in turn, may contribute 
to alleviating the cognitive deficits experienced by patients.  
Reports describing alterations in hippocampal neurogenesis in human AD patients have 
been conflicting. Analysis of post-mortem AD patients revealed increased protein 
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expression and immunolabelling of various markers associated with neuronal 
development and immature neurons (i.e., DCX, PSA-NCAM, TUC-4 and NeuroD) 
localised to the proliferative hippocampal SGZ region (Jin, Peel, et al., 2004). 
Furthermore, DCX-immunoreactive cells were also observed in the CA1 region, 
suggesting presence of new neurons. In contrast, subsequent studies have cited no change 
(Boekhoorn et al., 2006) or decreased SGZ neurogenesis in AD patients (Crews et al., 
2010). Additionally, a separate study reported a ninefold reduction in progenitor cell 
population in the SVZ of AD patients (Ziabreva et al., 2006). As results from post-mortem 
studies are typically reflective of the end stage of AD (Rodríguez & Verkhratsky, 2011), 
it can be difficult to draw definitive conclusions as to whether the difference in 
neurogenesis is a response to the disease or a pathological feature of AD. 
Findings from transgenic AD models have been similarly conflicting, with variations in 
experimental conditions and transgenic AD models producing both upregulation and 
decline in neurogenesis (Chuang, 2010; Winner & Winkler, 2015). Despite the 
complexity and challenges associated with modelling AD in rodents (see review 
Jankowsky & Zheng, 2017), most of the evidence derived from studies of transgenic AD 
mouse models suggest that neurogenesis is largely impaired (Wirths, 2017). What 
remains unclear however, is how dysregulations in the neurogenic process in AD may be 
contributing to and/or modulating cognitive deficits characteristic of the disease. 
Some studies have attempted to reconcile this problem through transgenic rodent models. 
In 3 month-old transgenic mice harbouring a mutation in the AD-linked presenilin-1 (PS1) 
gene, reduced hippocampal DG neurogenesis, assessed through quantification of 
newborn neurons co-immuno-labelled with BrdU and NeuN, was observed and appeared 
to coincide with impairments in contextual fear learning, a hippocampal-dependent 
learning paradigm  (Wang et al., 2004). Inhibition of microglial activation in the DG, 
through administration of minocycline, was found to increase the number of newly 
generated neurons in the granule cell layer of APP/PS1 transgenic mice (Biscaro et al., 
2012). Furthermore, this increased hippocampal neurogenesis coincided with improved 
performance on the hippocampus-dependent object recognition task. Lastly, Hsiao and 
colleagues investigated the effects of co-housing AD transgenic mice with unimpaired 
wild-type conspecifics on cognitive tasks (Hsiao et al., 2014). Co-housing increased 
levels of BDNF, a protein involved in survival and differentiation of neurons and 
hippocampal learning and memory processes, in the hippocampus of APP/PS1 transgenic 
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mice and was associated with both elevated DG neurogenesis and reversal of 
hippocampus-dependent contextual fear learning deficits. Together, the above studies 
suggest enhancement of hippocampal neurogenesis may be beneficial in ameliorating 
AD-related cognitive deficits. Nevertheless, the aforementioned findings only 
demonstrate a temporal correlation between enhanced neurogenesis and behavioural 
improvements, and it therefore remains to be determined the direct role these newly 
generated neurons contribute to cognitive recovery.  
 
1.6 Functional relevance of injury-induced neurogenesis to cognitive 
recovery 
The inherent regenerative capacity of the adult brain following injury is an area of intense 
interest. The overarching goal of most neurogenesis studies is to understand the functional 
relevance of the neurogenic process occurring after injury. Although many studies have 
observed temporal links between increased neurogenesis and improvements in 
sensorimotor and/ or learning and memory tasks, a causative correlation remains yet to 
be determined (Lagace, 2012; Lindvall & Kokaia, 2015).  
Many of the early studies investigating functional relevance focused on 
electrophysiological properties of the new neurons and their integration into the existing 
circuitry. Newly generated striatal neurons originating from the SVZ were observed 
forming synapses with neighbouring striatal cells following ischaemic injury, indicating 
the newly generated cells are capable of integrating into the pre-existing neuronal circuit 
(Yamashita et al., 2006). Further, electrophysiological recordings of retroviral-labelled 
dividing cells following ischaemia revealed the presence of GABAergic and cholinergic 
newborn neurons which could fire action potentials and receive excitatory and inhibitory 
synaptic inputs, suggesting functional integration of these newborn neurons into the 
existing circuitry of the injured striatum (Hou et al., 2008). Most recently, synaptic 
integration of TBI-induced dentate granule neurons was demonstrated through whole-cell 
recordings (Villasana et al., 2015). Despite gross alterations in dendritic structure, the 
authors demonstrated that the newly generated neurons were nevertheless excitable and 
capable of synaptic integration into the existing hippocampal circuit (Villasana et al., 
2015). 
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Later studies utilised immunohistochemical methods for determining activation and 
participation of newly-generated neurons in circuitry activity. Expression of c-fos, an 
immediate early gene, is strongly correlated with neuronal activation, and is therefore a 
useful assay for determining CNS neuronal activity (Guzowski et al., 2005). Co-immuno-
labelling of retroviral-mediated green fluorescent protein (GFP) with c-fos allowed 
investigators to determine activation of the newly generated neurons post-ischemic injury 
(Ohira et al., 2010). Rats that had been exposed to an enriched environment following 
ischaemia showed a higher proportion of GFP and c-fos co-immuno-labelled cells 
compared to control rats that were housed in their original environment, suggesting 
functional integration of a subset of the newly generated neurons following ischaemic 
injury (Ohira et al., 2010). Collectively, these studies demonstrated that newly generated 
cells following injury can actively participate in neurotransmission and circuitry 
communication, suggesting a functional role for injury-induced neurogenesis. However, 
these studies did not investigate cognitive recovery, leaving open the question of whether 
the newly-generated neurons are contributing to recovery of cognitive function following 
injury. 
Other studies have attempted to address this problem. Utilising an experimentally-
induced model of TBI, Sun and colleagues observed a temporal correlation between 
increased injury-induced neurogenesis and cognitive recovery (Sun et al., 2007). The 
authors assessed cognitive performance using the Morris water maze test and revealed 
that performance deficits that had been present in the first 4 weeks following injury were 
no longer apparent at 9 weeks post-injury. TBI also induced a four-fold increase in BrdU-
labelled cells in the DG 5 d post-injury compared to control animals, and furthermore, the 
majority of BrdU-labelled cells still present at 10 weeks post-injury were found to co-
express NeuN. Similarly, a small subset of BrdU-labelled neurons were found to co-
express synaptophysin, an integral protein present in synaptic vesicle membranes of CNS 
neurons that participate in synaptic transmission (Markakis & Gage, 1999), suggesting 
integration of these new cells into the existing hippocampal circuitry. As the timeline of 
the injury-induced neurogenesis coincided with behavioural recovery, their findings 
suggested that the observed neurogenesis could be contributing to the recovery process. 
Blaiss and colleagues extended these findings, suggesting that the newly-generated 
neurons may only be critical for specific forms of learning and memory and not others 
(Blaiss et al., 2011). Selective pharmacogenetic ablation of dividing neural stem and 
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progenitor cells at the same time as experimental TBI produced impairments in 
hippocampal-dependent spatial learning that were not present in TBI-injured animals that 
had intact hippocampal neurogenesis following TBI. Additionally, ablation of 
hippocampal neurogenesis did not contribute to further performance deficits in either 
contextual fear learning or rotarod motor coordination above the effects of TBI alone, 
suggesting that the newly generated neurons were critical for spatial memory but not 
contextual fear memory. Similar conclusions were drawn by Sun and colleagues, who 
found inhibition of TBI-induced hippocampal neurogenesis, via infusion of the 
antimitotic agent arabinofuranosyl cytidine (Ara-C), subsequently impaired spontaneous 
cognitive recovery in the Morris water maze task (Sun et al., 2015). Collectively, these 
studies suggest a functional role of injury-induced neurogenesis for mediating cognitive 
recovery following injury. 
Despite these promising findings however, a direct causative correlation between 
spontaneous injury-induced neurogenesis and cognitive recovery remains to be 
determined. In addition to concerns regarding the long-term persistence and low survival 
rates of the newly-generated neurons following injury (Arvidsson et al., 2002; Bueters et 
al., 2008; Ekdahl et al., 2001), many in the field remain sceptical regarding the potential 
of, in some cases very limited amount of, injury-induced neurogenesis in directly 
facilitating recovery of function following injury. It has been suggested by some that 
alternative processes, such as synaptic plasticity, may be directing functional recovery, 
through either synaptic reorganisation of existing neuronal circuits or synaptogenesis of 
the few surviving neurons generated following injury (Chen et al., 2003; Park & Biederer, 
2013; Xuan et al., 2015). Thus, elucidating the functional relationship of injury-induced 
hippocampal neurogenesis to cognitive recovery is imperative for understanding the 
endogenous regenerative potential of the adult mammalian brain. 
 
1.7 Aims and hypotheses 
As outlined in the preceding sections, there exists a wealth of evidence in the literature 
demonstrating spontaneous upregulation of neurogenesis following experimentally-
induced acute CNS injuries. Furthermore, surmounting evidence exists for the occurrence 
of injury-induced neurogenesis outside of the well-established neurogenic regions and 
this has, in some cases, been associated with recovery of cognitive function. In spite of 
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these findings however, a direct, functional relationship between injury-induced 
neurogenesis and cognitive recovery remains yet to be determined, leading many to 
question whether spontaneous regeneration is functionally relevant. Therefore, this thesis 
aims to address this query through the execution of the following aims: 
1. Demonstrate the occurrence of substantial spontaneous injury-induced 
neurogenesis in non-neurogenic regions in a mouse model of excitotoxic 
injury. 
Prior studies by our group have demonstrated a spontaneous neurogenic response 
in non-neurogenic regions of the hippocampus following acute injury (see 
Abdipranoto-Cowley et al., 2009 and Figure 2.2). In order to assess the functional 
contribution of newly generated neurons to cognitive recovery, we first aimed to 
replicate and validate prior findings from our group using the KA model of acute 
excitotoxic injury. Specifically, we were interested in investigating neuronal 
repopulation in non-neurogenic regions of the hippocampus, as this region has 
important functional relevance in cognitive tasks. 
 
2. Demonstrate a direct functional link between spontaneous injury-induced 
neurogenesis and cognitive recovery. 
Following validation of neurodegeneration and subsequent neuronal repopulation 
using the KA model of acute excitotoxic injury, we subsequently aimed to 
demonstrate a direct functional correlation between spontaneous injury-induced 
neurogenesis and hippocampal-dependent cognitive recovery. Specifically, we 
were interested in demonstrating the extent to which newly generated neurons of 
the CA1 and CA3 hippocampal regions contribute to recovery in learning and 
memory tasks. 
 
3. Identify the origin of the newly-generated neurons following injury. 
We aimed to elucidate the origin of the newly-generated neurons that may be 
repopulating the hippocampus following acute excitotoxic injury, and whether 
these neurons were being derived from the SVZ or SGZ, or whether regions 
outside of the canonical neurogenic niches were giving rise to these newly-
generated neurons. 
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4. Characterise the APPswe/PS1ΔE9 mouse model of Alzheimer’s disease. 
As previously outlined in the preface, our ultimate goal was to investigate the 
processes by which neurogenesis could be stimulated in a model of chronic 
neurodegeneration. Before we could fulfil this aim however, we first sought to 
characterise the baseline pathological and behavioural phenotype of the 
APPswe/PS1ΔE9 mouse model of AD in our own hands. 
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2.1 Introduction 
2.1.1 Kainic acid can be used to model excitotoxicity 
Excitotoxicity has been implicated in the pathology of many acute and chronic 
neurodegenerative diseases (Dong et al., 2009; Lai et al., 2014; Mehta et al., 2013; 
Prentice et al., 2015; Venugopal et al., 2017). Excitotoxicity is the pathological process 
of excessive stimulation of glutamate receptors by excitatory amino acids, which 
ultimately results in neuronal cell death through activation of apoptotic and necrotic 
pathways (Fujikawa, 2015; Velasco et al., 2017). In rodents, the administration of KA, an 
ionotropic glutamate receptor agonist, is commonly used to model excitotoxicity. After 
binding to kainate receptors in the brain, KA stimulates an influx of extracellular calcium 
which triggers the activation of various cell death signalling pathways, ultimately leading 
to extensive neuronal death through apoptosis and necrosis (Wang et al., 2005). Also used 
as a model of epilepsy, the KA model is characterised by an initial period of severe, 
continuous and recurrent seizures, followed by the development of latent spontaneous 
seizures (Morimoto et al., 2004). KA-mediated excitotoxicity is a useful model of 
hippocampal neurodegeneration as focal administration of KA via ICV injection results 
in selective and reproducible degeneration of CA1 and CA3 neurons (Abdipranoto-
Cowley et al., 2009; Matsuoka et al., 1999; Roe et al., 1998; Wang et al., 2005), along 
with increasing the excitability of surviving neurons (Ben-Ari, 2001; Zheng et al., 2011). 
 
2.1.2 Increasing evidence suggests spontaneous neurogenesis is possible following 
KA-induced neurodegenerative injury 
Interestingly, in addition to neurodegeneration, neurogenesis following KA-mediated 
excitotoxicity has been documented in rodents (Bengzon et al., 1997; Parent, 2003). KA 
injected into the left ventricle of rats caused a bilateral increase in progenitor cell 
proliferation within the SGZ one week following KA treatment (Gray & Sundstrom, 1998; 
Hattiangady et al., 2004), while intraperitoneal KA administration led to enhanced 
proliferation in both the SGZ and CA1 hippocampal region (Becq et al., 2005; Covolan 
et al., 2000). In addition, neurogenesis in regions outside of the SGZ has also been 
observed. KA-induced neurogenesis has been observed in the olfactory bulb (Parent et 
al., 2006; Parent et al., 2002; Park et al., 2006), amygdala (Park et al., 2006), piriform 
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cortex (Sakurai et al., 2017), and hippocampal CA1 region (Becq et al., 2005). These 
results corroborate the observations in human studies, where post-mortem analyses of 
brain tissue from epilepsy patients show evidence of postnatal neurogenesis (González-
Martínez et al., 2007; Liu et al., 2008). Despite the numerous observations of injury-
induced neurogenesis in regions both within and outside the neurogenic zones (Magavi 
et al., 2000; Nakatomi et al., 2002; Ohira et al., 2010), there remains doubt that 
spontaneous neurogenesis can mediate functional recovery in the absence of exogenous 
treatments. Furthermore, the molecular mechanisms involved in KA-induced 
neurogenesis, the anatomical source of the newborn cells and whether or not they 
integrate functionally into existing circuits remains poorly understood. 
 
2.1.3 Establishing a reproducible KA model is critical to robustly investigating 
neurogenesis 
The first step to unequivocally demonstrate the presence and functional significance of 
injury-induced neurogenesis following excitotoxic brain injury is to establish a reliable 
model of neuronal loss and subsequent spontaneous repopulation. Previous studies from 
our group have utilised the KA model of neurodegeneration for investigating 
neurogenesis following injury. Abdipranoto-Cowley and colleagues demonstrated 
enhanced neurogenesis in the DG, CA1 and CA3 regions 7 and 42 d following KA-
mediated injury. Intriguingly, this spontaneous response was prevented by inhibiting the 
endogenous activity of the growth factor activin A (Abdipranato-Cowley et al., 2009). 
This study therefore illustrated spontaneous neurogenesis is possible following KA-
induced neurodegeneration. Furthermore, the results showed newly generated neurons 
within the CA1 and CA3 neuronal layers, regions existing outside of the well-accepted 
neurogenic SGZ and SVZ, following KA-mediated injury. However, while this study 
demonstrated spontaneous neurogenesis was possible in the hippocampus following KA-
mediated injury, the timing of spontaneous recovery, extent of neuronal repopulation and 
the significance of repopulation for functional recovery (i.e. whether the newborn cells 
integrated functionally into existing circuits), was not explored.  
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2.1.4 Aims 
In the following chapter we detail our efforts to establish a reproducible model of KA-
induced excitotoxic neuronal injury that facilitates investigation of injury-induced 
hippocampal neurodegeneration and regeneration. Although initially assuming this would 
be a straightforward process, considering the establishment of the model in our group in 
the past (Abdipranoto-Cowley et al., 2009), as detailed in sections 2.3.2 to 2.3.7, we 
experienced several technical issues when attempting to induce a reproducible injury and 
observe reproducible repopulation. These issues hampered our attempts to take the study 
further and necessitated revisiting the methodology of the KA model in this chapter. 
There are many variables illustrated to impact the reproducibility of KA-mediated injuries 
including, but not limited to, the concentration of KA administrated, KA supplier, method 
of stereotaxic injection, and the location of intracerebral KA administration. In the 
following chapter, we systematically investigated the effect of several key variables, on 
animal mortality, seizure scores and total neuron population in the CA1 and CA3 regions 
of the hippocampus. Our aims were as follows: 
• To establish a reproducible model of kainic acid-induced excitotoxic neuronal 
injury to the hippocampus of C57BL/6 mice that facilitates subsequent neuronal 
repopulation by: 
o Determining the ideal concentration of KA for causing neurodegeneration 
and allowing repopulation 
o Investigating the effects of KA supplier on neuron loss and repopulation 
o Determining the ideal KA injection location for facilitating neuron loss 
and repopulation. 
  
Chapter 2: Kainic acid model of neuronal injury 
 
33 
2.2 Material and Methods 
2.2.1 Kainic acid administration 
2.2.1.1 Animals 
C57BL/6 male mice aged between 8 and 10 weeks were obtained from Australian 
BioResources (NSW, Australia). All animals were kept under standard housing 
conditions of 12 h light/dark cycle (lights on at 7:00am) with access to food and water ad 
libitum for the duration of experimentation. Mice were housed at a maximum five mice 
per cage prior to KA administration. Following KA administration, mice were single 
housed for the duration of the experiment.  
All experiments were performed with the approval of the Garvan Institute and St 
Vincent’s Hospital Animal Ethics Committee, in accordance with National Health and 
Medical Research Council animal experimentation guidelines and the Australian Code of 
Practice for the Care and Use of Animals for Scientific Purposes (8th Edition, 2013). 
 
2.2.1.2 Pre-surgery 
All surgical tools were sterilised overnight in 0.5% chlorhexidine in 70% ethanol. 
Animals were anaesthetised with an intraperitoneal injection of ketamine (100 mg/kg; 
Mavlab, QLD, Australia) and xylazine (20 mg/kg; Troy Laboratories, NSW, Australia) 
mixture and placed in a stereotaxic apparatus (Kopf Instruments, CA, USA). 
 
2.2.1.3 Stereotaxic injection of kainic acid 
KA was dissolved at various concentrations (see Table 2.1) in phosphate buffered saline 
(PBS; pH 7.4) filtered through a 0.2 μm syringe filter. KA stock solution was aliquoted 
and stored at -20°C for up to 1 month following reconstitution (as per supplier’s 
recommendation). A small burr hole was drilled in the cranium over the injection site and 
mice were given a single unilateral injection of 0.2 μL of either KA or PBS using a 0.5 
μL Hamilton syringe (model # 7000.5KH, Hamilton, NV, USA) into either the right 
lateral ventricle (ICV) or right dorsal hippocampus (IHPC). ICV co-ordinates were 
measured from bregma: antero-posterior (AP) -2.0 mm, medio-lateral (ML) -2.9 mm and 
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from dura (or bregma as indicated in the text) dorso-ventral (DV) -3.8 mm. IHPC co-
ordinates were measured from bregma: AP -1.7 mm, ML -1.6 mm and DV -1.9 mm. The 
injection needle remained in place for 5 min to allow diffusion of KA into the target 
structure and minimise backflow. The incision was closed with sutures (Cat # CD0057, 
Dynek, SA, Australia) and animals were allowed to recover overnight in their home cages 
on heating pads. 
 
Table 2.1. List of KA used in Chapter 2. 
Supplier Catalogue # Lot # Used in 
experiments 
Concentrations 
used 
Sigma-Aldrich 
(now Merck), 
NSW, Australia 
58002-62-3 SLBD1491V 
MKBQ0979V 
 
 
MKBR9848V, 
MKBQ0979V 
 
 
MKBR9848V 
2.3.2 
2.3.3 
 
 
2.3.4 
 
 
 
2.3.5 
1 mg/mL 
0.5 mg/mL, 0.75 
mg/mL, 
1 mg/mL 
0.05 mg/mL, 0.1 
mg/mL,  
0.3 mg/mL,  
0.5 mg/mL 
0.5 mg/mL 
1 mg/mL 
Tocris, VIC, 
Australia 
0222 65A/142407 2.3.5 0.5 mg/mL 
1 mg/mL 
Abcam, VIC, 
Australia 
ab144490 APN13058-1-1 2.3.5 0.5 mg/mL 
1 mg/mL 
calbiochem (now 
Merck), VIC, 
Australia 
420318 D00160459 
 
 
 
2748793 
2.3.5 
 
2.3.6 
2.3.7 
2.3.9 
2.3.10 
0.5 mg/mL 
1 mg/mL 
1 mg/mL 
1 mg/mL 
1 mg/mL 
1 mg/mL 
1.2 mg/mL 
1.5 mg/mL 
 
 
2.2.1.4 Seizure scoring 
After waking from anaesthesia, seizure activity was monitored and scored every 5 min 
over a period of 2 h according to a seizure scoring scale (Table 2.2). A modified version 
of the Racine scale of epileptic seizures (Racine, 1972) was used to determine the extent 
of seizure-like responses to KA. The time course of seizure-like activity for each 
experiment was graphed as a function of time. Scoring ceased after a mouse scored ‘2’ or 
lower for 3 consecutive 5 min intervals or 2 h after waking up from anaesthesia. 
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Table 2.2. Seizure scoring scale 
Score Characterisation 
0 Normal exploratory behaviour and grooming 
1 Cessation of typical activity (walking, grooming, exploring, sniffing) 
2 Forelimb and/or tail extension, appearance of rigidity 
3 Automatisms (repetitive scratching, circling, head bobbing) 
4 Forelimb clonus, rearing and falling 
5 Repetitive rearing and falling and forelimb clonus 
6 Severe tonic-clonic seizures 
7 Death 
 
2.2.2 Confirming stereotaxic injection co-ordinates 
2.2.2.1 Animals 
Refer to 2.2.1.1. 
 
2.2.2.2 Pre-surgery 
Refer to 2.2.1.2. 
 
2.2.2.3 Sham stereotaxic injection, tissue preparation and analysis 
All animals received a sham injection using a 2 µL Hamilton syringe (model # 7002KH, 
Hamilton, NV, USA) into desired stereotaxic co-ordinate (see Table 2.12-2.14 for exact 
co-ordinates). The injection needle remained in place for 5 min before removal. 
Immediately following sham injection, animals were sacrificed via cervical dislocation. 
Brains were harvested and post-fixed into 4% paraformaldehyde (PFA; Cat # P6148-1kg, 
Sigma Aldrich, NSW, Australia; pH 7.3-7.5) in 1x PBS for 24 h, and cryoprotected in 30% 
sucrose for 2-3 d until brains had sunk. Brains were prepared for cryosectioning by cutting 
away 1 mm of cerebellum to make a flat surface and then placed in a peel-away mould 
containing Optimal Cutting Temperature (OCT; Cat # 4583001CTN, Hurst Scientific, 
WA, Australia) medium. Brains were stored at -80°C until ready for cryosectioning. 
Brains were cryostat sectioned into 40 μm thick slices at -16°C and each section was 
placed serially into a 12 well plate containing 0.02% sodium azide in 1x PBS until needed 
for immunohistochemistry.  
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Following cresyl violet histology (2.2.3.4), tissue sections were analysed serially, using a 
bright-field microscope (Leica Microsystems, NSW, Australia) with 1x and 5x objectives, 
until the section corresponding to the stereotaxic injection location was observed. 
Representative images of the corresponding tissue section were taken at 1x and 5x 
magnification. Injection accuracy was determined by combining information from 1x and 
5x magnification images whereby 1x images provided approximate AP location from 
bregma and 5x images provided approximate DV location from bregma (or dura as stated 
in text) and comparing against the mouse atlas (Franklin & Paxinos, 2008) target image. 
 
2.2.3 Histology 
2.2.3.1 Tissue preparation 
Mice were anaesthetised with an intraperitoneal injection of ketamine (100 mg/kg) and 
xylazine (20 mg/kg) cocktail and transcardially perfused with ice-cold 0.9% sodium 
chloride followed with ice-cold 4% PFA (Cat # P6148-1kg, Sigma Aldrich, Australia; pH 
7.3-7.5) in 1x PBS at either 2 or 8 weeks following administration of KA or PBS. Brains 
were harvested and post-fixed in 4% PFA in 1x PBS for 6-8 h, cryoprotected in 30% 
sucrose for 2-3 d until brains had sunk. Brains were prepared for cryosectioning by cutting 
away 2-3 mm of cerebellum to make a flat surface, before placing in a peel-away mould 
containing OCT medium (Cat # 4583001CTN, Hurst Scientific, WA, Australia) and 
storing at -80°C. Brains were cryostat sectioned into 40 μm thick slices at -16°C with 
each vial containing every sixth slice. Sections were stored at 4°C in 5 mL vials 
containing 0.02% sodium azide in 1x PBS. 
 
2.2.3.2 Neuronal nuclei immunohistochemistry 
To stain for the neuronal marker NeuN, sections were washed in 1x PBS (3 x 10 min) 
prior to incubation in 50% ethanol (20 min at room temperature (RT)). The sections were 
incubated in 3% H2O2 in 50% ethanol for 20 min at 4°C. Sections were then washed in 
1x PBS (3 x 10 min) before blocking in 3% bovine serum albumin (BSA; Cat # BSAS1.0, 
Bovogen Biologicals, VIC, Australia) + 0.25% Triton X-100 in 1x PBS (1 h, RT). 
Sections were subsequently incubated in primary antibody (monoclonal mouse neuronal 
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nucleus (NeuN) antibody (1:250; Cat # MAB377, Millipore, VIC, Australia) diluted in 
blocking solution for 72 h at 4°C. Sections were then washed in 1x PBS (3 x 10 min) 
prior to incubation in secondary antibody (biotinylated chicken anti-mouse IgG (1:250; 
Cat # AB6813, Abcam, VIC, Australia) diluted in blocking solution, overnight at 4°C. 
Avidine-biotin enzyme solution (ABC; Cat # PK-6100, Abacus ALS, QLD, Australia) 
was prepared according to manufacturer’s instructions and left to complex for 30 min at 
RT. Sections were washed in 1x PBS (3 x 10 min) and then incubated in ABC solution 
for 1 h at RT. Next, tissue sections were washed free of ABC in 1x PBS (3 x 10 min). 
3,3’-Diaminobenzidine (DAB) solution (Cat # SK4100, Abacus ALS, QLD, Australia) 
was prepared according to manufacturer’s instructions, by mixing 2 drops of buffer 
solution to 5 mL of MilliQ water, then mixing 4 drops of DAB solution, and finally 
mixing 2 drops of H2O2 solution. Sections were incubated in DAB solution until desired 
staining achieved (approximately 5-10 min). Afterwards, sections were washed in 1x PBS 
(3 x 10 min) prior to being mounted onto SuperFrost-plus glass slides (Cat # SF41296PL, 
Lomb Scientific, NSW, Australia) and cover-slipped with 50% glycerol-gelatin mounting 
medium (Cat # GG1-10X15ML, Merck, MA, USA) diluted in 1x PBS. 
 
2.2.3.3 Fluoro-Jade C histology 
Fluoro-Jade C is a marker of degenerating neurons (Ehara & Ueda, 2009). Free-floating 
sections were mounted onto gelatin-coated glass slides and left to dry at RT for 24 h prior 
to staining. Tissue sections underwent rehydration through descending alcohols. Sections 
were immersed in 100% ethanol for 3 min, then 70% ethanol for 1 min, and distilled water 
for 1 min. Following rehydration steps, the slides were immersed in 0.06% potassium 
permanganate solution for 15 min with gentle shaking. Potassium permanganate solution 
serves to reduce background fluorescence in the tissue sections. Sections were washed in 
distilled water for 1 min and then incubated in 0.001% Fluoro-Jade C (Cat # AG310, 
Millipore, VIC, Australia) staining solution for 30 min in the dark with gentle shaking. 
Sections were washed in distilled water (3 x 1 min). Slides were then removed from the 
staining rack and left to dry overnight in the dark. Once they were completely dry, 
sections were immersed in xylene (3 x 2 min) and cover-slipped with DePex mounting 
medium. 
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2.2.3.4 Cresyl Violet histology 
Free-floating sections were mounted on gelatin-coated glass slides and left to dry at RT 
for 24 h prior to staining. Tissue sections were washed briefly in distilled water then 
placed in 100% ethanol (2 x 3 min). Sections were then immersed in 100% xylene for 15 
min to defat the tissue, and then in 100% ethanol for 10 min. Sections were dehydrated 
in 100% ethanol (2 x 3 min). Sections were then washed in distilled water briefly before 
incubating in 0.1% Cresyl Violet (Cat # C094, ProSciTech, QLD, Australia) solution for 
15 min. Following staining, slides were rinsed briefly in distilled water and again in 70% 
ethanol before dehydration in 100% ethanol (2 x 3 min). Finally, sections were immersed 
briefly in two changes of xylene and immediately cover-slipped with DePex mounting 
medium. 
 
2.2.4 Analysis of cell populations 
2.2.4.1 Stereological quantification of NeuN+ cells 
For quantification of hippocampal neuronal cells, a bright-field microscope (Zeiss 
AxioImager A1, Zeiss, NSW, Australia) was used in conjunction with the optical 
fractionator method in the StereoInvestigator 7 program (MBF Bioscience, VT, USA) to 
perform stereological estimation of NeuN+ cell populations in the dorsal hippocampal 
CA1 and CA3 regions. Following immunohistochemical labelling (2.2.3.2), the optical 
fractionator parameters were determined previously (Abdipranoto-Cowley et al., 2009). 
The parameters were as follows: 
-Guard zone height of 5 μm 
-Optical dissector height of 10 μm 
-Counting frame size of 40 μm x 40 μm 
-Grid size of 84 μm x 60 μm 
Average section thickness was determined by measuring the section thickness of the first 
section at a minimum of 5 sites prior to counting. Using the 10x objective, numerical 
aperture 1.40, the region of interest was traced. Sections were viewed under a 100x 
objective, numerical aperture 1.40, and the first counting frame placed within the grid 
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automatically by the program. Coefficient of error attributable to the sampling was 
calculated according to previously published methods (Gundersen & Jensen, 1987). 
Errors ≤ 0.10 were deemed acceptable. In our experiments, we implemented counting 
rules that could not be affected by shape, size, orientation and distribution of the object/ 
particle. The probe we used was called the optical fractionator displayed as a counting 
frame that was shown as a red and green probe representing rejection and acceptance lines, 
respectively. In order to eliminate experimenter bias, the counting rule used in this study 
was that the top of a cell nucleus (as determined when scrolling through the z-stack) was 
counted if it lay inside the counting frame and didn’t touch an exclusion line. However, 
when the top of a cell nucleus lay predominantly outside of the counting frame but 
touched an inclusion line, but not an exclusion line, then we also counted it. If the top of 
a cell nucleus touched both an inclusion and exclusion line, the exclusion line took 
precedence and the cell was not counted. Every sixth section was prepared from coronal 
brain slices. A total of 5 sections were sampled per brain with AP positions from bregma 
of approximately -1.34, -1.58, -1.82, -2.06, and -2.3 mm.  
 
2.2.4.2 Qualitative analysis of neuronal injury 
Stereology is the most accurate method to quantify total hippocampal neuron numbers in 
the CA1 and CA3 regions. However, throughout the course of optimising the 
experimental parameters for the KA model, as detailed in this chapter, we were dealing 
with large quantities of tissue. Although accurate, stereology is labour and time intensive. 
To overcome this we designed a high-throughput qualitative method ad hoc for rapidly 
screening the magnitude of hippocampal injury following KA administration.  
For qualitative analysis of hippocampal neuronal cells, NeuN+ cell populations in the 
dorsal hippocampal CA1 and CA3 regions were screened and assessed for neuronal injury 
according to a four-point scale (see Table 2.3) using a Leica DM4000 upright bright-field 
microscope (Leica Microsystems, Hesse, Germany) with 5x objective. 
Every sixth section was prepared from coronal brain slices. A total of 5 sections were 
screened and analysed, with the CA1 and CA3 analysed separately. Each section was 
given a qualitative analysis score (Table 2.3), and the sum of the scores from the 5 
sections were taken to achieve a final qualitative analysis score for the CA1 and CA3. 
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The final qualitative analysis score for each animal was graphed. To facilitate reporting 
of the qualitative analysis results, scores of zero (0) referred to no neuron loss, 
(cumulative) scores between 1 and 5 were assigned a ‘mild’ rating, scores between 6 and 
10 were assigned a ‘moderate’ rating, and scores between 11 and 15 were assigned a 
‘severe’ rating.  
 
Table 2.3. Qualitative analysis scoring reference scale. 
Qualitative analysis score Description of damage 
0 No visible cell damage 
1 Minimal visible cell damage, some thinning of CA1 or CA3 neuronal 
layer 
2 Moderate visible cell damage, small patches with no neurons 
3 Extensive visible cell damage, large patches with no neurons 
 
 
 
To validate the accuracy of our qualitative method, we conducted a correlation analysis 
of the relationship between qualitative analysis scores and quantitative stereological 
counts of the same animal retrospectively. Stereological counts of NeuN+ cells for each 
animal were plotted against the sum of qualitative analysis scores for each animal (Figure 
2.1). Spearman’s correlation revealed the qualitative scores had a significant negative 
correlation with NeuN+ cells from the same animals in both the CA1 (r(32) = -0.5674, p = 
0.0007) and CA3 (r(32) = -0.7978, p < 0.0001). Additionally, box-and-whisker plots were 
plotted for the CA1 and CA3 with a group interval of 5, illustrating a trend of decreased 
NeuN+ cells with increasing qualitative scores. Together, these results suggest our 
qualitative method is a useful high-throughput approach to rapidly assess neuronal 
damage.  
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Throughout this chapter, we utilised the qualitative method for analysis of experiments 
where stereology was neither practical nor possible.  
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Figure 2.1. Qualitative analysis results correlate with corresponding stereological results. (A) Spearman’s 
correlation of CA1 qualitative analysis scores and corresponding stereological counts for each animal. (B) Spearman’s 
correlation of CA3 qualitative analysis scores and corresponding stereological counts for each animal. (C) Box-and 
whisker-plots of CA1 qualitative analysis scores and corresponding stereological counts of NeuN+ cells for each animal, 
with a group interval of 5. (D) Box-and-whisker plots of CA3 qualitative analysis scores and corresponding 
stereological counts of NeuN+ cells for each animal, with a group interval of 5. 
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2.2.4.3 Image acquisition 
All non-fluorescent images were obtained using a Leica DM4000 upright bright-field 
microscope (Leica Microsystems, Hesse, Germany) equipped with DFC450 digital high 
resolution colour camera. Images were acquired using 5x dry objectives and LAS V4.9 
software, and were subsequently processed and analysed using Adobe Photoshop CS6 
(Adobe, CA, USA). Fluorescent Fluoro-Jade C images were obtained using a Leica 
DM5500 upright fluorescence microscope (Leica Microsystems, Hesse, Germany) 
equipped with DFC310Fx sensitive monochrome digital camera and fluorescence 
detection of dapi, greens, reds and far-reds. Images were acquired using 5x dry objectives 
and LAS X software, and were subsequently processed and analysed using Adobe 
Photoshop CS6. 
 
2.2.5 Statistical analysis 
Statistical analyses were performed using GraphPad Prism Version 7.0 (GraphPad 
Software, Inc), with the exception of data presented in Figure 2.2. For all other data 
presented in this chapter, data were tested for normality using the Shapiro-Wilks test. For 
normally distributed data, differences between means were assessed, as appropriate, by 
either Student’s t-test or two-way analysis of variance (ANOVA). Where Student’s t-test 
was performed, variances were assessed by F-test for equality of variances. Welch’s 
correction (Welch’s t-test) was applied for data with significant differences in variance. 
Where two-way ANOVA was performed, Bonferroni’s post-hoc analysis was applied. 
For all other non-normally distributed data, Mann-Whitney’s U test was performed and 
median (Mdn) values were reported in addition to mean and standard error of the mean 
(SEM). For all graphical representations, data are presented as mean with SEM, with the 
exception of seizure score data, where mean with standard deviation (SD) are presented. 
This is because for the seizure score data, we were interested in quantifying the variability 
of seizure scores at each observation time point for all KA-injected animals, rather than 
quantifying the uncertainty of the mean itself. 
As data presented in Figure 2.2 are from unpublished previous studies in our group, these 
data were analysed using SPSS Version 20 (SPSS Inc., Chicago, IL, USA). For Figure 
2.2, data were tested for normality using Levene’s test for homogeneity of variance. For 
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normally distributed data of more than two variables, differences between means were 
assessed by one-way ANOVA with Bonferroni’s post-hoc analysis. For non-normally 
distributed data of more than two variables, differences between means were assessed by 
one-way ANOVA with Dunnett’s post-hoc. For all other normally distributed data in 
Figure 2.2, differences between means were assessed by two-tailed independent samples 
(Student’s) t-test. 
For all statistical tests, a p value of ≤ 0.05 was considered to be significant.  
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2.3 Results 
2.3.1 Neuron repopulation following acute hippocampal injury 
Seizure-induced neurogenesis has been well documented in the literature (Kokaia, 2011). 
While the majority of studies focus on the SGZ/ DG region, few studies have focused on 
areas outside of these regions. The potential for neuronal repopulation in the CA1 and 
CA3 neuronal layers has previously been demonstrated in prior studies by our group 
(Figure 2.2; Abdipranoto-Cowley et al., 2009). 
Initially we aimed to replicate experiments carried out in prior studies by our group. In 
these studies (presented in Figure 2.2), animals received either 1 mg/mL KA or PBS and 
tissue was collected at 2, 4, 6 and 8 weeks post-injury (wpi). These time points were 
chosen as the process of adult neurogenesis has previously been shown to require 
approximately 4-7 weeks in the adult rodent brain (Jessberger & Kempermann, 2003; 
Kempermann et al., 2004; van Praag et al., 2002). The number of NeuN+ cells in the CA1 
and CA3 were quantified via stereology. A one-way ANOVA revealed no significant 
differences in the numbers of NeuN+ cells in PBS-injected animals across the time points 
studied (CA1: F(3,16) = 2.60, p > 0.05; CA3: F(3,16) = 1.41, p > 0.05; Figure 2.2B); therefore, 
data from PBS-injected animals were collapsed. A one-way ANOVA revealed significant 
differences in the number of NeuN+ cells in the CA1 (F(4,35) = 27.12, p < 0.0001; Figure 
2.2C-D) and CA3 (F(4,35) = 23.12, p < 0.0001; Figure 2.2C, E). Post-hoc analysis using 
Bonferroni’s test to correct for multiple comparisons revealed a significant decrease in 
NeuN+ cells at 2 (p < 0.001), 4 (p < 0.001) and 6 (p < 0.001) wpi compared to PBS-
injected animals. Additionally, the number of NeuN+ cells in the CA1 at 8 wpi was 
significantly different from 2 (p = 0.002) and 4 wpi (p < 0.001), suggesting recovery of 
the CA1 neuronal population at 8 wpi. Post-hoc analysis using Dunnett’s test to correct 
for multiple comparisons revealed a significant decrease in the CA3 neuronal population 
at 2 (p = 0.002) and 4 wpi (p < 0.001) compared to PBS-injected animals. Furthermore, 
the number of NeuN+ cells in the CA3 at 6 (p = 0.122) and 8 wpi (p = 0.340) did not 
significantly differ from PBS-injected animals. The observed neuronal loss and 
subsequent recovery was restricted to the side ipsilateral to KA injection as Student’s t-
test revealed the number of NeuN+ cells in the contralateral CA1 and CA3 of KA-injected 
animals were not significantly different to PBS-injected animals at both 4 (CA1: t(8) = 
0.1906, p = 0.8536; CA3: t(8) = 0.4911, p = 0.6365) and 8 wpi (CA1: t(8) = 1.141, p = 
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0.2867; CA3: t(8) = 1.552, p = 0.1593; Figure 2.2F-G). These results indicate KA injection 
results in severe neuronal cell loss in the CA1 and CA3 regions on the side ipsilateral to 
KA injury, which is repopulated by 8 wpi.  
 
Chapter 2: Kainic acid model of neuronal injury 
 
47 
 
Chapter 2: Kainic acid model of neuronal injury 
 
48 
Figure 2.2. Recovery of hippocampal neuron population ipsilateral to KA-induced neuronal injury. (A) 
Experimental protocol. (B) Stereological quantification of NeuN+ cells in the CA1 and CA3 of PBS-injected animals 
at 2, 4, 6 and 8 weeks post-injury (wpi; n = 5/group). (C) Representative images of hippocampal neuron layer in PBS- 
and KA-injected animals at 2 and 8 wpi. (D) Stereological quantification of NeuN+ cells in the ipsilateral CA1 of PBS- 
and KA-injected animals at 2, 4, 6 and 8 wpi. (E) Stereological quantification of NeuN+ cells in the ipsilateral CA3 of 
PBS- and KA-injected animals at 2, 4, 6 and 8 wpi. (F) Stereological quantification of NeuN+ cells in the contralateral 
CA1 of PBS- and KA-injected animals at 4 and 8 wpi. (G) Stereological quantification of NeuN+ cells in the 
contralateral CA3 of PBS- and KA-injected animals at 4 and 8 wpi. All values represent the mean ± standard error of 
the mean (SEM). **p < 0.01, ***p < 0.001, #p < 0.01. n = 20 for PBS groups and n = 5 for KA groups. The data 
represented in this figure were generated by Richard Tan and Lyndsey Konen. 
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2.3.2 1 mg/mL KA produces neuron loss at 2 and 4 weeks post-injury with no 
recovery of hippocampal neuron population at 8 weeks post-injury 
As illustrated in Figure 2.2 above, unpublished data from our group showed exciting 
evidence for the brain’s ability to repopulate following injury to the hippocampus (Figure 
2.2). This result provided the rationale for pursuing the experimental questions 
subsequently detailed in Chapter 3, which were conducted concurrently with the 
experiments of the present chapter. 
In the following experiment we attempted to first replicate the preliminary results in the 
hands of a different experimenter (Yu Shen Yin) to confirm that the initial results could 
be repeated in the hands of a different investigator. KA was purchased from the same 
supplier as used for the preliminary experiments (Cat # 58002-62-3, Sigma-Aldrich; 
Table 2.1) and was diluted to the desired concentration (1 mg/mL). Animals received 
either 1 mg/mL KA or PBS, via ICV injection and tissue was collected at 2, 4 and 8 wpi 
(Figure 2.3A).  
5 replicates per time point were allocated to each PBS group, while 7 replicates per time 
point were allocated to each KA group. Of the 43 animals entering the study, 1 animal 
died prematurely in the 2 wpi PBS-injected group and 7 animals died prematurely in the 
2 wpi KA-injected group (Table 2.4). This was unexpected and we predict it may have 
been due to researcher error of either contamination of the injection syringe, or 
contamination of the KA solution as the premature deaths were restricted to animals 
treated on the same surgery day (see Appendix Table 6.2). Thus, an additional 7 replicates 
were added to the 2 week time point group. Following ICV injection, KA administration 
resulted in consistent, mild seizure-like responses including circling, rearing and falling 
(seizure score 3) over the 2 h monitoring period (Figure 2.3B).  
The number of NeuN+ cells in the CA1 and CA3 ipsilateral to injury were quantified via 
stereology. NeuN+ cells in the CA1 and CA3 contralateral to injury were not assessed as 
they had been previously shown to reveal no difference between PBS- and KA-injected 
animals (Figure 2.2F-G). In the CA1, a two-way ANOVA revealed no overall effect of 
time on the number of NeuN+ cells (F(1,8) = 1.815, p = 0.2148), while the overall effect of 
treatment on the number of NeuN+ cells was significant (F(1,8) = 7.996, p = 0.0222; Figure 
2.3C-D). There was no significant interaction of time and treatment on the number of 
NeuN+ cells in each group (F(1,8) = 0.4541, p = 0.5194). Post-hoc analysis using 
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Bonferroni’s test to correct for multiple comparisons revealed no significant difference in 
NeuN+ cells between KA- and PBS-injected animals at 2 (p = 0.9976) or 4 wpi (p = 
0.2301). Additionally, there was no significant difference in NeuN+ cells between 2 and 
4 wpi in KA- (p > 0.9999) or PBS-injected animals (p > 0.9999). 
In the CA3, a two-way ANOVA revealed a significant overall effect of time (F(1,8) = 12.01, 
p = 0.0085) and treatment (F(1,8) = 22.26, p = 0.0015) on the number of NeuN
+ cells 
(Figure 2.3C, E). There was no significant interaction of time and treatment on the number 
of NeuN+ cells in each group (F(1,8) = 2.355, p = 0.1635). Post-hoc analysis using 
Bonferroni’s test to correct for multiple comparisons revealed no significant difference in 
NeuN+ cells of KA-injected animals between 2 and 4 wpi (p > 0.9999). Unexpectedly, 
PBS-injected animals showed a significant difference in NeuN+ cells between 2 and 4 
wpi (p = 0.0460). Compared to PBS-injected animals, KA-injected animals showed a 
non-significant decrease in NeuN+ cells at 2 wpi (p = 0.3268), while there was a 
significant decrease in NeuN+ cells at 4 wpi (p = 0.0133). 
At 8 wpi, KA-injected animals exhibited severe neuron loss across both the CA1 and CA3 
regions when compared visually to PBS-injected animals, suggesting absence of neuronal 
repopulation (Figure 2.3C). Due to time constraints, the need to move forward with 
subsequent experiments, and lack of repopulation qualitatively observed in KA-injected 
animals, the 8 wpi experimental groups were not quantified. Thus, the data from this 
experiment showed a lack of ability to replicate the findings observed in prior studies 
(2.3.1) from our group. 
 
Table 2.4. Mortality data for mice injected with either PBS or KA. 
 
 Total animals 
entered in 
study 
Premature 
mortality 
(0-1 week) 
Premature 
mortality 
(1-8 weeks) 
Removed 
(tissue processing 
complications) 
Total n’s 
processed 
Total n’s 
counted 
PBS 15 (n = 5 per 
time point) 
2 week = 1 0 0 2 week = 4 
4 week = 4 
8 week = 4 
2 week = 3 
4 week = 3 
KA 28 (n = 7-14 
per time point) 
2 week = 7 0 0 2 week = 5 
4 week = 4 
8 week = 4 
2 week = 3 
4 week = 3 
Total 43 8 0 0 25 12 
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Figure 2.3. 1 mg/mL KA produces neuron loss at 2 and 4 weeks post-injury with no recovery of hippocampal 
neuron population at 8 weeks post-injury. (A) Experimental protocol. (B) Seizure score of all KA-injected animals 
entered into study, monitored over 2 h following waking from anaesthesia. (C) Representative images of hippocampal 
neuron layer in PBS- or KA-injected animals at 2, 4 and 8 weeks post-injury (wpi). (D) Stereological quantification of 
NeuN+ cells in the CA1 of PBS- and KA-injected animals at 2 and 4 wpi. (E) Stereological quantification of NeuN+ 
cells in the CA3 of PBS- and KA-injected animals at 2 and 4 wpi. All values in (B) represent the mean ± standard 
deviation (SD). All other values represent the mean ± SEM. *p < 0.05. n = 3 for all groups. 
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2.3.3 0.5 mg/mL KA produces visible hippocampal neuron loss and may facilitate 
neuronal repopulation 
Our previous results showed that 1 mg/mL KA produced profound hippocampal neuronal 
loss in the absence of repopulation at 8 wpi (Figure 2.3), in contrast to findings observed 
in preliminary studies from our group (Figure 2.2). Two possible contributing factors 
could have been researcher inexperience in performing stereotaxic surgeries and 
variability in KA potency from the supplier (Sigma). To address the first possibility, a 
researcher experienced in stereotaxic surgery (Richard Tan, who also conducted the 
surgeries for Figure 2.2) performed stereotaxic injections for the following experiment 
(Figure 2.4). Second, to investigate the effect of KA dosage on neuronal loss, we analysed 
the effect of varying KA concentrations. The purpose of this was to observe whether a 
lower KA dose could produce hippocampal neuron loss and subsequent repopulation. 
KA (Sigma, see Table 2.1 for details) was diluted to desired concentrations (0.5 mg/mL, 
0.75 mg/mL, 1 mg/mL). Animals were administered ICV injections of 0.5 mg/mL, 0.75 
mg/mL, 1 mg/mL KA or PBS, and tissue was collected at 2 and 8 wpi (Figure 2.4A). Two 
animals died prematurely within the first week following KA injury (Table 2.5). KA 
concentrations of 0.5 mg/mL, 0.75 mg/mL and 1 mg/mL all resulted in consistent, mild 
seizure-like responses including circling, rearing and falling (seizure score 3) over the 2 
h monitoring period (Figure 2.4B), which did not appear to differ between doses.  
A qualitative assessment of NeuN+ neurons in the CA1 and CA3 was carried out using 
the qualitative analysis method detailed in 2.2.4.2. As shown in Figure 2.1, a higher 
qualitative score significantly correlates with lower numbers of NeuN+ cells (analysed 
using stereology). For pragmatic purposes, a minimum of 3 n’s were designated for each 
group, however the data were not statistically analysed as we were interested in observing 
the trends in qualitative scores between groups rather than comparing absolute means 
between groups. 
Compared to PBS-injected animals (2 wpi: mean = 0, SEM = 0; 8 wpi: mean = 0, SEM = 
0), qualitative analysis of CA1 region NeuN+ cells from 1 mg/mL KA-injected animals 
revealed moderate neuron loss at 2 wpi (mean = 6.333, SEM = 3.756) and severe neuron 
loss at 8 wpi (mean = 11.67, SEM = 2.404; Figure 2.4C-D). Qualitative analysis of CA1 
region NeuN+ neurons from 0.75 mg/mL KA-injected animals revealed neuron loss was 
severe at 2 wpi (mean = 15, SEM = 0) and moderate at 8 wpi (mean = 9.333, SEM = 
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2.028). Lastly, KA concentration of 0.5 mg/mL produced mild neuron loss at 2 wpi (mean 
= 5.667, SEM = 4.702) and no neuron loss at 8 wpi (mean = 0, SEM = 0). 
Compared to PBS-injected animals (2 wpi: mean = 1, SEM = 0.5774; 8 wpi: mean = 
1.333, SEM = 0.8819), qualitative analysis of CA3 region NeuN+ cells from 1 mg/mL 
KA-injected animals revealed moderate neuron loss at 2 wpi (mean = 9.333, SEM = 4.256) 
and severe neuron loss at 8 wpi (mean = 12, SEM = 0.5774; Figure 2.4C, E). Qualitative 
analysis of CA3 region NeuN+ cells from 0.75 mg/mL KA-injected animals revealed 
neuron loss was severe at 2 (mean = 13.67, SEM = 0.8819) and 8 wpi (mean = 11.33, 
SEM = 0.8819). Finally, KA concentration of 0.5 mg/mL produced mild neuron loss at 2 
(mean = 5.333, SEM = 1.856) and 8 wpi (mean = 1.5, SEM = 0.5). 
The conclusions drawn from this experiment are twofold. Firstly, researcher inexperience 
was unlikely to have contributed to the lack of neuronal repopulation seen in the previous 
experiment (2.3.2) as in the present experiment, 1 mg/mL KA concentration again failed 
to replicate previous data (Figure 2.2) and produced neuron loss at 2 and 8 wpi. Secondly, 
a lower concentration of KA, such as 0.5 mg/mL, may be a more useful tool for 
investigating hippocampal neuronal injury and neuronal repopulation as this KA 
concentration produced neuron loss at 2 wpi but little neuron loss at 8 wpi that appeared 
similar to PBS. Thus, in the next experiment, we investigated lower KA doses in more 
detail. 
 
Table 2.5. Mortality data for mice injected with either PBS or KA (0.5 mg/mL, 0.75 mg/mL, 
or 1 mg/mL). 
 Total 
animals 
entered in 
study 
Premature 
mortality 
(0-1 week) 
Premature 
mortality 
(1-8 weeks) 
Removed 
(tissue processing 
complications) 
Total n’s 
analysed 
PBS 10 0 0 0 2 week = 3 
8 week = 3 
0.5 mg/mL 
KA 
10 0 0 0 2 week = 3 
8 week = 3 
0.75 mg/mL 
KA 
10 1 0 0 2 week = 3 
8 week = 3 
1 mg/mL KA 13 1 0 0 2 week = 3 
8 week = 3 
Total 43 2 0 0 24 
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Figure 2.4. 0.5 mg/mL but not 0.75 mg/mL or 1 mg/mL, KA produces visible hippocampal neuronal loss and 
suggests neuronal repopulation. (A) Experimental protocol. (B) Seizure score of all KA-injected animals entered into 
study, monitored over 2 h following waking from anaesthesia. (C) Representative images of hippocampal neuron layer 
in PBS- and KA-injected animals at 2 and 8 wpi. (D) Qualitative scores of CA1 region NeuN+ cells in PBS- and KA-
injected animals at 2 and 8 wpi. (E) Qualitative scores of CA3 region NeuN+ cells in PBS- and KA-injected animals at 
2 and 8 wpi. All values in (B) represent the mean ± SD. All other values represent the mean ± SEM. n = 3 for all groups.  
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2.3.4 KA concentrations below 0.5 mg/mL KA do not produce visible hippocampal 
neuron loss 
In the previous results, we showed a KA concentration of 0.5 mg/mL was sufficient to 
produce visible neuronal loss in the hippocampal CA1 and CA3 regions at 2 wpi and little 
neuron loss at 8 wpi compared to PBS-injected animals (Figure 2.4). However, due to the 
qualitative nature of the analysis, we wanted to replicate the experiment to show 
reliability and consistency of the dose across separate trials. Additionally, as previous 
studies from our group (Figure 2.2) have shown neuronal loss and repopulation at double 
this concentration, we began to question the consistency and reliability of the KA 
obtained from our supplier (Sigma). We theorised that the production of the KA may have 
changed over the last few years as the results we were observing were highly variable and 
inconsistent with previous investigations (Figure 2.2; Abdipranoto-Cowley et al., 2009). 
We contacted the supplier (Sigma) regarding our concerns with the KA who confirmed 
their product, nor the method of producing it, had not been modified. Thus, we 
hypothesised that there may have been a miscalculation of the weight stated on the reagent 
vial by the supplier. Our aim for the present experiment was therefore twofold: Firstly, 
we wanted to investigate whether concentrations lower than 0.5 mg/mL would produce 
visible hippocampal neuronal loss, in order to find the point at which neuronal loss was 
no longer qualitatively detectable. Secondly, we wanted to assess the reliability of 
separate batches of KA, ordered from the same company, with the aim of producing 
consistent results. 
Two separate batches of KA were purchased from Sigma (designated here as Trial 1 and 
Trial 2; see Table 2.1 for details) and KA was diluted to desired concentrations (0.05 
mg/mL, 0.1 mg/mL, 0.3 mg/mL, 0.5 mg/mL). Animals received ICV injections of 0.05 
mg/mL, 0.1 mg/mL, 0.3 mg/mL or 0.5 mg/mL KA or PBS and tissue was collected at 2 
wpi (Figure 2.5A). One animal in total died prematurely prior to study end (0.3 mg/mL 
KA; Table 2.6). KA concentrations of 0.5 mg/mL resulted in consistent, mild seizure-like 
responses including circling, rearing and falling (seizure score 3) over the 2 h monitoring 
period (Figure 2.5B). KA concentrations of 0.05 mg/mL, 0.1 mg/mL and 0.3 mg/mL also 
resulted in mild seizure-like response but returned to baseline within 2 h.  
A qualitative assessment of NeuN+ neurons in the CA1 and CA3 was carried out using 
the qualitative analysis method detailed in 2.2.4.2. As shown in Figure 2.1, a higher 
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qualitative score correlates with lower NeuN+ neurons. For pragmatic purposes, a 
minimum of 3 replicates were designated for each KA group, as these were our 
experimental groups of interest. PBS groups were designated a minimum of 2 replicates 
as the previous experiment (2.3.3) showed the expected minimal neuron loss in these 
groups. The data were not statistically analysed as we were interested in observing the 
trends in qualitative scores between groups rather than comparing absolute means 
between groups. 
Across both trials, qualitative analysis of CA1 region NeuN+ cells in KA-injected animals 
revealed no neuron loss at KA concentrations of 0.05 mg/mL (Trial 1: mean = 0, SEM = 
0; Trial 2: mean = 0, SEM = 0) and 0.1 mg/mL (Trial 1: mean = 0, SEM = 0; Trial 2: 
mean = 0, SEM = 0) at 2 wpi compared to PBS-injected animals (Trial 1: mean = 0, SEM 
= 0; Trial 2: mean = 0, SEM = 0; Figure 2.5C-D). 0.3 mg/mL and 0.5 mg/mL KA-injected 
animals both displayed mild neuron loss across both trials (0.3 mg/mL Trial 1: mean = 3, 
SEM = 3 and Trial 2: mean = 0.6667, SEM = 0.6667; 0.5 mg/mL Trial 1: M = 0.75, SEM 
= 0.75 and Trial 2: mean = 3.75, SEM = 3.75). 
Qualitative analysis of CA3 region NeuN+ cells in KA-injected animals showed mild 
neuron loss at KA concentrations of 0.05 mg/mL (Trial 1: mean = 0.75, SEM = 0.25; 
Trial 2: mean = 1.75, SEM = 1.031), 0.1 mg/mL (Trial 1: mean = 2, SEM = 1.155; Trial 
2: mean = 2.25, SEM = 0.8539), and 0.3 mg/mL (Trial 1: mean = 2.333, SEM = 1.202; 
Trial 2: mean = 2.667, SEM = 1.202) across both trials at 2 wpi compared to PBS-injected 
animals (Trial 1: mean = 3, SEM = 1; Trial 2: mean = 0, SEM = 0; Figure 2.5C, E). 0.5 
mg/mL KA-injected animals revealed moderate neuron loss across both trials (Trial 1: 
mean = 7, SEM = 1.683; Trial 2: mean = 9.5, SEM = 1.848). 
The conclusions drawn from this experiment are twofold: Firstly, KA concentrations 
below 0.5 mg/mL do not produce visible (or extremely low) hippocampal neuronal loss. 
Secondly, KA concentrations of 0.5 mg/mL produce variable neuron loss between trials. 
Interestingly, the severity of neuron loss in 0.5 mg/mL KA-injected animals was more 
severe in trial 2 compared to trial 1, suggesting KA concentrations of 0.5 mg/mL do not 
produce reliable or consistent neuron loss between trials. Furthermore, compared to the 
results from 0.5 mg/mL KA-injected animals observed in the previous experiment (Figure 
2.4), the neuron loss in trial 2 was equally severe. It was clear Sigma KA was not 
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producing reliable and consistent neuron loss between trials at concentrations of 0.5 
mg/mL. 
 
Table 2.6. Mortality data for mice injected with either PBS or KA (0.05 mg/mL, 0.1 mg/mL, 
0.3 mg/mL, or 0.5 mg/mL dose). 
 Total 
animals 
entered in 
study 
Premature 
mortality 
(0-1 week) 
Premature 
mortality 
(1-2 weeks) 
Removed 
(tissue processing 
complications) 
Total n’s 
analysed 
PBS 4 0 0 0 Trial 1 = 2 
Trial 2 = 2 
0.05 mg/mL KA 8 0 0 0 Trial 1 = 4 
Trial 2 = 4 
0.1 mg/mL KA 8 0 0 1 Trial 1 = 3 
Trial 2 = 4 
0.3 mg/mL KA 8 0 1 1 Trial 1 = 3 
Trial 2 = 3 
0.5 mg/mL KA 8 0 0 0 Trial 1 = 4 
Trial 2 = 4 
Total 36 0 1 2 33 
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Figure 2.5. KA concentrations below 0.5 mg/mL KA produce little to no visible hippocampal neuronal loss. (A) 
Experimental protocol. (B) Seizure score of all KA-injected animals entered into study, monitored over 2 h following 
waking from anaesthesia. (C) Representative images of hippocampal neuron layer in PBS- and KA-injected animals at 
2 wpi. (D) Qualitative scores of CA1 region NeuN+ cells in PBS- and KA-injected animals at 2 wpi. (E) Qualitative 
scores of CA3 region NeuN+ cells in PBS- and KA-injected animals at 2 wpi. All values in (B) represent the mean ± 
SD. All other values represent the mean ± SEM. n = 2 for PBS groups and n = 3-4 for KA groups. 
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2.3.5 1 mg/mL of calbiochem KA produces visible hippocampal neuron loss at 2 
weeks post-injury, and this loss appears lessened at 8 weeks post-injury 
Our previous results showed 0.5 mg/mL of KA purchased from Sigma produced highly 
variable hippocampal neuron loss at 2 wpi both within and between trials, suggesting the 
KA sourced from Sigma may be unreliable. Our aim for the present experiment was 
therefore twofold: firstly, we wanted to trial different suppliers of KA to determine if 
alternative sources could produce more consistent hippocampal injuries at 2 wpi. 
Secondly, we wanted to determine a KA concentration that would yield consistent 
hippocampal neuron loss at 2 wpi, yet also facilitate neuronal repopulation at 8 wpi. 
KA was sourced from four different suppliers (Tocris, Sigma, Abcam, calbiochem; see 
Table 2.1 for details) and was diluted to desired concentrations (0.5 mg/mL, 1 mg/mL). 
Animals received ICV injections of 0.5 mg/mL, 1 mg/mL KA (Tocris, Sigma, Abcam or 
calbiochem) or PBS and tissue was collected at 2 and 8 wpi (Figure 2.6A). Four animals 
died prematurely following administration of 1 mg/mL Tocris KA while three died within 
the first week following KA administration and one died prior to study end (Table 2.7). 
Calbiochem KA concentrations of 0.5 mg/mL resulted in consistent, mild seizure-like 
responses including circling, rearing and falling (seizure score 3) over the 2 h monitoring 
period, while Tocris, Sigma and Abcam all produced more variable responses after the 
initial 30 min period (seizure scores 1-3; Figure 2.6B). At a KA concentration of 1 mg/mL, 
Abcam and calbiochem KA also resulted in consistent, mild seizure-like responses 
including circling, rearing and falling over the 2 h monitoring period, whereas Tocris and 
Sigma 1 mg/mL KA produced more variable responses after the initial 60 min period 
(seizure scores 2-3; Figure 2.6C).  
A qualitative assessment of NeuN+ neurons in the CA1 and CA3 was carried out 
according to the qualitative analysis method detailed in 2.2.4.2. As shown in Figure 2.1, 
a higher qualitative score significantly correlates with lower numbers of NeuN+ cell 
numbers (analysed using stereology). For pragmatic purposes, a minimum of 5 replicates 
were designated for each KA group, as these were our experimental groups of interest. 
PBS groups were designated a minimum of 3 replicates as the previous experiment (2.2.4) 
showed the expected minimal neuron loss in these groups.  The data were not statistically 
analysed as we were interested in observing the trends in qualitative scores between 
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groups rather than comparing absolute means between groups. Nevertheless, the patterns 
observed enabled us to draw useful conclusions, as described below. 
Compared to PBS-injected animals (2 wpi: mean = 0.3333, SEM = 0.3333; 8 wpi: mean 
= 0, SEM = 0), qualitative analysis of CA1 region NeuN+ cells from 0.5 mg/mL KA-
injected animals revealed Tocris KA produced moderate neuron loss at 2 (mean = 5.6, 
SEM = 2.731) and 8 wpi (mean = 7.8, SEM = 3.247; Figure 2.6D, F). 0.5 mg/mL Sigma 
KA produced no neuron loss at 2 wpi (mean = 0, SEM = 0) and mild neuron loss at 8 wpi 
(mean = 0.4, SEM = 0.4), while 0.5 mg/mL Abcam KA produced no neuron loss at 2 
(mean = 0, SEM = 0) and 8 wpi (mean = 0, SEM = 0). In contrast, 0.5 mg/mL calbiochem 
KA produced mild neuron loss at 2 wpi (mean = 3, SEM = 3) and no neuron loss at 8 wpi 
(mean = 0, SEM = 0). 
Qualitative analysis of CA3 region NeuN+ cells revealed moderate neuron loss in 0.5 
mg/mL Tocris KA-injected animals at 2 (mean = 9.8, SEM = 2.818) and 8 wpi (mean = 
9.6, SEM = 3.341) compared to PBS-injected animals (2 wpi: mean = 2, SEM = 2; 8 wpi: 
mean = 1, SEM = 1; Figure 2.6D, G). Unlike Tocris KA, 0.5 mg/mL of Sigma, Abcam 
and calbiochem KA all produced only mild neuron loss at both 2 wpi (Sigma: mean = 2, 
SEM = 0.7071; Abcam: mean = 3.2, SEM = 1.2; calbiochem: mean = 1, SEM = 1) and 8 
wpi (Sigma: mean = 0.8, SEM = 0.3742; Abcam: mean = 2.4, SEM = 0.4; calbiochem: 
mean = 2.2, SEM = 0.8). 
Compared to PBS-injected animals (2 wpi: mean = 0, SEM = 0; 8 wpi: mean = 0, SEM = 
0), qualitative analysis of CA1 region NeuN+ cells in 1 mg/mL KA-injected animals 
revealed Tocris KA produced severe neuron loss at 2 (mean = 12.25, SEM = 0.8539) and 
8 wpi (mean = 13, SEM = 2; Figure 2.6E, H). However, 1 mg/mL Abcam KA produced 
moderate neuron loss at 2 wpi (mean = 7.6, SEM = 3.059) and only mild neuron loss at 8 
wpi (mean = 2, SEM = 1.304). Furthermore, 1 mg/mL of Sigma and calbiochem KA both 
produced mild neuron loss at 2 (Sigma: mean = 3.8, SEM = 2.853; calbiochem: mean = 
4.8, SEM = 2.577) and 8 wpi (Sigma: mean = 2.6, SEM = 2.112; calbiochem: mean = 2.4, 
SEM = 1.03). 
Qualitative analysis of CA3 region NeuN+ cells revealed severe neuron loss in 1 mg/mL 
Tocris KA-injected animals at 2 wpi (mean = 14.75, SEM = 0.25) but moderate neuron 
loss at 8 wpi (mean = 9, SEM = 4) compared to PBS-injected animals (2 wpi: mean = 
0.6667, SEM = 0.6667; 8 wpi: mean = 0, SEM = 0; Figure 2.6E, I). Similarly, 1 mg/mL 
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Sigma KA produced moderate neuron loss at 2 (mean = 6.6, SEM = 2.786) and 8 wpi 
(mean = 6.2, SEM = 1.393). However, 1 mg/mL Abcam KA also produced moderate 
neuron loss at 2 wpi (mean = 9.6, SEM = 1.166) but only mild neuron loss at 8 wpi (mean 
= 5.4, SEM = 2.112). Interestingly, 1 mg/mL calbiochem KA produced severe neuron 
loss at 2 wpi (mean = 11.2, SEM = 0.4899) but only mild neuron loss at 8 wpi (mean = 
5.4, SEM = 0.6782).  
Comparatively, 1 mg/mL calbiochem KA showed the largest difference in qualitative 
scores between 2 and 8 wpi in the CA3 and a reduction in qualitative scores in both the 
CA1 and CA3 from 2 wpi to 8 wpi. Qualitative scores of 1 mg/mL Sigma KA were similar 
across 2 and 8 wpi in both CA1 and CA3 regions. Based on the results of the qualitative 
analysis a concentration of 1 mg/mL KA from Abcam and calbiochem both appeared to 
produce visible neuron loss at 2 wpi and a neuronal layer not noticeably different to PBS-
injected animals at 8 wpi across both the CA1 and CA3; although, Abcam KA appeared 
more variable. 
 
Table 2.7. Mortality data for mice injected with either PBS or KA (0.5 mg/mL or 1 mg/mL 
dose) from four different suppliers: Tocris, Sigma, Abcam, or calbiochem. 
 Total animals entered 
in study 
Premature 
mortality 
(0-1 week) 
Premature 
mortality 
(1-8 weeks) 
Removed 
(tissue 
processing 
complications) 
Total n’s 
analysed 
PBS 12 (n = 3 per dose 
per time point) 
0 0 0 2 week = 6 
8 week = 6 
0.5 mg/mL 
Tocris KA 
10 (n = 5 per time 
point) 
0 0 0 2 week = 5 
8 week = 5 
0.5 mg/mL 
Sigma KA 
10 (n = 5 per time 
point) 
0 0 0 2 week = 5 
8 week = 5 
0.5 mg/mL 
Abcam KA 
10 (n = 5 per time 
point) 
0 0 0 2 week = 5 
8 week = 5 
0.5 mg/mL 
calbiochem 
KA 
10 (n = 5 per time 
point) 
0 0 0 2 week = 5 
8 week = 5 
1 mg/mL 
Tocris KA 
10 (n = 5 per time 
point) 
3 1 0 2 week = 4 
8 week = 2 
1 mg/mL 
Sigma KA 
10 (n = 5 per time 
point) 
0 0 0 2 week = 5 
8 week = 5 
1 mg/mL 
Abcam KA 
10 (n = 5 per time 
point) 
0 0 0 2 week = 5 
8 week = 5 
1 mg/mL 
calbiochem 
KA 
10 (n = 5 per time 
point) 
0 0 0 2 week = 5 
8 week = 5 
Total 92 3 1 0 88 
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Figure 2.6. 1 mg/mL calbiochem KA produces visible hippocampal neuron loss at 2 weeks post-injury, and this 
loss appears lessened at 8 weeks post-injury. (A) Experimental protocol. (B and C) Seizure scores of all KA-injected 
animals entered into study that received 0.5 mg/mL (B) or 1.0 mg/mL (C) KA, monitored over 2 h following waking 
from anaesthesia. (D) Representative images of hippocampal neuron layer in PBS- and 0.5 mg/mL KA-injected animals 
at 2 and 8 wpi. (E) Representative images of hippocampal neuron layer in PBS- and 1 mg/mL KA-injected animals at 
2 and 8 wpi. (F and G) Qualitative scores of CA1 (F) and CA3 (G) region NeuN+ cells in PBS- and 0.5 mg/mL KA-
injected animals at 2 and 8 wpi. (H and I) Qualitative scores of CA1 (H) and CA3 (I) region NeuN+ cells in PBS- and 
1 mg/mL KA-injected animals at 2 and 8 wpi. All values in (B) and (C) represent the mean ± SD. All other values 
represent the mean ± SEM. n = 3 for PBS groups and n = 2-5 for KA groups.  
Chapter 2: Kainic acid model of neuronal injury 
 
66 
The results of the qualitative analysis demonstrated 1 mg/mL Abcam and calbiochem KA 
to be promising, with a decrease in qualitative scores from 2 to 8 wpi across both the CA1 
and CA3 regions. To take our analysis further, we used stereology to quantify the number 
of NeuN+ cells in the CA1 and CA3 of 1 mg/mL calbiochem KA-injected or PBS-injected 
animals. The calbiochem experimental group was chosen over the Abcam experimental 
group as 1 mg/mL calbiochem KA resulted in less variable neuron loss compared to 1 
mg/mL Abcam KA. 
In the CA1, a two-way ANOVA revealed a significant overall effect of time (F(1,12) = 
4.867, p = 0.0476) and treatment (F(1,12) = 13.31, p = 0.0033) on the number of NeuN
+ 
cells (Figure 2.7A). However, the interaction of time and treatment on the number of 
NeuN+ cells in each group was not significant (F(1,12) = 0.768, p = 0.3980). Post-hoc 
analysis using Bonferroni’s test to correct for multiple comparisons revealed a significant 
decrease in NeuN+ cells of KA-injected animals compared to PBS-injected animals at 2 
wpi (p = 0.0458), while the difference at 8 wpi was not significant (p = 0.4417). However, 
the number of NeuN+ cells in KA-injected animals did not significantly differ between 2 
and 8 wpi (p = 0.1624). Similarly, no differences in neuronal population were observed 
across time in PBS-injected animals (p > 0.9999). 
In the CA3, a two-way ANOVA revealed no overall effect of time on the number of 
NeuN+ cells (F(1,12) = 2.844, p = 0.1175), while the overall effect of treatment on the 
number of NeuN+ cells was significant (F(1,12) = 23.9, p = 0.0004; Figure 2.7B). The 
interaction of time and treatment on the number of NeuN+ cells in each group was not 
significant (F(1,12) = 2.19, p = 0.1647). Post-hoc analysis using Bonferroni’s test to correct 
for multiple comparisons revealed a significant decrease in NeuN+ cells of KA-injected 
animals compared to PBS-injected animals at 2 wpi (p = 0.0043), while the difference at 
8 wpi was not significant (p = 0.1974). However, the number of NeuN+ cells in KA-
injected animals did not significantly differ between 2 and 8 wpi (p = 0.1432). Similarly, 
no differences in neuronal population were observed across time in PBS-injected animals 
(p > 0.9999). 
In summary, stereological quantification of NeuN+ neurons in the pyramidal layers of 1 
mg/mL calbiochem KA-injected animals confirms the trend observed in the qualitative 
analysis, specifically that 1 mg/mL calbiochem KA induced hippocampal neuron loss at 
2 wpi which appears to be repopulated at 8 wpi.   
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Figure 2.7. 1 mg/mL calbiochem KA produces significant hippocampal neuron loss at 2 weeks post-injury, with 
a trend towards neuronal repopulation at 8 weeks post-injury. (A) Stereological quantification of NeuN+ cells in 
the CA1 of PBS- and 1 mg/mL calbiochem KA-injected animals at 2 and 8 wpi. (B) Stereological quantification of 
NeuN+ cells in the CA3 of PBS- and 1 mg/mL calbiochem KA-injected animals at 2 and 8 wpi. All values represent 
the mean ± SEM. *p < 0.05, **p < 0.01. n = 3 for PBS groups and n = 5 for KA groups.  
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2.3.6 1 mg/mL calbiochem KA produces moderate hippocampal neuron loss at 2 and 
8 weeks post-injury 
Our previous qualitative analysis results showed a calbiochem KA concentration of 1 
mg/mL produced visible hippocampal neuron loss at 2 wpi, while the neuronal population 
at 8 wpi was not noticeably different to PBS-injected animals (Figure 2.6F-G, I). 
Furthermore, stereological quantification results were consistent with our qualitative 
analysis findings (Figure 2.7) and, most importantly, also supported our previous findings 
(Figure 2.2). However, an ongoing issue we were experiencing with our previous KA 
supplier (Sigma) was the issue of reliability between separate lots of KA for producing 
consistent results. We therefore sought to reproduce, at least qualitatively, the findings of 
the previous experiment with our new KA supplier (calbiochem). 
A new batch of calbiochem KA was sourced from the supplier (see Table 2.1 for details) 
and diluted to the desired concentration. Animals received either 1 mg/mL calbiochem 
KA or PBS and tissue was collected at 2 or 8 wpi (Figure 2.8A). In addition, separate 
cohorts of animals were injected with either 1 mg/mL calbiochem KA or PBS and tissue 
was collected at 3 or 7 d post injury in order to stain for Fluoro-Jade C+, a marker of 
degenerating neurons. No premature deaths occurred prior to study end (Table 2.8). 1 
mg/mL calbiochem KA concentration resulted in consistent, mild seizure-like responses 
including circling, rearing and falling (seizure score 3) over the 2 h monitoring period 
(Figure 2.8B). Furthermore, hippocampal neuronal injury was confirmed by Fluoro-Jade 
C+ staining of degenerating neurons in the CA1 and CA3 regions of KA-injected but not 
PBS-injected animals shortly following injury (Figure 2.8C).  
A qualitative assessment of NeuN+ cells in the CA1 and CA3 was carried out using the 
qualitative analysis method detailed in 2.2.4.2. Compared to PBS-injected animals (2 wpi: 
mean = 0, SEM = 0; 8 wpi: mean = 0, SEM = 0), qualitative analysis of CA1 region 
NeuN+ cells from 1 mg/mL calbiochem KA-injected animals revealed moderate neuron 
loss at both 2 (mean = 6.667, SEM = 2.871) and 8 wpi (mean = 5.833, SEM = 2.12; Figure 
2.8D-E). Qualitative analysis of CA3 region NeuN+ cells also revealed moderate neuron 
loss at both 2 (mean = 10, SEM = 1.461) and 8 wpi (mean = 7.333, SEM = 2.216; Figure 
2.8E-F) compared to PBS-injected animals (2 wpi: mean = 0, SEM = 0; 8 wpi: mean = 0, 
SEM = 0; Figure 2.8D, F). 
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In contrast to our previous findings (2.3.5), where qualitative scores decreased between 2 
and 8 wpi in 1 mg/mL calbiochem KA-injected animals in both the CA1 and CA3 regions, 
the present experiment shows no change in qualitative scores of KA-injected animals 
between 2 and 8 wpi across both the CA1 and CA3 regions. These results suggest that 1 
mg/mL calbiochem KA may not produce consistent results between trials. 
 
Table 2.8. Mortality data for mice injected with either PBS or 1 mg/mL calbiochem KA. 
 Total animals 
entered in study 
Premature 
mortality 
(0-1 week) 
Premature 
mortality 
(1-8 weeks) 
Removed 
(tissue processing 
complications) 
Total n’s 
analysed 
PBS 4 0 0 0 2 week = 2 
8 week = 2 
1 mg/mL 
calbiochem 
KA 
14 0 0 2 2 week = 6 
8 week = 6 
Total 18 0 0 2 16 
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Figure 2.8. 1 mg/mL calbiochem KA produces moderate hippocampal neuron loss at both 2 and 8 weeks post-
injury. (A) Experimental protocol. (B) Seizure scores of all KA-injected animals entered into study, monitored over a 
2 h period following waking from anaesthesia. (C) Representative images of Fluoro-Jade C-labelled degenerating 
neurons in the hippocampus of PBS- and KA-injected animals 3 and 7 d post-injury. (D) Representative images of 
hippocampal neuron layer in PBS- and KA-injected animals at 2 and 8 wpi. (E) Qualitative analysis of CA1 region 
NeuN+ cells in PBS- and KA-injected animals at 2 and 8 wpi. (F) Qualitative analysis of CA3 region NeuN+ cells in 
PBS- and KA-injected animals at 2 and 8 wpi. All values in (B) represent the mean ± SD. All other values represent 
the mean ± SEM. n = 2 for PBS groups and n = 6 for KA groups.  
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2.3.7 1 mg/mL calbiochem KA produces moderate to severe hippocampal neuron 
loss at 2 and 8 weeks post-injury 
Our previous results demonstrated that a calbiochem KA concentration of 1 mg/mL 
produced moderate hippocampal neuronal loss at both 2 and 8 wpi and is inconsistent 
with our results shown in Figure 2.7. We therefore remained unconvinced of the reliability 
and consistency of neuronal injury produced by 1 mg/mL calbiochem KA. Thus, in the 
present experiment, we sought to qualitatively reproduce the results from the previous 
two experiments a third time to confirm whether 1 mg/mL calbiochem produces 
consistent neuronal injury and subsequent repopulation. 
Calbiochem KA (see Table 2.1 for details) was diluted to desired concentration. Animals 
received either 1 mg/mL calbiochem KA or PBS and tissue was collected at 2 or 8 wpi 
(Figure 2.9A). One animal died prematurely within the first week following KA injury 
(Table 2.9). 1 mg/mL calbiochem KA concentration resulted in consistent, mild seizure-
like responses, including circling, rearing and falling (seizure score 3) over the 2 h 
monitoring period (Figure 2.9B).  
A qualitative assessment of NeuN+ neurons in the CA1 and CA3 was carried out using 
the qualitative analysis method detailed in 2.2.4.2. In the CA1, PBS-injected animals 
showed mild neuron loss at 2 wpi (mean = 4.667, SEM = 1.202) and no neuron loss at 8 
wpi (mean = 0, SEM = 0; Figure 2.9C-D). Comparatively, KA-injected animals showed 
moderate neuron loss at both 2 (mean = 7.333, SEM = 2.231) and 8 wpi (mean = 9.6, 
SEM = 1.327). In the CA3, PBS-injected animals showed moderate neuron loss at 2 wpi 
(mean = 6.667, SEM = 1.333) and no neuron loss at 8 wpi (mean = 0, SEM = 0; Figure 
2.9C, E). Comparatively, KA-injected animals showed severe neuron loss in the CA3 at 
2 (mean = 12.83, SEM = 0.654) and 8 wpi (mean = 12.4, SEM = 1.288). 
Similar to the findings from our previous experiment (2.3.6), the present experiment 
shows no change in qualitative scores of 1 mg/mL calbiochem KA-injected animals from 
2 to 8 wpi across both the CA1 and CA3 regions. These results suggest that 1 mg/mL 
calbiochem KA can produce consistent neuron loss between trials, however, unlike 
experiment 2.3.5, this loss doesn’t appear to be repopulated at 8 wpi. Curiously, PBS-
injected animals in the present experiment appeared to show some neuron loss, which is 
not consistent with previous trials and may suggest contamination of the syringe or PBS 
itself.  
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Table 2.9. Mortality data for mice injected with either PBS or 1 mg/mL calbiochem KA. 
 Total animals 
entered in study 
Premature 
mortality 
(0-1 week) 
Premature 
mortality 
(1-8 weeks) 
Removed 
(tissue processing 
complications) 
Total n’s 
analysed 
PBS 6 0 0 0 2 week = 3 
8 week = 3 
1 mg/mL 
calbiochem KA 
12 1 0 0 2 week = 6 
8 week = 5 
Total 18 1 0 0 17 
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Figure 2.9. 1 mg/mL calbiochem KA produces moderate to severe hippocampal neuronal loss at 2 and 8 weeks 
post-injury. (A) Experimental protocol. (B) Seizure scores of all KA-injected animals entered into study, monitored 
over a 2 h period following waking from anaesthesia. (C) Representative images of hippocampal neuron layer in PBS 
and KA-injected animals at 2 and 8 wpi. (D) Qualitative analysis of CA1 region NeuN+ cells in PBS- and KA-injected 
animals at 2 and 8 wpi. (E) Qualitative analysis of CA3 region NeuN+ cells in PBS- and KA-injected animals at 2 and 
8 wpi. All values in (B) represent the mean ± SD. All other values represent the mean ± SEM. n = 3 for PBS groups 
and n = 5-6 for KA groups.  
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2.3.8 Optimising our stereotaxic injection methodology 
Our results from the previous few trials using 1 mg/mL calbiochem KA have yielded 
inconsistencies in the level of severity of observed neuron loss at both 2 and 8 wpi. When 
reflecting on the preceding experiments in this chapter, we hypothesised the possible 
variables that could still be contributing to the inconsistencies that we observed in our 
results. Table 2.10 summarises the variables which have been manipulated thus far. 
 
Table 2.10. Summary of experiments to date and the variables manipulated in each 
experiment. 
Reference 
number 
Reference 
figure 
Variable manipulated Conclusion 
2.3.2 2.3 -None, attempting to 
replicate previous data 
from the lab in the hands 
of another researcher 
-No recovery of hippocampal neuron 
population following 1 mg/mL KA injury 
(when KA purchased from Sigma) 
2.3.3 2.4 -Researcher performing 
the stereotaxic surgeries 
-Sigma KA concentration 
(0.5mg/mL, 0.75mg/mL, 
1mg/mL) 
-0.5mg/mL Sigma KA produced visible 
hippocampal neuron loss that may facilitate 
neuronal repopulation, however, results were 
highly variable 
2.3.4 2.5 -Sigma KA concentration 
(0.05mg/mL, 0.1mg/mL, 
0.3mg/mL, 0.5mg/mL) 
-Sigma KA concentrations below 0.5mg/mL 
KA do no produce visible hippocampal 
neuron loss 
2.3.5 2.6, 2.7 -KA supplier (Tocris, 
Sigma, Abcam, 
calbiochem) 
-KA concentration 
(0.5mg/mL, 1mg/mL) 
-1mg/mL concentration of calbiochem KA 
produced visible hippocampal neuron loss at 
2 weeks post-injury, and this loss appeared 
reduced at 8 weeks post-injury 
2.3.6 2.8 -None, repeating previous 
experiment with 1mg/mL 
calbiochem KA 
-1mg/mL calbiochem KA produced moderate 
hippocampal neuron loss at both 2 and 8 
weeks post-injury 
2.3.7 2.9 -None, repeating previous 
experiment with 1mg/mL 
calbiochem KA 
-1mg/mL calbiochem KA produced moderate 
to severe hippocampal neuron loss at both 2 
and 8 weeks post-injury 
 
 
The aim of this chapter was to establish a reproducible model of KA-induced excitotoxic 
neuronal injury to the hippocampus. Thus far, KA administration was performed via ICV 
injection directed at the lateral ventricle near the hippocampus. We hypothesised that KA 
administration via IHPC injection may yield more reliable and consistent results 
regarding neuron loss (Hypothesis 1), as previous studies have demonstrated reproducible 
lesions of hippocampal CA1 and CA3 regions following IHPC administration of KA 
(Suzuki et al., 1995; Tomioka et al., 2002). To test this idea, we examined several 
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variations of IHPC and ICV co-ordinates (Table 2.12-2.14) to observe which co-ordinates 
would yield the most consistency in injecting to the target location. 
Our second hypothesis suggested that the current method for measuring stereotaxic DV 
co-ordinates may be contributing to the inconsistencies we saw in our results (Hypothesis 
2). The stereotaxic injection protocol used in the experiments thus far involved measuring 
the DV co-ordinate from the dura of the injection location as zero (see Table 2.11). This 
stereotaxic injection protocol was used in prior studies by our group (Figure 2.2; 
Abdipranoto-Cowley et al., 2009) and has also been used by other investigators 
(Schauwecker, 2002; Suzuki et al., 1995; Yamada et al., 2004; Zhao et al., 2006). 
However, through the course of conducting experiments for this chapter, we observed 
variability in measuring the DV co-ordinate from dura as zero. Occasionally, drilling the 
burr hole would result in a small amount of bleeding, which obstructed the view of the 
dura and resulted in a proximal estimation of the dural surface when measuring the DV 
co-ordinate. To address this issue, a literature search uncovered two alternate methods for 
measuring co-ordinates for stereotaxic injection. These include: 
1. Measuring the distance between bregma and lambda and divide by 4.21 mm (the 
published average distance between bregma and lambda for C57BL/6J mice; 
Franklin and Paxinos, 1997). Apply this ratio value to your predetermined target 
co-ordinates by multiplying with the stereotaxic co-ordinate values for DV, ML 
and AP (this is known as the ratio method; Christian et al., 2013; Melón & Boehm, 
2011; Moore et al., 2009). 
2. Measure all co-ordinates from bregma as zero (including DV; bregma-zero 
method; Bouilleret et al., 1999; Suzuki et al., 1995). 
In order to establish consistency in our stereotaxic injection method we tested both 
methods to compare which one provided the most precision and accuracy for reaching 
the target location (Table 2.12-2.13). We then directly compared the precision and 
accuracy of measuring the DV co-ordinate from bregma versus measuring from the dura 
(Table 2.14). 
Our third hypothesis proposed that our current method for preparing the KA solution may 
be contributing to the inconsistencies in neuron loss that we observed both within and 
between experiments (Hypothesis 3). For all preceding experiments, KA was diluted to 
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the desired concentration according to the weight stated on the reagent vial, which was 
either 1 or 10 mg. This meant the investigator assumed the weight stated by the supplier 
was accurate. To mitigate this variable, for all subsequent experiments, we sourced a 
larger supply of KA (250 mg) and aliquoted it into smaller fractions that were then diluted 
to the desired concentration according to the investigator’s measured weight of each 
aliquot. 
The purpose of the following experiments were therefore to: 
1. Test the accuracy and precision of the ratio method (Experiment 2.3.8.1). 
2. Test the accuracy and precision of the bregma-zero method (Experiment 2.3.8.2).  
3. Compare the accuracy and precision of our proposed injection co-ordinates 
against the previously used method of measuring bregma from the dura 
(Experiment 2.3.8.3). 
 
Table 2.11. Stereotaxic injection protocol used for experiments 2.3.1-2.3.7. 
Stereotaxic injection protocol 
1. Prepare animals for stereotaxic surgery according to pre-surgery method outlined in 2.2.1.2. 
2. Measure the DV co-ordinates for bregma and lambda and ensure they are within 0.005 mm of one 
another. 
3. Adjust ML and AP co-ordinates using bregma as zero. 
4. Drill burr hole in the cranium over the injection site. 
5. Move DV co-ordinate of injection syringe until it appears to be touching the dural surface. 
6. Move to target DV co-ordinate using dura as zero. 
 
 
2.3.8.1 Ratio method produces consistent intrahippocampal injections but may not be 
appropriate for ventricle co-ordinates 
All animals received a sham injection using the ratio method of stereotaxic injection 
aimed at the desired co-ordinate and tissue was immediately collected. For stereotaxic co-
ordinates used in this experiment, refer to Table 2.12. Utilising the ratio method yielded 
100% accuracy and precision for the IHPC-A (anterior intrahippocampal) co-ordinate, 
while the IHPC-P (posterior intrahippocampal) co-ordinate successfully reached the 
target location in 2 out of 3 animals (Table 2.12). While the ICV co-ordinate showed poor 
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accuracy by only reaching the target location in 1 out of 3 animals, the precision of 
injection was consistent with 2 out of 3 animals having been injected at approximately 
AP -2.0 mm, ML -2.0 mm and DV -3.0 mm. Similarly, the ICV-wV (ICV within ventricle) 
co-ordinate also showed poor accuracy by only reaching the target location in 1 out of 3 
animals, while precision of injection was consistent with 2 out of 3 animals having been 
injected at approximately AP -2.0 mm, ML -2.0 mm and DV -1.5 mm. Accuracy and 
precision were both poor for the bLV (below lateral ventricle) co-ordinate, reaching the 
target location in only 1 out of 3 animals and imprecise injections in all animals examined. 
The ICV-adjV (ICV adjacent to ventricle) co-ordinate failed to inject to the target location 
in any of the animals, however the precision of injection was consistent with 2 out of 3 
animals having been injected at approximately AP -2.0 mm, ML -2.5 mm and DV -2.0 
mm.  
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Table 2.12. Summary of results for experiment 2.3.8.1. 
Target 
region 
Stereotaxic  
co-ordinate 
(mm) 
Measurement 
method 
Accuracy Mouse Atlas target Representative 
image 
Intrahipp
ocampal 
– anterior 
(IHPC-A) 
AP: -1.7 
ML: -1.6 
DV: -1.9 
Ratio method 3/3 = 
100% 
 
Bregma -1.70 mm  
Intrahipp
ocampal 
– 
posterior 
(IHPC-P) 
AP: -3.0 
ML: -3.0 
DV: -3.2 
Ratio method 2/3 = 
66.66% 
 
Bregma -3.08 mm 
 
ICV – 
original 
co-
ordinates 
(ICV) 
AP: -2.0 
ML: -2.9 
DV: -3.8 
Ratio method 1/3 = 
33.33% 
 
Bregma -2.06 mm 
 
ICV – 
within 
ventricle 
(ICV-wV) 
AP: -2.0 
ML: -2.9 
DV: -3.0 
Ratio method 1/3 = 
33.33% 
 
Bregma -2.06 mm  
ICV – 
adjacent 
to 
ventricle 
(ICV-
adjV) 
AP: -2.0 
ML: -2.5 
DV: -3.0 
Ratio method 0/3 = 0% 
 
Bregma -2.06 mm  
Below 
lateral 
ventricle 
(bLV) 
AP: -2.0 
ML: -2.5 
DV: -4.8 
Ratio method 1/3 = 
33.33% 
 
Bregma -2.06 mm  
Black scale bar is 1 mm, red scale bar is the length of the corresponding DV co-ordinate for that image. Red dot 
represents target co-ordinate, green dots represent approximate injected DV co-ordinate (yellow dots represent a 
differing AP co-ordinate from that shown in mouse atlas target). 
 
In summary, the results of the present experiment suggest the ratio method is sufficient 
for accurately and consistently injecting into the hippocampus, but may not be appropriate 
for consistently injecting into ventricle co-ordinates. In order to test hypothesis 2, we 
repeated this experiment using the bregma-zero method.  
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2.3.8.2 Bregma-zero method results in accurate and consistent injections to the IHPC-A, 
ICV and ICV-wV co-ordinates 
The previous results demonstrated that the ratio method produced consistent IHPC 
injections but may not be appropriate for ventricle co-ordinates. The present experiment 
was performed to test the bregma-zero method for the same target co-ordinates. 
Additionally, the results of experiment 2.3.8.1 revealed that the stereotaxic co-ordinates 
of bLV, IHPC-P and ICV-adjV failed to accurately hit the target location. Based on this 
information, we eliminated the bLV co-ordinate and modified the stereotaxic co-ordinates 
of IHPC-P and ICV-adjV in an attempt to improve the accuracy of the injection (see Table 
2.13).  
All animals received a sham injection using the bregma-zero method of stereotaxic 
injection aimed at the desired co-ordinate and tissue was immediately collected. For 
stereotaxic co-ordinates used in this experiment, refer to Table 2.13. Utilising the bregma-
zero method yielded 75% accuracy for the IHPC-A co-ordinate, reaching the target 
location in 3 out of 4 animals (Table 2.13). Precision of injection was consistent in 3 out 
of 4 animals. Although the ICV co-ordinate successfully reached the target location in 3 
out of 4 animals, precision was only consistent in 2 out of 4 animals as 1 animal was 
injected in the ICV at approximate AP -2.5 mm. Accuracy and precision were both 100% 
in ICV-wV co-ordinate. The IHPC-P co-ordinate failed to inject to the target location in 
any of the animals and was not consistent across all animals. Similarly, the ICV-adjV co-
ordinate failed to inject to the target location in any of the animals, although precision of 
injection was consistent with 2 out of 4 animals having been injected at approximately 
AP -1.0 mm, ML -1.7 mm and DV -1.9 mm. 
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Table 2.13. Summary of results for experiment 2.3.8.2. 
Target 
region 
Stereotaxic  
co-ordinate 
(mm) 
Measurement 
method 
Accuracy Mouse Atlas target Representative 
image 
Intrahipp
ocampal 
– anterior 
(IHPC-A) 
AP: -1.7 
ML: -1.6 
DV: -1.9 
Bregma-zero 3/4 = 
75% 
 
Bregma -1.70 mm 
 
Intrahipp
ocampal 
– 
posterior 
(IHPC-P) 
AP: -3.0 
ML: -2.5 
DV: -2.0 
Bregma-zero 0/4 = 0% 
 
Bregma -3.08 mm 
 
ICV – 
original 
co-
ordinates 
(ICV) 
AP: -2.0 
ML: -2.9 
DV: -3.8 
Bregma-zero 3/4 = 
75% 
 
Bregma -2.06 mm 
 
ICV – 
within 
ventricle 
(ICV-wV) 
AP: -2.0 
ML: -2.9 
DV: -3.0 
Bregma-zero 4/4 = 
100% 
 
Bregma -2.06 mm 
 
ICV – 
adjacent 
to 
ventricle 
(ICV-
adjV) 
AP: -1.6 
ML: -2.1 
DV: -2.5 
Bregma-zero 0/4 = 0% 
 
Bregma -1.58 mm 
 
Black scale bar is 1 mm, red scale bar is the length of the corresponding DV co-ordinate for that image. Red dot 
represents target co-ordinate, green dots represent approximate injected DV co-ordinate (yellow dots represent a 
differing AP co-ordinate from that shown in mouse atlas target). 
 
The results of the present experiment suggested that measuring stereotaxic co-ordinates 
from bregma-zero, consistently targeted the IHPC-A, ICV and ICV-wV co-ordinates, but 
does not consistently target the IHPC-P or ICV-adjV co-ordinates. Unlike the ratio 
method, the bregma-zero method was accurate and precise for coordinates targeted to 
both the hippocampus and lateral ventricle. Thus, the bregma-zero method was selected 
as the more appropriate method to measure stereotaxic co-ordinates. This decision was 
also influenced by information gained through personal communication with Scientia 
Professor G. Paxinos, co-author of The Mouse Brain in Stereotaxic Coordinates, 4th 
Edition. In this communication, Paxinos informed us that his method was to use bregma-
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zero for stereotaxic injections (personal communication, 6th May, 2016). The reason given 
for this was due to the fact that although bregma is a stable reference point, lambda is not 
and can vary between mouse brains. This adds an extra level of variability to stereotaxic 
measurements. Additionally, Paxinos advised the use of bregma-zero when your target 
injection location is proximal to bregma. 
 
2.3.8.3 Bregma-zero method is accurate and precise for targeting IHPC-A and ICV co-
ordinates across trials 
Experiment 2.3.8.2 demonstrated that the bregma-zero method accurately targeted both 
IHPC and ICV co-ordinates. To confirm whether accuracy would remain consistent 
between trials using the bregma-zero method, experiment 2.3.8.2 was repeated (Table 
2.14). Co-ordinates for IHPC-P and ICV-adjV were removed due to poor accuracy in 
experiments 2.3.8.1 and 2.3.8.2. Additionally, the original ICV co-ordinate in which DV 
was measured from dura as zero (dura-zero) was also included to allow us to directly 
compare the accuracy and precision of measuring the same stereotaxic injection co-
ordinates using bregma or dura as zero. 
All animals received a sham injection using either the bregma- or dura-zero method of 
stereotaxic injection aimed at the desired co-ordinate and tissue was immediately 
collected. For stereotaxic co-ordinates used in this experiment, refer to Table 2.14. 
Utilising the bregma-zero method yielded 83.33% accuracy for IHPC-A, ICV, ICV-wV, 
and ICV-dura co-ordinates (Table 2.14) and is consistent with that observed in 
experiment 2.3.8.2 above. Furthermore, precision of injection was also consistent in 5 out 
of 6 animals for all co-ordinates investigated.  
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Table 2.14. Summary of results for experiment 2.3.8.3. 
Target 
region 
Stereotaxic  
co-ordinate 
(mm) 
Measurement 
method 
Accuracy Mouse Atlas target Representative 
image 
Intrahipp
ocampal 
– anterior 
(IHPC-A) 
AP: -1.7 
ML: -1.6 
DV: -1.9 
Bregma-zero 5/6 = 
83.33% 
 
Bregma -1.70 mm 
 
ICV – 
original 
co-
ordinates 
(ICV) 
AP: -2.0 
ML: -2.9 
DV: -3.8 
Bregma-zero 5/6 = 
83.33% 
 
Bregma -2.06 mm 
 
ICV – 
within 
ventricle 
(ICV-wV) 
AP: -2.0 
ML: -2.9 
DV: -3.0 
Bregma-zero 5/6 = 
83.33% 
 
Bregma -2.06 mm 
 
ICV – 
original 
co-
ordinates 
measurin
g from 
dura as 
zero 
(ICV-
dura) 
AP: -2.0 
ML: -2.9 
DV: -3.8 
Dura-zero 5/6 = 
83.33% 
 
Bregma -2.06 mm 
 
Black scale bar is 1 mm, red scale bar is the length of the corresponding DV co-ordinate for that image. Red dot 
represents target co-ordinate, green dots represent approximate injected DV co-ordinate (yellow dots represent a 
differing AP co-ordinate from that shown in mouse atlas target). 
 
The results of the present experiment suggest measuring stereotaxic co-ordinates from 
bregma-zero produces accurate and precise targeting of IHPC-A co-ordinates as well as 
ICV co-ordinates between trials. Additionally, bregma-zero and dura-zero appear to be 
equally accurate methods for measuring stereotaxic injection co-ordinates and further, 
both the original ICV co-ordinates and that of ICV-wV accurately and consistently 
reached the target location. Based on these results, combined with the information gained 
from Paxinos, bregma-zero was chosen over dura-zero. Furthermore, as there were no 
differences in accuracy or precision between ICV and ICV-wV co-ordinated, the original 
ICV co-ordinates were chosen over ICV-wV for all subsequent experiments. Maintaining 
the original ICV co-ordinate will facilitate direct comparison of future results with 
preceding experiments of this chapter.   
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In summary, based on the combined results of 2.3.8, the following modifications were 
made to our stereotaxic injection methodology for all subsequent experiments: 
1. All stereotaxic injection co-ordinates will be measured from bregma as zero, 
including the DV co-ordinate. 
2. KA will be individually weighed out using a 6 decimal place analytical balance 
from a stock bottle into separate aliquots and diluted to desired concentration 
according to investigator’s measured weight. 
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2.3.9 Intrahippocampal injection of 1 mg/mL calbiochem KA produces extensive 
hippocampal neuronal injury at 2 and 8 weeks post-injury 
Our previous results showed us the method of measuring injection co-ordinates from 
bregma as zero was reliable in producing consistent injection placements. Additionally, 
we confirmed an accurate injection co-ordinate for IHPC injections. Our aim for the 
present experiment was to determine whether 1 mg/mL calbiochem KA injected IHPC, 
from bregma as zero, would yield consistent hippocampal neuronal loss at 2 wpi, yet also 
facilitate neuronal repopulation at 8 wpi. 
Calbiochem KA (see Table 2.1 for details) was aliquoted, weighed and diluted to desired 
concentration according to the investigator’s (Yu Shen Yin) measured weight. Animals 
received either 1 mg/mL calbiochem KA or PBS via IHPC-A stereotaxic injection (see 
Table 2.14 for co-ordinates) and tissue was collected at 2 or 8 wpi and 
immunohistochemically stained for NeuN (Figure 2.10A). No premature deaths occurred 
prior to study end (Table 2.15). 1 mg/mL calbiochem KA resulted in consistent, mild 
seizure-like responses including circling, rearing and falling (seizure score 3) over the 2 
h monitoring period (Figure 2.10B). The number of NeuN+ cells in the CA1 and CA3 
were quantified via stereology. Only the 2 wpi time point was quantified as the 8 wpi KA 
tissue was unsuitable for stereological analysis (see Figure 2.10C). 
In both the CA1 and CA3 regions, Mann-Whitney’s U tests revealed a significant 
decrease in NeuN+ cells of KA-injected animals (CA1: Mdn = 7780, mean = 11872, SEM 
= 3632; CA3: Mdn = 10373, mean = 15396, SEM = 2860) compared to PBS-injected 
animals (CA1: Mdn = 84619, mean = 83757, SEM = 3107; CA3: Mdn = 54543, mean = 
54296, SEM = 1430) at 2 wpi (Figure 2.10C-E; CA1: U = 0, p = 0.0002; CA3: U = 0, p 
= 0.0002). Expansion of the DG was observed in KA-injected animals at both 2 and 8 
wpi and precluded us from quantifying NeuN+ cells at 8 wpi. Despite not quantifying the 
KA-injected animals at 8 wpi, a visual assessment of the tissue revealed severe 
hippocampal neuron loss at this time point (Figure 2.10C). Qualitative assessment of 
NeuN+ neurons in the CA1 and CA3 of IHPC KA-injected animals at 8 wpi was not 
conducted due to gross anatomical differences in the neuronal layer that were different 
from the typical anatomical patterns observed in the neuronal layer of ICV KA-injected 
animals, making this type of assessment inappropriate in this instance. 
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In summary, injection of 1 mg/mL calbiochem KA targeted at the IHPC-A produced 
severe hippocampal neuronal loss at 2 wpi, confirmed through stereological 
quantification of NeuN+ cells in the pyramidal layers of KA-injected animals. 
Furthermore, this neuronal injury does not appear to improve at 8 wpi, demonstrating that 
IHPC injection of KA is not a suitable model of injury-induced regeneration.  
 
Table 2.15. Mortality data for mice injected intrahippocampally (IHPC-A) with either PBS 
or 1 mg/mL calbiochem KA. 
 Total 
animals 
entered in 
study 
Premature 
mortality 
(0-1 week) 
Premature 
mortality 
(1-8 
weeks) 
Removed 
(tissue 
processing 
complications) 
Total n’s 
processed 
Total n’s 
counted 
PBS 9 0 0 0 9 2 week = 6 
1mg/mL 
calbiochem 
KA 
18 0 0 0 18 2 week = 10 
Total 27 0 0 0 27 16 
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Figure 2.10. Intrahippocampal injection of 1 mg/mL calbiochem KA produces extensive hippocampal neuronal 
injury. (A) Experimental protocol. (B) Seizure score of all KA-injected animals entered into study, monitored over 2 
h period following waking from anaesthesia. (C) Representative images of hippocampal neuron layer in PBS- or KA-
injected animals at 2 and 8 wpi. (D) Stereological quantification of NeuN+ cells in the CA1 of PBS- and KA-injected 
animals at 2 wpi. (E) Stereological quantification of NeuN+ cells in the CA3 of PBS- and KA-injected animals at 2 wpi. 
All values in (B) represent the mean ± SD. All other values represent the mean ± SEM. ****p < 0.0001. n = 6 for PBS 
groups and n = 10 for KA groups. 
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2.3.10. Optimising our KA concentration for investigating neuronal injury and 
repopulation 
The previous experiment demonstrated that IHPC injection of KA resulted in severe 
hippocampal neuron loss at 2 wpi that failed to show recovery at 8 wpi, making this co-
ordinate unsuitable to model neuronal repopulation. Therefore, we next sought to 
investigate whether spontaneous neuronal repopulation could occur following injection 
of KA using our original ICV co-ordinates; however, now using the bregma-zero method 
to measure co-ordinates. To do this, we performed a concentration curve of KA injury. 
Calbiochem KA (see Table 2.1 for details) was aliquoted, weighed and diluted to desired 
concentration according to investigator’s (Yu Shen Yin) measured weight. Animals 
received either 1 mg/mL, 1.2 mg/mL or 1.5 mg/mL calbiochem KA or PBS via ICV 
injection and tissue was collected at 2 or 8 wpi (Figure 2.11A). No premature deaths 
occurred prior to study end (Table 2.16). All doses of calbiochem KA resulted in 
consistent, mild seizure-like responses including circling, rearing and falling (seizure 
score 3) over the 2 h monitoring period (Figure 2.11B). The number of NeuN+ cells in the 
CA1 and CA3 were quantified via stereology. 
In the CA1, for the 1 mg/mL dose, a two-way ANOVA revealed no overall effect of 
treatment on the number of NeuN+ cells (F(1,27) = 4.205, p = 0.0501), while the overall 
effect of time on the number of NeuN+ cells was significant (F(1,27) = 10.17, p = 0.0036; 
2.11C-D). There was no interaction of time and treatment on the number of NeuN+ cells 
in each group (F(1,27) = 1.523, p = 0.2277; Figure 2.11C-D). Post-hoc analysis using 
Bonferroni’s test to correct for multiple comparisons revealed no significant difference in 
NeuN+ cells of PBS-injected animals at 2 and 8 wpi (p > 0.9999), while a significant 
increase in NeuN+ cells was observed in 1 mg/mL KA-injected animals between 2 and 8 
wpi (p = 0.0038). No significant differences in NeuN+ cells between PBS- and 1 mg/mL 
KA-injected animals were observed at 2 (p = 0.1481) or 8 wpi (p > 0.9999). 
For the 1.2 mg/mL dose, a two-way ANOVA revealed no overall effect of time on the 
number of NeuN+ cells (F(1,27) = 0.1945, p = 0.6627), while the overall effect of treatment 
on number of NeuN+ cells was significant (F(1,27) = 10.22, p = 0.0035; Figure 2.11C-D). 
There was no interaction of time and treatment on number of NeuN+ cells in each group 
(F(1,27) = 0.0436, p = 0.8362). Post-hoc analysis using Bonferroni’s test to correct for 
multiple comparisons revealed no significant differences in the number of NeuN+ cells 
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between PBS- and 1.2 mg/mL KA-injected animals at 2 (p = 0.2729) or 8 wpi (p = 0.1330). 
Furthermore, no significant differences in NeuN+ cells between 2 and 8 wpi were 
observed in PBS- or 1.2 mg/mL KA-injected animals (PBS: p > 0.9999; KA: p = 0.1330). 
For the 1.5 mg/mL dose, a two-way ANOVA revealed no overall effect of time on the 
number of NeuN+ cells (F(1,26) = 0.6457, p = 0.4289), while the overall effect of treatment 
on number of NeuN+ cells was significant (F(1,26) = 29.64, p < 0.0001; Figure 2.11C-D). 
There was no interaction of time and treatment on number of NeuN+ cells in each group 
(F(1,26) = 0.3809, p = 0.5425). Post-hoc analysis using Bonferroni’s test to correct for 
multiple comparisons revealed a significant decrease in NeuN+ cells of 1.5 mg/mL KA-
injected animals compared to PBS-injected animals at 2 (p = 0.0127) and 8 wpi (p = 
0.0013). Furthermore, no significant differences in NeuN+ cells between 2 and 8 wpi were 
observed in PBS- or 1.5 mg/mL KA-injected animals (PBS: p > 0.9999; KA: p > 0.9999). 
 
In the CA3, for the 1 mg/mL dose, a two-way ANOVA revealed a significant overall 
effect of both time (F(1,27) = 5.65, p = 0.0248) and treatment (F(1,27) = 23.12, p < 0.0001) 
on the number of NeuN+ cells (Figure 2.11C, E). Furthermore, there was a significant 
interaction between time and treatment on the number of NeuN+ cells (F(1,27) = 6.621, p 
= 0.0159; Figure 2.11C, E). Post-hoc analysis using Bonferroni’s test revealed a 
significant decrease in NeuN+ cells of 1mg/mL KA-injected animals compared to PBS-
injected animals at 2 wpi (p < 0.0001), while the difference at 8 wpi was not significant 
(p = 0.8044). A significant increase in NeuN+ cells of 1 mg/mL KA-injected animals was 
observed between 2 and 8 wpi (p = 0.0011), while the difference in NeuN+ cells of PBS-
injected animals between 2 and 8 wpi was not significant (p > 0.9999). 
For the 1.2 mg/mL dose, a two-way ANOVA revealed no overall effect of time on the 
number of NeuN+ cells (F(1,27) = 0.6517, p = 0.4266), while the overall effect of treatment 
on the number of NeuN+ cells was significant (F(1,27) = 21.14, p < 0.0001; Figure 2.11C, 
E). There was no interaction of time and treatment on the number of NeuN+ cells in each 
group (F(1,27) = 0.1102, p = 0.7425). Post-hoc analysis using Bonferroni’s test to correct 
for multiple comparisons revealed a significant decrease in NeuN+ cells of 1.2 mg/mL 
KA-injected animals compared to PBS-injected animals at 2 (p = 0.0350) and 8 wpi (p = 
0.0095). Furthermore, no significant differences in NeuN+ cells between 2 and 8 wpi were 
observed in PBS- or 1.2 mg/mL KA-injected animals (PBS: p > 0.9999; KA: p > 0.9999). 
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For the 1.5 mg/mL dose, a two-way ANOVA revealed no overall effect of time on the 
number of NeuN+ cells (F(1,26) = 0.6969, p = 0.4114), while the overall effect of treatment 
on the number of NeuN+ cells was significant (F(1,26) = 83.57, p < 0.0001; Figure 2.11C, 
E). There was no interaction of time and treatment on number of NeuN+ cells in each 
group (F(1,26) = 0.0019, p = 0.9654). Post-hoc analysis using Bonferroni’s test to correct 
for multiple comparisons revealed a significant decrease in NeuN+ cells of 1.5 mg/mL 
KA-injected animals compared to PBS-injected animals at 2 (p < 0.0001) and 8 wpi (p < 
0.0001). Furthermore, no significant differences in NeuN+ cells between 2 and 8 wpi were 
observed in PBS- or 1.5 mg/mL KA-injected animals (PBS: p > 0.9999; KA: p > 0.9999). 
In summary, the present experiment revealed 1 mg/mL calbiochem KA concentration 
using the bregma-zero method produces hippocampal neuron loss across the CA3 at 2 
wpi and neuronal repopulation at 8 wpi as well as an obvious trend for the same findings 
in the CA1 region. Furthermore, doses of 1.2 mg/mL and 1.5 mg/mL calbiochem KA 
produce hippocampal neuronal loss across the CA1 and CA3 at 2 and 8 wpi. Thus, our 
previous results shown in Figure 2.2 appear to have been replicated using our modified 
version of the KA-induced model of neuronal repopulation. 
 
Table 2.16. Mortality data for mice injected with 1 mg/mL, 1.2 mg/mL, 1.5 mg/mL KA or 
PBS. 
 Total 
animals 
entered 
study 
Premature 
mortality 
(0-1 week) 
Premature 
mortality 
(1-8 
weeks) 
Removed 
(tissue 
processing 
complications) 
Tissue not 
stereologically 
quantified 
Total n’s 
counted 
PBS 11 (n = 5-
6 per 
time point 
0 0 1 0 2 week = 5 
8 week = 5 
1 mg/mL 
KA 
23 (n = 
11-12 per 
time 
point) 
0 0 1 1 2 week = 12 
8 week = 9 
PBS 12 (n = 6 
per time 
point 
0 0 1 1 2 week = 5 
8 week = 5 
1.2 mg/mL 24 (n = 
12 per 
time point 
0 0 0 3 2 week = 10 
8 week = 11 
PBS 12 (n = 6 
per time 
point) 
0 0 0 2 2 week = 5 
8 week = 5 
1.5 mg/mL 24 (n = 
12 per 
time 
point) 
0 0 0 4 2 week = 10 
8 week = 10 
Total 106 0 0 3 11 92 
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Figure 2.11. Increasing concentrations of KA produce hippocampal neuronal injury with cumulative severity. 
(A) Experimental protocol. (B) Seizure scores of all KA-injected animals entered into study, monitored over 2 h period 
following waking from anaesthesia. (C) Representative images of hippocampal neuron layer in PBS, 1 mg/mL, 1.2 
mg/mL and 1.5 mg/mL KA-injected animals at 2 and 8 wpi. (D) Stereological quantification of NeuN+ cells in the CA1 
of PBS-, 1 mg/mL, 1.2 mg/mL and 1.5 mg/mL KA-injected animals at 2 and 8 wpi. (E) Stereological quantification of 
NeuN+ cells in the CA3 of PBS-, 1 mg/mL, 1.2 mg/mL and 1.5 mg/mL KA-injected animals at 2 and 8 wpi. All values 
in (B) represent the mean ± SD. All other values represent the mean ± SEM. *p < 0.05, **p < 0.01, ****p < 0.0001. n 
= 5 for PBS groups and n = 9-12 for KA groups. 
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2.4 Discussion 
Our initial attempts to replicate experiments carried out in prior studies by our group 
reporting reproducible neurodegeneration followed by neuronal repopulation following 
acute hippocampal injury were unsuccessful (Figure 2.2; Figure 2.3). Throughout the 
process of optimising our model, we investigated a number of variables which may 
contribute to the magnitude of neuronal injury following ICV KA administration. Factors 
contributing to this variability include surgical experience of the investigator, KA 
concentration administered, brand of KA used, method of measuring stereotaxic injection 
co-ordinates, and inconsistencies in preparation of KA solution. In the following section, 
we discuss these variables, along with the experimental decisions we made along the way, 
in the context of the wider literature, as well as discussing the directions we next took to 
address these issues and improve the model for our experimental purposes. 
 
2.4.1 Qualitative analysis provides an adequate assessment of gross 
neurodegeneration and neuron repopulation in the CA1 and CA3 regions following 
KA-induced hippocampal injury 
Accurate cell quantification is an integral tool for determining the magnitude of neuron 
numbers in discrete regions of the CNS for various experimental purposes, in particular 
for elucidating subtle variations in neuron numbers after neurodegeneration and 
neurogenesis (Coggeshall & Lekan, 1996; Yurt et al., 2018). Stereology is the gold 
standard for unbiased quantification of hippocampal neuron populations (West & 
Gundersen, 1990), but the method is cumbersome and time intensive. Through the 
process of optimising the experimental parameters for the KA model described in this 
chapter, we realised that we would need a high-throughput method for quick, efficient, 
and unbiased assessment of neuron loss and repopulation in response to the numerous 
variables we were assessing. 
Many methods for quantification of cell populations with higher throughput than 
stereology have previously been described. These include the isotropic fractionator 
method (Herculano-Houzel & Lent, 2005; Herculano-Houzel et al., 2015), cell density 
analysis (Woeffler-Maucler et al., 2014), and semi-quantitative analysis through visual 
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assessment of tissue sections (Fujikawa et al., 2000; Fujikawa et al., 2000; Rattka et al., 
2013). 
An early description of a semi-quantitative analysis method was described by Schwob 
and colleagues. In this technique, the authors, similarly to the method we developed here, 
utilised a four-point scale to describe severity of lesions in various brain regions following 
KA administration. In their model, 0 = no damage, + = mild to moderate cellular 
destruction, ++ = moderate to severe cellular destruction, and +++ = near total destruction 
of the neuronal population accompanied by disruption of the neuropil (Schwob et al., 
1980). This same scale was later modified by Magloczky and colleagues for histological 
assessment of hippocampal lesions following a dose response experiment (Magloczky & 
Freund, 1993). 
Another version of a semi-quantitative analysis method for histological assessment of 
CA1 and CA3 hippocampal lesions was later described by Mikati and colleagues (1994), 
where the investigators utilised cresyl violet and/ or hematoxylin and eosin histology to 
examine histological lesions of the CA1 and CA3 following KA-induced seizures in rats 
(Mikati et al., 1994). Later studies utilised a modified version of this scale combined with 
Thionin staining, which is a histological method for detection of Nissl substances in 
neurons, to assess severity of lesions in hippocampal subregions (Bankstahl et al., 2008; 
Brandt et al., 2007; Cilio et al., 2001; Halonen et al., 2001; Rattka et al., 2013). Alternative 
versions of a semi-quantitative four-point rating scale to assess presence/absence of 
pathology have also been described (Benkovic et al., 2004; Kesslak et al., 1995). Similar 
to the present study, Mikati and colleagues (1994) and other studies also utilised a four-
point scale. A comparison summary of our scale with those of Mikati and colleagues and 
others is shown below in Table 2.17: 
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Table 2.17. Side-by-side comparison of qualitative analysis scoring reference scale of the 
present study with Mikati and colleagues (1994) and others. 
Qualitative 
analysis 
score 
Description of damage 
Present study Mikati et al., 1994 Cilio et al., 2001; 
Halonen et al., 2001 
Bankstahl et al., 
2008; Brandt et al., 
2007; Rattka et al., 
2013 
0 No visible cell 
damage 
No lesions No damage No obvious damage 
1 Minimal visible cell 
damage, some 
thinning of CA1 or 
CA3 neuronal layer 
A minimal lesion 
localised to part of 
the hippocampal 
area of interest 
(CA1 or CA3) 
Lesions involving < 
10% of neurons in 
the region of 
interest 
Slightly abnormal 
appearance of the 
structure without 
clear evidence of 
visible neuronal loss 
2 Moderate visible cell 
damage, small 
patches with no 
neurons 
Cellular loss 
affecting all the area 
of interest with 
preservation of the 
general cellular 
architecture and of 
some normal 
cellular elements 
Lesions involving 
10-50% of neurons 
Lesions involving 
20-50% of neurons 
3 Extensive visible 
cell damage, large 
patches with no 
neurons 
Complete disruption 
of the normal 
cellular architecture 
and essentially 
complete loss of 
normal cellular 
elements 
Lesions involving > 
50% of neurons 
Lesions involving > 
50% of neurons 
 
 
However, later studies reduced the scale to a three-point scale, such as in the paper by 
Brandt and colleagues (2003). In this study, the following scale was utilised (Table 2.18):  
 
Table 2.18. Three-point qualitative analysis scale used by Brandt and colleagues (2003) 
describing a modified version of the original four-point scale described by Mikati and 
colleagues (1994). 
Qualitative analysis score Description of damage 
(Brandt et al., 2003) 
0 No obvious damage 
1 Lesions involving 20-50% of neurons 
2 Lesions involving > 50% of neurons 
 
 
The investigators’ rational for reducing the original four-point scale described by 
(Halonen et al., 2001) and (Cilio et al., 2001) to a three-point scale related to the general 
lesion patterns observed following KA-induced injury. The authors noted that in most 
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sections, neurodegeneration was an “all-or-none” event; either no obvious degeneration 
was present, or neuronal loss of at least 50% of control condition was observed (Brandt 
et al., 2003). Indeed, previous studies have noted that in order for visual assessments of 
cell population to be a reliable indicator of cell loss, cell loss must exceed 15-20% of the 
total population (Cavazos & Sutula, 1990; Fujikawa et al., 2000). This point is most 
evident in our box-and-whisker plots of the CA1 and CA3, where the range and variability 
for corresponding stereological counts was much higher for cumulative qualitative scores 
of 1-5 than they were for 0, 6-10 and 11-15 (Figure 2.1). Based on our findings and those 
of previous investigators, it would be prudent to suggest that future studies requiring the 
use of a qualitative method for assessment of hippocampal lesions following KA-induced 
injury in the rodent brain may benefit from the use of a three-point scale, similar to the 
one described by (Brandt et al., 2003). 
It must be noted however that the method we employed is not appropriate for analysis of 
cell lesions in the DG. Indeed, this observation was also made by Brandt and colleagues 
(2007) when they indicated DG lesions are more difficult to assess in the absence of cell 
counting methods. Although the DG was not an area of interest to the present study (as 
DG neurons have previously been found to be resistant to KA-induced 
neurodegeneration), and therefore not analysed, a quick scan of the representative images 
throughout this chapter of KA-injected animals demonstrates that DG lesions were not 
detectable based on visual assessment alone. 
In our method, the investigator was blinded with respect to treatment of the animal during 
qualitative assessment, allowing for unbiased assessment in relation to overall patterns of 
cell loss. However, this may have been responsible for the subtle amounts of cell loss 
noted in PBS-injected animals which may have been due to individual differences in 
hippocampal anatomy rather than discrete cell loss.  
An advantage of the qualitative analysis method is that it allows for assessment of gross 
changes in hippocampal neuron population without the reliance or confounding factor of 
tissue shrinkage. Furthermore, it does not necessarily destroy the tissue as in the case of 
the isotropic fractionator method, which involves accurate dissection and subsequent 
homogenisation of the brain region of interest for total cell population estimates. 
To the best of our knowledge, we are the first to validate the accuracy of qualitative 
assessment of neuronal populations against unbiased stereological analysis of the same 
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hippocampal subpopulations. Our correlation analyses clearly illustrate the efficacy of 
this method for the purposes of gross anatomical assessment of hippocampal CA region 
cell populations (Figure 2.1), and further, demonstrate that gross patterns of CA1 and 
CA3 hippocampal lesions can be accurately and rapidly assessed using semi-quantitative 
scales.    
In summary, we have devised a robust method for high-throughput screening of KA-
induced CA1 and CA3 hippocampal lesions in the rodent brain that provides an adequate 
gross anatomical assessment of hippocampal lesions that significantly correlate with 
stereological counts. 
Although useful for high-throughput, the semi-quantitative method should certainly not 
be considered a substitute for gold standard stereological cell counting. As an example of 
discrepancies that can emerge between semi-quantitative and quantitative counting 
methods, KA has previously been demonstrated to preferentially lesion the CA3 subfield 
(Nadler et al., 1980), while the CA1 is lesioned only at higher doses (Abdipranoto-
Cowley et al., 2009; Nadler et al., 1980) (also see Table 2.20). Indeed, our findings from 
experiment 2.3.4 show that at doses lower than 0.5 mg/mL KA, CA1 neuron loss is not 
readily detectable by the qualitative method alone, while the CA3 still exhibits evidence 
of minor cell damage detectable by visual assessment. Our findings therefore suggest that 
the qualitative analysis method described in the present study may only be appropriate 
for KA-induced lesions of concentrations equal to or greater than 0.5 mg/mL.  
 
2.4.2 Surgical experience is likely a major contributor to consistency in experimental 
outcomes 
It is well known that outcomes generated by inexperienced surgeons can be more variable 
than those generated by experienced operators in many disciplines of science. In this 
study, the consistency of neuronal damage in PBS groups throughout this chapter 
provided evidence of this. In our first experiment (Figure 2.3), we found neuron loss in 
the CA1 and CA3 of PBS-injected animals that was much lower than neuron population 
previously cited in the literature (Abdipranoto-Cowley et al., 2009). Although we cannot 
directly rule out many other variables having a hand in this failure to reproduce the result 
(such as contamination of the PBS with trace amounts of KA or small sample size), a 
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primary hypothesis for this failure was that surgical experience was the main contributing 
factor, considering the relative inexperience of the experimenter (Yu Shen Yin) at the 
beginning of this project.  
This inexperience may have affected various facets of the complex procedures required 
to undertake these studies such as poor aseptic technique, inexperience in stereotaxic 
surgeries and inexperience in stereological cell counting. Although it is difficult to pick 
out any one variable, as with any inexperienced operator, practice greatly improved these 
variables over time. Improved consistency in control groups is perhaps evidence of this 
improvement;  there was minimal damage to CA1 and CA3 neuronal layers in our 
qualitative analyses of PBS-injected animals in later experiments and stereological 
quantifications of PBS-injected animals (Figure 2.7; Figure 2.10; Figure 2.11) showed 
similar populations to previously published results (Abdipranoto-Cowley et al., 2009).  
As mentioned above, although surgical experience may have been a primary contributing 
factor to the failure of reproducing previous experiments from our group, it certainly was 
not the only factor. We did in fact attempt to repeat the result with a researcher from our 
group who had extensive experience conducting such experiments (see Experiment 2.3.3). 
They too were unable to replicate our original findings from Figure 2.2. Nonetheless, 
surgical skill is unique to each individual and it would be prudent to ensure practice and 
validation of correctly injecting to the target location is thorough prior to beginning any 
experimental investigations, as we did extensively throughout this chapter. 
 
2.4.3 High doses of KA produce variable levels of neuronal loss between trials 
In the mouse brain, KA doses of 0.1 and 0.2 μg have previously been shown to induce 
consistent neuron loss of the CA3 region (Ferraguti et al., 2001; Lee et al., 2005; Nadler 
et al., 1978; Roe et al., 1998; Tretter et al., 1996; Tretter et al., 2000; also see Table 2.20), 
while prior studies by our group have shown substantial neuron loss across both CA1 and 
CA3 regions following 0.2 μg ICV KA administration (Figure 2.2; Abdipranoto-Cowley 
et al., 2009). Based on these prior studies, we initially trialled 0.2 μg KA as our baseline 
dose as we were attempting to re-establish a reproducible model of neuronal injury and 
repopulation (Figure 2.3). When our initial attempts at re-establishing the KA model of 
neuronal injury and repopulation previously described by our group proved unsuccessful, 
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we took a step back and decided to re-assess our methodology. One notable observation 
resulting from our initial experiment was that the neuron loss in the CA3 was unusually 
high (Figure 2.3) in comparison to previous findings from our group (Figure 2.2; 
Abdipranoto-Cowley et al., 2009). Thus, in subsequent experiments, we utilised 
variations of this baseline dose of 0.2 μg KA (see Table 2.19). 
A prominent observation resulting from our subsequent experiments was the high level 
of variability observed in KA concentrations equal to or above 0.5 mg/mL (equivalent to 
0.1 μg KA; Figures 2.4 and 2.5). Variability in neuron loss following ICV KA 
administration is not without precedence. In a 1997 study, Ferraguti and colleagues 
demonstrated a subconvulsive dose (one that does not produce the behavioural 
manifestation of seizures) of 0.5 nmol KA in 5 μL PBS (i.e., 0.1 μg KA) produced no 
differences in CA3 neuron loss between KA-treated and vehicle-treated mice at 5 d post-
injury (Ferraguti et al., 1997). In a later study however, the same dose of KA produced 
variable CA3 neuron loss 5 d post-injury, as assessed through cresyl violet staining 
(Ferraguti et al., 2001). Notably, the authors described four out of ten animals exhibiting 
CA3 lesions of around 30-40%, while two out of ten animals produced undetectable levels 
of neuron loss (Ferraguti et al., 2001). In the present study, we consistently observed 
variable levels of neuron loss at higher doses of KA (i.e., total KA dose administered 
above 0.1 μg) that varied both within trials (Figure 2.5) and between trials (Figure 2.4 
and 2.5). Thus, our findings are in agreement with those of previous investigators, which 
show variations in cell loss at total KA doses of ~0.1 μg. As the authors did not describe 
their procedure for assessment of neuron loss in the 2001 study (Ferraguti et al., 2001), a 
direct quantitative comparison between the two studies is not possible. Nevertheless, it is 
clear that ICV KA administration is prone to variable levels of neuron loss at doses of 0.5 
mg/mL (0.1 μg total) and above. 
At doses below 0.1 μg, neuron loss did not appear to vary between trials. However, as 
previously mentioned, for visual assessment of cell populations to be a reliable indicator 
of cell loss, the loss must exceed 15-20% of the total cell population (Cavazos & Sutula, 
1990; Fujikawa et al., 2000). Thus, although observable neuron loss at doses below 0.1 
μg did not vary between trials, this does not indicate that neurodegeneration severity did 
not vary between trials at the lower doses, but rather that our qualitative analysis method 
may not have been sensitive enough to detect differences in neuron loss between trials. A 
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conclusive assessment of neuron loss variability at lower KA doses would require 
stereological assessment.  
  
Table 2.19. Summary of doses used in the present chapter. 
Supplier Used in 
experiments 
Concentrations used Total KA administered 
Sigma-Aldrich (now 
Merck), NSW, 
Australia 
2.3.2 
2.3.3 
 
 
2.3.4 
 
 
 
2.3.5 
1 mg/mL 
0.5 mg/mL 
0.75 mg/mL 
1 mg/mL 
0.05 mg/mL 
0.1 mg/mL,  
0.3 mg/mL,  
0.5 mg/mL 
0.5 mg/mL 
1 mg/mL 
0.2 μg 
0.1 μg 
0.15 μg 
0.2 μg 
0.01 μg 
0.02 μg 
0.06 μg 
0.1 μg 
0.1 μg 
0.2 μg 
Tocris, VIC, Australia 2.3.5 0.5 mg/mL 
1 mg/mL 
0.1 μg 
0.2 μg 
Abcam, VIC, Australia 2.3.5 0.5 mg/mL 
1 mg/mL 
0.1 μg 
0.2 μg 
calbiochem (now 
Merck), VIC, Australia 
2.3.5 
 
2.3.6 
2.3.7 
2.3.9 
2.3.10 
0.5 mg/mL 
1 mg/mL 
1 mg/mL 
1 mg/mL 
1 mg/mL 
1 mg/mL 
1.2 mg/mL 
1.5 mg/mL 
0.1 μg 
0.2 μg 
0.2 μg 
0.2 μg 
0.2 μg 
0.2 μg 
0.24 μg 
0.3 μg 
 
 
2.4.4 Different brands of KA produce differential levels of neurodegeneration across 
the CA1 and CA3 regions despite being administered at equal doses 
In one of our early experiments, we investigated the effect of KA sourced from different 
suppliers on resulting hippocampal neurodegeneration and neuron repopulation. The KA 
used in prior studies by our group, sourced from Sigma, has been widely used in studies 
investigating KA-induced neurodegeneration in rodents (Abdipranoto-Cowley et al., 
2009; Dong et al., 2003; Franck, 1984; Lancaster & Wheal, 1982; Schwob et al., 1980; 
Sierra et al., 2015; Wang et al., 2005; Yoshimura et al., 2001; also see Table 2.20). KA 
was additionally sourced from three other suppliers, including Tocris, Abcam and 
calbiochem. KA supplied from Abcam, Tocris, and calbiochem had all previously been 
used in studies involving seizure-induced neurodegeneration in vivo in rodents (Domin et 
al., 2014; Jeong et al., 2010; Koeller et al., 2008; Kralic et al., 2005; Krook-Magnuson et 
al., 2013; Snyder et al., 2009; also see Table 2.20). 
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Unexpectedly we found that different suppliers of KA produced variable levels of 
neurodegeneration, despite being administered at identical doses (Figure 2.6). This effect 
was most noticeable with administration of 0.5 mg/mL Tocris KA, which produced 
moderate to severe neurodegeneration in both the CA1 and CA3 regions at 2 wpi. 
Comparatively, Sigma, Abcam and calbiochem produced mild neuron loss at the same 
dose. Although differences in reagent suppliers are inevitable from laboratory to 
laboratory, the name of the reagent suppliers’ are not always reported (see Table 2.20), 
which can hamper efforts to replicate prior investigators’ findings. To the best of our 
knowledge, no other investigators have systematically compared the effects of different 
suppliers of KA on resulting hippocampal neurodegeneration and neuron repopulation. 
In summary, our findings highlight the importance of reporting reagent suppliers, along 
with validating KA doses, for individual experimental purposes.  
As previously described in section 2.3.5, following the qualitative analysis, the 1 mg/mL 
calbiochem KA experimental group was chosen over the 1 mg/mL Abcam  KA 
experimental group for further quantitative stereological analysis as the calbiochem group 
exhibited less variable neuron loss compared to the Abcam group. Stereological analysis 
of the 1 mg/mL calbiochem KA group revealed significant neuron loss at 2 wpi and a 
trend towards neuron repopulation at 8 wpi (Figure 2.7), confirming the results of the 
qualitative analysis (Figure 2.6H-I). Thus, calbiochem was chosen as our KA supplier for 
all subsequent experiments moving forward. 
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Table 2.20. Summary of KA suppliers and doses used by other investigators cited in the 
present chapter. 
Investigators Specie
s 
Strain Method of 
administration 
Supplier Total KA 
administered 
Hippocampa
l regions 
damaged 
Abdipranoto-
Cowley et al., 
2009 
Mice C57BL/6 ICV Sigma 0.2 μg CA1 and 
CA3 
Balchen et 
al., 1993 
Rats Wistar Intraperitoneal Sigma 10 or 20 
mg/kg 
CA1 and 
CA3 
Benkovic et 
al., 2004 
Mice C57BL/6J Systemic Sigma 3.5 mg/mL CA1 and 
CA3 
Bouilleret et 
al., 1999 
Mice Swiss IHPC Not 
reported 
0.2 μg CA1 and 
CA3 
Bouilleret et 
al., 2000 
Mice Swiss IHPC Not 
reported 
0.21 μg CA1 and 
CA3 
Brandt et al., 
2003 
Rats Wistar Intraperitoneal Sigma 10 mg/kg CA1 and 
CA3 
Cilio et al., 
2001 
Rats Sprague-
Dawley 
Intraperitoneal Not 
reported 
15 mg/kg CA1 and 
CA3 
Csernansky 
et al., 1998 
Rats Sprague-
Dawley 
ICV, bilateral Sigma 1.0 μg CA1 and 
CA3 
Domin et al., 
2014 
Rats Wistar IHPC 
(targeting 
CA1) via 
unilateral 
cannula 
infusion 
Tocris 0.5 μg CA1 and 
CA3 
Dong et al., 
2003 
Rats Sprague-
Dawley 
ICV, bilateral Sigma 0.53 μg CA1 and 
CA3 
Ferraguti et 
al., 1997 
Mice Transgenic ICV Not 
reported 
0.11 μg None (only 
CA3 
assessed) 
Ferraguti et 
al., 2001 
Mice CD1 ICV Not 
reported 
0.11 μg CA3 
Franck, 1984 Rats Long Evans ICV Sigma 0.5 μg CA1 and 
CA3 
Gray & 
Sundstrom, 
1998 
Rats Wistar ICV Not 
reported 
5 μg CA3 (CA1 
not 
assessed) 
Jeong et al., 
2010 
Mice ICR Intraperitoneal Ascent 
Scientific 
30 mg/kg CA3 
Jørgensen et 
al., 1993 
Rats Wistar ICV, bilateral Not 
reported 
0.5 μg CA3 and 
some CA1 
Kesslak et 
al., 1995 
Rats Sprague-
Dawley 
IHPC, bilateral Sigma 0.5 μg CA1 and 
CA3 
Koeller et al., 
2008 
Mice Transgenic, 
C57BL/6 
background 
Intraperitoneal Ascent 
Scientific 
25 mg/kg CA1 and 
CA3 
Kralic et al., 
2005 
Mice Swiss IHPC 
(targeting 
CA1) 
calbioche
m 
0.21 μg CA1 and 
CA3 
Krook-
Magnuson et 
al., 2013 
Mice Transgenic IHPC Tocris 0.43 μg n/a 
Lancaster & 
Wheal, 1982 
Rats Wistar ICV Sigma 0.5 μg CA3 
Lee et al., 
2005 
Mice ICR ICV Sigma 0.1 μg CA3 (CA1 
not 
assessed) 
Magloczky & 
Freund, 1993 
Rats Wistar IHPC 
(targeting 
CA3) 
Not 
reported 
0.05-1.5 μg Ipsilateral 
CA3 and 
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contralateral 
CA1 
Matsuoka et 
al., 1999 
Rats Wistar ICV Sigma 1 μg CA3 
Mikati et al., 
1994 
Rats Sprague-
Dawley 
Intraperitoneal Not 
reported 
15 or 70 
mg/kg 
CA1 and 
CA3 
Nadler et al., 
1978 
Rats Sprague-
Dawley 
ICV, bilateral Not 
reported 
0.5 or 0.8 μg CA1 and 
CA3 
Nadler & 
Cuthbertson, 
1980 
Rats Sprague-
Dawley 
ICV or IHPC Not 
reported 
 
0.8 μg ICV; 
0.5 μg IHPC 
CA3 only 
following 
ICV; CA1 
and CA3 
following 
IHPC 
Rattka et al., 
2013 
Rats Sprague-
Dawley 
IHPC 
(targeting 
CA3) 
Not 
reported 
0.4 μg CA1 and 
CA3 
Roe et al., 
1998 
Rats Sprague-
Dawley 
ICV, bilateral Sigma 1.0 μg CA1 and 
CA3 
Schauwecker
, 2002 
Mice C57BL/6 
and FVB/N 
IHPC  0.03, 0.11, or 
0.32 μg 
CA3 
Schwob et 
al., 1980 
Rats Sprague-
Dawley 
Intracerebral 
(IHPC, 
striatum, & 
diencephalon)
; 
Intraperitoneal 
Sigma 0.85 μg for 
intracerebral; 
5, 7.5, or 12 
mg/kg for 
intraperitonea
l 
CA1 and 
CA3 
Shetty & 
Turner, 1999 
Rats Fischer 344 ICV Not 
reported 
0.5 μg CA3 
Sierra et al., 
2015 
Mice C57BL/6 IHPC Sigma 0.008 or 0.01 
μg 
n/a 
Snyder et al., 
2009 
Mice C57BL/6 Intraperitoneal Tocris 35 mg/kg n/a 
Suzuki et al., 
1995 
Mice C57BL/6 x 
DBA 
IHPC Not 
reported 
0.11-0.43 μg CA1 and 
CA3 
Tretter et al., 
1996 
Mice C57BL/6 ICV Not 
reported 
0.25 μg CA3 
Tretter et al., 
2000 
Mice C57BL/6 ICV Not 
reported 
0.2 μg CA3 
Yoshimura et 
al., 2001 
Mice Transgenic, 
SV129/Blac
k Swiss 
background 
Intraperitoneal  Sigma 20mg/kg n/a 
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2.4.5 KA-induced neurodegeneration is consistent in the CA3 but more variable in 
the CA1 
The hippocampus is particularly susceptible to neurodegeneration resulting from KA 
injection, even if the hippocampus itself is not the injection target, in large part due to the 
high expression of KA receptors in the region (Ben-Ari & Cossart, 2000; Lévesque & 
Avoli, 2013; Monaghan & Cotman, 1982). Nevertheless, discrete regions within the 
hippocampus exhibit differential responses to KA injury. Focal injection of KA has been 
well documented to cause selective damage to CA3 neurons (Abdipranoto-Cowley et al., 
2009; Matsuoka et al., 1999; Roe et al., 1998; Wang et al., 2005). Additionally, previous 
studies have found ICV injection of KA to cause selective damage to the CA3, leaving 
the CA1 and DG virtually intact (Balchen et al., 1993; Lancaster & Wheal, 1982; Nadler 
et al., 1978; Nadler & Cuthbertson, 1980). This selective damage may be attributable to 
the particularly high abundance of kainate receptors in the CA3 region compared to the 
CA1 and DG (Carta et al., 2014; Monaghan & Cotman, 1982). Nevertheless, damage to 
CA1 has also been observed (Abdipranoto-Cowley et al., 2009; Matsuoka et al., 1999), 
with cell loss occurring at delayed intervals of approximately 14 d following the initial 
KA injury (Csernansky et al., 1998). 
CA1 neurodegeneration may be mediated, in part, by prolonged excitation of CA1 
neurons via axonal connections from neighbouring CA3 neurons (Sloviter, 1983). An 
earlier study by Schwob and colleagues demonstrated variations in cell loss depending 
on location of intracerebral injection (Schwob et al., 1980). Intracerebral injection of KA 
into the posterior piriform cortex of the rat produced severe neuron loss in CA1 region, 
while KA administered directly into the diencephalon produced neuronal damage in CA3 
field. Notably, the authors concluded that direct intrahippocampal or intraventricular 
injection produced more severe damage to the CA3 than CA1 while damage involving 
the piriform cortical area produced more severe damage to the CA1. Their results suggest 
that cell populations distant from the site of KA injection can be damaged due to their 
axonal connections to cells proximal to lesion site. This suggests that the specific 
populations of cells damaged in the CA3 may be a key determinant of subsequent neuron 
loss in the CA1. Despite our efforts to minimise variability and increase consistency in 
our stereotaxic injection protocols, manual stereotaxic injections of reagents are 
nevertheless prone to human error. Thus, discrete differences in the populations of CA3 
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cells damaged following KA may affect the resulting CA1 damage, subsequently 
affecting the variability in CA1 neuron loss observed. 
In the experiments presented in this chapter we consistently observed significant 
neurodegeneration in the CA3 following KA of varying doses, while neuron loss in the 
CA1 appeared more sporadic, in an all-or-none fashion (Figure 2.11). Specifically, the 
CA3 consistently displayed significant neurodegeneration at 2 wpi in KA-injected 
animals across all dose groups, consistent with previous findings from our group and 
others (Balchen et al., 1993; Lancaster & Wheal, 1982; Nadler et al., 1978; Schwob et al., 
1980; Nadler & Cuthbertson, 1980). Comparatively, in the CA1, KA induced damage 
was only significant compared to vehicle treated controls in higher dose groups (1.5 
mg/mL KA) at 2 wpi, despite clear trends towards neurodegeneration in lower dose 
groups (Figure 2.11D). This, too, is consistent with existing literature from our group and 
others (Balchen et al., 1993; Lancaster & Wheal, 1982; Nadler et al., 1978; Schwob et al., 
1980; Nadler & Cuthbertson, 1980), illustrating the reproducibility of our revised 
methodology. 
 
2.4.6 The method of KA administration influences the variability of hippocampal 
neuron loss 
In addition to dose, the method of KA administration is an important determinant of the 
level of neurodegeneration (Shetty & Turner, 1999). Within the literature, KA-induced 
neurodegeneration and neurogenesis have been demonstrated following various methods 
of KA administration, including intranasal (Zhang et al., 2008), subcutaneous (Morrison 
et al., 1996; Otani et al., 2006), intraperitoneal (Yoshimura et al., 2001; Young et al., 
1999), and intracerebral stereotaxic injection directly into various brain structures, 
including the ventricular system (Shetty & Turner, 1999; Tretter et al., 2000; Nadler & 
Cuthbertson, 1980), hippocampus (Bouilleret et al., 1999; Kesslak et al., 1995; 
Schauwecker, 2002) and amygdala (Araki et al., 2002). These various methods of 
administration clearly modulate the final concentration of KA reaching the desired target 
region, thereby affecting severity of neurodegeneration (Shetty & Turner, 1999). 
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2.4.6.1 Intrahippocampal administration of KA produces more severe damage than 
intracerebroventricular administration 
In the present study, we primarily administered KA via stereotaxic injections into the 
ventricular system, although we also trialled IHPC injections in some experiments (i.e., 
section 2.3.9). Our findings illustrated that identical doses of KA administrated ICV or 
IHPC produced disparate patterns of neuron loss (Figure 2.10; Figure 2.11). Specifically, 
following ICV injections of 1 mg/mL KA, 40-50% neuron loss was consistently 
demonstrated in the CA3, while neuron loss in the CA1 was more variable; although 
neurodegeneration was ~40%, individual animals exhibited either an all-or-none response 
to CA1 neurodegeneration, with some animals exhibiting 30% loss, while others showed 
over 75% loss (Figure 2.11). In contrast, IHPC injections of 1 mg/mL KA consistently 
produced severe neuron loss across both the CA1 and CA3, with 85% neuron loss in the 
CA1 and 30% loss in the CA3 (Figure 2.10). In contrast to the response following ICV 
injection described above, the response following IHPC was not an all-or-none response, 
as 100% of animals exhibited severe neuron loss in both the CA1 and CA3 regions. 
Overall, our results demonstrated a direct influence of the specific route of intracerebral 
KA administration on the magnitude of hippocampal neurodegeneration assessed through 
stereological quantification, and these patterns corroborate the results of previous 
investigators (Kesslak et al., 1995; Schauwecker, 2002; Shetty & Turner, 1999). Shetty 
and Turner showed that ICV administration of KA in rats produced highly consistent 
ipsilateral CA3 cell loss across animals of all age groups investigated (4, 12, and 24 
months), while cell loss in the ipsilateral CA1 was not visibly apparent in all age groups 
investigated (Shetty & Turner, 1999). Utilising a similar four-point lesion scale to the one 
used in this thesis (see Table 2.3), Kesslak and colleagues show that IHPC administration 
of KA consistently produced extensive neuron loss (ratings above 2) in the anterior 
hippocampus (Kesslak et al., 1995). Lastly, Schauwecker (2002) found a dose-dependent 
effect of IHPC KA administration on subsequent CA3 neuron loss, whereby CA3 neuron 
loss was only evident at high doses of 0.32 µg KA and not at lower doses of 0.03 µg and 
0.11 µg KA (also see Table 2.20). We extended these findings, and provide preliminary 
evidence that 1 mg/mL dose of KA leads to both hippocampal neurodegeneration and 
neuron repopulation when administered via ICV injection, while IHPC administration of 
the same KA dose leads to more severe hippocampal neuron loss in the absence of 
apparent neuron repopulation. Notwithstanding the findings in the present thesis must be 
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confirmed, there could be a number of possible reasons for the disparity in outcomes 
following ICV or IHPC injections of KA, including:  
1. The final concentration of KA reaching the hippocampus may be higher following 
IHPC administration, leading to the increased severity of neuron loss following 
IHPC administration observed in the present study (Figure 2.10). 
2. The increased severity of neuron loss following IHPC may have precluded neuron 
repopulation as a result of increased inflammation, loss of pro-neurogenic signals, 
ablation of potentially quiescent neural stem and/ or progenitor cells populations, 
or a multitude of other variables outside the scope of the work presented in this 
chapter. 
Future studies seeking to use IHPC administration of KA for investigating neuron 
repopulation may benefit from utilising a lower KA dose (e.g., Schauwecker, 2002). 
 
2.4.6.2 The pattern of neurodegeneration in the hippocampus differs depending on where 
KA is administered (intrahippocampal or intracerebroventricular) 
The pattern of neurodegeneration observed following IHPC administration of KA has 
been described extensively by other investigators (Bouilleret et al., 1999; Bouilleret et al., 
2000; Kesslak et al., 1995; Kralic et al., 2005; Schauwecker, 2002; Suzuki et al., 1995). 
Specifically, we observed extensive neuron loss in both the CA1 and CA3 hippocampal 
regions, but did not observe any subsequent recovery of neuron numbers (Figure 2.10). 
At 2 wpi, there was extensive neuronal damage to both the CA1 and CA3 regions and by 
8 wpi, IHPC injection of KA had caused substantial anatomical malformation to the 
hippocampus resulting in hypertrophy of the DG, along with complete ablation of the 
CA1 and CA3 regions. Thus, our findings are in agreement with the results of previous 
investigators, indicating successful replication of neurodegeneration following IHPC 
administration of KA into the mouse brain. Clearly, this was in contrast to the results we 
achieved with ICV administration, where we never observed DG hypertrophy, the CA1 
was only affected in an all-or-none fashion, rather than consistent severe 
neurodegeneration, and we were able to observe apparent recovery of neuron numbers at 
8 wpi under specific conditions (i.e., utilising 1 mg/mL concentration of calbiochem KA 
administered via ICV injection with bregma-zero method).  
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A notable observation from our study was that not all animals developed DG hypertrophy 
following IHPC KA administration (see Appendix Figure 6.1). In a 1995 study by Suzuki 
and colleagues, the authors subtly modified the placement of stereotaxic injections of 0.21 
μg KA into the dorsal hippocampus. Injections into the lateral region of the hippocampus, 
proximal to CA3 (AP: -2.0 mm, ML: -2.0 mm, DV: -2.0 mm from dura), induced 
neurodegeneration in the CA3 while sparing DG cells at 2 wpi, while KA injection into 
the medial area of the hippocampus proximal to CA1 (AP: -2.0 mm, ML: -1.5 mm, DV: 
-2.0 mm from dura) induced DG hypertrophy while preserving CA3 neurons from 
degeneration at 2 wpi (Suzuki et al., 1995). Their results demonstrate that precise and 
minute differences in stereotaxic injection locations (i.e., a ML difference of 0.5 mm) can 
have distinct effects on resulting hippocampal degeneration. Indeed, their findings may 
help explain why we observed such disparity in hippocampal anatomy between different 
mice injected IHPC with KA, with some mice exhibiting DG hypertrophy while others 
showed no DG hypertrophy (see Appendix Figure 6.1), and suggest that minute errors in 
accuracy and/ or precision in injecting to the target location within the hippocampus 
proper may have profound effects on subsequent neuron loss and DG hypertrophy. Thus, 
these results highlight the importance of attaining accuracy and precision in stereotaxic 
injection of KA for producing controlled and specific cell loss, an issue we discuss in 
more depth in the following section. 
 
2.4.7 Accurately validating the location of stereotaxic injections improves the 
consistency of outcomes 
Stereotaxic surgery is a widely used tool in neuroscience that takes practice to master. In 
most instances, intracerebral stereotaxic administration of KA results in consistent and 
reproducible seizure responses in rodents (Wang et al., 2005), as we corroborated in this 
chapter. Nevertheless, as discussed in the previous section, precise intracerebral 
injections are critical for achieving reproducible outcomes. There are a number of 
variables which can influence the accuracy of intracerebral injections (Rangarajan et al., 
2016) including: inter- and intra- species differences in brain anatomy (Chen et al., 2006; 
Wahlsten et al., 1975), the angle of brain positioning in stereotaxic frames (Whishaw et 
al., 1977), difficulties in accurately determining bregma (Blasiak et al., 2010), and 
surgical experience of the investigator. Furthermore, due to the smaller size of the rodent 
Chapter 2: Kainic acid model of neuronal injury 
 
108 
brain, accuracy of stereotaxic injections in these organisms may be more susceptible to 
variability. Considering these factors, it is clearly imperative to properly validate the 
accuracy and precision of intracerebral injection methods for any study utilising this tool.  
Numerous studies have used a method in which KA is administered by beginning the DV 
injection from the position of the bregma co-ordinate (Bouilleret et al., 1999; Dong et al., 
2003; Suzuki et al., 1995; Tretter et al., 1996; Tretter et al., 2000). Alternatively, others 
have described beginning the DV injection from the position of the dura mater (Gray & 
Sundstrom, 1998; Jørgensen et al., 1993; Lee & Kesner, 2004; Schauwecker, 2002; Shetty 
& Turner, 1999; Suzuki et al., 1995). Furthermore, some have utilised the ratio method, 
previously discussed in section 2.3.8, in an attempt to mitigate intra-strain variations in 
mouse brain size (Christian et al., 2013; Melón & Boehm, 2011; Moore et al., 2009). 
In this chapter, we compared the accuracy and precision of stereotaxic injections to target 
regions by beginning DV injections from either bregma or dura as zero, or utilising the 
ratio method for calculating stereotaxic injection co-ordinates, to determine which of 
these methods was the most reproducible (see section 2.3.8). As previously described in 
section 2.3.8, we hypothesised that our prior stereotaxic injection protocol may have been 
contributing to the inconsistencies that we were observing in our results using KA. Our 
initial experiment showed the ratio method was both accurate and consistent for IHPC 
injections, while ICV injections were largely inaccurate (Table 2.12). Our subsequent 
experiments show no differences in accuracy or precision of injections to the lateral 
ventricle when utilising either the bregma-zero or dura-zero method (Table 2.13; Table 
2.14), suggesting both methods were equally effective for accurately and precisely 
injecting to the target location in both the lateral ventricle and dorsal hippocampus. Thus, 
based on our results, and combined with the information we gained through personal 
communication with Paxinos (see section 2.3.8.2), we ultimately chose to utilise the 
bregma-zero method for all subsequent experiments.  
Furthermore, despite the bregma-zero method producing both accurate and precise results 
for the IHPC-A co-ordinate, and indeed we trailed this co-ordinate in a subsequent 
experiment (see section 2.3.9), this stereotaxic co-ordinate was ultimately not chosen for 
our KA model of neurodegeneration. This decision was made in part due to the severe 
hippocampal neurodegeneration and DG hypertrophy observed resulting from 1 mg/mL 
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KA injected IHPC (previously discussed in detail in section 2.4.6), which may have 
precluded any possibility of neuronal repopulation. 
In summary, the results of the present study highlight the importance of accurately 
validating stereotaxic injection co-ordinates prior to commencing experimental 
investigations. In order to improve accuracy and decrease variability resulting from 
human error, future studies may benefit from utilisation of a robotic stereotaxic frame for 
in vivo rodent investigations of seizure-induced neurodegeneration. Indeed, we have 
already commenced investigations into the use of robotic stereotaxic frames for our 
research and will endeavour, in future, to validate our KA model using this novel tool. 
Currently, Neurostar (Baden-Württemberg, Germany) is only supplier worldwide that 
manufactures robotic stereotaxic frames for small animal research. 
 
2.4.8 KA induced neurodegeneration can lead to neuronal repopulation in the 
hippocampal CA1 and CA3 regions under specific conditions 
KA-induced neurodegeneration and neurogenesis in the hippocampus has previously 
been described by us and others (Abdipranoto-Cowley et al., 2009; Bengzon et al., 1997; 
Parent, 2003). In the present study, we chose two time-points in which to investigate 
neurodegeneration and neuron repopulation. Previous studies have observed the presence 
of dying cells from 24 h up to 3 wpi (Gould & Tanapat, 1997; Magloczky & Freund, 
1993). Meanwhile, the process of adult neurogenesis under physiological conditions has 
been described to require approximately 4-7 weeks from cellular proliferation to 
functional integration (Jessberger & Kempermann, 2003; Kempermann et al., 2004; van 
Praag et al., 2002). Prior studies by our group have demonstrated significantly decreased 
neuronal populations in the hippocampal CA1 and CA3 regions at both 7 d (Abdipranoto-
Cowley et al., 2009) and 2 weeks following KA-induced injury (Figure 2.2). Furthermore, 
differences in neuronal populations were not significantly different between 2 and 4 wpi 
(Figure 2.2; Figure 2.3). Meanwhile, we have previously observed significant neuron 
repopulation at 8 wpi (Figure 2.2). Considering the time-intensive process involved in 
stereologically quantifying neuronal populations, it was not possible in this study to 
assess neuronal levels across a wide range of time points post-injury. Thus, based on 
previous evidence from our group, we chose to assess neurodegeneration at 2 wpi and 
look for evidence of neuron repopulation at 8 wpi. 
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In this chapter, despite many difficulties in reproducing work from our own group and 
others, we eventually found that neuron repopulation can occur in the hippocampal CA1 
and CA3 regions following a controlled injury, under specific conditions. In particular, 
we demonstrated that 1 mg/mL calbiochem KA administered via ICV injection produces 
neurodegeneration at 2 wpi and neuron repopulation at 8 wpi in both the CA1 and CA3 
regions (Figure 2.11). The recovery we observed did not appear to be possible when using 
doses of KA above 1 mg/mL, suggesting more severe neurodegeneration prevents the 
ability of the hippocampus to recover.  
Although the present study shows the occurrence of neuron repopulation in areas of the 
brain generally regarded as non-neurogenic, our study is by no means the first to 
demonstrate that severity of injury may influence the brain’s neurogenic response in non-
neurogenic regions of the adult CNS. Indeed, the notion that severity of injury may 
influence the brain’s neurogenic response to injury has been suggested by numerous 
investigators (Magavi et al., 2000; Ohira et al., 2010). Notably, the study by Magavi and 
colleagues also showed neuronal repopulation in a non-neurogenic region, the anterior 
neocortex, following a very precise and controlled apoptotic injury of corticothalamic 
neurons in layer VI of this region (Magavi et al., 2000). The injury they induced resulted 
in lesion to approximately 20% of the neurons in the targeted region, and the surrounding 
tissue remained unaffected. The authors acknowledged that under more severe injury 
conditions, neurogenesis in this region may not have been observed. In a similar vein, 
Ohira and colleagues observed injury-induced neurogenesis originating from the 
neocortical region following mild ischaemic injury (Ohira et al., 2010). The authors 
acknowledged that previous experiments demonstrating migration of new neurons from 
the neurogenic SVZ had produced a much more severe ischaemic injury than their study 
and concluded that the origin of newly generated neurons may vary depending on the 
nature and severity of injury induced. 
Nevertheless, our finding of neuron ‘repopulation’ is not without its caveats. These 
limitations will be mentioned here briefly but will be discussed in detail in the general 
discussion chapter (Chapter 5). First and foremost, given the high level of variability 
observed in the CA1 region following KA doses higher than 0.5 mg/mL, the findings 
observed in Figure 2.11 will certainly need to be confirmed to determine reproducibility. 
An additional point to note is whether the phenomenon we observed in Figure 2.11 was 
indeed evidence of neurodegeneration and neuron repopulation or whether it could be 
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attributable to downregulation of the NeuN protein at 2 wpi and subsequent re-expression 
of NeuN protein at 8 wpi (discussed in section 5.3.1). Furthermore, if indeed this is 
preliminary evidence of neuron repopulation, then where are these newly generated 
neurons originating from? We address these limitations in the following chapter, where 
we attempt to provide conclusive evidence that the ‘repopulation’ we have observed is 
real and is functionally significant. 
 
2.4.9 Conclusion 
In the present study, we sought to establish a reproducible model of KA-induced 
excitotoxic neuronal injury to the hippocampus of C57BL/6 mice that facilitates 
subsequent neuronal repopulation through systematic investigation of a multitude of 
different variables that could have been affecting the inconsistencies we observed in our 
initial attempts to reproduce the model. Through our process of KA model optimisation, 
we developed and validated a qualitative analysis method for high-throughput screening 
of KA-induced hippocampal lesions, established the importance of surgical experience 
and thorough validation of stereotaxic injection co-ordinates for producing consistent 
results, illustrated the importance of reporting reagent suppliers when detailing 
experimental methodology, and deduced the optimal KA concentration and stereotaxic 
injection co-ordinate for producing reproducible neuron loss and repopulation across the 
CA1 and CA3 hippocampal regions. Excitingly, we have shown preliminary evidence for 
the occurrence of substantial neuron repopulation of the CA1 and CA3 regions following 
significant KA-induced lesioning of these regions. However, it remains to be determined 
whether this constitutes a new neurogenic niche that can be activated under specific injury 
conditions, or whether neurons repopulating the CA1 and CA3 have migrated from the 
known neurogenic regions of the SVZ or SGZ. Furthermore, the functional relevance of 
the CA1 and CA3 neuron repopulation remains unclear. Our experiments in the 
subsequent chapter will aim to address these questions. 
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3.1 Introduction 
Acute brain injuries, such as seizure-induced injury and traumatic brain injury, are 
characteristically accompanied by severe neuronal loss in cognitively important areas of 
the CNS, in particular the hippocampus, which often lead to subsequent deficits in 
cognitive function (West et al., 1994). Evidence of cognitive recovery following acute 
CNS injury is sparse, leading to the assumption that the CNS is unable to functionally 
recover in the absence of exogenous treatment following acute CNS injury and/ or trauma, 
often resulting in permanent deficits (see sections 1.4.3 and 1.6). Nevertheless, previous 
studies in both humans and animals have demonstrated recovery of cognitive function 
following acute brain injuries (Cramer, 2008; Gorantla et al., 2016; Hochstenbach et al., 
2003), suggesting the existence of endogenous recovery processes such as neurogenesis. 
While under physiological conditions, neurogenesis has been observed to be beneficial to 
the organism (see sections 1.3.1.1 and 1.3.2.1), it remains unclear whether neurogenesis 
under pathological conditions is similarly beneficial (Neuberger et al., 2017). 
Furthermore, although endogenous recovery processes may be important for promoting 
the brain’s ability to recover from injury (Chen et al., 2003; Scheff et al., 2005), it remains 
unclear whether endogenous levels of neurogenesis alone are sufficient for significant 
functional recovery to occur in the absence of exogenous stimulatory factors and 
processes. Therefore, understanding the functional relevance of the neurogenic process 
under pathological conditions is of paramount importance. Elucidating the role of 
individual cell types and their contribution to functional output may aid in clarifying the 
role of neurogenesis following injury.  
In spite of the overwhelming evidence demonstrating increased neurogenesis following 
brain injury (see section 1.4), the field remains sceptical regarding the biological 
relevance of injury-induced neurogenesis. Indeed, much of the research over the past 
decade has focused on enhancing the neurogenic response following injury with 
administration of exogenous treatments (discussed briefly in section 1.4.3), including 
growth factor treatments, stem cell therapy, and de-differentiation and trans-
differentiation studies. Nevertheless, concerns arise regarding exogenous cellular 
replacement therapies, including regional specificity of cell differentiation and long-term 
survival and integration of the cells into the surrounding circuitry (Quadrato et al., 2014). 
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Understanding mechanisms of adult neurogenesis is therefore crucially important to 
develop viable treatment strategies to facilitate this recovery. 
An increase in neurogenesis following various acute insults to the adult brain has been 
well documented within the literature (Yu et al., 2014). Furthermore, although existing 
evidence supports the integration of a small portion of adult-born neurons generated 
following injury (Hou et al., 2008; Villasana et al., 2015; Yamashita et al., 2006), a direct 
causative relationship between injury-induced neurogenesis and functional recovery has 
yet to be conclusively demonstrated and has led to the view that other compensatory 
mechanisms, such as synaptic plasticity (Chen et al., 2003; Park & Biederer, 2013; Xuan 
et al., 2015), are contributing to endogenous recovery processes. Various methods have 
now been established to allow investigators to track the development and examine the 
functional role of newborn cells within the adult mammalian brain (for detailed review 
see Enikolopov et al., 2015). 
 
3.1.1 Methods for investigating adult neurogenesis 
3.1.1.1 5-bromo-3’-deoxyuridine 
The turning point in neurogenesis research came with the development of BrdU labelling 
(Gratzner, 1982; Miller & Nowakowski, 1988; Nowakowski et al., 1989), allowing 
investigators to identify (Kuhn et al., 1996) and quantify (Kempermann et al., 1997) 
neural progenitor cells using immunohistochemistry and stereology. Indeed, one of the 
key findings of this era was the presence of constitutively occurring neurogenesis in two 
key regions of the adult mammalian brain; the SVZ of the lateral ventricles and the SGZ 
of the DG (Ming & Song, 2005). However, BrdU is not without its caveats, chief among 
those being its toxicity and non-specificity for labelling dividing cells (Taupin, 2007a). 
As BrdU is a marker of DNA synthesis, labelling of cells undergoing DNA repair can 
confound investigations of adult neurogenesis (Taupin, 2007b). Furthermore, BrdU 
administration during prenatal and neonatal development is known to be toxic and can 
cause deleterious effects to brain development of the organism (Bannigan & Langman, 
1979; Duque & Rakic, 2011; Kolb et al., 1999; Kuwagata & Nagao, 1998). 
Comparatively, the toxic effects of BrdU appear inconsequential when administered to 
adult rodents (Cameron & McKay, 2001), with the completed development of the blood 
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brain barrier (BBB) being attributed to this effect (Taupin, 2007b). Nevertheless, injuries 
to the brain have been previously shown to disrupt the permeability of the BBB (Pont et 
al., 1995), contributing to increased BrdU toxicity to the organism and/ or confounding 
effects resulting from non-specific labelling of neural progenitor cells. Indeed, subsequent 
increases in BrdU uptake resulting from increased BBB permeability could be falsely 
attributed to increases in infiltrating immune cells (Gould & Gross, 2002). Although 
BrdU labelling is still widely used today (Le et al., 2018; Nguemeni et al., 2018; Seong 
et al., 2018; Yang et al., 2018), complementary strategies to investigate adult 
neurogenesis have been developed, such as retroviral labelling and transgenic animal 
models (Semerci & Maletic-Savatic, 2016; Taupin, 2007b). These new sophisticated 
technologies enable the tracking and tracing of the developmental trajectory of newly 
generated neurons and, combined with birth dating cells using BrdU, facilitate 
investigations into the functional relevance of adult neurogenesis in vivo. 
 
3.1.1.2 Retroviral vectors 
Viruses have evolved specialised mechanisms to efficiently transport their genomes 
inside the host cells they infect (Kitamura et al., 2003). The discovery of viral mechanisms 
of infection has revolutionised scientific research through the use of re-engineered viruses, 
including retroviruses to label neural progenitor cells (Luskin, 1994; Luskin, 1993; Price 
et al., 1987). When injected directly into the mammalian brain, retroviral particles 
exclusively infect cells undergoing active cell division, making them a good fit for 
labelling proliferating neural progenitor cells (Parent et al., 2002; Petreanu & Alvarez-
Buylla, 2002; Yamada et al., 2004). Following infection, the genome of the retrovirus 
becomes stably integrated into the host cell’s chromosomal DNA, allowing subsequent 
host cell progeny to inherit and further express the retroviral genome. Visualisation of 
newly generated cells’ developmental trajectory can be achieved through the use of 
reporter genes transformed into the virus genome, such as β-galactosidase and GFP. In 
addition to the use of retrovirus-tagged reporter genes, other more sophisticated 
engineered retroviruses have also been recently developed. For example, Vivar and 
colleagues recently combined retroviral labelling with rabies virus to generate a novel 
retrovirus capable of targeted labelling of dividing neural progenitor cells (Vivar et al., 
2016; Vivar & van Praag, 2013). 
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3.1.1.3 Transgenic animals 
Transgenic mice expressing GFP under the control of the nestin gene allow visualisation 
of neuronal development in vivo (Yamaguchi et al., 2000). Nestin is an intermediate 
filament protein that is expressed during development in undifferentiated cells, and in 
neural progenitor cells in the adult mammalian brain (Lendahl et al., 1990). As cells 
undergo terminal differentiation and maturation, nestin expression becomes 
downregulated (Dahlstrand et al., 1995; Frederiksen & McKay, 1988; Suzuki et al., 2010). 
Visualisation of the neurogenic process throughout the lifespan of the animal can be 
achieved through utilisation of nestin-GFP transgenic mice (Encinas et al., 2011; 
Mignone et al., 2004; Yamaguchi et al., 2000), arguably the most prevalent model for 
investigating adult neurogenesis (Semerci & Maletic-Savatic, 2016). The first nestin-GFP 
transgenic mouse line generated by Yamaguchi and colleagues was used to visualise GFP 
and nestin co-localisation in the neurogenic niches, which has previously never been 
reported (Yamaguchi et al., 2000), while later models differentiated the specific cell types 
in both the SGZ (Encinas et al., 2011) and SVZ (Mignone et al., 2004) where GFP and 
nestin expression were being localised to. This same idea has also been applied to other 
markers of neuronal fate such as glial fibrillary acidic protein (GFAP; Codega et al., 2014; 
Pastrana et al., 2009), Sox2 (D’Amour & Gage, 2003; Suh et al., 2007) and DCX 
(Couillard-Despres et al., 2006; Walker et al., 2007). This, in turn, has led to exciting 
discoveries regarding the self-renewal capacity of SGZ cells (Suh et al., 2007), the 
neurogenic potential of reactive astrocytes to enact neurogenesis following injury (Götz 
et al., 2015), along with elucidating the functional roles of newly-generated neuroblasts 
and granule neurons in discrete memory processes (McHugh et al., 2007; Nakashiba et 
al., 2012). 
Additionally, a prevalent method used for investigating adult neurogenesis in vivo is the 
generation of transgenic animals utilising an inducible gene regulatory system (Semerci 
& Maletic-Savatic, 2016) such as the CreER-loxP (Bonaguidi et al., 2011; Dranovsky et 
al., 2011; Encinas et al., 2011) and TetOn/TetOff systems (Dupret et al., 2008; Yu et al., 
2005). Integration of these systems with expression of the Drosophila allatostatin receptor 
(AlstR), a G protein-coupled inward rectifying K+ channel (Birgül et al., 1999), allows 
for transient and temporally-controlled inactivation of specific cell populations, which 
can be achieved through exogenous administration of allatostatin to AlstR-expressing 
neurons in vivo (Tan et al., 2006). This system has previously been used to elucidate the 
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functional roles of discrete neuronal populations to behavioural outputs (Gosgnach et al., 
2006; Tan et al., 2008), making it a useful application for characterising the functional 
significance of newly generated neurons.  
Other widely used pharmacogenetic strategies for conditional ablation of specific cell 
populations include the targeted expression of the herpes simplex virus thymidine kinase 
(HSV-TK; Garcia et al., 2004; Morshead et al., 2003) or the diphtheria toxin fragment in 
genetically modified animals (Sakamoto et al., 2011). For example, administration of the 
antiviral agent ganciclovir in transgenic animals expressing promotor-specific HSV-TK 
receptor allows temporally-specified ablation of cell populations, and has previously been 
used to investigate the effects of ablating hippocampal neurogenesis immediately 
following injury on subsequent performance in hippocampal-dependent spatial learning 
tasks (Blaiss et al., 2011). The key advantage of the allatostatin system over these other 
pharmacogenetic tools however, is that it allows for reversible inactivation of a target cell 
population, facilitating a more direct approach to investigating the contribution of specific 
cell populations to functional output without the need to ablate a cell population which 
may have unknown effects on the overall circuit function. 
 
3.1.2 Origin and functional relevance of neurogenesis following injury 
A key finding from prior studies from our group is that following an acute brain injury, 
the adult rodent brain is capable of regenerating regions of the brain not previously 
believed to have neurogenic properties (Abdipranoto-Cowley et al., 2009). Most 
astoundingly, these findings demonstrate that regeneration of the hippocampal CA1 and 
CA3 regions, areas not previously thought to have regenerative properties, is possible. 
However, the functional and physiological characteristics of these newborn neurons are 
currently not well understood. Therefore, in the present study, we sought to investigate 
the origin of the newly generated cells following KA-induced injury, along with 
characterising their contribution to cognitive processes following injury. Inconsistencies 
in methodology compared to those of the previous chapter can be attributed to the fact 
that the experimental investigations presented in this chapter were carried out 
concurrently with those of Chapter 2. 
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3.1.3 Aims 
• Identify the origin of the neural stem cells that repopulate the injured hippocampus 
• Investigate the functional significance of the newly generated neurons following 
KA-induced excitotoxic injury  
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3.2 Materials and Methods 
3.2.1 Animals 
All animal experiments were performed with the approval of the Garvan Institute and St 
Vincent’s Hospital Animal Ethics Committee, in accordance with National Health and 
Medical Research Council animal experimentation guidelines and the Australian Code of 
Practice for the Care and Use of Animals for Scientific Purposes (2013). For all studies, 
mice were kept under standard housing conditions of 12 h light/ dark cycle (lights on at 
7:00am) and access to food and water ad libitum for the duration of experimentation. 
Mice were housed at a maximum of five mice per cage prior to KA or PBS administration. 
Following KA or PBS administration, mice were single housed for the duration of the 
experiment. 
 
3.2.1.1 C57BL/6 mice 
C57BL/6 male mice aged between 8 and 10 weeks were obtained from Australian 
BioResources (NSW, Australia).  
 
3.2.1.2 Nescre-ERT2/R26-AlstR mice 
C57BL/6-Tg(Nes-cre/ERT2)KEisc/J (known as Nes-Cre/ERT2) mice were obtained 
from The Jackson Laboratory (stock: 016261). Briefly, a transgene containing the rat 
promoter region of the nestin gene followed by the Cre-ERT2 sequence was microinjected 
into fertilised C57BL/6 oocytes. Resulting mice express Cre recombinase fused to the 
triple mutant form of the human estrogen receptor binding domain in nestin-expressing 
cells (Battiste et al., 2007). Mice were maintained on a C57BL/6J background. 
R26-AlstR mice were kindly donated by Professor Martyn Goulding. Briefly, the 
Drosophila AlstR sequence followed by an IRES-EGFP cassette was placed downstream 
of the CAG promoter and FSL-LSL (Frt-stop-Frt, LoxP-stop-LoxP) double-stop cassette. 
The entire construct was targeted to the ROSA26 gene locus via electroporation in 129/Sv 
ES cells. Founder mice were crossed with ACTB:Flpe mice (described elsewhere: C.I. 
Rodríguez et al., 2000) to remove the Frt-Neo cassette. Resulting mice express AlstR and 
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EGFP preceded by a loxP-flanked stop cassette. Thus, expression of both transgenes is 
enabled only when crossed with a cre recombinase-expressing line. Mice were 
backcrossed to C57BL/6J background for 6 generations before crossing with Nes-
Cre/ERT2 mice. 
Nescre-ERT2/R26-AlstR mice were created by Professor Bryce Vissel and colleagues 
(unpublished). Hemizygous male Nes-Cre/ERT2 mice were crossed with hemizygous 
female R26-AlstR mice to create Nescre-ERT2/R26-AlstR mice. Resulting female cre-
positive, AlstR hemizygous mice were mated with R26-AlstR hemizygous male mice to 
obtain cre-positive, AlstR homozygous mice (AlstR-cre+). The colony was then 
maintained by mating AlstR-cre+ females with AlstR-cre- males. 
 
3.2.1.3 Genotyping 
Genomic DNA from tail biopsies was obtained for genotyping analysis at the mouse 
breeding facility (Australian BioResources). Genomic DNA was isolated from samples 
using the QIAmp 96 DNA QIAcube HT kit (Chadstone, Australia) and was performed 
by the Scientific Services Team at Australian BioResources. DNA was sent to the Garvan 
Institute Molecular Genetics Facility for realtime PCR (via a LightCycler 480; Roche 
Molecular Systems) and High Resolution Meltcurve analysis.  
Genotyping of Nes-Cre/ERT2 mice was performed using primers targeted to the Cre-
ERT2 sequence as well as an internal positive control as suggested by Jackson Laboratory 
for this transgenic mouse strain. Primers for the target allele were as follows: forward – 
5’-GCG GTC TGG CAG TAA AAA CTA TC-3’; and reverse – 5’-GTG AAA CAG CAT 
TGC TGT CAC TT-3’. Internal control primer sequences were as follows: forward – 5’-
CTA GGC CAC AGA ATT GAA AGA TCT-3’; and reverse – 5’-GTA GGT GGA AAT 
TCT AGC ATC ATC C-3’. Each primer set was run in a separate PCR performed by the 
Garvan Institute Molecular Genetics Facility as described above. 
Genotyping of R26-AlstR mice was performed using primers targeted to the ROSA gene 
locus and EGFP gene sequence. Primers for the ROSA allele were as follows: WT forward 
– 5’-CTC TGC TGC CTC CTG GCT TCT-3’; WT reverse – 5’-CGA GGC GGA TCA 
CAA GCA ATA-3’; and mutant reverse – 5’-TCA ATG GGC GGG GGT CGT T-3’. 
EGFP primer sequences were as follows: forward – 5’-GAC GTA AAC GGC CAC AAG 
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TT-3’; and reverse – 5’-GAA CTC CAG CAG GAC CAT GT-3’. Primers for the ROSA 
and EGFP alleles were used in two separate reactions and performed by the Garvan 
Institute Molecular Genetics Facility as described above. 
 
3.2.2 Kainic acid administration 
3.2.2.1 Pre-surgery 
All surgical tools were sterilised overnight in 0.5% chlorhexidine in 70% ethanol. 
Animals were anaesthetised with an intraperitoneal injection of ketamine (100 mg/kg; 
Mavlab, QLD, Australia) and xylazine (20 mg/kg; Troy Laboratories, NSW, Australia) 
mixture and placed in a stereotaxic apparatus (Kopf Instruments, CA, USA). 
 
3.2.2.2 Stereotaxic injection of kainic acid 
KA (calbiochem (Merck Millipore), MA, USA) was dissolved to a concentration of 1 
mg/mL in PBS (pH 7.4) filtered through a 0.2 μm syringe filter. KA stock solution was 
aliquoted and stored at -20°C for up to 1 month following reconstitution (as per supplier’s 
recommendation). A small burr hole was drilled in the cranium over the injection site and 
mice were given a single unilateral injection of 0.2 μL of either KA or PBS using a 0.5 
μL Hamilton syringe (model # 7000.5KH, Hamilton, NV, USA) into the right lateral 
ventricle at co-ordinates from bregma: AP -2.0 mm, ML -2.9 mm, and from dura DV -
3.8 mm. The injection needle remained in place for 5 min to allow diffusion of the KA 
into the right lateral ventricle and minimise backflow. The incision was closed with 
sutures (Cat # CD0057, Dynek, SA, Australia) and animals were allowed to recover 
overnight in their home cages on heating pads. 
 
3.2.2.3 Seizure scoring 
After waking from anaesthesia, seizure activity was monitored and scored every 5 min 
over a period of 2 h according to a seizure scoring scale (Table 2.2). A modified version 
of the Racine scale of epileptic seizures (Racine, 1972) was used to determine the extent 
of seizure-like responses to KA. The time course of seizure-like activity for each 
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experiment was graphed as a function of time. Scoring ceased after a mouse scored ‘2’ or 
lower for 3 consecutive 5 min intervals or 2 h after waking up from anaesthesia. 
 
Table 3.1. Seizure scoring scale. 
Score Characterisation 
0 Normal exploratory behaviour and grooming 
1 Cessation of typical activity (walking, grooming, exploring, sniffing) 
2 Forelimb and/or tail extension, appearance of rigidity 
3 Automatisms (repetitive scratching, circling, head bobbing) 
4 Forelimb clonus, rearing and falling 
5 Repetitive rearing and falling and forelimb clonus 
6 Severe tonic-clonic seizures 
7 Death 
 
 
3.2.3 Confirming stereotaxic injection co-ordinates for retroviral administration 
3.2.3.1 Animals 
Refer to 3.2.1.1. 
 
3.2.3.2 Pre-surgery 
Refer to 3.2.2.1. 
 
3.2.3.3 Sham stereotaxic injection, tissue preparation and analysis 
Animals received a sham injection using a 2 μL Hamilton syringe (model # 7002KH, 
Hamilton, NV, USA) into the desired stereotaxic co-ordinate (see Table 3.5-3.6 for exact 
co-ordinates). The injection needle remained in place for 5 min before removal. 
Immediately following sham injection, animals were sacrificed via cervical dislocation. 
Brains were harvested, post-fixed in 4% PFA (Cat # P6148-1kg, Sigma Aldrich, NSW, 
Australia; pH 7.3-7.5) in 1x PBS for 24 h, and cryoprotected in 30% sucrose for 2-3 d 
until brains had sunk. Brains were prepared for cryosectioning by cutting away 1 mm of 
cerebellum to make a flat surface and then placed in a peel-away mould containing OCT 
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(Cat # 4583001CTN, Hurst Scientific, WA, Australia) medium. Brains were stored at -
80°C until ready for cryosectioning. Brains were cryostat sectioned into 40 μm thick 
slices at -16°C and each section was placed serially into a 12 well plate containing 0.02% 
sodium azide in 1x PBS until needed for immunohistochemistry. 
Following cresyl violet histology (3.2.3.4), tissue sections were analysed serially, using a 
bright-field microscope (Leica Microsystems, NSW, Australia) with 1x and 5x objective, 
until the section corresponding to the stereotaxic injection location was observed. 
Representative images of the corresponding tissue section were taken at 1x and 5x 
magnification. Injection accuracy was determined by combining information from 1x and 
5x magnification images whereby 1x images provided approximate AP location from 
bregma and 5x images provided approximate DV location from dura (or bregma as stated 
in text) and comparing against the mouse atlas target image. 
 
3.2.3.4 Cresyl violet histology 
Free-floating sections were mounted on gelatin-coated glass slides and left to dry for 24 
h prior to staining. Tissue sections were washed briefly in distilled water then placed in 
100% ethanol (2 x 3 min). Sections were then immersed in 100% xylene for 15 min to 
defat the tissue, and then in 100% ethanol for 10 min. Sections were dehydrated in 100% 
ethanol (2 x 3 min). Sections were then washed in distilled water briefly before incubating 
in 0.1% Cresyl Violet (Cat # C094, ProSciTech, QLD, Australia) solution for 15 min. 
Following staining, slides were rinsed briefly in distilled water and again in 70% ethanol 
before dehydration in 100% ethanol (2 x 3 min). Finally, sections were immersed briefly 
in two changes of xylene and immediately cover-slipped with DePex mounting medium. 
 
3.2.4 Retroviral administration 
To investigate the origin of the neural stem cells repopulating the injured hippocampus, 
retroviral particles were administered 48 h following KA injury. 
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3.2.4.1 Animals 
Refer to 3.2.1.1. 
 
3.2.4.2 Pre-surgery 
Refer to 3.2.2.1. 
 
3.2.4.3 Stereotaxic injection of retroviral particles 
Expression ready retroviral particles expressing monomeric GFP were sourced from 
Allele Biotechnology (CA, USA) at a viral titre of 109 TU/mL and stored at -80°C until 
ready for use (Figure 3.1). A small burr hole was drilled in the cranium over the injection 
site and mice were given a single unilateral injection of 1.5 μL of retroviral particles (109 
TU/mL) using a 2 μL Hamilton syringe (model # 7002KH, Hamilton, NV, USA) into 
desired co-ordinate (see Table 3.2.) Retroviral particles were injected over the course of 
3 min, at a flow rate of 0.5 μL/min. The injection needle remained in place for an 
additional 5 min following cessation of retroviral injection to allow diffusion of retroviral 
particles into the target brain region and minimise backflow. The incision was closed with 
sutures (Cat # CD0057, Dynek, SA, Australia) and animals were allowed to recover 
overnight in their home cages on heating pads. 
 
 
Figure 3.1. Construct of GFP retrovirus (image obtained from Allele Biotechnology). 
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Table 3.2. Stereotaxic co-ordinates used for injection of retroviral particles. 
Target region Stereotaxic co-ordinate DV Measurement method 
Subventricular zone (SVZ) AP: +0.5 mm 
ML: -1.0mm 
DV: -2.9 mm 
Bregma-zero 
Dentate gyrus (DG) AP: half the distance between 
bregma and lambda 
ML: -1.6mm 
DV: -1.9 mm 
Bregma-zero 
Dorsal hippocampus (dHPC) AP: half the distance between 
bregma and lambda 
ML: -1.5 mm 
DV: -1.8 mm 
Bregma-zero 
 
 
3.2.5 Inactivation of newly generated cells following KA injury 
3.2.5.1 Tamoxifen administration 
(Z)-4-hydroxytamoxifen (tamoxifen; Cat # H7904, Sigma-Aldrich (now Merck 
Millipore), NSW, Australia), was made up in solution at a concentration of 18 mg/mL. 
Tamoxifen was first dissolved in 100% ethanol at a volume that was 10% of final solution 
volume. The remainder of solution volume was made up with the addition of sunflower 
oil to achieve final concentration of 18 mg/mL. Solution was sonicated until tamoxifen 
was completely mixed in solution. Tamoxifen solution was protected from light and 
stored at 4°C for up to 7 d. Immediately prior to use, tamoxifen solution was heated to 
37°C in a portable water bath and maintained at this temperature for all injections. Mice 
received an intraperitoneal body weight injection of tamoxifen solution (180 mg/kg), 
commencing on the third day following KA or PBS injection. Mice continued to receive 
intraperitoneal body weight injections of tamoxifen solution every other day for 20 d 
following KA or PBS injection, resulting in a total of 10 intraperitoneal injections of 
tamoxifen solution per animal.  
 
3.2.5.2 Cannula implantation surgery 
8 weeks following KA or PBS injection, animals were prepared for stereotaxic surgery 
as described in 3.2.1.2. Unilateral guide cannulae (Cat # C315GRL4/SPC, PlasticsOne, 
VA, USA) were implanted targeting the dorsal hippocampus at co-ordinates from bregma: 
AP -1.8 mm, ML -1.5 mm and projected 0.8 mm below the pedestal (DV -0.8 mm from 
Chapter 3: Functional significance of injury-induced neurogenesis 
 
126 
bregma). Cannulae were fixed to the skull using dental acrylic (Dentavision, NSW, 
Australia). Cannulae were capped with a dummy (Cat # C315DC/SPC, PlasticsOne) at 
all times and dummy cannulae were replaced every other day until AL infusion. The 
injector cannulae (Cat # C3151/SPC, PlasticsOne) were 33 gauge and projected 1.0 mm 
below the end of the guide cannula, to a total DV depth of -1.8 mm from bregma. Mice 
were given 2 weeks to recover prior to behavioural testing.  
 
3.2.5.3 Allatostatin administration 
3.2.5.3.1 Preparation of allatostatin peptide 
A stock solution of 100 μM allatostatin 3 peptide (AL; Drm-AST-3, Cat # 037-11, 
Phoenix Pharmaceuticals, CA, USA) diluted in sterile water was prepared and aliquoted 
in 100 μL volumes. Stock solution was stored at -20°C for a maximum of 3 months (as 
per supplier’s recommendation). Immediately prior to AL infusion, one aliquot of stock 
solution was thawed and diluted to 10 μM in sterile saline. 
 
3.2.5.3.2 Infusion of allatostatin peptide 
Infusions were carried out using injectors connected via P50 tubing to a 25 μL Hamilton 
syringe (model # 702N, Hamilton, NV, USA) driven by an infusion pump (Harvard 
Apparatus, MA, USA). To investigate the functional significance of the newly generated 
neurons following KA-induced excitotoxic injury, 10 μM AL was administered via 
cannula 30 min prior to behavioural testing. AL solution was infused at a rate of 0.25 
μL/min for a total infusion volume of 0.5 μL. The injector was left in place for an 
additional 1 min before removal to minimise backflow. 
 
3.2.5.4 Behavioural analysis 
Behavioural testing was used to determine the hippocampal function of the newly 
generated cells. Behavioural testing experiments were conducted by Dr Raphael Zinn, 
Lyndsey Konen and Jessica Leake.  
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3.2.5.4.1 Contextual fear conditioning 
Training and testing took place in two identical cube-shaped fear conditioning chambers 
(32 x 27 x 26cm; Med Associates Inc., VT, USA; see Figure 3.2 for example of chamber 
setup) located in the same room. Chambers had a clear plexiglass door, ceiling and rear 
wall with grey aluminium side walls. A removable grid floor consisting of 36 parallel 
rods spaced 8mm apart was inside each chamber. A removable grey aluminium tray was 
positioned under the grid floor for waste collection. The rods were connected to a shock 
generating and scrambling system, which delivered a current to elicit a mild foot shock. 
This system was controlled by computer software (FreezeFrame2, Actimetrics, IL, USA). 
During training and testing, behaviour of the mice was recorded by a video camera 
positioned in front of the chambers.  
The chambers served as the context (context A). Context A, the conditioning context, 
consisted of cleaning the chamber with 70% ethanol and scenting the waste tray with 5 
drops of aniseed essence. Mice were carried into the fear conditioning room in their 
homecages under full fluorescence. The fear conditioning room was also fully lit, 
permitting full vision of the room from within the chambers. A houselight was also turned 
on during training and testing.  
On conditioning day (day 1), mice were exposed to the context A chamber for 180 s prior 
to presenting a mild foot shock (0.8 mA, 2 s duration). Following shock, mice remained 
in the chamber for 30 s before being returned to their home cages. Long-term memory 
testing took place in context A 24 h following conditioning day (day 2). No further shock 
was applied on day 2.  
The conditional response used to track memory was freezing. Freezing is a species 
specific fear response defined as the absence of all movement, except that necessary for 
breathing (Fanselow, 1986). During each session, freezing of each animal was scored at 
4 second intervals for the first 3 min, yielding 45 samples per mouse. The number of 
samples in which mice were freezing was divided by the total number of samples to yield 
a freezing percentage per mouse. Group averages were used for analysis. 
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Figure 3.2. Example of fear conditioning chamber setup. 
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3.2.6 Analysis of cell populations 
3.2.6.1 Tissue preparation 
Mice were anesthetised with an intraperitoneal injection of ketamine (100 mg/kg) and 
xylazine (20 mg/kg) mixture and transcardially perfused with ice-cold 0.9% sodium 
chloride followed with ice-cold 4% PFA (Cat # P6148-1kg, Sigma Aldrich, NSW, 
Australia; pH 7.3-7.5) in 1x PBS at various time-points following KA injury (see Table 
3.3). Brains were harvested and post-fixed in 4% PFA in 1x PBS for 6-8 h, cryoprotected 
in 30% sucrose for 2-3 d until brains had sunk. Brains were prepared for cryosectioning 
by cutting away 2-3 mm of cerebellum to make a flat surface, before placing in a peel-
away mould containing OCT medium and storing at -80°C. Brains were cryostat 
sectioned into 40 μm thick slices at -16°C with each vial containing every sixth slice. 
Sections were stored at 4°C in 5 mL vials containing 0.02% sodium azide in 1x PBS. 
 
Table 3.3. Summary of tissue harvest time-points following KA injury. 
Section reference number Additional treatments following KA injury Tissue harvest time-points 
3.3.2 Stereotaxic injection of retroviral particles 3 d post-retroviral injection 
5 d post-retroviral injection 
7 d post-retroviral injection 
2 weeks post-retroviral injection 
8 weeks post-retroviral injection 
3.3.4 Tamoxifen intraperitoneal injections 
Cannula implantation 
Allatostatin peptide infusion 
72 d post-KA injury 
3.3.5 Tamoxifen intraperitoneal injections 
Cannula implantation 
Allatostatin peptide infusion 
2 weeks post-KA injury 
4 weeks post-KA injury 
10 weeks post-KA injury 
3.3.6 Tamoxifen intraperitoneal injections 8 weeks post-KA injury 
 
 
3.2.6.2 Fluorescent immunohistochemistry 
Tissue sections were washed in 1x PBS (3 x 10 min), then blocked in 3% BSA (Cat # 
BSAS1.0, Bovogen Biologicals, VIC, Australia) + 0.25% Triton X-100 in 1x PBS (1 h, 
RT). Sections were subsequently incubated in the primary antibody diluted in blocking 
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solution for 72 h at 4°C. Sections were then washed in 1x PBS (3 x 10 min) prior to 
incubation in secondary antibody (Invitrogen, VIC, Australia) diluted in blocking solution, 
overnight in the dark at 4°C. Details of the antibodies used in this chapter are provided in 
Table 3.4.  
For co-immuno-labelling, the above steps were repeated with antibodies targeting the 
second protein of interest. On the final day, sections were washed in 1x PBS (3 x 10 min) 
prior to incubation in the counterstain, DAPI, diluted in 1x PBS (1:1000 dilution) at RT 
for 10 min. Afterwards, sections were washed in 1x PBS (3 x 10 min) prior to being 
mounted onto SuperFrost-plus glass slides (Cat # SF41296PL, Lomb Scientific, NSW, 
Australia) and cover-slipped with 50% glycerol-gelatin mounting medium (Cat # GG1-
10X15ML, Merck, MA, USA) diluted in 1x PBS. 
 
Table 3.4. Summary of antibodies utilised for immunohistochemistry. 
Primary 
antibody 
Target Concentration Supplier Secondary 
antibody 
Concentration Used 
in 
figure 
Goat anti-
GFP 
GFP-
expressing 
cells 
1:500 Abcam 
Cat # 
AB6673 
Donkey 
anti-goat 
(H&L) 488 
1:250 3.2 
Rabbit anti-
GFP 
GFP-
expressing 
cells 
1:500 Life 
Technologies 
Australia 
Cat # A-
11122 
Goat anti-
rabbit (H&L) 
488 
1:250 3.2; 
3.6; 
3.7 
Mouse anti-
GFP 
GFP-
expressing 
cells 
1:500 Thermo 
Fisher 
Scientific 
Cat # GF28R 
Goat anti-
mouse 
(H&L) 488 
1:250 3.2; 
3.3 
Mouse anti-
rat nestin 
Neural 
precursor 
cells 
1:1000 BD 
Biosciences 
Cat # 556309 
Goat anti-
mouse 
(H&L) 568 
1:250 3.6 
Rabbit anti-
doublecortin 
(DCX) 
Immature 
neurons 
1:100 Sapphire 
Bioscience 
Cat # 
AB18723 
Goat anti-
rabbit (H&L) 
568 
1:250 3.6 
Mouse anti-
neuronal 
nuclei 
(NeuN) 
Mature 
neurons 
1:250 Millipore 
Cat # 
MAB377 
Goat anti-
mouse 
(H&L) 568 
1:250 3.6; 
3.7 
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3.2.6.3 Image acquisition 
All images were obtained using Leica DMI 6000 SP8 inverted laser scanning confocal 
microscope (Leica Microsystems, Wetzlar, Germany) equipped with laser excitation lines 
of 405 nm, 488 nm, 552 nm, and 638 nm. Low and high magnification images were 
acquired using a 20x dry objective, and a 40x and 100x oil objectives, respectively. 
Images were processed and analysed using Adobe Photoshop CS6 (Adobe, CA, USA) 
and Fiji software (Schindelin et al., 2012). 
 
3.2.7 Genetic sequencing 
Sequencing experiments were conducted with the assistance of Lyndsey Konen. Genomic 
DNA samples used for gene sequencing were obtained from tail biopsies as per the DNA 
extraction method described in 3.2.1.3. The Cre-ERT2 gene sequence was obtained from 
addgene.org (pCAG-CreERT2). As gene sequencing is optimal with PCR product sizes 
up to around 500bp, two sets of overlapping primer sequences were used to cover 
the >1,000 bp Cre sequence. Primers 1F and 1R corresponded to the first half of the 
sequence (PCR 1) and were as follows: primer 1F – 5’-GAC CGT ACA CCA AAA TTT 
GCC-3’; and primer 1R – 5’-AGC AAT CCC CAG AAA TGC CA-3’. Primers 2F and 
2R corresponded to latter half of the Cre sequence (PCR 2) and were as follows: primer 
2F – 5’-GTT TCA CTG GTT ATG CGG CG-3’; and primer 2R – 5’-TCC AGA CCA 
GGC CAG GTA TCT C-3’. A PCR reaction containing 2.5x 5Prime HotMaster mix, 20 
μM primers and 2 μL template DNA was run using the following amplification conditions: 
95°C for 2 min followed by 35 cycles of 95°C for 30 sec, 55°C (for PCR 1) or 58°C (for 
PCR 2) for 1 min, 72°C for 1 min and a 10 min incubation at 72°C at the end of the run. 
PCR products were purified using QIAquick PCR Purification kit (Qiagen, VIC, 
Australia) according to manufacturer’s instructions followed by measurement of DNA 
concentration. Up to 10 ng/μL per sample was combined with 3.2 pmol of forward or 
reverse primer and the mixture was dried. Samples were sequenced by the Garvan 
Institute Molecular Genetics Facility using an ABI3130XL Genetic Analyzer (Applied 
Biosystems, CA, USA) with Big Dye 3.0 chemistry. Sequences were assembled and 
analysed using Finch TV (Geospiza Inc.) and sequence alignment with the Cre-ERT2 gene 
sequence was conducted using the European Molecular Biology Open Software Suite 
(EMBOSS) Needle Nucleotide Alignment tool (Li et al., 2015). 
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3.2.8 Statistical Analysis 
All statistical analyses were performed using GraphPad Prism Version 7.0 (GraphPad 
Software, Inc). Data was tested for normality using the Shapiro-Wilks test. For survival 
analysis, Kaplan-Meier survival plot with Mantel-Cox test was conducted. For all other 
graphical representations, data are presented as mean with SEM. For all statistical tests, 
a p value of ≤ 0.05 was considered to be significant. 
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3.3 Results 
3.3.1 Confirming retrovirus placements 
In order to determine the origin of the stem cells giving rise to the suspected regenerated 
neurons observed in the CA1 and CA3 regions following KA injury, we used retroviral 
vectors to label proliferating cells. To do this, we chose three key locations which we 
hypothesised could be the birthplace of these stem cells: SVZ, SGZ in the DG and the 
dorsal hippocampus (dHPC), which includes the CA1 and CA3 regions where we have 
previously observed neurogenesis (see section 2.3.1 and Abdipranoto-Cowley et al., 
2009). These locations were first validated prior to the injection of retroviral particles. 
 
3.3.1.1 Dura-zero produces inconsistent injections to SVZ and dHPC co-ordinates 
For validation of retrovirus injection co-ordinates, co-ordinates for the SGZ and dHPC 
were based on measurements previously trialled by our group and others (Zhao et al., 
2006). Because the SVZ co-ordinate was more exploratory and had not been previously 
utilised in our laboratory, we trialled two different co-ordinates for the SVZ (i.e., SVZ1 
and SVZ2; Table 3.5) to see which co-ordinate would yield more consistent results. SVZ1 
was chosen based on estimates from the brain atlas, while SVZ2 was based on previously 
published co-ordinates for retroviral injection (Yamada et al., 2004). 
As these experiments were performed concurrently with those in Chapter 2, stereotaxic 
AP and ML co-ordinates were measured from bregma, while DV co-ordinates were 
measured from dura (dura-zero). All animals received a sham injection using the dura-
zero method of stereotaxic injection aimed at the desired co-ordinate and tissue was 
immediately collected. For stereotaxic co-ordinates used in this experiment, refer to Table 
3.5. Utilising dura-zero method for measuring stereotaxic injection co-ordinates yielded 
only 50% accuracy for both SVZ1 and SVZ2 co-ordinates (Table 3.5). Meanwhile, the 
precision of injection for SVZ1 was consistent, with 2 out of 2 animals having been 
injected at approximately AP +0.5 mm, ML -0.8 mm and DV -2.9 mm, while the precision 
of injection was not consistent for SVZ2 co-ordinate. The DG co-ordinate injected to the 
target location in 2 out of 3 animals and furthermore, precision of injection was also 
consistent in 2 out of 3 animals, having been injected at approximately AP -2.06 mm, ML 
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-1.2 mm and DV -1.9 mm. The dHPC co-ordinate injected to the target location in only 1 
out of 3 animals and precision was similarly poor, consistent in only 1 out of 3 animals. 
 
Table 3.5. Summary of results for experiment 3.3.1.1. 
Target 
region 
Stereotaxic 
co-ordinate 
(mm) 
Measure-
ment 
method 
Accuracy Mouse Atlas target Representative 
image 
Subventricula
r zone 
location 1 
(SVZ1) 
AP: +0.5 
mm 
ML: -1.0 mm 
DV: -2.9 mm 
Dura-zero 1/2 = 
50% 
 
Bregma +0.50 mm  
Subventricula
r zone 
location 2 
(SVZ2) 
AP: ±0.0 
mm 
ML: -1.7 mm 
DV: -3.0 mm 
Dura-zero 1/2  = 
50% 
 
Bregma +0.02 mm  
Dentate gyrus 
(DG) 
AP: half the 
distance 
between 
bregma and 
lambda 
ML: -1.6 mm 
DV: -1.9 mm 
Dura-zero 2/3 = 
66.66% 
 
Bregma -2.06 mm 
 
Dorsal 
hippocampus 
(dHPC) 
AP: -1.8 mm 
ML: -1.5 mm 
DV: -1.8 mm 
Dura-zero 1/3 = 
33.33% 
 
Bregma -1.82 mm 
 
Black scale bar is 1 mm, red scale bar is the length of the corresponding DV co-ordinate for that image. Red dot 
represents target co-ordinate, green dots represent approximate injected DV co-ordinate (yellow dots represent a 
differing AP co-ordinate from that shown in mouse atlas target). 
 
In summary, the results of the present experiment suggest measuring stereotaxic co-
ordinates from dura-zero does not produce consistent results for SVZ or dHPC co-
ordinates. 
 
3.3.1.2 Bregma-zero produces consistent injections to hippocampal co-ordinates 
Our previous results showed that measuring stereotaxic co-ordinates from dura-zero does 
not yield consistent results for SVZ or dHPC co-ordinates. However, the accuracy for DG 
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appeared sufficient. As mouse brains can often vary in size (Badea et al., 2007; Chen et 
al., 2006), measuring the distance between bregma and lambda and travelling half that 
distance to achieve AP co-ordinate for hippocampal regions seemed logical. Thus, we 
modified our dHPC co-ordinate to measure AP in the same way as the DG co-ordinate. 
Additionally, as we found with ICV injections in Chapter 2, measuring dorsoventral co-
ordinates from the dura is not consistently accurate. Therefore, stereotaxic co-ordinates 
were subsequently measured from bregma (bregma-zero). 
All animals received a sham injection using the bregma-zero method of stereotaxic 
injection aimed at the desired co-ordinate and tissue was immediately collected. For 
stereotaxic co-ordinates used in this experiment, refer to Table 3.6. Utilising the bregma-
zero method for measuring stereotaxic injection co-ordinates yielded 66.66% accuracy 
for SVZ1, reaching the target location in 4 out of 6 animals (Table 3.6). Precision of 
injection was also consistent in 4 out of 6 animals, having been injected at approximately 
AP +0.5 mm, ML -1.0 mm and DV -2.9 mm. In comparison, utilising the SVZ2 co-
ordinate only yielded 50% accuracy, reaching the target location in 3 out of 6 animals. 
Precision of injection was also consistent in only 3 out of 6 animals, having been injected 
at approximately AP ±0.0 mm, ML -1.7 mm and DV -3.0 mm. A high level of accuracy 
for hippocampal co-ordinates was achieved in the DG and dHPC, with both co-ordinates 
yielding 83.33% accuracy. Furthermore, precision of injection was also consistent in 5 
out of 6 animals for both hippocampal co-ordinates, having been injected at 
approximately AP -2.06 mm, ML -1.6 mm and DV -1.9 mm for the DG co-ordinate and 
approximately AP -2.06 mm, ML -1.5 mm and DV -1.8 mm for the dHPC co-ordinate. 
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Table 3.6. Summary of results for experiment 3.3.1.2. 
Target 
region 
Stereotaxic 
co-ordinate 
(mm) 
Measure-
ment 
method 
Accuracy Mouse Atlas target Representative 
image 
Subventricula
r zone 
location 1 
(SVZ1) 
AP: +0.5 
mm 
ML: -1.0 mm 
DV: -2.9 mm 
Bregma-
zero 
4/6 = 
66.66% 
 
Bregma +0.50 mm  
Subventricula
r zone 
location 2 
(SVZ2) 
AP: ±0.0 
mm 
ML: -1.7 mm 
DV: -3.0 mm 
Bregma-
zero 
3/6 = 
50% 
 
Bregma +0.02 mm  
Dentate gyrus 
(DG) 
AP: half the 
distance 
between 
bregma and 
lambda 
ML: -1.6 mm 
DV: -1.9 mm 
Bregma-
zero 
5/6 = 
83.33% 
 
Bregma -2.06 mm 
 
Dorsal 
hippocampus 
(dHPC) 
AP: half the 
distance 
between 
bregma and 
lambda 
ML: -1.5 mm 
DV: -1.8 mm 
Bregma-
zero 
5/6 = 
83.33% 
 
Bregma -2.06 mm 
 
Black scale bar is 1 mm, red scale bar is the length of the corresponding DV co-ordinate for that image. Red dot 
represents target co-ordinate, green dots represent approximate injected DV co-ordinate (yellow dots represent a 
differing AP co-ordinate from that shown in mouse atlas target). 
 
In summary, the results of the present experiment suggest measuring stereotaxic co-
ordinates from bregma-zero, combined with using half the distance between bregma and 
lambda as the AP co-ordinate, is sufficient for consistently injecting to hippocampal co-
ordinates. Furthermore, as SVZ1 co-ordinate yielded better accuracy than SVZ2, this 
measurement was selected for retroviral injection into the SVZ.  
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3.3.2 Monoclonal mouse antibody against GFP produces sufficient labelling of 
retroviral-infected cells 
Our previous results validated the injection co-ordinates to be used for injection of 
retrovirus (see Table 3.2). Our next aim was to validate the efficacy of different anti-GFP 
antibodies for immunohistochemistry that would allow us to visualise the GFP expression 
as previous pilot studies found that retroviral GFP expression alone was insufficient (data 
not shown). The purpose of the following experiment was to trial three different suppliers 
of anti-GFP primary antibodies to determine which primary antibody gives the optimal 
signal for labelling retroviral-infected cells. 
C57BL/6 mice were stereotaxically injected with GFP-retroviral particles into the SVZ 
48 h following KA and tissue was collected 7 d following retroviral injection. Tissue 
sections were immuno-labelled with various GFP antibodies (see Table 3.7) and 
counterstained with DAPI.  
Cellular autofluorescence was substantially higher in SVZ tissue sections stained with 
goat and rabbit antibodies, while tissue sections stained with mouse GFP antibody 
produced positive labelling of retroviral-infected cells co-labelled with DAPI in the 
absence of endogenous autofluorescence (Figure 3.3). 
In summary, these results show that mouse anti-GFP antibody produces sufficient 
labelling of GFP retroviral-infected cells. 
 
Table 3.7. Summary of GFP antibodies trialled for immunohistochemistry. 
Primary 
antibody 
Concentration Supplier Secondary 
antibody 
Supplier Concentration 
Goat pAb to 
GFP 
1:500 Abcam 
Cat # AB6673 
Goat anti-
rabbit 488 
Invitrogen 1:250 
Rabbit pAb 
anti-GFP 
1:500 Life Technologies 
Australia 
Cat # A-11122 
Goat anti-
mouse 488 
Invitrogen 1:250 
Mouse mAb 
anti-GFP 
1:500 Thermo Fisher 
Scientific Cat # 
GF28R 
Donkey anti-
goat 488 
Invitrogen 1:250 
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Figure 3.3. Monoclonal mouse antibody against GFP produces sufficient labelling of retroviral-infected cells. 
(A-F) Confocal images of GFP (green) and DAPI (blue) immunostaining in the SVZ of mice at 7 d post-retroviral 
injection using goat anti-GFP antibody (A-B), mouse anti-GFP antibody (C-D), and rabbit anti-GFP antibody (E-F). 
Magnified regions show absence of GFP labelling using goat (B) and rabbit (F) while mouse anti-GFP antibody co-
labelled with nuclear marker DAPI. 
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3.3.3 GFP expression varies across mice at 2 weeks post-retroviral injection 
Our previous results showed that mouse anti-GFP antibody produces sufficient labelling 
of GFP retroviral-infected cells. Our next aim was to determine the origin of the neural 
stem cells that repopulate the injured hippocampus. The existence of two key neurogenic 
regions in the adult mammalian brain is well established (SVZ and SGZ). In addition, 
neurogenesis following injury has previously been observed outside of these regions (see 
sections 1.4.1.2 and 1.4.2.2). As previously described, three key locations were 
hypothesised to be the potential birthplace of these stem cells: SVZ, SGZ in the DG and 
the dHPC. 
In order to investigate the origin of the stem cells along with observing their 
developmental trajectory, C57BL/6 mice were stereotaxically injected with GFP-
retroviral particles into the SVZ, DG, and dHPC 48 h following KA or PBS and tissue 
was collected at 3 d, 5 d, 7 d, 2 weeks and 8 weeks following retroviral injection. We 
commenced our analysis with tissue where retroviral particles had been injected into the 
SVZ as this is one of the well-established neurogenic regions. Thus, SVZ retroviral-
injected tissue sections were immuno-labelled with mouse anti-GFP antibody and 
counterstained with DAPI. 
GFP expression was similar in SVZ tissue sections collected at 5 d and 2 weeks following 
retroviral injection (Figure 3.4A-B). However, when analysing the 2 week tissue, we 
noticed variations in GFP expression from different mice. In mouse 1, GFP expression 
was observed in the cellular processes (Figure 3.4C-D), while in mouse 2, the GFP 
expression was localised to the cell nucleus (Figure 3.4E-F). This was unexpected. 
Although our initial intention was to analyse the other time-points by co-immuno-
labelling GFP with various markers of neuronal development, these preliminary results 
indicated to us that the retrovirus we had sourced may not be appropriate for our 
experimental investigations as expression was varied across animals within the same 
tissue collection time-point. Furthermore, expression appeared to be diffuse throughout 
the cell making lineage tracing with other markers of neuronal fate problematic and 
therefore precluded us from continuing these experiments. In summary, the results of the 
present experiment show variations in GFP expression across mice, suggesting 
incompatibility for our experimental pursuits. 
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Figure 3.4. GFP expression varies across mice at 2 weeks post-retroviral injection. (A-F) Confocal images of GFP 
(green) and DAPI (blue) immunostaining in the SVZ of mice at 5 d (A) and 2 weeks (B-F) post-retroviral injection. 
GFP expression in mice 2 weeks post-retroviral injection was different across mice (C-F). Magnified regions in the 
SVZ show GFP expression in the cellular processes of mouse 1 (D), while GFP expression was localised to the cell 
nucleus in mouse 2 (F). 
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3.3.4 Optimisation of tamoxifen administration following KA injury 
Excitotoxic injury has previously been shown to stimulate cell proliferation in the DG for 
up to 3 weeks (Parent et al., 1997). As our tamoxifen-inducible Cre/LoxP system is driven 
by nestin, a marker of neural progenitor cells (Reynolds & Weiss, 1992), we desired 
maximal activation of neural progenitor cells following KA injury in order to observe the 
functional effect of turning off these newly generated cells with the allatostatin 
inactivation system during behavioural testing. Prior pilot studies by our group showed 
that once-daily injections of tamoxifen solution for 5 d resulted in high mortality (data 
not shown). Thus, it would not have been practical to inject our animals with tamoxifen 
solution daily for 20 d. Therefore, we trialled a protocol whereby tamoxifen solution was 
administered every other day for 20 d.  
C57BL/6, AlstR-cre+ and wild-type littermates (AlstR-cre-) received either 1 mg/mL KA 
or PBS via ICV injection. Beginning on the third day following injury, animals received 
a once-daily intraperitoneal injection of tamoxifen solution (180 mg/kg) every other day, 
lasting 20 d for a total of 10 injections per animal. Due to the viscosity of the tamoxifen 
solution, the solution was heated immediately prior to intraperitoneal injections to 
facilitate administration. Our initial method for heating the tamoxifen solution involved 
use of a microwave. However, over the course of the experiment, we noticed high 
mortality in KA-injected mice (regardless of genotype) receiving tamoxifen solution 
(65.22% survival; Figure 3.5A) compared with PBS-injected controls receiving 
tamoxifen solution (100% survival) heated with this method. We therefore modified the 
method used for heating the tamoxifen solution by instead heating via 37°C water bath. 
A noticeable decrease in mortality of KA-injected mice receiving water bath-heated 
tamoxifen (90.91% survival) was observed compared with KA-injected mice that had 
previously received microwave-heated tamoxifen. A Kaplan-Meier survival plot with 
Mantel-Cox test revealed a significant increase in survival of KA-injected mice that 
received water bath-heated tamoxifen solution compared to mice that received 
microwave-heated tamoxifen solution (χ2(1,86) = 5.067, p = 0.0244; Figure 3.5B). 
Therefore, our results demonstrate that heating tamoxifen solution in the water bath aids 
in the survival of KA-injected mice receiving tamoxifen.  
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 Total animals 
entered study 
Premature mortality 
(0-8 weeks post-KA 
injection) 
Total n’s surviving at 8 
weeks post-injection / % 
survival 
KA, microwave 23 8 15 = 65.22% 
PBS, microwave 6 0 6 = 100% 
KA, water bath 33 3 30 = 90.91%    
PBS, water bath 24 0 24 = 100% 
 
 
 
Figure 3.5. Water bath-heated tamoxifen solution improves survival of KA-injected animals. (A) Mortality and 
survival data of PBS- and KA-injected animals receiving microwave- or water bath-heated tamoxifen solution. (B) 
Kaplan-Meier survival plot of KA-injected mice that received microwave- or water-bath-heated tamoxifen solution.  
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3.3.5 No difference in fear memory of mice administered allatostatin compared with 
saline 
Prior studies from our group have demonstrated that KA-induced hippocampal injury 
results in spontaneous neuron repopulation in the CA1 and CA3 hippocampal regions at 
8 wpi (see Figure 2.2 and Abdipranoto-Cowley et al., 2009) as well as cognitive recovery 
measured in a contextual fear conditioning paradigm (see Appendix Figure 6.2). We now 
seek to characterise the potential role in which the newly generated neurons participate in 
hippocampal-dependent learning tasks. Contextual fear conditioning is a commonly used 
assay of memory which can be used to track changes in fear memory of rodents (Maren 
et al., 2013). In order to determine whether the newly generated cells are participating in 
learning and memory functions, AlstR-cre+, AlstR-cre- and C57BL/6 (WT) mice were 
administered AL 30 min prior to conditioning on day 1 of the contextual fear conditioning 
paradigm (Figure 3.6A). Utilising the tamoxifen-inducible Cre/LoxP system, the nestin 
gene promoter drives expression of Cre recombinase in neural precursor cells, which 
removes the loxP-flanked stop codon allowing expression of the AlstR and eGFP in 
neural precursor cells. Therefore, following tamoxifen treatment, only neural precursor 
cells will express Cre recombinase allowing expression of eGFP and the AlstR in these 
cells, which will persist as they mature. Binding of the AL to the AlstR causes the cell to 
hyperpolarise (through activation of G-protein-coupled inward rectifying K+ channels), 
preventing any action potentials from being elicited and thereby temporarily shutting off 
neurotransmission in our newly generated neuron population (Tan et al., 2006). Upon 
clearance of AL from the extracellular space, the cell repolarises and normal transmission 
is restored. 
Due to the extensive length of the study, along with various challenges associated with 
the experimental protocol, 51 animals were removed from the final analysis, resulting in 
< 3 replicates for some groups (Figure 3.6B; also see Appendix Table 6.10) and thereby 
precluding statistical analyses. Additionally, due to limitations in animal availability 
within the Nescre-ERT2/R26-AlstR mouse colony at the time of testing, not all 
appropriate control groups could be included and, additionally, some treatment groups 
had a low number of replicates. Nevertheless, the patterns observed enabled us to draw 
useful conclusions. 
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As described in 3.2.5.4, all animals were exposed to context A on conditioning day (day 
1). 24 h following conditioning day, animals were re-exposed to the same context (day 
2). Average freezing on day 2 is presented in Figure 3.6B. As expected, all PBS-injected 
animals exhibited similar levels of freezing (WT, PBS+saline: mean = 38.54, SEM = 
3.125; AlstR-cre+, PBS+AL: mean = 28.95, SEM = 4.255; AlstR-cre-, PBS+AL: mean = 
32.64, SEM = 4.861; Figure 3.6C). However, all KA-injected animals exhibited similar 
levels of freezing (WT, KA+saline: mean = 14.58, SEM = 3.182; AlstR-cre+, KA+saline: 
mean = 10.94, 7.672; AlstR-cre+, KA+AL: mean = 9.603, SEM = 2.02; AlstR-cre-, 
KA+AL: mean = 25, SEM = 0) that was lower than their PBS-injected counterparts. 
Furthermore, KA-injected AlstR-cre+ mice receiving AL froze at similar levels to KA-
injected AlstR-cre+ mice receiving saline, thus indicating a deficit in fear memory 
regardless of whether or not AL was administered. Overall, these results show no 
differences in freezing across injury. Additionally, mice administered AL do not behave 
differently compared to mice administered with saline suggesting a lack of cognitive 
recovery after KA injury, which is inconsistent with our unpublished data.  
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Figure 3.6. No difference in fear memory of mice administered allatostatin compared with saline. (A) 
Experimental protocol. (B) Mortality data for all animals entered into experiment. (C) Behavioural results from long-
term memory test 24 h after context acquisition. All values in (C) represent the mean ± standard error of the mean 
(SEM). 
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3.3.6 No evidence of eGFP-labelled cells in the hippocampal CA1 region of KA-
injected AlstR-cre+ mice 
Our previous results showed no difference in fear memory of KA-injected mice 
administered AL compared with saline. This suggests either a lack of cognitive recovery 
following KA injury or a complication with the experimental procedure such as secondary 
brain injury from cannulae implantation. 
In the following experiment, we sought to investigate the cellular identity of eGFP 
labelled cells in AlstR-cre+ mice at different time points following KA injury. AlstR-cre+ 
mice received KA and tissue was collected at 2, 4 and 10 wpi. Tissue collected at 10 wpi 
were from animals which had undergone behavioural testing (see experiment 3.3.5). In 
order to observe the developmental trajectory of the newly generated cells following KA 
injury, tissue from KA-injected animals were co-immuno-labelled with GFP and various 
markers of neuronal development (see Table 3.4). The DG, CA1 and CA3 hippocampal 
regions were analysed (Figure 3.7). 
In the CA1, we found no evidence of co-immuno-labelling of eGFP with nestin at 2 wpi, 
DCX at 4 wpi or NeuN at 10 wpi (Figure 3.7A-F), suggesting newly generated cells were 
not present and did not mature in this region following KA injury. 
In the CA3, we observed co-immuno-labelling of eGFP with nestin at 2 wpi (Figure 3.7G-
H). However, no evidence of co-immuno-labelling of eGFP with DCX at 4 wpi or NeuN 
at 10 wpi was observed in the CA3 (Figure 3.7I-L). This suggests that neuronal precursor 
cells were present in the CA3 at 2 wpi but did not persist or mature in the CA3 later in 
development. 
In the DG, we observed co-immuno-labelling of eGFP with nestin at 2 wpi (Figure 3.7M-
N) and NeuN at 10 wpi (Figure 3.7Q-R). Cells immuno-labelled with eGFP and DCX 
appear to have cross-reacted and therefore results cannot be assessed (Figure 3.7O-P). 
These results are in agreement with previous studies showing neurogenesis following 
KA-induced injury in the DG (Jessberger & Parent, 2015). 
Supplementary analyses using NeuN immunohistochemistry and cresyl violet histology 
revealed persistent hippocampal neurodegeneration in KA-injected AlstR-cre+ mice 10 
wpi (see Appendix Figure 6.6). 
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In summary, our results demonstrate no evidence of eGFP-labelled cells in the 
hippocampal CA1 region and no evidence of newly generated mature neurons in the CA1 
or CA3 regions of KA-injected AlstR-cre+ mice. Thus, these results suggest a lack of 
neuronal regeneration that is consistent with our lack of cognitive recovery in KA-
injected mice. 
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Figure 3.7. No evidence of eGFP-labelled cells in the hippocampal CA1 or CA3 regions of KA-injected AlstR-
cre+ mice. (A-B, G-H, M-N) Confocal images of eGFP (green) and nestin (red) immunostaining in the CA1 (A-B), 
CA3 (G-H), and DG (M-N) of KA-injected AlstR-cre+ mice at 2 wpi. (C-D, I-J, O-P) Confocal images of eGFP (green) 
and DCX (red) immunostaining in the CA1 (C-D), CA3 (I-J), and DG (O-P) of KA-injected AlstR-cre+ mice at 4 wpi. 
(E-F, K-L, Q-R) Confocal images of eGFP (green) and NeuN (red) immunostaining in the CA1 (E-F), CA3 (K-L) and 
DG (Q-R) of KA-injected AlstR-cre+ mice at 10 wpi. Magnified regions in the CA1 show absence of co-immuno-
labelling of eGFP with nestin (B), DCX (D), or NeuN (F). Magnified regions in the CA3 show co-immuno-labelling 
of eGFP with nestin (H) and absence of co-immuno-labelling of eGFP with DCX (J) and NeuN (L). Magnified regions 
in the DG show co-immuno-labelling of eGFP with nestin (N) and NeuN (R), and cross-reactivity of cells immuno-
labelled with eGFP and DCX (P). 
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3.3.7 eGFP expression present in AlstR-cre+ and AlstR-cre- mice 
During our immunohistochemical analysis of AlstR-cre+ mouse brain tissue in the 
previous experiment (section 3.3.6), we observed eGFP expression in tissue from both 
AlstR-cre+ and AlstR-cre- mice. The eGFP staining pattern in the DG of AlstR-cre- mice 
was identical to that of AlstR-cre+ mice 8 weeks following KA injury (Figure 3.8). This 
was highly unexpected as, prior to commencing experiments with Nescre-ERT2/R26-
AlstR mice, all AlstR-cre- mice had been genotyped as not possessing the Cre-ERT2 gene. 
Furthermore, as previously described in 3.2.1.2, a stop codon precedes the AlstR and 
EGFP genes and this floxed allele is expressed ubiquitously in all cells as it is driven by 
the ROSA26 gene promoter. Thus, the presence of the stop sequence prevents AlstR and 
EGFP transcription and subsequent expression in all cells until tamoxifen-induced 
excision of the floxed stop sequence in nestin expressing cells at the time of tamoxifen 
administration. Therefore, it should be impossible to observe eGFP expression in Alst-
cre- animals. To further investigate this phenomenon, we performed gene sequencing of 
the Cre-ERT2 gene using the same genomic DNA that was used to genotype the animals 
at weaning. 
As described in 3.2.7, the Cre-ERT2 gene sequence was obtained from addgene.org 
(pCAG-CreERT2). Two sets of primer sequences were used to cover the Cre sequence 
and a separate PCR was run for each set. Following purification of PCR products, samples 
were submitted to the Garvan Institute Molecular Genetics Facility for sequencing.  
Analysis of sequencing results was performed using FinchTV and EMBOSS Pairwise 
Sequence Alignment tool and revealed all DNA samples from C57BL/6 mice showed no 
amplification of the Cre sequence (Figure 3.9A). All samples from AlstR-cre+ mice 
displayed robust amplification from both primer sets which corresponded to perfect 
sequence alignment to the Cre sequence as well as possessed both the forward and reverse 
primer sequences used in our genotyping protocol (Figure 3.9B; also see Appendix Figure 
6.3). Interestingly, all DNA samples from AlstR-cre- mice revealed strong amplification 
from both primer sets which partially aligned with the Cre sequence and possessed one 
but not both genotyping primer sequences (Figure 3.9C; also see Appendix Figures 6.4 
and 6.5). Thus, our sequencing data suggests that the AlstR-cre- mice are, in fact, not 
negative for Cre and therefore signifies that all data from these animals is confounded. 
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Additionally, the presence of the Cre gene may explain why we observed eGFP 
expression in AlstR-cre- mice (Figure 3.8C-D). 
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Figure 3.8. eGFP expression present in AlstR-cre+ and AlstR-cre- mice. (A-D) Confocal images of eGFP (green) 
and NeuN (red) immunostaining in the DG of KA-injected AlstR-cre+ (A-B) and AlstR-cre- (C-D) mice 8 wpi. 
Magnified regions in the DG show co-immuno-labelling of eGFP with NeuN in both AlstR-cre+ (B) and AlstR-cre- (D) 
mice. 
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Figure 3.9. AlstR-cre+ and AlstR-cre- mice possess the Cre-ERT2 gene sequence. (A-C) Assembly of sequencing results using FinchTV for DNA samples from C57BL/6 (A), AlstR-cre+ (B) 
and AlstR-cre- (C) mice.
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3.4 Discussion 
In this chapter, we aimed to identify the origin of the neural stem cells that repopulate the 
injured hippocampus, along with investigating the functional significance of the newly 
generated neurons following KA-induced excitotoxic injury. Through the process of 
carrying out these aims, we established and optimised a number of protocols that 
enhanced experimental outcomes, as well as hitting a number of experimental roadblocks 
which deterred our investigations. In the following section, we discuss these results in the 
context of the wider literature. We also acknowledge the limitations of the present study, 
make suggestions for future avenues of research, and outline future directions of research 
which will better allow us to fulfil the experimental aims of the present study. 
 
3.4.1 Autofluorescence was observed in the SVZ of KA-injected animals following 
retroviral injection 
Autofluorescence is the natural fluorescence emission of intrinsic biomolecules in 
biological tissue in the absence of exogenous fluorophores (Croce & Bottiroli, 2014). 
Lipofuscin, a biomolecule known to accumulate with age in CNS cells, is a common 
source of endogenous autofluorescence in various mammalian cells (Schnell et al., 1999). 
Endogenous autofluorescence of lipofuscin in mammalian cells is known to possess a 
broad spectral range for excitation, often overlapping with the GFP emission wavelengths 
(Billinton & Knight, 2001). Flavins are another source of endogenous autofluorescence 
in mammalian tissue with a similar emission spectrum to GFP (Croce & Bottiroli, 2014). 
In response to CNS injury, autofluorescence is also known to be increased (Liu et al., 
2002; Riew et al., 2017; Spanswick et al., 2009). Thus, autofluorescence presents a 
confounding factor which may influence immunohistochemical analyses of tissue using 
fluorescent protein markers, and therefore highlights the necessity of including 
appropriate negative controls for histological analyses. 
In the present study, we observed substantial levels of autofluorescence in the SVZ of 
KA-injected animals when trialling various antibodies for GFP detection (Figure 3.3). 
Although the identity of the autofluorescence remains unclear, the cause is likely 
attributable to a combination of the aforementioned factors. What is interesting to note 
however, was that autofluorescence was only present in the tissue sections stained with 
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the goat and rabbit GFP antibodies, and was not present or visible in the mouse GFP 
antibody-stained tissue sections (Figure 3.3). Use of formaldehyde for tissue fixation has 
previously been described to enhance endogenous autofluorescence of flavins (Billinton 
& Knight, 2001). However, as the tissue samples used for the three antibodies were all 
derived from the same mouse brain sample, it is unlikely that variations in tissue fixation 
and processing, or inter-subject variability, were to blame for the variation in 
autofluorescence. Furthermore, tissue samples processed with no antibody application 
also showed similar patterns of autofluorescence to tissue samples processed with GFP 
antibody application (data not shown), eliminating nonspecific binding of the antibodies 
as the cause. 
Previous studies have described various methods for quenching endogenous 
autofluorescence, including histochemical treatment of tissue sections with sodium 
borohydride (Clancy & Cauller, 1998), copper sulphate in ammonium acetate buffer 
(Schnell et al., 1999; Yang et al., 2017), or both (Spitzer et al., 2011). However, chemical 
quenching failed to reduce background autofluorescence in a subpopulation of cells in the 
hippocampus (Spitzer et al., 2011). Hippocampal-injected retroviral tissue was precluded 
from further analysis in the present study due to a combination of time constraints, 
competing experimental priorities with the present and preceding chapter, and 
experimental/ technical complications relating to the retrovirus itself, the latter of which 
we discuss in the following subsection. Nevertheless, analysis of hippocampal subregions 
forms a critical component of our original aims for the present chapter and thus, strategies 
for reducing autofluorescence, if present, should be explored in future studies. Increasing 
the intensity of GFP fluorescence, through the use of specifically enhanced GFPs, is a 
useful method for reducing the potential for experimental confounds resulting from 
endogenous autofluorescence (Billinton & Knight, 2001), and indeed the retrovirus we 
used in the present study was chosen for its brightness and photostability as it was 
engineered to fluoresce 1.6-fold brighter than eGFP and resist photobleaching (Ai et al., 
2008). Nevertheless, future studies involving analysis of the hippocampus may benefit 
from the use of alternative retroviral particles expressing eGFP as our preliminary results 
indicate that this particular virus may not be suitable for our specific experimental 
purposes. 
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3.4.2 Evidence of cell proliferation in the SVZ following KA injury 
Previous studies have shown increases in cellular proliferation following various injuries 
(Niv et al., 2012; Tanaka et al., 2004). Furthermore, increases in cellular proliferation 
following KA-induced injury have been well documented to occur in the DG (Jessberger 
& Parent, 2015). Notably, in the present study, we observed co-localisation of GFP and 
DAPI in the SVZ region of KA-injected animals (Figure 3.3 and 3.4). This result is 
unlikely attributable to autofluorescence, as previous studies have demonstrated that 
autofluorescence does not co-localise with nuclear-specific markers such as DAPI 
(Spanswick et al., 2009). Although the cellular identity of the co-localised cells remains 
to be determined, our result provides preliminary evidence of cellular proliferation 
occurring in the SVZ following KA-induced injury. Whether the cellular proliferation 
observed in this instance constitutes an increase, decrease or identical levels to baseline 
proliferation under physiological conditions remains unclear. Unfortunately, issues 
relating to GFP expression (explained below) precluded further investigations into this 
matter. 
One of the primary problems encountered with use of the retrovirus in the present study 
related to variations in GFP expression across mice (Figure 3.4). In some mice, GFP 
expression was localised to the cell nucleus and visualised as a punctate pattern while in 
others, it appeared to be expressed exclusively in the cellular processes. Various factors 
have previously been described to affect the expression of the GFP reporter gene in fine 
neuronal substructures; these include virus quality and titer, promoter used for GFP tag, 
and the latency between viral infection and tissue analysis (Enikolopov et al., 2015). As 
the tissue from the two separate mice were both treated with the same virus and titer, 
along with identical harvest time-points, it is unlikely that these factors contributed to the 
differential GFP expression patterns observed. Rather, the variations in GFP expression 
observed in our study may be attributable to the skewed, but nevertheless random, mode 
of viral integration following viral transduction (Barquinero et al., 2004), as retroviral-
mediated insertion of viral DNA has previously been described to preferentially integrate 
in gene-rich regions of the host cell’s genome (Wu et al., 2003), or loci exhibiting high 
transcriptional activity (Mitchell et al., 2004). In summary, this result suggests differential 
insertion of the GFP transgene across subjects in our study, making its use unsuitable for 
our experimental purposes. Future studies may benefit from the use of an alternative GFP 
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retrovirus construct that has previously been shown to be successful in rodent studies of 
neurogenesis (e.g., Zhao et al., 2006). 
 
3.4.3 High attrition in KA-injected animals following tamoxifen administration. 
The tamoxifen inducible Cre-loxP recombination system is an important tool for stage-
specific temporal gene expression (Metzger et al., 1995). Although widely used within 
the field of neurogenesis research, the system remains imperfect. One commonly cited 
problem is the issue of tamoxifen toxicity. Previous studies have noted tamoxifen toxicity 
as a problem in achieving sufficient or maximal target gene recombination (Seibler et al., 
2003). Furthermore, tamoxifen toxicity appears apparent regardless of dose administered, 
with one study noting increased morbidity associated with increasing doses of tamoxifen 
(Huh et al., 2012), while another showed that even low doses of tamoxifen resulted in 
adverse side effects (Patel & Sun, 2016). Given the extensive length of the experimental 
protocol in the present study (i.e., animals were subjected to a total of 10 tamoxifen 
injections spanning a 20 d period), there was substantial concern to mitigate these adverse 
side effects in our AlstR mice. 
In the present study, we utilised the Cre-ERT2 system, as previous studies have shown 
that activation of Cre recombinase activity requires a much lower tamoxifen dose than 
the original Cre-ERT system, mitigating the effects of potential tamoxifen toxicity-related 
side effects (Indra et al., 1999). While we substantially improved morbidity in our study 
by maintaining tamoxifen solution at mouse body temperature, nevertheless, through the 
course of our investigations, we consistently noted higher rates of mortality in KA-
injected animals compared with PBS-injected animals. Although the cause of the 
increased morbidity in KA-injected animals is uncertain, it may be related to the 
cumulative effects of tamoxifen administered over the 20 d period. This seems an unlikely 
conclusion however, as premature morbidity of PBS-injected animals was non-existent 
(see Figure 3.5A). 
Rather, another possible factor contributing to mortality in KA-injected animals could be 
dysregulated interaction of the tamoxifen metabolite in the brain following KA injury. 
Indeed, hippocampal neuronal excitability and seizure susceptibility can be influenced by 
endogenous oestogen levels (Stevens & Harden, 2011; Woolley, 1998) and selective 
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oestrogen receptor modulators, such as tamoxifen, have previously been shown to exert 
a neuroprotective effect on neurons following KA-induced excitotoxicity (Ciriza et al., 
2004; Kajta & Lasoń, 2000; Schauwecker et al., 2009). These studies, however, 
administered tamoxifen prior to KA injury whereas in the present study, tamoxifen was 
administered subsequent to KA injection. Thus, it is possible that tamoxifen administered 
following KA injury may be contributing to increased mortality via dysregulated 
interactions with the KA-induced hyper excitable state of the CNS. Future studies may 
benefit from investigating the effects of tamoxifen on hippocampal neuronal excitability 
and seizure susceptibility post-KA injury. 
 
3.4.4 No recovery of long-term contextual fear memory 10 weeks following KA 
injury 
KA-induced hippocampal lesions have previously been shown to induce deficits in 
contextual fear learning and memory (Logue et al., 1997; Maia et al., 2014; Martin et al., 
2005; Stubley-Weatherly et al., 1996; Yin et al., 2002). Additionally, prior investigations 
by our group have demonstrated long-term contextual fear learning and memory 
impairments 2 weeks following unilateral KA-induced hippocampal lesion (see Appendix 
Figure 6.2). Most interestingly, our previous unpublished findings also demonstrated 
recovery of long-term fear memory at 8 wpi (Appendix Figure 6.2), coincident with 
previously observed neuron repopulation in the CA1 and CA3 regions (Figure 2.2). In 
contrast, however, the present study demonstrated deficits in long-term contextual fear 
memory in KA-injected animals at 10 wpi (Figure 3.6). It is unlikely that this cognitive 
deficit was attributable to infusion of AL or saline prior to behavioural testing as non-
lesioned (PBS) animals that were also infused with AL or saline did not exhibit memory 
impairments equivalent to KA-injected animals. Rather, this result is likely attributable 
to a lack of neuronal repopulation and permanent neurodegeneration. 
The hippocampus plays a critical role in various learning and memory processes, 
including spatial learning (Jarrard, 1993; Morris et al., 1982; Morris, 1981), and 
contextual fear conditioning (Anagnostaras et al., 2001; Rudy et al., 2002; Wiltgen et al., 
2006; Zelikowsky et al., 2012). Evidence regarding hippocampal involvement in 
contextual fear conditioning processes following anterograde damage, that is, 
hippocampal lesioning prior to behavioural testing, have produced varied, and oftentimes 
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conflicting, results (Rudy et al., 2004). While early studies showed significant 
impairments in memory acquisition and expression of contextual fear-related memory 
following lesions specific to the dorsal hippocampus (Kim et al., 1993; Kim & Fanselow, 
1992; Maren et al., 1997; Phillips & LeDoux, 1992, 1994), later studies demonstrated that 
lesioned animals can overcome these deficits in context fear-related memory following a 
more intense training paradigm (Wiltgen et al., 2006; Zelikowsky et al., 2012), suggesting 
that extra-hippocampal regions may possess the ability to compensate in the absence of a 
functioning hippocampus.  
In general, long-term memory formation incorporates three distinct stages; the first stage 
typically involves acquisition or encoding of the memory, while the second stage 
comprises short-term memory consolidation, and the final stage encompassing long-term 
memory consolidation (McGaugh, 2000). Previous studies in the literature have indicated 
differential roles of hippocampal subregions to the different stages of long-term memory. 
Although the CA3 is critically involved in the initial acquisition and encoding of the 
memory, it is minimally involved in the consolidation and long-term memory retrieval 24 
h following acquisition (Daumas et al., 2005; Lee & Kesner, 2004). Conversely, previous 
studies have demonstrated a significant role of the CA1 in processes of consolidation and 
long-term memory retrieval (Daumas et al., 2005; Lee & Kesner, 2004). Taken together, 
it is entirely possible that the deficits in long-term memory we observed in the present 
study could be attributable to neuron loss in the CA3, resulting in an inability to 
adequately acquire and consolidate the memory in the first place and/or neuron loss in the 
CA1, resulting in failed long-term memory consolidation and thus, inadequate fear 
memory expression. Notably, one of the original aims of the present study was to 
investigate the contribution of CA1 and CA3 neuron repopulation to four discrete 
memory processes; memory acquisition or formation, memory consolidation, long-term 
memory recall (24 h post-acquisition), and remote memory recall (4 weeks post-
acquisition). Resulting difficulties with our transgenic mouse model halted further 
investigations relating to these experimental aims and thus, it remains to be determined 
whether the neuron repopulation we observed at the conclusion of the previous chapter 
(Chapter 2) contributes to the functional restoration of these discrete memory processes. 
Indeed, the deficits we observed in long-term contextual fear memory of KA-injected 
animals 10 wpi are not surprising when considered against our findings in Chapter 2, 
where we demonstrated a repeated inability to replicate prior research generated from our 
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group (Figure 2.2; Abdipranoto-Cowley et al., 2009). A key finding from Chapter 2 was 
that measuring the DV co-ordinate from dura as zero resulted in more variable levels of 
KA-induced neurodegeneration in both the CA1 and CA3 areas (see Figures 2.8 and 2.9). 
In the present study, DV co-ordinates were measured from dura as zero (rather than from 
bregma as zero) as these experiments were performed concurrently with those in Chapter 
2. Additionally, the apparent absence of newly-generated neurons in the CA1 and CA3 
hippocampal regions in AlstR-cre+ mice at 10 wpi (Figure 3.7), combined with persistent 
neurodegeneration (see Appendix Figure 6.6B), further supports this conclusion. Thus, it 
is likely that the KA-induced lesions in the AlstR mice resulted in permanent 
neurodegeneration within the hippocampal CA1 and/or CA3 regions. To confirm this 
hypothesis will require repeating the behavioural experiments with the optimised 
stereotaxic injection method previously described in Chapter 2 (see Experiment 2.3.8). 
Future studies would also benefit from investigating the relative contributions of CA1 
versus CA3 neuron repopulation to recovery of these memory processes, and whether 
discrete neuron repopulation in one region, in the absence of recovery in another, may be 
able to compensate and contribute to recovery of cognitive deficits to a similar extent as 
neuron repopulation in both regions. 
 
3.4.5 Lower than expected fear memory in PBS-injected animals 
Notably, in the present study, the freezing behaviour of PBS-injected animals at long-
term memory test was much lower than previously observed findings by our group 
(Appendix Figure 6.2). Furthermore, freezing behaviour was highly variable in the PBS-
injected AlstR-cre+ mice receiving AL infusions, with some animals exhibiting freezing 
behaviour equivalent to KA-injected animals (Figure 3.6). It is entirely likely that this 
variability is attributable to the low n’s utilised, however, another possible explanation 
could be mechanical secondary hippocampal damage resulting from the cannula 
implantation surgery. Indeed, the negative consequences of intracranial surgical 
implantation procedures on memory function in rodents have been previously described 
by other investigators (Frumberg et al., 2007; Hirshler et al., 2010; Seyer et al., 2016). 
Furthermore, stereotaxic surgery to mice can often be more challenging due to smaller 
brain size of mice in comparison to rats (Ellenbroek & Youn, 2016). Invasive procedures 
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such as intracerebral cannula implantations tend to cause damage to a larger comparative 
proportion of the mouse brain than in larger mammals (Ellenbroek & Youn, 2016). 
Taking these factors into consideration, in the present study, we attempted to mitigate the 
effects of secondary hippocampal damage via cannula implantation surgery through the 
exclusive use of dental cement, in the absence of skull screws, to adhere the cannula to 
the surface of the skull. Nevertheless, ad hoc histological analysis of tissue from the 
behavioural trial revealed mechanical damage of the CA1 in a subset of the PBS-injected 
animals (see Appendix Figure 6.6A). Thus, mechanical damage resulting from cannula 
implantation surgery may have contributed to lower freezing behaviour at long-term 
memory test in PBS-injected mice and this should therefore be taken into consideration 
for future studies. 
 
3.4.6 Aberrant neurogenesis may be contributing to cognitive deficits observed 
following KA injury 
Seizure-induced neurogenesis is known to be associated with ectopic migration, whereby 
a subset of newly generated neurons migrate ectopically to the hilus where they become 
involved in spontaneous seizure generation (Jessberger & Parent, 2015; Parent et al., 
1997). Furthermore, aberrant seizure-induced neurogenesis has been hypothesised to 
contribute to cognitive decline, with inhibition of neurogenesis following seizures 
associated with normal cognitive functioning (Cho et al., 2015; Jessberger, Nakashima, 
et al., 2007). Although aberrant neurogenesis was not the focus of our analysis, it may 
have contributed to the lack of cognitive recovery observed in KA-injected animals. In 
the present study, KA-lesioned mice exhibit spontaneous seizures for the duration of the 
study following recovery from the initial status epilepticus period immediately following 
KA injection, and this is a key feature of the KA model of status epilepticus (Jessberger 
& Parent, 2015). Although no animals displayed spontaneous seizure activity 
immediately prior to behavioural testing and only one animal experienced spontaneous 
seizure during behavioural testing (see Figure 3.6B and Appendix Table 6.10), it is 
nevertheless likely that KA-injected animals experienced spontaneous seizures at some 
stage prior to tissue harvest. As the animals were not continuously monitored, estimation 
of spontaneous seizure frequency is difficult. Future studies may benefit from continuous 
Chapter 3: Functional significance of injury-induced neurogenesis 
 
163 
monitoring of a random subset of KA-injected animals for estimation of spontaneous 
seizure frequency. 
 
3.4.7 Neurogenesis in the dentate gyrus following KA-induced injury 
The occurrence of adult neurogenesis in the DG is well established in the literature (Ming 
& Song, 2011). Additionally, increases in injury-induced dentate granule cell 
proliferation and neurogenesis have been well documented, particularly in response to 
seizure-induced excitotoxic injury (Abdipranoto-Cowley et al., 2009; Bengzon et al., 
1997; Gould & Tanapat, 1997; Gray & Sundstrom, 1998; Parent et al., 1997; Parent et al., 
1998; Scott et al., 1998). In the present study, we observed preliminary evidence of 
neurogenesis in the DG of AlstR-cre+ mice, with co-localisation of eGFP with nestin and 
NeuN at 2 and 10 wpi, respectively (Figure 3.7M-R). The expression pattern of eGFP 
observed in the present study is in accordance with previous studies in the literature, 
where the soma and processes are illuminated by the fluorescent GFP signal (Mignone et 
al., 2004). In particular, the co-localisation of eGFP with NeuN at 10 wpi is indicative of 
cells which were actively proliferating at the time tamoxifen administration commenced, 
roughly 72 h following KA injury, and subsequently matured. Our findings corroborate 
previously described results of DG neurogenesis following KA-induced injury 
(Abdipranoto-Cowley et al., 2009; Parent et al., 1997; Parent et al., 1998; Scott et al., 
1998). It remains to be determined however, whether the neurogenesis we observed is 
significantly increased beyond baseline levels following KA injury as we were unable to 
assess KA-induced neurogenesis in our negative control animals, the KA-injected AlstR-
cre- mice, due to technical issues with our transgenic mouse line (described in section 
3.3.7; discussed in detail in section 3.4.9). 
 
3.4.8 Preliminary evidence of neural precursor cells observed in the CA3 
3.4.8.1 Ectopic migration of newly generated cells from the SVZ or SGZ may be 
responsible for observed nestin expression in the CA3 
In addition to neurogenesis in the DG, we also observed preliminary evidence of neuronal 
precursor cells in the CA3 at 2 wpi (Figure 3.7G-H). Evidence of injury-induced 
Chapter 3: Functional significance of injury-induced neurogenesis 
 
164 
neurogenesis occurring in regions outside of the DG is sparse. Indeed, neuronal precursor 
cells and newly generated neurons in the CA1 have previously been observed in various 
models of ischaemic injury, although the origin of these newly generated cells remains 
inconclusive (Bendel et al., 2005; Nakatomi et al., 2002; Schmidt & Reymann, 2002). 
Additionally, a previous study of seizure-induced neurogenesis described a novel 
population of granule-like neurons that had ectopically migrated to the CA3 border 
proximal to the hilus (Scharfman et al., 2000). Most interestingly, although these granule-
like neurons exhibited morphological and electrophysiological characteristics similar to 
the granule cells of the DG, the granule-like neurons also exhibited epileptiform activity 
synchronous with the surrounding CA3 circuitry.  
Under physiological conditions, the process of adult neurogenesis has previously been 
described to take anywhere between 4 and 7 weeks (Cameron & McKay, 2001; Jessberger 
& Kempermann, 2003; Kempermann et al., 2004; van Praag et al., 2002). Under 
pathological conditions, particularly in response to seizure-induced injury, the 
developmental and migratory patterns of injury-induced cells have been shown to be 
altered. Chemoconvulsant-induced seizure injury, such as that facilitated by pilocarpine 
or KA, has previously been shown to induce ectopic migration of newly-generated DG 
cells into the hilar/CA3 region (Parent et al., 1997; Parent et al., 2006; Scharfman et al., 
2000). Pilocarpine-induced seizure injury has previously been shown to accelerate 
migration of SVZ-generated neuroblasts to the olfactory bulb, with BrdU-labelled cells 
co-expressing neuronal markers between 9 and 21 d following pilocarpine-induced 
seizure injury (Parent et al., 2002), while Prox-1 expression, a marker specific to post-
mitotic dentate granule cells of the DG, was observed in the hilar region within 2 weeks 
following pilocarpine-induced injury (Parent et al., 2006). Furthermore, seizure-induced 
ectopically migrated cells have previously demonstrated accelerated morphological 
development and functional integration (Fournier et al., 2010; Overstreet-Wadiche & 
Westbrook, 2006). Taken together, these studies suggest that the developmental timeline 
of seizure-induced neurogenesis may be altered, and in some cases, accelerated following 
injury. 
In the present study, we observed preliminary evidence of the existence of neural 
precursor cells in the CA3 2 weeks following KA-induced injury. A possible 
interpretation of this preliminary result could be attributed to ectopic migration of the 
cells from either the SGZ or SVZ. Given the accelerated developmental timeline of 
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seizure-generated cells previously described, this is a likely possibility. Furthermore, we 
did not observe co-localisation of eGFP with post-mitotic or mature neuronal markers at 
4 and 10 wpi respectively, suggesting absence of cell survival of the neural precursor cell 
following differentiation. Indeed, this interpretation is harmonious with previously 
described findings, where investigators observed premature migratory stream departure 
and migration to injured non-olfactory cortical regions in the forebrain of newly-
generated SVZ-derived neuroblasts following pilocarpine-induced seizure injury (Parent 
et al., 2002). Furthermore, survival of these ectopically migrated neuroblasts was low. 
Thus, it is possible that the CA3 neural precursor cells observed in the present study are 
the result of ectopic migration from either the SVZ or SGZ. Furthermore, absence of 
eGFP labelling at 4 or 10 wpi suggest that the newly generated cells did not persist or 
mature in the CA3 later in development, which is in accordance with previous findings 
(Parent et al., 2002). 
 
3.4.8.2 Observed nestin expression in the CA3 may not necessarily be indicative of neural 
precursor cell presence 
An alternative theory to explain the observation of eGFP and nestin co-localisation in the 
CA3 observed in the present study (Figure 3.7G-H) could be that this may not necessarily 
be indicative of neural precursor cell presence. In the adult CNS, expression of nestin is 
thought to be restricted to neural precursor cells (Dahlstrand et al., 1995; Lendahl et al., 
1990; Mckay, 1997), with terminal differentiation leading to downregulation of the nestin 
protein. Thus, nestin protein expression is often used as a marker of neural precursor cells 
in transgenic models investigating adult neurogenesis (Semerci & Maletic-Savatic, 2016). 
Nevertheless, recent evidence suggests that nestin expression may not be exclusive to 
neural precursor cells; these studies observed expression of the nestin protein in mature 
neurons of the adult mouse brain (Farzanehfar et al., 2017; Hendrickson et al., 2011), 
while others observed ectopic transgene expression that was not restricted to adult-born 
neurons (Sun et al., 2014). Furthermore, under pathological conditions following CNS 
injury, nestin expression can become upregulated in processes such as glial scar formation 
(Frisén et al., 1995; Michalczyk & Ziman, 2005). Reactive astrocytes involved in 
formation of the glial scar were observed to express nestin within 48 h following CNS 
injury (Frisén et al., 1995). As inflammation is known to occur following KA injury 
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(Zhang & Zhu, 2011), and further, has previously been associated with glial scar 
formation (Dusart et al., 1991; Sperk et al., 1983), it is likely that the CA3 nestin 
expression observed in the present study is due to aberrant protein expression in 
inflammatory cells at the time of nestin-eGFP transgene activation, up to 2 weeks 
following KA injury. Alternatively, it is equally likely that the observed co-localisation 
of eGFP and nestin is attributable to nestin expression from a mature neuron, rather than 
a neural precursor cell. 
Lastly, nestin expression has also been observed in oligodendrocyte progenitor cells 
(Gallo & Armstrong, 1995). Oligodendrocyte precursor cells are dynamically involved in 
the inflammatory response to CNS injuries, displaying altered morphology at the injury 
site (Keirstead et al., 1998; Levine, 1994; McTigue et al., 2001) and increased cellular 
proliferation (Levine, 1994; McTigue et al., 2001). Therefore, another likely possibility 
is that the CA3 nestin expression we observed was due to the presence of oligodendrocyte 
progenitor cells rather than neural progenitor cells. Future studies will need to address 
these concerns by co-immuno-labelling eGFP with markers of glial scar formation, 
oligodendrocyte precursor cells, and mature neuronal cells in order to delineate the true 
identity of the observed nestin-expressing cells. 
 
3.4.9 Spontaneous mutation of Cre-ERT2 gene 
In the present study, we observed eGFP expression in tissue from both AlstR-cre+ and 
AlstR-cre- mice at 8 wpi. This was unexpected, as prior to commencing experiments with 
Nescre-ERT2/R26-AlstR mice, all AlstR-cre- mice had been genotyped as not possessing 
the Cre-ERT2 gene. Gene sequencing for the Cre-ERT2 gene in DNA samples taken from 
AlstR-cre- mice revealed strong amplification from both primer sets which partially 
aligned with the Cre-ERT2 sequence and possessed one or neither of the genotyping 
primer sequences suggesting why the preliminary genotyping in these mice showed they 
were negative for the Cre-ERT2 transgene. 
A well-established problem within the Cre-loxP system is the occurrence of ‘leaky’ 
transgene expression, whereby rogue expression of floxed transgenes, such as eYFP or 
eGFP, become activated in the absence of promoter gene-driven Cre expression or Cre-
loxP recombination (Farzanehfar et al., 2017; Feil et al., 2008; Jaisser, 2000; Sharma & 
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Zhu, 2014). Additionally, in the inducible system, there is evidence of Cre-loxP 
recombination in the absence of tamoxifen (Liu et al., 2010). Although in the present 
study there were no non-tamoxifen treated control mice to observe leaky transgene 
expression, this cannot account for the unexpected eGFP-labeled cells as this tissue came 
from mice that were believed to not have the Cre-ERT2 transgene at all. Furthermore, it is 
also unlikely that our floxed transgene was aberrantly expressing eGFP in the absence of 
Cre expression, as the staining pattern that we observed in the AlstR-cre- mice suggests 
that this was not the case. In our Nescre-ERT2/R26-AlstR mice, expression of the AlstR-
eGFP sequence was driven by the ROSA26 gene locus, which is ubiquitously expressed 
in every cell type of the adult mouse (Mao et al., 1999; Soriano, 1999; Zambrowicz et al., 
1997). Therefore, aberrant eGFP expression in the absence of Cre expression would have 
resulted in eGFP expression in all cell types in the hippocampus, which was not what was 
observed in the present study. 
A more likely possibility could be attributable to the spontaneous mutation of the Cre-
ERT2 gene sequence in AlstR-cre- mice. Indeed, gene sequencing of the Cre-ERT2 gene in 
DNA samples from AlstR-cre- mice revealed strong amplification which partially aligned 
with the Cre-ERT2 sequence (Figure 3.9C; also see Appendix Figures 6.4 and 6.5). The 
partial alignment occurred in the first half of the gene sequence, which corresponds to the 
first half of the cre recombinase protein, while near perfect alignment was observed for 
the second half of the gene sequence which corresponds to the latter half. Thus, our gene 
sequencing data suggests evidence of spontaneous mutation of the Cre-ERT2 gene in 
AlstR-cre- mice, resulting in aberrant expression of the Cre-ERT2 gene and subsequent 
tamoxifen-induced transgene activation of eGFP in AlstR-cre- mice. 
In further support of our hypothesis, we crossed AlstR-cre+ mice back to a C57BL/6 
wildtype background and repeated the gene sequencing on the resulting progeny. Our 
results confirmed mutation of the Cre-ERT2 gene sequence had occurred in the AlstR-cre- 
mice as the re-crossed AlstR-cre- progeny showed no amplification to the primer 
sequences (see Appendix Figure 6.7). In order to minimise the likelihood of unexpected 
transgene mutations from affecting experimental investigations, future studies may 
benefit from periodic sequencing of the transgene sequence throughout the duration of 
the study. In addition, refreshing the genetic background of the transgenic mouse line by 
using transgenic mice from the R26-AlstR colony as breeders in conjunction with the 
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NescreERT2/R26-AlstR colony, rather than breeding solely within the NescreERT2/R26-
AlstR colony, may further mitigate problems relating to genetic drift. 
In order to circumvent the problems previously discussed in the present chapter, our 
prospective experiments will utilise alternative methods for conditional expression of 
transgenes, specifically the system known as “designer receptors exclusively activated by 
designer drugs” (DREADDs; Urban & Roth, 2015). The key advantage with DREADDs 
is that it will negate the need for cannula implantation surgery, a key obstacle in the 
present experimental investigations. 
 
3.4.10 Conclusion 
In the present study, we sought to investigate the origin and functional significance of the 
newly generated hippocampal neurons previously observed following KA-induced 
excitotoxic injury. The numerous obstacles we encountered throughout the course of our 
experimental investigations precluded us from drawing firm conclusions relating to the 
origin and functional relevance of injury-induced hippocampal neurogenesis. 
Nevertheless, our efforts allowed us to derive some useful methodological conclusions 
which will inform future experimental work. Notably, we successfully established a 
working protocol for extended tamoxifen administration that substantially reduced animal 
mortality. Furthermore, the results of the present study prompted our investigations into 
alternative strategies for conditional activation of transgenes and viral-mediated cell 
labelling, in order to circumvent the problems previously discussed in the present chapter 
for our prospective experiments. These limitations and future directions will be 
collectively discussed in detail in Chapter 5. 
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4.1 Introduction 
Our primary aims for this thesis were to understand the molecular mechanisms underlying 
spontaneous injury-induced neurogenesis, as we have discussed in the preceding two 
chapters. A longer-term goal of this work is to translate any promising findings to the 
clinic. With this goal in mind, we were interested in studying the molecular mechanisms 
of injury-induced neurogenesis in an in vivo disease model of brain injury. We were 
particularly interested in translating our findings to the study of neurogenesis in AD, a 
chronic neurodegenerative disease in which the role of neurogenesis is relatively poorly 
understood (as we discuss below). The decision to target AD was also aided in part by 
our group’s previous experience with an in vivo mouse model of AD (Wright et al., 2013). 
Although the bulk of the experimental efforts for this thesis were directed toward 
achieving the experimental aims laid out in the preceding two chapters, alongside these 
experiments, and with the above aim in mind, we characterised the pathological and 
behavioural phenotypes of the APPswe/PS1ΔE9 mouse model of AD (MMRRC Stock: 
34829-JAX, formerly JAX stock: 004462), a model that has not been previously used in 
our group. Although phenotypes for this mouse have previously been described in the 
literature, we aimed to confirm the phenotypes in our own hands to provide baseline 
measurements for our future studies. 
 
4.1.1 Mouse models of Alzheimer’s disease 
Alzheimer’s disease (AD), the most common form of dementia, is a debilitating 
neurodegenerative disorder clinically characterised by memory impairment and other 
cognitive and olfactory deficits (Horgusluoglu et al., 2017). The major histopathological 
hallmarks include amyloid plaque deposition (composed of insoluble aggregated 
amyloid-β (Aβ) peptides), neurofibrilliary tangle formation (composed of 
hyperphosphorylated tau protein), neuroinflammation (driven by altered microglia and 
astrocyte morphology and phenotype), and synapse loss and neurodegeneration in 
multiple brain regions, including the hippocampus (Haass & Selkoe, 2007; Jankowsky et 
al., 2004; Morris et al., 2014).   
The predominant theory of AD pathogenesis, the amyloid cascade hypothesis, posits that 
the enhanced production, increased accumulation, or failure of clearance of the Aβ protein 
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triggers the beginning of AD pathophysiology (Morris et al., 2014). Under physiological 
conditions, the two most abundant isoforms of Aβ, Aβ1-42 and Aβ1-40, co-exist in the brain 
at a ratio of approximately 1:9 (Pauwels et al., 2012). Evidence suggests that in familial 
early-onset AD cases linked to mutations in one of three genes (the amyloid precursor 
protein (APP), presenilin-1 (PS1) or presenilin-2 (PS2)), there is an increase in the Aβ1-
42: Aβ1-40 ratio, resulting in higher levels of the longer, more aggregation prone Aβ1-42 
peptide (Sun et al., 2017; Suzuki et al., 1994). Furthermore, relevant to this thesis are the 
roles of APP, PS1 and PS2 proteins as potent modulators of adult neurogenesis. Evidence 
has illustrated PS1, for instance, modulates neural stem cell differentiation in the adult 
rodent brain, while the secreted APP (sAPPα), cleaved from the longer APP precursor, 
regulates proliferation of neural stem cells (Gadadhar et al., 2011; Gakhar-Koppole et al., 
2008).  
Mouse models of AD, despite their limitations (Morris et al., 2014), are a useful resource 
for studying the development of the pathological hallmarks of AD and are a useful testing 
ground for novel therapeutics. The majority of these mouse models have been created by 
genetically engineering mice to express one, or a combination of familial dementia-linked 
mutations in APP, PS1, PS2 or tau, with the goal of recapitulating the human pathological 
phenotypes (Bilkei-Gorzo, 2014; Elder et al., 2010).  
In this chapter, we have utilised APPswe/PS1ΔE9 mice carrying the familial AD-linked 
human APP with Swedish double mutation (APPswe), co-integrated with a familial AD-
linked loss of function mutation in PS1, which results in the deletion of  exon 9  within 
the PS1 protein (PS1ΔE9; Jankowsky et al., 2004). In this line, evidence has shown 
overexpression of the human APP encoding gene with the Swedish mutation together 
with the mutant PS1 gene leads to elevated Aβ1-42 levels and a concomitant increase in 
the Aβ1-42:Aβ1-40 ratio (Holcomb et al., 1998; Jankowsky et al., 2004). Previous 
pathological characterisations have observed increased production of soluble Aβ1-40 and 
Aβ1-42 in APPswe/PS1ΔE9 mice as early as 3 months (Volianskis et al., 2010). Additionally, 
plaques have been visualised in the cortex from 3 months onwards, and plaque size and 
number have been shown to consistently increase with age (Hamilton & Holscher, 2012). 
In addition to pathological changes, alterations in learning and behaviour have also been 
observed. Evidence has suggested synaptic transmission is perturbed at 3 months of age 
(Goto et al., 2008), while corresponding deficits in spatial memory have been observed 
as early as 7 months (Ferguson et al., 2013; Volianskis et al., 2010). APPswe/PS1ΔE9 mice 
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also exhibit loss in working memory during both early and late stage of disease 
progression (Lagadec et al., 2012; Olesen et al., 2017) along with deficits in taste aversion 
learning (Pistell et al., 2008) at later stages of disease progression. Furthermore, amyloid 
plaque formation precedes neuron loss and neuroinflammatory changes in this model 
(Meyer-Luehmann et al., 2008). 
 
4.1.2 Adult hippocampal neurogenesis in Alzheimer’s disease 
Under physiological conditions, adult hippocampal neurogenesis is critical for 
hippocampal function, and interfering with this process can lead to deficits in learning 
and memory (Lazarov & Hollands, 2016). Furthermore, hippocampal neurogenesis 
declines with age (Kempermann et al., 2006; Kuhn et al., 2007) and is known to be 
dysregulated under pathological conditions such as AD (Abdipranoto et al., 2008; Winner 
& Winkler, 2015). Alterations and disruptions in adult hippocampal neurogenesis have 
been previously described in the aetiology of AD (Abdipranoto et al., 2008; Horgusluoglu 
et al., 2017). Specifically, decreased neurogenesis is thought to contribute to the decline 
in cognitive function observed in both humans and mouse models of AD (Faure et al., 
2011; Mu & Gage, 2011; Verret et al., 2007). Further, maturation of newborn 
hippocampal neurons is impaired by alterations in Aβ deposition and inflammation (Mu 
and Gage, 2011).  
In the APPswe/PS1ΔE9 mouse model, impaired hippocampal neurogenesis has been 
previously described (Hamilton & Holscher, 2012; Verret et al., 2007; Zeng et al., 2016). 
Hamilton and Holscher linked decreased hippocampal neurogenesis to increased 
oxidative stress, a feature of AD pathogenesis (Hamilton & Holscher, 2012), while Verret 
and colleagues observed decreased survival of newly generated neurons in the DG (Verret 
et al., 2007). Furthermore, a recent study found conditional ablation of adult hippocampal 
neurogenesis in APPswe/PS1ΔE9 mice led to exacerbated cognitive impairments in learning 
and memory paradigms (Hollands et al., 2017). Although there does not appear to be a 
general mass loss of neurons in this model (Zeng et al., 2016), discrete neuronal 
populations, such as catecholaminergic neurons in the locus coeruleus and interneurons, 
are decreased compared with wild-type controls (Bilkei-Gorzo, 2014). More recently, 
APPswe/PS1ΔE9 mice aged 18 months were found to have reduced differentiation of 
neuroblasts in the absence of neuron loss, which in turn was related to deficits in spatial 
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working memory (Olesen et al., 2017). Moreover, decreased levels of SGZ neurogenesis 
have been observed in this mouse model as early as 2 months, preceding onset of amyloid 
deposition and onset of memory impairments (Demars et al., 2010; Unger et al., 2016).  
In unimpaired animals, neurogenesis is modulated by different physiological stimuli such 
as running, exposure to environmental enrichment, learning and stress (Brown et al., 2003; 
Gould & Tanapat, 1999; van Praag et al., 1999). Similarly, accumulating evidence shows 
that various physiological stimuli can modulate and/ or stimulate hippocampal 
neurogenesis in the APPswe/PS1ΔE9 mouse model, mitigating cognitive deficits. Voluntary 
running was shown to alleviate neuropathological hallmarks of AD, along with reducing 
neuronal loss and spatial memory deficits and increasing hippocampal neurogenesis 
(Tapia-Rojas et al., 2016), while environmental enrichment has been shown to ameliorate 
impairments in neurogenesis (Hu et al., 2010) and cognitive deficits in learning and 
memory (Jankowsky et al., 2005). This may, in part, be mediated by the reduction in Aβ 
levels and amyloid deposition (Lazarov et al., 2005). This idea was supported by a 
subsequent study where administration of a retro-inverso peptide inhibitor that binds to 
amyloid plaques and activated microglial cells was found to reduce the presence of Aβ 
oligomers and plaques, activated microglial cells, and oxidative stress while increasing 
hippocampal neurogenesis in APPswe/PS1ΔE9 mice (Parthsarathy et al., 2013). 
Furthermore, exposure to chronic hypoxia led to increased cell proliferation and 
neurogenesis in APPswe/PS1ΔE9 mice (Varela-Nallar et al., 2014), while conditional 
ablation of hippocampal neurogenesis resulted in impaired performance in contextual fear 
conditioning and pattern separation tasks (Hollands et al., 2017). Lastly, disease 
progression appears linked to the level of neuroinflammation as inhibition of microglial 
activation leads to increased survival of newly generated dentate granule cells along with 
behavioural improvements in a hippocampal-dependent learning task (Biscaro et al., 
2012). Together, these results show that stimulation of neurogenesis in APPswe/PS1ΔE9 
mice can alleviate AD-related neuropathology while also improving cognitive deficits, 
providing a promising therapeutic target for future research. 
Given the apparent link between impaired hippocampal neurogenesis and AD, the 
overarching aim of the present study was to investigate how neurogenesis can be 
modulated and/ or stimulated in the APPswe/PS1ΔE9 mouse model of AD by crossing this 
mouse line with the Nescre-ERT2/R26-AlstR mice previously described in Chapter 3 
(3.2.1.2). Crossing the two mouse lines would allow investigation of how endogenous 
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neurogenesis is dysfunctional in a neurodegenerative disease model and further, would 
facilitate investigations into the functional significance of enhancing endogenous 
neurogenesis on cognitive tests. Prior to investigating neurogenesis, however, we first 
aimed to confirm the histopathological and behavioural phenotype of the APPswe/PS1ΔE9 
mouse line. Specifically, we wanted to determine the severity of long-term memory 
impairments with age, along with determining baseline levels of total soluble Aβ and 
plaque deposition, neuron population and inflammation, and comparing these across 
different age groups. The experiments in this chapter were carried out in parallel with 
experiments in the preceding two experimental chapters. 
 
4.1.3 Aims 
• To determine if APPswe/PS1ΔE9 mice exhibit deficits in long-term contextual fear 
memory and remote memory recall. 
• To investigate alterations in the levels of soluble A and A plaque deposition 
over time in the APPswe/PS1ΔE9 model. 
• To determine if APPswe/PS1ΔE9 mice exhibit hippocampal neurodegeneration. 
• To determine if APPswe/PS1ΔE9 mice exhibit alterations in total microglial and 
astrocyte numbers within the hippocampus. 
• To determine the temporal relationship of alterations in soluble and plaque A 
levels, neurodegeneration and microglial/astrocyte numbers to the emergence of 
cognitive dysfunction in APPswe/PS1ΔE9 mice. 
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4.2 Materials and Methods 
4.2.1 Animals 
Male hemizygous transgenic (APPswe/PS1ΔE9) and non-transgenic littermates (wild-type) 
were from the B6C3-Tg(APPswe,PSEN1∆E9)85Dbo/Mmjax (APP/PS1) mouse line 
obtained from The Jackson Laboratory (MMRRC Stock: 34829-JAX, formerly JAX 
stock: 004462). Hemizygous mice were crossed to C57BL/6J mice for 1-12 generations 
to produce APPswe/PS1ΔE9 mice and wild-type littermates.  
There are at least two similar strains to the APPswe/PS1ΔE9 mouse, with subtle differences. 
They share highly similar names and can therefore sometimes be confused (MMRRC 
Stock: 34832-JAX, formerly JAX stock: 005864; MMRRC Stock: 41848-JAX, formerly 
JAX stock: 003378). In reviewing the literature we found several instances of studies in 
which it was unclear which one of these three strains had been used. To ensure 
consistency, we did not include these for review when placing our data in the context of 
the wider literature. The studies we do include for discussion were derived from the list 
of references on The Jackson Laboratory website for this strain, along with references 
found using keyword searches (for example “APPswe/PS1ΔE9”) in PubMed and Google 
Scholar.  
All animals were kept under standard housing conditions of 12 h light/dark cycle (lights 
on at 7:00 am) with access to food and water ad libitum for the duration of 
experimentation. Mice were housed at a maximum five mice per cage. All animal 
experiments were performed with the approval of the Garvan Institute and St. Vincent’s 
Hospital Animal Ethics Committee, in accordance with National Health and Medical 
Research Council animal experimentation guidelines and the Australian Code of Practice 
for the Care and Use of Animals for Scientific Purposes (2013). 
 
4.2.2 Quantification of cell populations 
4.2.2.1 Tissue preparation 
Mice were anesthetised with an intraperitoneal injection of ketamine (100 mg/kg) and 
xylazine (20 mg/kg) cocktail and transcardially perfused with ice-cold 0.9% sodium 
chloride followed with ice-cold 4% PFA (Cat # P6148-1kg, Sigma Aldrich, NSW, 
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Australia; pH 7.3-7.5) in 1x PBS at either 4, 6 or 10 months of age. Brains were harvested 
and post-fixed in 4% PFA in 1x PBS for 24 h then cryoprotected in 30% sucrose for 2-3 
d until brains had sunk. Brains were prepared for cryosectioning by cutting away 2-3 mm 
of cerebellum to make a flat surface, before placing in a peel-away mould containing 
OCT (Cat # 4583001CTN, Hurst Scientific, WA, Australia) medium and storing at -80°C. 
Brains were cryostat sectioned into 40 μm thick slices at -16°C with each vial containing 
every sixth slice. Sections were stored at 4°C in 5 mL vials containing 0.02% sodium 
azide in 1x PBS. 
 
4.2.2.2 Immunohistochemistry 
Tissue sections were washed in 1x PBS (3 x 10 min) prior to incubation in 50% ethanol 
(20 min at RT). The sections were incubated in 3% H2O2 in 50% ethanol for 20 min at 
4°C. Sections were then washed in 1x PBS (3 x 10 min) followed by blocking in 3% BSA 
(Cat # BSAS1.0, Bovogen Biologicals, VIC, Australia) + 0.25% Triton X-100 in 1x PBS 
(1 h, RT). Sections were subsequently incubated in primary antibody diluted in blocking 
solution for 72 h at 4°C. Sections were then washed in 1x PBS (3 x 10 min) prior to 
incubation in biotinylated secondary antibody diluted in blocking solution, overnight at 
4°C. A summary of the antibodies utilised for immunohistochemistry are described in 
Table 4.1. 
ABC (Vector Labs, CA, USA) was prepared according to manufacturer instructions and 
left to complex for 30 min at RT. Sections were washed in 1x PBS (3 x 10 min) and then 
incubated in ABC solution for 1 h at RT. Next, tissue sections were washed free of ABC 
in 1x PBS (3 x 10 min). DAB solution (Cat # SK4100, Abacus ALS, QLD, Australia) 
was prepared according to manufacturer’s instructions, by mixing 2 drops of buffer 
solution to 5 mL of MilliQ water, then mixing 4 drops of DAB solution, and finally 2 
drops of H2O2 solution. Sections were incubated in DAB solution until desired staining 
was achieved (approximately 5-10 min). Afterwards, sections were washed in 1x PBS (3 
x 10 min) prior to being mounted onto SuperFrost-plus glass slides (Cat # SF41296PL, 
Lomb Scientific, NSW, Australia) and cover-slipped with 50% glycerol-gelatin mounting 
medium (Cat # GG1-10X15ML, Merck, MA, USA) diluted in 1x PBS. 
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For tissue immunostained with anti- GFAP and IBA1 antibodies, sections were first 
processed for NeuN and the protocol was repeated using the appropriate antibody as 
described above. In order to visualise the region of interest, sections were processed for 
NeuN using NovaRED peroxidase solution (Vector Labs, Burlingame, CA, USA) to stain 
NeuN position cells red. NovaRED solution was prepared according to manufacturer’s 
instructions by mixing 3 drops of reagent 1, 2 drops of reagent 2, 2 drops of reagent 3 and 
2 drops of H2O2 solution to 5 mL of MilliQ water. Sections were then processed for GFAP 
or IBA1 using DAB, with the addition of 2 drops of Nickel to stain positive cells black. 
 
Table 4.1. Summary of antibodies utilised for immunohistochemistry. 
Primary 
antibody 
Target Concen-
tration 
Company Secondary 
antibody 
Concen-
tration 
Company 
Neuronal 
Nuclei 
(NeuN) 
Neurons 1:250 Millipore 
Cat # MAB377 
Biotin Anti- 
Mouse 
H&L 
1:250 Abcam 
Cat # AB6813                      
Glial 
fibrillary 
acidic 
protein 
(GFAP) 
Astrocytes 1:300 Dako 
Cat # Z033401 
Biotin Anti-
Rabbit 
H&L 
1:250 Thermo Fisher 
Scientific (formerly 
Life Technologies) 
Cat # B-2770 
Ionised 
calcium-
binding 
adapter 
molecule 1 
(IBA1) 
Microglia 1:500 Wako 
Cat # 019-
19741 
Biotin Anti-
Rabbit 
H&L 
1:250 Thermo Fisher 
Scientific (formerly 
Life Technologies) 
Cat # B-2770 
 
 
4.2.2.3 Stereology 
For quantification of hippocampal neurons, astrocytes and microglia, a bright-field 
microscope (Zeiss AxioImager A1, Zeiss, NSW, Australia) was used in conjunction with 
the optical fractionator method in the StereoInvestigator 7 program (MBF Bioscience, 
VT, USA) to perform stereological estimation of NeuN+, GFAP+ and IBA1+ cell 
populations in the dorsal hippocampal CA1 and CA3 regions, respectively. Following 
immunohistochemical labelling, the optical fractionator parameters were determined 
prior to experimental counting. The final parameters for each cell type quantified are 
summarised in Table 4.2. 
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Table 4.2. Parameters used for stereological quantification of different cell populations. 
Cell type Final parameters 
Neurons (NeuN) -Guard zone height of 5 μm 
-Optical dissector height of 10 μm 
-Counting frame size of 40 μm x 40 μm 
-Grid size of 84 μm x 60 μm 
Astrocytes (GFAP) -Guard zone height of 5 μm 
-Optical dissector height of 10 μm 
-Counting frame size of 65 μm x 65 μm 
-Grid size of 68 μm x 68 μm 
Microglia (IBA1) -Guard zone height of 5 μm 
-Optical dissector height of 10 μm 
-Counting frame size of 65 μm x 65 μm 
-Grid size of 68 μm x 68 μm 
 
 
Average section thickness was determined by measuring the section thickness of the first 
section at a minimum of 5 sites prior to counting. Using the 10x objective, numerical 
aperture 1.40, the region of interest was traced. Sections were viewed under a 100x 
objective, numerical aperture 1.40, and the first counting frame placed within the grid 
automatically by the program. Coefficient of error attributable to the sampling was 
calculated according to previously published methods (Gundersen and Jenson 1987). 
Errors ≤ 0.10 were deemed acceptable. In our experiments, we implemented counting 
rules that could not be affected by shape, size, orientation and distribution of the object/ 
particle. The probe we used to count was called the optical fractionator displayed as a 
counting frame that was shown as a red and green probe representing rejection and 
acceptance lines, respectively. In order to eliminate experimenter bias, the counting rule 
used in this study was that the top of a cell nucleus (as determined when scrolling through 
the z-stack) was counted if it lay inside the counting frame and didn’t touch an exclusion 
line. However, when the top of a cell nucleus lay predominantly outside of the counting 
frame but touched an inclusion line, but not an exclusion line, then we also counted it. If 
the top of a cell nucleus touched both an inclusion and exclusion line, the exclusion line 
took precedence and the cell was not counted. Every sixth section was prepared from 
coronal brain slices. A total of 5 sections were sampled per brain with AP positions from 
bregma of approximately -1.34, -1.58, -1.82, -2.06, and -2.3mm. 
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4.2.2.4 Image acquisition 
All non-fluorescent images were obtained using a Leica DM4000 upright bright-field 
microscope (Leica Microsystems, Hesse, Germany) equipped with DFC450 digital high 
resolution colour camera. Low and high magnification images were acquired using 5x 
and 40x dry objectives, respectively. Images were captured using LAS V4.9 software, 
and were subsequently processed and analysed using Adobe Photoshop CS6 (Adobe, CA, 
USA). 
 
4.2.3. Analysis of A 
4.2.3.1 Quantification of A plaque load 
Thioflavin S staining was used to determine fibrillar A plaque deposition. Free-floating 
sections were mounted onto gelatin-coated glass slides and left to dry for 24 h prior to 
staining. Tissue sections were washed briefly with distilled water then underwent 
dehydration through ascending alcohols. Sections were immersed in 70% ethanol for 1 
min, followed by 80% ethanol for 1 min. 1% Thioflavin S (Sigma-Aldrich; MO, USA) in 
80% ethanol solution was filtered through a 0.2 μm filter in the dark. Slides were 
incubated for 15 min in filtered 1% Thioflavin S in 80% ethanol solution in the dark. 
Sections were then immersed in 80% ethanol for 1 min, followed by 70% ethanol for 1 
min. Sections were rinsed briefly in two changes of distilled water before removal from 
staining rack and then left to dry overnight in the dark. Once they were completely dry, 
sections were cover-slipped with 50% glycerol-gelatin mounting medium (Merck, MA, 
USA) diluted in 1x PBS. 
Plaque quantification was conducted in the hippocampal region subfield from five 
sections per animal (using a section interval of 6) at the AP positions from bregma 
between -1.34 mm and -2.30 mm. All plaque counts were conducted manually and were 
blind to genotype and age. All images were obtained using a Leica DM5500 upright 
fluorescence microscope (Leica Microsystems, Hesse, Germany) equipped with 
DFC310Fx sensitive monochrome digital camera and fluorescence detection of dapi, 
greens, reds and far-reds. Low and high magnification images were acquired using 5x and 
20x dry objectives, respectively. Images were captured using LAS X software, and were 
subsequently processed and analysed using Adobe Photoshop CS6 (Adobe, CA, USA). 
Chapter 4: Characterisation of the APPswe/PS1ΔE9 mouse model 
 
 
180 
4.2.3.2 Quantification of soluble A by ELISAs 
All enzyme linked immunosorbent assays (ELISAs) were conducted by Lyndsey Konen. 
Mice were cervically dislocated and the hippocampus was rapidly dissected and stored at 
-80°C. Unilateral hippocampal tissue samples were thawed, weighed and homogenised 
in 5 vol/wt of tris buffered saline (TBS; Tris-HCL 50 mM pH 7.4; NaCl 150 mM; EDTA 
2 mM) containing a cocktail of protease inhibitors (1:100, Sigma-Aldrich, NSW, 
Australia). Samples were then centrifuged at 350,000 x g for 20 min at 4°C. The 
supernatant containing the soluble A fraction was collected.  
A levels were determined using the BetaMark™ Beta-Amyloid x-40 Colorimetric 
ELISA Kit (Cat #: 842301; BioLegend, CA, USA) and BetaMark™ Beta-Amyloid x-42 
Colorimetric ELISA Kit (Cat #: 842401; BioLegend, CA, USA). Briefly, the pre-coated 
plates were washed with the provided wash buffer prior to adding 100 L of the sample 
that contained the horseradish peroxidase A specific antibody, in duplicates. The plate 
was incubated at 4°C with shaking for 18 h. The plate was washed 5x with wash buffer 
and the TMB substrate was added. The plate was then incubated at RT in the dark for 45 
min with shaking. The absorbance was measured at 620 nm using a SpectraMax 5 
luminometer/plate reader. Measurements were converted to total protein concentration 
based on the standard curve with a 4 parameter curve fit and log-transformed. 
 
4.2.4 Behavioural analysis 
Behavioural testing was used to assess hippocampal function and cognitive integrity 
amongst ages and genotypes. All behavioural testing experiments and data acquisition 
were conducted by Dr Raphael Zinn and are presented here to provide context to the 
behavioural data analysis, pathological experiments and overall interpretations carried 
out by Yu Shen (Shelley) Yin. 
 
4.2.4.1 Contextual fear conditioning 
Training and testing took place in two identical cube-shaped fear conditioning chambers 
(32 x 27 x 26cm; Med Associates Inc.; see Figure 4.1 for example of chamber setup) 
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located in the same room. Chambers had a clear plexiglass door, ceiling and rear wall 
with grey aluminium side walls. A removable grid floor consisting of 36 parallel rods 
spaced 8 mm apart was inside each chamber. A removable grey aluminium tray was 
positioned under the grid for waste collection. The rods were connected to a shock 
generating and scrambling system, which delivered a current to elicit a foot shock. This 
system was connected to and controlled by computer software (FreezeFrame2, 
Actimetrics). During training and testing, behaviour of the mice was recorded by a video 
camera positioned in front of the chambers.  
The chambers served as two different contexts (context A and A’). Context A, the 
conditioning context, was produced by cleaning the chamber with 70% ethanol and 
scenting the waste trays with 5 drops of aniseed essence. Context A’ was designed to be 
relatively similar to context A and was produced by cleaning the chamber with 70% 
isopropanol and placing a white plastic sheet over the grid, as well as curving another 
white plastic sheet to create an arch. For both contexts A and A’, mice were carried into 
the fear conditioning room in their homecages under full fluorescence. The fear 
conditioning room was also fully lit, permitting full vision of the room from within the 
chambers. In both contexts A and A’, a houselight was also turned on during training and 
testing. Thus, all extra-chamber and select intra-chamber cues were identical between 
contexts A and A’. 
On conditioning days, mice were exposed to the context A chamber for 180 s prior to 
shock administration (0.8 mA, 2 s duration). Following shock, mice remained in the 
chamber for 30 s before being returned to their home cages. Long-term memory testing 
took place in either context A or A’ 24 h following conditioning day. For this test, mice 
remained in the chamber for 180 s and did not receive a shock. Remote memory testing 
took place in context A 28 d following long-term memory testing. For this test, mice again 
remained in the chamber for 180 s and did not receive a shock. Upon completion of each 
testing session, mice were returned to their home cages. 
The conditional response used to measure memory was freezing. Freezing is a species-
specific fear response defined as the absence of all movement, except that necessary for 
breathing (Fanselow, 1986). During each session, freezing of each animal was scored at 
4 second intervals for the first 3 min, yielding 45 samples per mouse. The number of 
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samples in which mice were freezing was divided by the total number of samples to yield 
a freezing percentage per mouse. Group averages were used for analysis. 
 
 
Figure 4.1. Example of fear conditioning chamber setup. 
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4.2.5 Statistical Analysis 
Statistical analyses were performed using GraphPad Prism Version 7.0 (GraphPad 
Software, Inc). Data were tested for normality using the Shapiro-Wilks test. For normally 
distributed data of more than two variables, differences between means were assessed, as 
appropriate, by one- or two-way ANOVA or an ANOVA with repeated measures. 
Bonferroni or Tukey’s post-hoc analyses were applied as appropriate. For all graphical 
representations, data are presented as mean with SEM. For all statistical tests, a p value 
of ≤ 0.05 was considered to be significant. 
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4.3 Results 
4.3.1 APPswe/PS1∆E9 mice show impaired long-term memory at 4 and 6 months but 
not 10 months compared to wild-type 
A fundamental clinical manifestation of AD is progressive impairment in memory and 
cognitive function (Caselli et al., 2006). These encompass deficits in episodic and 
semantic memory early on, with deficits eventually spreading to working memory, and 
long-term memory (Jahn, 2013). An early clinical symptom of AD involves an impaired 
ability to acquire and consolidate new information, or recall events subsequent to disease 
onset, together defined as anterograde amnesia (Haj et al., 2015). Previous studies 
utilising the APPswe/PS1∆E9 mouse model have shown deficits in contextual fear learning 
and memory at ages ranging from 3-13 months  (Bartolotti et al., 2015; Cramer et al., 
2012; Frost et al., 2015; Kilgore et al., 2010; Knafo et al., 2016; Rumbaugh et al., 2015; 
Végh et al., 2014). Additionally, deficits in both spatial and long-term contextual memory 
(assessed through passive avoidance tests) have also been observed (Janus et al., 2015; 
Zhang et al., 2011). 
In the present study, anterograde amnesia in APPswe/PS1∆E9 mice was investigated using 
contextual fear conditioning, a hippocampus-dependent learning task. Contextual fear 
conditioning is a robust form of associative learning whereby animals learn to associate 
a contextual environment with the presence of an aversive footshock (Izquierdo et al., 
2016). In addition to assessing anterograde amnesia, quality of memory encoding, 
memory precision, generalisation of memory (assessed through context discrimination 
testing), and long-term memory stability are all readily assessable through this paradigm. 
We specifically aimed to assess long-term memory stability, discrimination, and remote 
memory stability in APPswe/PS1∆E9 mice aged 4, 6 and 10 months. To achieve this, mice 
from each age were conditioned in context A and re-exposed to either context A or A’ 24 
h later (Figure 4.2A). Re-exposure to context A allows assessment of long-term memory 
stability while re-exposure to A’ allows assessment of a mouse’s ability to discriminate 
between similar contexts, a process thought to depend on hippocampal pattern separation 
(Yassa & Stark, 2011). Remote memory stability was assessed through re-exposure to the 
original conditioning context A 28 d following re-exposure to context A. For our 
investigations of remote memory deficits in APPswe/PS1∆E9 mice, a separate cohort of 6-
month-old mice were conditioned in context A and subsequently re-exposed to context A 
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at both 24 h after conditioning and 28 d following re-exposure. Due to animal number 
constraints, separate cohorts of 4- and 10-month-old mice could not be sourced for 
assessment of remote memory stability. Therefore, for these age groups, we used the same 
cohort of mice from the discrimination experiments that had been re-exposed to context 
A 24 h following conditioning, and subsequently re-exposed them to context A 28 d 
following re-exposure. 
At long-term memory testing, a two-way ANOVA of genotype and context for each age 
revealed a significant interaction at all ages (4 month: F(1,29) = 6.322, p = 0.0177; 6 month: 
F(1,29) = 6.322, p = 0.0177; 10 month: F(1,29) = 26.97, p < 0.0001; Figure 4.2B-D). Post-
hoc analysis using Tukey’s test to correct for multiple comparisons revealed wild-type 
mice froze significantly more than APPswe/PS1∆E9 mice in context A at 4 (p = 0.0169) and 
6 months (p = 0.0169) but not at 10 months (p = 0.1504). Post-hoc analyses also revealed 
that wild-type mice at all ages discriminated between context A and A’ (4 month: p = 
0.0204; 6 month: p = 0.0204; 10 month: p < 0.0001) whereas APPswe/PS1∆E9 mice of all 
ages did not (4 month: p = 0.9627; 6 month: p = 0.9627; 10 month: p = 0.4123). Together, 
these results suggest the presence of impaired long-term context fear memory at 4 and 6 
months, but not 10 months in APPswe/PS1∆E9 mice. Moreover, APPswe/PS1∆E9 mice 
showed no context discrimination at any age, even though wild-types showed successful 
context discrimination at all ages investigated. 
At remote memory testing, a two-way ANOVA with repeated measures of genotype and 
test day revealed a main effect of test day (4 month: F(1, 15) = 4.606, p = 0.0486; 6 month: 
F(1, 15) = 13.12, p = 0.0025) and genotype (4 month: F(1, 15) = 102.8, p < 0.0001. 6 month: 
F(1, 15) = 17.93, p = 0.0007) on freezing percentage in each group at 4 and 6 months. There 
was no interaction of test day and genotype on freezing percentage at 4 (F(1, 15) = 0.2079, 
p = 0.6550) or 6 months (F(1, 15) = 0.3278, p = 0.5754). Post-hoc analysis using Tukey’s 
test to correct for multiple comparisons revealed 4 and 6 month APPswe/PS1∆E9 mice froze 
significantly less than their wild-type counterparts at both long-term (4 month: p < 0.0001; 
6 month: p = 0.0019) and remote memory testing (4 month: p < 0.0001; 6 month: p = 
0.0006). Post-hoc analyses also revealed no differences in freezing percentage between 
long-term and remote memory tests in APPswe/PS1∆E9 mice at 4 (p = 0.4738) or 6 months 
of age (p = 0.1070). In wild-type mice, there were no differences in freezing percentage 
between long-term and remote memory tests at 4 months (p = 0.1879), however freezing 
percentage was significantly higher in remote memory test at 6 months of age (p = 0.0160). 
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In 10 month animals, a two-way ANOVA with repeated measures revealed a main effect 
of test day (F(1, 15) = 6.428, p = 0.0229) and genotype (F(1, 15) = 18.51, p = 0.0006) on 
freezing percentage in each group. Furthermore, there was a significant interaction of 
genotype and test day on freezing percentage at 10 months (F(1, 15) = 15.48, p = 0.0013). 
Post-hoc analysis using Tukey’s test to correct for multiple comparisons revealed 
significantly less freezing from APPswe/PS1∆E9 mice compared to their wild-type 
counterparts during remote memory testing (p < 0.0001), but not at long-term memory 
test (p = 0.0991). Post-hoc analyses also revealed no differences in freezing percentage 
across test days in wild-type mice (p = 0.6482), while APPswe/PS1∆E9 mice froze 
significantly less during the remote memory test compared with long-term memory test 
(p = 0.0009). 
To confirm that the absence of long-term memory deficits observed at 10 months in 
APPswe/PS1∆E9 mice was not due to small sample size, we pooled all data from 10 month 
APPswe/PS1∆E9 and wild-type mice conditioned in these same parameters in this 
experiment (n = 48-49 per genotype) and performed a Student’s t-test with Welch’s 
correction comparing the genotypes (see Appendix Figure 6.8). These results showed no 
differences in freezing percentage between APPswe/PS1∆E9 or wild-type mice at 10 months 
(t(94.93) = 1.932, p = 0.0563), confirming our initial analysis of no significant deficits in 
long-term fear memory at 10 months in APPswe/PS1∆E9 mice. 
In summary, APPswe/PS1∆E9 mice exhibit deficits in both long-term and remote memory 
at 4 and 6 months, while at 10 months the deficit in long-term memory was not apparent 
until remote memory test. 
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Figure 4.2. APPswe/PS1∆E9 mice show impaired long-term memory at 4 and 6 months but not 10 months 
compared to wild-type. (A) Experimental protocol. (B-D) Contextual fear memory in wild-type and APPswe/PS1∆E9 
mice aged 4 (B), 6 (C) and 10 (D) months. All values represent mean ± standard error of the mean (SEM). *p < 0.05, 
**p < 0.01, ***p < 0.001. n = 8-9 for all groups. The data represented in this figure were generated by Dr Raphael Zinn. 
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4.3.2 Amyloid-β plaque formation occurs in an age-dependent manner in the 
APPswe/PS1∆E9 model of Alzheimer’s disease 
The relative abundance of Aβ plaques in post-mortem brain tissue is a key biomarker 
used to confirm a diagnosis of AD in patients who exhibited clinical signs of AD dementia 
(Hyman et al., 2012). The temporal appearance of Aβ plaques has been studied in various 
mouse models of AD (Bilkei-Gorzo, 2014; Hall & Roberson, 2012; Ly et al., 2011). In 
the APPswe/PS1∆E9 mouse model of AD, plaques have been observed in the cortex from 3 
months onwards, and plaque size and number consistently increase with age (Garcia-
Alloza et al., 2006; Hamilton & Holscher, 2012; Olesen et al., 2016), with abundant 
plaques in the hippocampus and cortex by 9 months (Jankowsky et al., 2004). Plaque 
burden has been correlated to working memory deficits at 13-18 months but not at 6-7 
months of age, the age at which plaques become observable (Savonenko et al., 2005; 
Volianskis et al., 2010).  
In the present study, we aimed to confirm, in our own hands, plaque load over time in the 
APPswe/PS1∆E9 mouse model of AD and determine whether this correlated with the 
behavioural changes observed in the previous experiment (4.3.1). The number of 
hippocampal plaques was analysed by manually counting Thioflavin S+ plaques, as 
described in 4.2.3.1. Thioflavin S binds -sheet structures, which are present in fibrillar 
amyloid plaques, leading to a blue shift of the emission spectrum under a florescent 
microscope (Ly et al., 2011). Coronal sections from wild-type and APPswe/PS1∆E9 mice 
aged 4, 6 and 10 months were stained with Thioflavin S and plaques were manually 
counted within five coronal sections from the hippocampus bilaterally (Figure 4.3A). 
A two-way ANOVA revealed a significant main effect of age (F(2,23) = 189.3, p < 0.0001) 
and genotype (F(1,23) = 282.7, p < 0.0001) on the number of Thioflavin S
+ plaques (Figure 
4.3B). Furthermore, there was a significant interaction between age and genotype on the 
number of Thioflavin S+ plaques (F(2,23) = 186.1,  p < 0.0001). Post-hoc analysis using 
Bonferroni’s test to correct for multiple comparisons revealed a significant increase in 
plaque formation in APPswe/PS1∆E9 mice between 4 and 6 months (p = 0.0141), 6 and 10 
months (p < 0.0001), and 4 and 10 months of age (p < 0.0001). Furthermore, in 
comparison to wild-type littermates, APPswe/PS1∆E9 mice showed a significant increase 
in plaque formation at 6 (p = 0.0240) and 10 months of age (p < 0.0001). No differences 
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in plaque formation were observed at 4 months between APPswe/PS1∆E9 mice and wild-
type littermates (p > 0.9999). 
In line with previous findings, our results therefore demonstrate age-dependent Aβ plaque 
formation in the hippocampus of APPswe/PS1∆E9 mice beginning at 6 months of age and 
increasing at 10 months.  
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Figure 4.3. Age-dependent Aβ plaque deposition in the APPswe/PS1∆E9 mouse model. (A) Representative images 
of Thioflavin S-stained hippocampal layer in wild-type and APPswe/PS1∆E9 mice aged 4, 6 and 10 months. (B) 
Quantification of Thioflavin S+ plaques in wild-type and APPswe/PS1∆E9 mice aged 4, 6 and 10 months. All values 
represent mean ± SEM. *p < 0.05, ****p < 0.0001. n = 4-6 per group. 
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4.3.3 Total levels of soluble amyloid-β increase with age in APPswe/PS1∆E9 mice 
According to the amyloid cascade hypothesis, soluble Aβ oligomers play a major role in 
the pathophysiology of AD through either enhanced production, reduced clearance or a 
shift in the ratio toward longer, more pathogenic forms of the Aβ peptide (Viola & Klein, 
2015). Levels of soluble Aβ oligomers have previously been shown to correlate well with 
cognitive impairments and disease severity in both humans and mouse models of AD 
(Cleary et al., 2005; McLean et al., 1999; Näslund et al., 2000; Viola & Klein, 2015). 
Furthermore, soluble Aβ oligomers extracted directly from post-mortem brains of AD 
patients was found to disrupt synaptic plasticity and memory processes when applied to 
rodent brains both in vitro and in vivo (Shankar et al., 2008). 
Under physiological conditions, the most abundant soluble Aβ isoform in the brain is the 
40-residue peptide (Aβ1-40). However, under pathological conditions such as AD, 
homeostasis is disrupted by a shift towards increased levels of the 42-residue peptide 
(Aβ1-42; Selkoe, 1994). Compared to Aβ1-40, the more hydrophobic and fibrillogenic Aβ1-
42 is considered more prone to aggregate into Aβ-containing plaques (Bitan et al., 2003; 
Snyder et al., 1994). Soluble Aβ1-42 is highly toxic to mature CNS neurons (Lambert et 
al., 1998). Furthermore, increased production of Aβ1-42, in comparison to Aβ1-40, has been 
strongly implicated as the initiator of the disease in many studies of familial AD (Selkoe 
& Hardy, 2016), with levels of Aβ1-42 remaining consistently higher than Aβ1-40 levels 
throughout disease progression in post-mortem brains of AD patients (Näslund et al., 
2000).  
In the following experiment, we aimed to investigate the temporal relationship of soluble 
Aβ1-40 and Aβ1-42 to the behavioural deficits previously observed in APPswe/PS1∆E9 mice 
(Experiment 4.3.1), and determine whether the relative levels of Aβ1-42 compared with 
Aβ1-40 increased with age. To examine the profile of soluble Aβ accumulation throughout 
aging in APPswe/PS1∆E9 mice, we utilized Aβ40 and Aβ42 antibody-specific ELISAs 
specific for human Aβ. 
A one-way ANOVA revealed a significant main effect of age on soluble human Aβ1-40 in 
APPswe/PS1∆E9 mice (F(2,12) = 4.139, p = 0.0430; Figure 4.4A). Post-hoc analysis using 
Tukey’s test to correct for multiple comparisons revealed a significant difference in 
soluble human Aβ1-40 between transgenic animals aged 4 and 10 months (p = 0.0402). 
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Soluble human Aβ1-40 was not significantly different in transgenic animals aged between 
4 and 6 months (p = 0.1545) and 6 and 10 months (p = 0.7156). 
A one-way ANOVA revealed a significant main effect of age on soluble human Aβ1-42 in 
transgenic mice (F(2,15) = 10.97, p = 0.0012; Figure 4.4B). Post-hoc analysis using 
Tukey’s test to correct for multiple comparisons revealed a significant difference in 
soluble human Aβ1-42 in APPswe/PS1∆E9 mice aged between 4 and 10 months (p = 0.0011) 
and 6 and 10 months (p = 0.0116). Soluble human Aβ1-42 was not significantly different 
in APPswe/PS1∆E9 mice aged between 4 and 6 months (p = 0.4900). 
To determine the relative levels of Aβ1-42 compared with Aβ1-40 across age groups, the 
normalised average concentration of Aβ1-40 was divided by the normalised average 
concentration of Aβ1-42 to achieve a ratio value, whereby a value of 1.0 indicated 
equivalent levels of hippocampal Aβ1-42 to Aβ1-40 and values greater than 1.0 indicative 
of elevated levels of Aβ1-42 over Aβ1-40. A one-way ANOVA revealed no significant main 
effect of age on the ratio of Aβ1-42 to Aβ1-40 (F(2,12) = 1.925, p = 0.1884; Figure 4.4C). In 
summary, our results show no change in the ratio of Aβ1-42 to Aβ1-40 over time in 
APPswe/PS1∆E9 mice. 
Overall, the findings of the present experiment demonstrate levels of both soluble Aβ1-40 
and Aβ1-42 increase with age in APPswe/PS1∆E9 mice, with levels of Aβ42 remaining 
consistently elevated across all aged groups studied compared with Aβ40.  
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Figure 4.4. Soluble Aβ increases with age in APPswe/PS1∆E9 mice. (A) ELISA quantification of soluble human Aβ40 
in APPswe/PS1∆E9 mice aged 4, 6 and 10 months. (B) ELISA quantification of soluble human Aβ42 in APPswe/PS1∆E9 
mice aged 4, 6 and 10 months. (C) Ratio of Aβ42 to Aβ40 in APPswe/PS1∆E9 mice aged 4, 6 and 10 months. All values 
represent mean ± SEM. *p < 0.05, **p < 0.01. n = 5-6 for all groups. The data represented in this figure were generated 
by Lyndsey Konen. 
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4.3.4 Absence of hippocampal neuron cell loss over time in APPswe/PS1∆E9 mice 
Neurodegeneration is a well characterised feature of AD in humans (Blanchard et al., 
2003; Oakley et al., 2006; Wirths et al., 2010; Wirths & Bayer, 2010). Furthermore, 
regions of the brain such as the cortex and hippocampus are particularly vulnerable to 
neuronal degeneration in the preliminary stages of disease progression (Dubois et al., 
2007; Kaye et al., 1997). In human AD, deficits in neuronal density were most 
pronounced in the CA1 and CA3 hippocampal regions of AD patients compared to age-
matched control patients (Padurariu et al., 2012). Despite the relative importance of 
neurodegeneration in human AD pathology however, many of the currently used 
transgenic AD mouse models do not show neuron loss as a key feature of the AD 
pathology (Jankowsky & Zheng, 2017; Radde et al., 2008). 
Given the importance of hippocampal CA1 and CA3 regions in learning and memory 
processes (Daumas et al., 2005), we investigated whether temporal changes in 
hippocampal neuronal populations were related to the previously observed learning and 
memory deficits and Aβ accumulation in the APPswe/PS1∆E9 model. The number of 
NeuN+ cells in the CA1 and CA3 were quantified via stereology as previously described 
(section 4.2.2.3). Coronal sections were taken from APPswe/PS1∆E9 mice and wild-type 
littermates aged 6 and 10 months and immunohistochemically stained for the neuronal 
nuclei marker, NeuN, to label the pyramidal cell layer of the hippocampus (Figure 4.5A). 
In the CA1, a two-way ANOVA revealed no main effect of age (F(1,16) = 1.832, p = 0.1947) 
or genotype (F(1,16) = 0.0615, p = 0.8073) on the number of NeuN
+ cells (Figure 4.5B). 
Furthermore, there was no significant interaction of age and genotype on the number of 
NeuN+ cells in each group (F(1,16) = 0.9093, p = 0.3545). 
In the CA3, a two-way ANOVA revealed a significant main effect of age on the number 
of NeuN+ cells (F(1,16) = 4.856, p = 0.0425) while the main effect of genotype was not 
significant (F(1,16) = 0.9589, p = 0.3420; Figure 4.5C). Furthermore, there was no 
significant interaction of age and genotype on the number of NeuN+ cells in 
APPswe/PS1∆E9 mice in each group (F(1,16) = 0.0085, p = 0.9276). Post-hoc analysis using 
Bonferroni’s test to correct for multiple comparisons revealed no significant differences 
in the number of NeuN+ cells over time in wild-type (p = 0.7441) and APPswe/PS1∆E9 mice 
(p = 0.9294). 
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In summary, our results show there are no changes in total hippocampal neuron 
populations in the CA1 or CA3 of APPswe/PS1∆E9 mice compared to wild-type littermates 
at 6 and 10 months. 
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Figure 4.5. No age-dependent hippocampal neuronal cell loss in APPswe/PS1∆E9 mice. (A) Representative images 
of hippocampal neuron layer in wild-type and APPswe/PS1∆E9 mice aged 6 and 10 months. (B) Stereological 
quantification of NeuN+ cells in the CA1 of wild-type and APPswe/PS1∆E9 mice aged 6 and 10 months. (C) Stereological 
quantification of NeuN+ cells in the CA3 of wild-type and APPswe/PS1∆E9 mice aged 6 and 10 months. All values 
represent mean ± SEM. n = 5 for all groups. 
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4.3.5 There are no alterations in the total number of astrocytes over time in the 
hippocampus of APPswe/PS1∆E9 mice 
In addition to memory loss, Aβ plaques and neurodegeneration, neuroinflammation is 
another well-described pathological feature of AD (Zimmer et al., 2014). Astrogliosis, a 
neuroinflammatory event common in AD, is the process whereby activation of resident 
astrocytic populations leads to morphological changes and abnormal increases in the 
number of astrocytes (Heneka et al., 2015). Astrocytes have a dynamic role in 
homeostatic brain processes under physiological conditions and are thought to participate 
in synaptic communication (Volterra & Meldolesi, 2005). Under the pathological 
conditions of AD, astrocytes may have differential roles at various stages of disease 
progression. For example, disruption of homeostatic processes may be caused by 
astrocytic atrophy during the early stages of the disease, while astrogliosis occurring at 
later stages of disease is thought to contribute to neuroinflammatory responses 
(Verkhratsky et al., 2010). In both humans and mouse models of AD, amyloid plaques 
have been observed surrounded by reactive astrocytes with increased GFAP expression 
(Ingelsson et al., 2004; Kamphuis, Orre, et al., 2012; Middeldorp & Hol, 2011; Rodríguez 
et al., 2009).  
Therefore, in the following experiment, we aimed to examine whether hippocampal 
astrogliosis increased with disease progression in APPswe/PS1∆E9 mice using stereological 
methods. Coronal sections were taken from wild-type and APPswe/PS1∆E9 mice aged 6 
and 10 months and immunohistochemically stained for the astrocyte marker, GFAP 
(Figure 4.6A). The number of GFAP+ cells in the CA1 and CA3 were quantified via 
stereology. 
In the CA1, a two-way ANOVA revealed no main effect of age (F(1,16) = 0.1927, p = 
0.6666) or genotype (F(1,16) = 1.235, p = 0.2829) on the number of GFAP
+ cells (Figure 
4.6B). In the CA3, a two-way ANOVA also revealed no main effect of age (F(1,16) = 
0.5873, p = 0.4546) or genotype (F(1,16) = 1.605, p = 0.2233) on the number of GFAP
+ 
cells (Figure 4.6C). Combined, these results show no increases in astrogliosis in the CA1 
or CA3 regions of the hippocampus in APPswe/PS1∆E9 mice between 6 and 10 months. 
Furthermore, total astrogliosis was not significantly elevated in APPswe/PS1∆E9 mice 
compared to wild-type mice of the same age. 
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Figure 4.6. No increase in hippocampal GFAP+ astrocytes over time in APPswe/PS1∆E9 mice. (A) Representative 
images of GFAP+ hippocampal layer in wild-type and APPswe/PS1∆E9 mice aged 6 and 10 months. (B) Stereological 
quantification of GFAP+ cells in the CA1 of wild-type and APPswe/PS1∆E9 mice aged 6 and 10 months. (C) Stereological 
quantification of GFAP+ cells in the CA3 of wild-type and APPswe/PS1∆E9 mice aged 6 and 10 months. All values 
represent mean ± SEM. n = 5 for all groups. 
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4.3.6 There are no alterations in the total number of microglia over time in the 
hippocampus of APPswe/PS1∆E9 mice 
In addition to astrogliosis, microgliosis, a process in which resident microglial cells 
become activated, is another component of the neuroinflammatory response in AD. 
Similarly to astrogliosis, clusters of microglia surrounding amyloid plaques have been 
observed in both human and mouse models of AD (Bolmont et al., 2008; Mattiace et al., 
1990; Meyer-Luehmann et al., 2008). 
Therefore, in the present study, we aimed to examine whether hippocampal microgliosis 
increased with disease progression in APPswe/PS1∆E9 mice using stereological methods. 
Coronal sections were taken from wild-type and APPswe/PS1∆E9 mice aged 6 and 10 
months and immunohistochemically stained for the microglial marker, IBA1 (Figure 
4.7A). IBA1 is expressed by CNS resident microglia and peripheral macrophages and is 
used as a marker of total (both resting and activated) microglia (Ito et al., 1998). The 
number of IBA1+ cells in the CA1 and CA3 were quantified via stereology. 
In the CA1, a two-way ANOVA revealed no main effect of age (F(1,16) = 7.379e-006, p = 
0.9979) or genotype (F(1,16) = 0.1929, p = 0.6664) on the number of IBA1
+ cells (Figure 
4.7B). In the CA3, a two-way ANOVA also revealed no main effect of age (F(1,16) = 3.771, 
p = 0.0700) or genotype (F(1,16) = 0.0969, p = 0.7596) on the number of IBA1
+ cells 
(Figure 4.7C). Combined, these results show no increases in total microglial populations 
in the CA1 or CA3 regions of the hippocampus in APPswe/PS1∆E9 mice aged 6 and 10 
months. Furthermore, total microglial population was not significantly elevated in 
APPswe/PS1∆E9 mice compared to wild-type mice of the same age. 
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Figure 4.7. No increase in hippocampal IBA1+ microglia over time in APPswe/PS1∆E9 mice. (A) Representative 
images of IBA1+ hippocampal layer in wild-type and APPswe/PS1∆E9 mice aged 6 and 10 months. (B) Stereological 
quantification of IBA1+ cells in the CA1 of wild-type and APPswe/PS1∆E9 mice aged 6 and 10 months. (C) Stereological 
quantification of IBA1+ cells in the CA3 of wild-type and APPswe/PS1∆E9 mice aged 6 and 10 months. All values 
represent mean ± SEM. n = 5 for all groups.  
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4.4 Discussion 
In this chapter, we aimed to establish a mouse model of AD in our own hands by 
determining the temporal relationship of soluble and plaque Aβ, neurodegeneration, 
microglia and astrocyte populations to cognitive dysfunction in the APPswe/PS1∆E9 mouse 
model of AD. As previously described, the overarching aim of this study was to 
investigate how modulation and/or stimulation of neurogenesis under pathological 
conditions affects learning and memory outcomes by crossing the APPswe/PS1ΔE9 mouse 
model of AD with the Nescre-ERT2/R26-AlstR mouse line previously described in 
Chapter 3 (3.2.1.2), but prior to this we aimed to first establish the baseline cognitive and 
pathological phenotypes of the APPswe/PS1∆E9 model. Our results illustrated 
hippocampus-dependent memory deficits coincided with increases in soluble Aβ in the 
hippocampus prior to widespread plaque deposition and in the absence of hippocampal 
neurodegeneration and neuroinflammation. In the following section, we discuss these 
results in the context of the wider literature. 
 
4.4.1 Impaired long-term fear memory in APPswe/PS1∆E9 mice at 4 and 6 months but 
not at 10 months of age 
The defining feature of clinical AD is progressive loss of memory and decline in cognitive 
function (Caselli et al., 2006). In particular, anterograde amnesia, which involves memory 
loss for events subsequent to disease onset or newly acquired information, is an earlier 
indicator of disease onset (Dubois & Albert, 2004). Nevertheless, it is also a highly 
variable cognitive measure in transgenic mouse models of AD, and indeed, previous 
studies investigating long-term contextual fear memory in the APPswe/PS1ΔE9 mouse 
model have shown conflicting results. While a subset of studies observed long-term 
context fear memory deficits at ages ranging from 3-13 months (Bartolotti et al., 2015; 
Cramer et al., 2012; Frost et al., 2015; Hsiao et al., 2014; Kilgore et al., 2010; Knafo et 
al., 2016; Rumbaugh et al., 2015; Végh et al., 2014), others have also shown no deficits 
in long-term context fear memory within this same age range (Bonardi et al., 2011; Cheng 
et al., 2013, 2014a, 2014b; Hsiao et al., 2014; Janus et al., 2015; Kilgore et al., 2010; 
LaClair et al., 2013; Maroof et al., 2014; Pardon et al., 2009; Park et al., 2010; Rattray et 
al., 2009).  
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In the present study, we observed deficits in long-term and remote fear memory at 4 and 
6 months in APPswe/PS1∆E9 mice (Figure 4.2). Unexpectedly, long-term fear memory at 
10 months in APPswe/PS1∆E9 mice was similar to wild-type counterparts at this age, while 
remote memory remained impaired across all age groups tested in APPswe/PS1∆E9 mice. 
Although the ability to discriminate between different contexts was similarly impaired 
across all age groups tested in APPswe/PS1∆E9 mice, fear responding was much higher in 
10 month APPswe/PS1∆E9 mice than in 4 or 6 month APPswe/PS1∆E9 mice. 
The apparent recovery of long-term fear in 10 month APPswe/PS1∆E9 mice is consistent 
with previous findings in the literature, where absence of long-term fear memory deficits 
in APPswe/PS1ΔE9 mice aged 8 to 11 months have previously been shown (Cheng et al., 
2013, 2014a, 2014b; Janus et al., 2015; LaClair et al., 2013; Maroof et al., 2014; Park et 
al., 2010). The cause of this apparent recovery however, remains elusive. Furthermore, 
the apparent recovery may be transient, as previous studies have described re-emergence 
of long-term memory deficits from 11 months onwards (Cramer et al., 2012; Frost et al., 
2015; Hsiao et al., 2014; Zhang et al., 2011). 
 
4.4.2 Age-dependent increase in amyloid-β plaque deposition in APPswe/PS1∆E9 mice 
Aβ plaque deposition is thought to be one of the distinguishing neuropathological features 
of AD (Selkoe, 1997), despite the unresolved paradox of its presence in cognitively 
normal individuals (Morris et al., 2014). The relative abundance of Aβ plaques in post-
mortem brain tissue of AD patients in comparison to brain tissue from cognitively normal 
patients remains an essential distinguishing feature in the diagnostic pathology of AD and 
subsequently, has become a widely used pathological hallmark in many mouse models of 
AD, including the APPswe/PS1∆E9 model.  
In the present study, we observed an age-dependent increase in Aβ plaque deposition in 
the hippocampus of APPswe/PS1∆E9 mice (Figure 4.3). No plaques were observed in the 
hippocampus of APPswe/PS1∆E9 mice at 4 months of age. This result contradicts some 
previously published findings, which have described, albeit minimal, hippocampal plaque 
formation in APPswe/PS1∆E9 mice aged 3 (Hamilton & Holscher, 2012) and 4 months 
(Garcia-Alloza et al., 2006; Liu et al., 2008; Ruan et al., 2009), while supporting others, 
which have observed no plaque deposition at 3-4 months (Kamphuis, Orre, et al., 2012; 
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Wang et al., 2003; Zhang et al., 2012). Furthermore, although plaque deposition in 
cortical regions was not quantitatively analysed in the present study, representative 
images of Thioflavin S-stained tissue sections of the cortical regions show the same 
pattern of plaque deposition observed in the hippocampus, that is, absence of Aβ plaques 
at 4 months of age in APPswe/PS1∆E9 mice (see Appendix Figure 6.9). 
In contrast, the presence of Aβ plaques in the hippocampus of APPswe/PS1∆E9 mice aged 
6 and 10 months is in agreement with previously published findings, which have 
described significant plaque deposition in both the hippocampus and cortex from 6 
months onwards (Cisternas et al., 2015; Currais et al., 2014; Ding et al., 2008; Garcia-
Alloza et al., 2006; Hamilton & Holscher, 2012; Jankowsky et al., 2004; Liu et al., 2008; 
Mei et al., 2010; Verret et al., 2007). Furthermore, the temporal pattern of hippocampal 
plaque increase is similar to previous findings (Garcia-Alloza et al., 2006; Hamilton & 
Holscher, 2012), with a sharp increase in plaque deposition typically observed between 6 
and 10 months of age.  
The discrepancy in the onset of plaque deposition in APPswe/PS1∆E9 mice between studies 
may be attributable, in part, to gender differences. Indeed, differences in the extent of Aβ 
plaque deposition in male and female APPswe/PS1∆E9 mice have previously been 
described. Pistell and colleagues showed intermittent Aβ plaque deposition in the 
hippocampus and amygdala/ cortex regions of female APPswe/PS1∆E9 mice aged 2-5 
months while male APPswe/PS1∆E9 mice comparatively exhibited little to no Aβ deposits 
within the same age range (Pistell et al., 2008). Similarly, an earlier study by Wang and 
colleagues showed no hippocampal plaque deposition in both male and female 
APPswe/PS1∆E9 mice aged 4 months, while at 12 and 17 months, female mice consistently 
exhibited higher plaque load that males (Wang et al., 2003). Together, these studies 
suggest plaque deposition may occur earlier and accrue more aggressively in female 
APPswe/PS1∆E9 mice. This may partially explain the discrepancy in onset of plaque 
deposition observed between the present study and previous findings from other 
investigators (Hamilton & Holscher, 2012), who utilised female APPswe/PS1∆E9 mice in 
their study. Nevertheless, this does not account for the discrepancy between our findings 
and those of Ruan and colleagues (2009) as they utilised male APPswe/PS1∆E9 mice. 
Mouse gender was not reported in the studies by Garcia-Alloza and colleagues (2006) 
and Liu and colleagues (2008).  
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Additionally, variations in mouse strain may have contributed to the discrepancy in onset 
of plaque deposition observed in the present study compared with others (Garcia-Alloza 
et al., 2006; Hamilton & Holscher, 2012; Liu et al., 2008; Ruan et al., 2009). Many AD 
mouse models are made congenic on inbred strains, such as the C57BL/6J strain used in 
the present study, FVB/N, BALB/c and SJL/J (among others; Duff & Suleman, 2004), 
and background strain differences are known to modulate the pathological and 
behavioural phenotype of AD mouse models (Hall & Roberson, 2012; Onos et al., 2016). 
This in turn may differentially affect the susceptibility of certain AD mouse models bred 
on different strains to subsequent AD-related dysfunctions. The APPswe/PS1∆E9 mice used 
in the present study were made congenic on a C57BL/6J background, while the 
background strains of the APPswe/PS1∆E9 mice utilised by Garcia-Alloza and colleagues 
(2006), Liu and colleagues (2008), and Ruan and colleagues (2009) were not reported. 
Nevertheless, this does not account for discrepancies between our findings and those of 
Hamilton and Holscher (2012), who also used APPswe/PS1∆E9 mice, albeit female, bred 
on a C57BL/6J background. 
In summary, our results corroborate previously published findings showing an increase 
in Aβ plaque deposition over time, but differ as to the timing of plaque deposition onset. 
Further, we extend previous findings by demonstrating that deficits in contextual fear 
memory precede onset of hippocampal Aβ plaque deposition in the APPswe/PS1∆E9 mouse 
model, suggesting that plaque deposition is not a direct correlate of contextual fear 
memory deficits in the APPswe/PS1∆E9 mouse model. This finding is in agreement with 
other transgenic mouse models of AD, which have similarly described onset of cognitive 
deficits preceding plaque deposition (Hsia et al., 1999; Mucke et al., 2000; Westerman et 
al., 2002).  
 
4.4.3 Total levels of soluble amyloid-β increase with age in APPswe/PS1∆E9 mice 
Although plaque deposition remains one of the prevalent pathological hallmarks in many 
mouse models of AD, research efforts have increasingly been directed towards soluble 
Aβ oligomers as the cause of AD (Ferreira & Klein, 2011; Morris et al., 2014; Selkoe & 
Hardy, 2016; Walsh & Selkoe, 2004) and its role in AD-related learning and memory 
dysfunctions (Eriksen & Janus, 2007; Kobayashi & Chen, 2005; Shankar et al., 2008). In 
the APPswe/PS1∆E9 mouse model of AD, detectable levels of both soluble Aβ1-40 and Aβ1-
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42 have been previously described as early as 3 months (Volianskis et al., 2010), with 
investigators demonstrating an age-dependent increase in both soluble Aβ1-40 and Aβ1-42 
in the hippocampus (Minkeviciene et al., 2008; Wang et al., 2003), forebrain (Savonenko 
et al., 2005), and cortex (Volianskis et al., 2010). Levels of soluble Aβ1-42 increased more 
steeply than Aβ1-40 with disease progression, with the sharpest increase often coinciding 
with onset of plaque deposition; between 4 and 12 months (Wang et al., 2003), 7 and 19 
months (Savonenko et al., 2005), 9 and 16 months (Minkeviciene et al., 2008), and 9 and 
12 months (Volianskis et al., 2010). Furthermore, studies investigating cognitive deficits 
in APPswe/PS1∆E9 mice have shown levels of soluble Aβ1-40 and Aβ1-42 to be significantly 
correlated with deficits in episodic-like memory (Savonenko et al., 2005; Zhang et al., 
2011) and contextual memory (Zhang et al., 2011). 
In the present study we demonstrated an age-dependent increase in both soluble Aβ1-40 
and Aβ1-42 in the hippocampus of APPswe/PS1∆E9 mice (Figure 4.4A-B). Soluble Aβ1-42 
protein levels increased concurrently with, and remained elevated over, soluble protein 
levels of Aβ1-40 in the hippocampus of APPswe/PS1∆E9 mice aged 4, 6, and 10 months. 
Specifically, levels of soluble Aβ1-42 protein were found to increase more steeply between 
6 and 10 months compared with Aβ1-40, which corroborates previous findings showing 
elevated Aβ1-42 protein levels at later stages of disease progression, despite concurrent 
increases in both proteins across time (Minkeviciene et al., 2008; Savonenko et al., 2005; 
Volianskis et al., 2010; Wang et al., 2003).  
Previous studies characterising APPswe/PS1∆E9 mice have shown Aβ1-42 to be the 
dominant isoform compared to Aβ1-40 (Jankowsky et al., 2004), with an approximate ratio 
of 2:1 for soluble Aβ1-42 to Aβ1-40 observed in the hippocampus (Cisternas et al., 2015; 
Malm et al., 2007; Minkeviciene et al., 2008; Wang et al., 2003; Xiong et al., 2011), 
cortex (Volianskis et al., 2010; Xiong et al., 2011), and hemi-sected brain tissue of 
APPswe/PS1∆E9 mice (Jankowsky et al., 2004). However, findings relating to the ratio of 
Aβ1-42 to Aβ1-40 in the hippocampus of APPswe/PS1∆E9 mice with increasing age have been 
conflicting. An analysis of Aβ protein levels in the cortex of female APPswe/PS1∆E9 mice 
revealed levels of Aβ1-42 remained elevated above Aβ1-40 in mice aged 3, 6, 9, and 12 
months, with no age-dependent change in the ratio of Aβ1-42 to Aβ1-40 (Volianskis et al., 
2010). This conflicted with an earlier study, which showed a substantial increase in the 
ratio of Aβ1-42:Aβ1-40 in both male and female mice between the ages of 4 and 12 months; 
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the ratio of Aβ1-42:Aβ1-40 increased from 0.2 to 3 in males, and 0.3 to 2.2 in females (Wang 
et al., 2003). 
A comparison of the ratio of soluble Aβ1-42 to Aβ1-40 protein levels in the present study 
revealed no age-dependent change in the ratio of soluble hippocampal Aβ1-42 to Aβ1-40 
(Figure 4.4C). Furthermore, we show soluble Aβ1-42 to be the dominant species over Aβ1-
40 from as early as 4 months, prior to onset of observable Aβ plaque deposition at 6 months. 
This result corroborates the findings of Volianskis and colleagues (2010) who, similarly, 
demonstrated no temporal change in the ratio of Aβ1-42 to Aβ1-40 protein levels in 
APPswe/PS1∆E9 mice and whom, similarly, demonstrated detectable levels of soluble Aβ1-
42 and Aβ1-40 at 3 months preceding plaque deposition at 6 months in the APPswe/PS1∆E9 
mouse model (Volianskis et al., 2010). However, this result conflicts with the findings of 
Wang and colleagues (2003), where an increase in the ratio of Aβ1-42 to Aβ1-40 was 
observed between 4 and 12 months; specifically, at 4 months, Aβ1-40 was observed to be 
the dominant species in the hippocampus of both male and female APPswe/PS1∆E9 mice 
while the pattern became inverted at 12 months, with Aβ1-42 becoming the dominant 
species. 
In summary, the results of the present study show an age-dependent increase in the soluble 
protein levels of both Aβ1-40 and Aβ1-42 in the APPswe/PS1∆E9 mouse model of AD. 
Furthermore, the levels of detectable soluble Aβ1-40 and Aβ1-42 appear to coincide with 
the onset of contextual fear memory deficits previously described (4.4.1), while also 
preceding onset of widespread Aβ plaque deposition. Lastly, the ratio of Aβ1-42 to Aβ1-40 
remained unchanged over time, with elevated levels of Aβ1-42 relative to Aβ1-40 observed 
across all age groups. Together, these findings suggest that measures of soluble Aβ1-40 
and Aβ1-42 may be a better correlate of contextual fear learning and memory deficits than 
plaque deposition in the APPswe/PS1∆E9 mouse model of AD. 
 
4.4.4 APPswe/PS1∆E9 mice do not exhibit temporal changes in CA1 and CA3 
hippocampal neurodegeneration 
Neurodegeneration is a major pathological hallmark of AD in humans and a strong 
correlate of observed memory impairments in AD patients (Buckner, 2004; 
Giannakopoulos et al., 2003; Gómez-Isla et al., 1996; Gómez-Isla et al., 1997; Walsh & 
Chapter 4: Characterisation of the APPswe/PS1ΔE9 mouse model 
 
 
207 
Selkoe, 2004). Brain regions critical to memory processing functions, such as the 
hippocampus and adjacent cortical areas, are particularly vulnerable to neuron loss, with 
stereological quantification revealing up to 90% reduction in the neuronal population in 
layer II of the entorhinal cortex of AD patients (Gómez-Isla et al., 1996). Despite the 
importance of neuron loss in the pathogenesis of AD, successfully modelling neuron loss 
in transgenic AD mouse models has proven challenging  (Radde et al., 2008; Wirths & 
Bayer, 2010), with only a few APP and/or PS1-expressing models exhibiting phenotypic 
neuron loss (Calhoun et al., 1998; Hall & Roberson, 2012; Oakley et al., 2006; Wright et 
al., 2013). Furthermore, in transgenic models co-expressing APP and PS1, widespread 
neuron loss is often not a prominent feature, even in the presence of advanced amyloid 
pathology (Radde et al., 2008; Rupp et al., 2011). 
In the APPswe/PS1∆E9 mouse model of AD, neuron loss is not a key feature, even in aged 
mice (~ 17-18 months; Ma et al., 2017). Previous investigations characterizing neuronal 
loss in this model have been limited, and when done, have largely focused on mice in the 
middle-to-late stages of AD (12-24 months; Huang et al., 2016; Lok et al., 2013; Ma et 
al., 2017; Soto et al., 2016). Although the hippocampal neuron population in 
APPswe/PS1∆E9 mice was not significantly attenuated at 9 months (Lok et al., 2013), 
significant neuron loss was observed in the CA1 hippocampal region at 14 months (Soto 
et al., 2016).  A recent study utilising unbiased stereological analysis of toluidine blue-
stained neurons found discrete, region-specific changes in hippocampal neuronal 
population of 17-18 month-old APPswe/PS1∆E9 mice (Ma et al., 2017). Specifically, a 
decrease in neuronal population was observed in both the DG and CA1 hippocampal 
regions of 17-18 month APPswe/PS1∆E9 mice compared to wild-type counterparts, while 
neuronal population in the CA3 regions remained unchanged across genotypes (Ma et al., 
2017). An earlier study of aged 24-month-old APPswe/PS1∆E9 mice similarly observed a 
significant reduction in neuronal population in both the CA1 and DG hippocampal 
regions using unbiased stereological analysis (Huang et al., 2016). 
The temporal pattern of hippocampal neurodegeneration within this specific mouse model 
has not been investigated previously, particularly in mice of the earlier stages of AD (i.e., 
6-10 months). Thus, in the present study, we utilised design-based stereology to quantify 
the CA1 and CA3 hippocampal neuron population. Through this, we observed no 
significant changes in neuronal population of the CA1 or CA3 hippocampal regions in 
APPswe/PS1∆E9 mice compared to wild-type controls at both 6 and 10 months of age 
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(Figure 4.5). To the best of our knowledge, this is the first assessment of temporal changes 
in neurodegeneration using stereological methods in APPswe/PS1∆E9 mice aged under 10 
months. Our findings corroborate earlier findings by Lok and colleagues (2013), whom 
similarly observed no changes in hippocampal neuron population in APPswe/PS1∆E9 mice 
aged 9 months compared to wild-type littermates using automated image analysis 
software based on colour segmentation for assessment of neuron loss. In summary, our 
findings suggest that hippocampal neurodegeneration in the APPswe/PS1∆E9 mouse model 
is not present at 6 or 10 months, despite the presence of amyloidosis and contextual fear 
memory deficits at these ages. Furthermore, our results suggest deficits in memory may 
be driven independently of neuron loss. It is possible synapse dysfunction and loss could 
account for memory deficits (Scheff et al., 2006), but we have not assessed this in the 
present study. 
Despite the absence of significant neurodegeneration in discrete hippocampal regions 
observed in the present study, this does not preclude the possibility of neurodegeneration 
in extra-hippocampal areas. Indeed, although Lok and colleagues observed no changes in 
hippocampal neuron population of APPswe/PS1∆E9 mice aged 9 months, they found a 
significant reduction in neuronal populations in the cortex at the same age (Lok et al., 
2013). Additionally, an earlier study utilising unbiased stereological methods to quantify 
the neuronal population of the frontal cortex of 7 month APPswe/PS1∆E9 mice showed no 
change in density of MAP2+ neurons, but observed a significant decrease in the volume 
of neuronal bodies of APPswe/PS1∆E9 mice compared to wild-type controls (Ding et al., 
2008). Conflictingly, no differences in neuron loss were observed in the cortex of 
APPswe/PS1∆E9 mice aged 14 months (Soto et al., 2016). Differences in methodology may 
account for these discrepancies, as the latter study (Soto et al., 2016) did not utilise 
stereology-based methods for quantification, and this may have masked any subtle 
changes in neurodegeneration. Together, these studies suggest that cortical 
neurodegeneration may precede changes in hippocampal neuron population in the 
APPswe/PS1∆E9 mouse model of AD. 
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4.4.5 Alterations in hippocampal astrocyte and microglia populations were not 
observed in APPswe/PS1∆E9 mice with increasing age 
Neuroinflammation is a key pathogenic feature of AD and has been implicated in the 
pathogenesis of AD (Morris et al., 2013). In post-mortem immunohistochemical analyses 
of human AD patients, reactive astrocytes and activated microglia have previously been 
observed in close association with amyloid plaques (Itagaki et al., 1989; Serrano-Pozo et 
al., 2011; Vehmas et al., 2003), suggesting accumulation of Aβ may be involved in 
upregulation and activation of both astrocytes and microglial cells in AD pathogenesis 
(McGeer & McGeer, 1995; Selkoe, 2001). Prior studies investigating neuroinflammation 
in transgenic models co-expressing APP and PS1 have demonstrated morphological 
changes in astrocytes and reactive microglia with increasing age, with newly-formed 
plaques in both the cortex and hippocampus observed in close association with microglia 
and astrocytes (Haim et al., 2015; Bolmont et al., 2008; Kamphuis, Mamber, et al., 2012; 
Kamphuis, Orre, et al., 2012; Meyer-Luehmann et al., 2008; Ruan et al., 2009).  
In the present study, we utilised design-based stereology to quantify populations of 
astrocytes and microglia in the hippocampus of APPswe/PS1∆E9 mice. Despite the 
temporal increase in plaque deposition previously discussed, populations of GFAP+ 
astrocytes and IBA1+ microglia remained unchanged across all age groups and genotypes 
investigated (Figure 4.6; Figure 4.7). To the best of our knowledge, this is the first 
stereological assessment of astrocyte and microglial populations in discrete hippocampal 
regions of the CA1 and CA3 in APPswe/PS1∆E9 mice over time. 
This finding is not without precedence. Ding and colleagues (2008) utilised unbiased 
stereological methods to quantify the number of GFAP+ astrocytes and IBA1+ microglia 
in the hippocampus of 7 month APPswe/PS1∆E9 mice, observing no significant differences 
between APPswe/PS1∆E9 mice and their wild-type counterparts (Ding et al., 2008). 
Utilising image analysis quantification, Bennett and colleagues showed no change in 
hippocampal CA1 or CA3 GFAP+ astrocytes in 9 month APPswe/PS1∆E9 mice compared 
to wild-type controls (Bennett et al., 2013). Similarly, Duffy and Hölscher showed no 
significant age-related change in GFAP+ astrocytes in the hippocampal CA1 region of 
APPswe/PS1∆E9 mice aged 6, 12, and 19 months (Duffy & Hölscher, 2013). Lastly, 
quantification of IBA1-immunoreactive microglial populations in the hippocampus of 
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APPswe/PS1∆E9 mice revealed no significant differences in IBA1
+ microglia compared to 
wild-type controls at both 2 and 12 months (Go et al., 2016). 
Although stereology is the gold standard for unbiased quantification of cell populations 
(Mark J. West & Gundersen, 1990) and was the primary method of analysis used in the 
present study, previous findings in the literature suggest that supplemental analyses may 
be required for detection of subtle changes in astrogliosis in the APPswe/PS1∆E9 mouse 
model. Minkeviciene and colleagues utilised two separate measures to determine age-
related changes in astrogliosis of APPswe/PS1∆E9 mice (Minkeviciene et al., 2008). Firstly, 
by calculating the hippocampal surface area percentage of cells immunoreactive for 
GFAP, the authors found no significant differences in GFAP+ cells in APPswe/PS1∆E9 mice 
aged 6 and 16 months when compared to wild-type littermates, despite an age-related 
trend towards increase in GFAP+ cells in APPswe/PS1∆E9 mice (Minkeviciene et al., 2008). 
A supplemental analysis via western blotting subsequently revealed no differences in 
GFAP levels of APPswe/PS1∆E9 mice at 5 months but a significant increase at 14 months 
when compared to wild-type controls (Minkeviciene et al., 2008). Ding and colleagues 
similarly showed supplemental analyses were able to reveal subtle changes in both 
astrocyte and microglia activity that were undetected by quantification analyses (Ding et 
al., 2008). Although quantification of total GFAP+ astrocyte and IBA1+ microglia 
numbers in the hippocampus of 7 month APPswe/PS1∆E9 mice revealed no significant 
differences compared to wild-type controls, supplemental analyses of the average volume 
(measured as per μm3) taken up by GFAP+ astrocytes and IBA1+ microglia along with 
GFAP+ staining intensity revealed increases in the volume of GFAP and IBA1 cells in 
APPswe/PS1∆E9 mice, along with corresponding increases in GFAP staining intensity 
(Ding et al., 2008). A similar analysis was also recently conducted by Currais and 
colleagues, who showed no changes in total GFAP+ astrocytes numbers in the 
hippocampus of 12 month APPswe/PS1∆E9 mice, but corresponding increases in area 
(measured as per μm2) and intensity of GFAP staining, and GFAP protein levels 
(measured via western blot analysis) in 12 month APPswe/PS1∆E9 mice (Currais et al., 
2014). Together, these studies highlight the importance of supplemental analyses for 
detection of subtle changes in astrogliosis and microgliosis. Future characterisation 
studies would benefit from analysis of changes in morphological structure or protein 
levels, rather than total cell counts. In the case of microgliosis, this may include utilisation 
of protein markers specific to the various phenotypes of microglia. 
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Furthermore, similar to the previously discussed results of neurodegeneration, the 
absence of significant neuroinflammation in discrete hippocampal regions observed in 
the present study does not preclude the possibility of increased neuroinflammation in both 
hippocampal and/or extra-hippocampal areas of the CNS. Indeed, immunolabelling of 
GFAP+ astrocytes is just one measure of neuroinflammation. Future studies may benefit 
from an extended assessment of neuroinflammation, such as morphological analyses of 
hippocampal astrocytes, or measurements of cytokines and chemokines associated with 
neuroinflammation, which may be more capable of detecting subtle alterations in GFAP 
expression that staining alone cannot detect. Additionally, prior studies within the 
literature have observed significant increases in immunolabelling of GFAP+ astrocytes 
and IBA1+ microglia in the cortex of APPswe/PS1∆E9 mice from 6 months onwards (Go et 
al., 2016; Kamphuis, Orre, et al., 2012; Soto et al., 2016). Although neuroinflammation 
in areas outside of the hippocampus were not the focus of the present study, future studies 
would also benefit from analysis of neuroinflammation in extra-hippocampal regions 
when investigating AD pathology in the APPswe/PS1∆E9 mouse model. 
 
4.4.6 Conclusion 
In the present study, we sought to characterise the anatomical and behavioural phenotype 
of APPswe/PS1∆E9 mice, with the eventual goal to investigate whether neurogenesis is 
altered under pathological conditions of AD and subsequently to assess the effectiveness 
of stimulating neurogenesis in promoting recovery of cognitive deficits. Our findings 
show age-related deficits in contextual fear memory coinciding with detectable levels of 
soluble Aβ in APPswe/PS1∆E9 mice aged 4 months. Gross Aβ plaque deposition preceded 
onset of memory impairments. Furthermore, no significant changes in hippocampal 
neurodegeneration or neuroinflammation were observed at 6 and 10 months. As 
previously described in the introduction to this chapter, our eventual goal is to investigate 
hippocampal neurogenesis in a neurodegenerative disease model. The results described 
in this chapter thus provide a baseline with which to commence future experiments.
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5.1 Revisiting the overall aims of the thesis 
Since the discovery of enhanced neurogenesis in both neurogenic and non-neurogenic 
regions following acute injury (summarised in section 1.4), understanding the function of 
this spontaneous injury-induced response has been an important area of research for both 
scientists and clinicians. Importantly, defining whether this inherent regenerative 
response contributes to recovery following injury is an important step to determine the 
therapeutic potential of this response. 
At the outset of this thesis, we had two long term aims in mind; 1. We were interested in 
understanding the functional relevance of injury-induced neurogenesis to hippocampal-
dependent cognitive recovery. 2. To apply our understanding of injury-induced 
neurogenesis to a model of neurodegenerative disease to investigate whether 
neurogenesis is dysfunctional and whether increasing and/or stimulation of neurogenesis 
under chronic neurodegenerative disease conditions may provide an effective therapeutic 
target for improvement of cognitive deficits. Extensive discussions of the experimental 
data have been presented within each research chapter (see sections 2.4, 3.4, 4.4). In the 
following chapter, we discuss our findings in the context of the two overarching long-
term aims of this study. We summarise the key findings from this thesis, discuss their 
significance in the context of the wider literature attempting to answer our two 
overarching aims, and highlight the limitations of our findings. Furthermore, taking into 
account the lessons we’ve learned, we outline future research directions required to fulfil 
the long-term experimental aims.  
 
5.2 Unifying summary of key findings derived from this thesis 
The main theme permeating the research presented in this thesis is building towards an 
analysis of the functional role of injury-induced hippocampal neurogenesis in the 
recovery of cognitive deficits post-injury. Indeed, this theme is the main focus of the 
overall introductory and background content of Chapter 1 and we attempted to directly 
address this question experimentally in Chapter 3. Our experiments in Chapter 2 
document our efforts to establish a reproducible model of hippocampal injury and 
neuronal repopulation, while in Chapter 4, we characterised the behavioural and 
pathological phenotype of the APPswe/PS1ΔE9 transgenic mouse model of AD, with the 
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goal in mind of translating our understanding of spontaneous injury-induced neurogenesis 
in cognitive recovery to a chronic neurodegenerative disease model. 
Under physiological conditions, neurogenesis has been observed to occur in both the SVZ 
and DG of the hippocampus (Ming & Song, 2011). Furthermore, an increase in DG and 
SVZ neurogenesis has been well established to occur following various forms of acute 
experimentally-induced CNS injury (Ruddy & Morshead, 2018). Although injury-
induced neurogenesis has also been observed in areas outside of the canonical neurogenic 
niches, the magnitude of the regenerative response is oftentimes limited and combined 
with poor survival of the newborn neurons, has led some to suggest this endogenous 
response alone is not sufficient for effecting long-term functional benefits (Adams & 
Morshead, 2018; Sun, 2016). Prior to commencing the work presented in this thesis, the 
KA model of acute excitotoxic injury had been well established in our group. 
Nevertheless, as described throughout Chapter 2, numerous experimental and technical 
difficulties compelled us to revise our methodology. Through our optimisation of the KA 
model of acute excitotoxic injury described in Chapter 2, we obtained exciting 
preliminary evidence for the occurrence of spontaneous neuron repopulation in the CA1 
and CA3 regions of the hippocampus, areas previously thought to be incapable of 
neurogenesis, following a controlled intracerebral injury. Notably, our experiments in 
Chapter 2 highlight the importance of thorough experimenter training and validation of 
the CNS injury model prior to commencement of experimental investigations. 
Prior studies by our group and others have demonstrated the occurrence of injury-induced 
neurogenesis in areas outside of the canonical neurogenic regions (see sections 1.4.1.2 
and 1.4.2.2). A key question remaining is whether these newly generated neurons are 
functional following injury, and specifically, whether they’re contributing to recovery of 
cognitive function. Furthermore, it is unknown where these newborn neurons originate 
from. Do they migrate from the neurogenic niches? Or do certain types of injury cause 
“activation” of normally quiescent populations in generally-regarded non-neurogenic 
regions? The experiments described in Chapter 3 were directly aimed at addressing these 
questions. Ultimately, a composite of factors, including the extensive length of our 
experimental protocol, technical difficulties associated with our Nescre-ERT2/R26-AlstR 
transgenic mouse line and other experimental methodologies, combined with our 
difficulties in establishing a reliable model of KA-induced hippocampal degeneration and 
repopulation, hindered our efforts to conclusively elucidate the functional role of injury-
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induced hippocampal neurogenesis in cognitive recovery. Nevertheless, we were able to 
derive some useful conclusions that will inform our future investigations. 
With the incidence of neurodegeneration-related disorders projected to increase 
exponentially over the next few decades (such as Alzheimer’s disease and other 
dementias), there is now more than ever an increased need for understanding the 
mechanisms underlying endogenous brain repair for restoration of cognitive functions 
following CNS injury. In the present thesis, we chose to focus our efforts on AD, in part 
because it is the most common form of neurodegenerative disease worldwide 
(Horgusluoglu et al., 2017) and is a disease which prominently impacts the hippocampus 
and learning and memory capacities early on in disease progression (Dubois et al., 2007; 
Kaye et al., 1997). Although the relationship between neurogenesis and AD pathology 
remains elusive, evidence derived from studies in transgenic AD mouse models largely 
suggest there are deficits in neurogenesis (Wirths, 2017). Thus, with our second long-
term aim of investigating neurogenesis in a chronic neurodegenerative model, we 
characterised the anatomical and behavioural phenotype of the APPswe/PS1ΔE9 transgenic 
mouse model of AD, thus providing a baseline with which to commence future 
investigations into neurogenesis under chronic neurodegenerative diseases conditions. 
 
5.3 Limitations and future directions 
Although the occurrence of injury-induced neurogenesis outside of the canonical 
neurogenic niches has previously been described (see sections 1.4.1.2 and 1.4.2.2), the 
field remains sceptical regarding the robustness of the endogenous neurogenic response 
and its capacity to contribute to functional recovery following injury (Bonfanti, 2016; 
Sun, 2016; Yu et al., 2014). Our key findings in Chapter 2 provide preliminary evidence 
for the robustness of the endogenous neurogenic response in the hippocampus following 
a controlled cerebral injury. Nevertheless, there are numerous limitations that prevent a 
firm conclusion being drawn that substantial injury-induced neurogenesis definitively 
exists in our model. Furthermore, establishing whether or not injury-induced 
neurogenesis contributes to cognitive recovery requires a significant body of further 
research. We discuss these issues in the following section.  
 
Chapter 5: General discussion and conclusions 
 
 
216 
5.3.1 Is the expression of NeuN reduced post-injury, rather than the cells actually 
dying? 
A clear limitation of our experiments in Chapter 2 is the almost exclusive use of NeuN as 
our primary marker for confirming neuronal loss and neuronal repopulation. Under 
physiological conditions, NeuN is reliably expressed in the nucleus of post-mitotic 
neurons and not in adjacent cell types such as glia (Gusel’nikova & Korzhevskiy, 2015). 
Further, it has been widely used in neurogenesis research to monitor the maturation of 
newly generated cells (Brazelton et al., 2000; Duan et al., 2016; Goetz et al., 2006). 
However, under pathological conditions, expression of neuronal and glial markers can 
become dysregulated (Duan et al., 2016). For example, a study looking at neuron loss 
resulting from ischaemic injury attributed decreases in NeuN labelling to loss of NeuN 
antigenicity rather than neuronal death (Ünal-Çevik et al., 2004). Corresponding analyses 
via western blot revealed no alteration of NeuN protein expression and the addition of 
using antigen retrieval successfully restored NeuN immunoreactivity, suggesting that 
NeuN immunolabeling should not be used as the sole marker of neuronal death and 
repopulation under pathological conditions (Duan et al., 2016; Ünal-Çevik et al., 2004). 
Notably, however, Unal-Cevik and colleagues (2014) examined NeuN immunolabaling 
in tissue collected 6 h following a 30 min ischemic injury. Although it is possible that 
perturbations affecting NeuN immunolabeling would persist at longer tissue collection 
time points, such as the 2 wpi and 8 week time points used in the present study, we also 
demonstrated widespread Fluor-Jade C immunoreactivity in the hippocampal CA regions 
at shorter collection time points of 3 and 7 d post-KA injury (Figure 2.8), suggesting that 
neurodegeneration was indeed present and not attributable to downregulation of NeuN 
protein expression. Nevertheless, future studies would benefit from the use of additional 
complementary markers to confirm neurodegeneration and neuronal repopulation, such 
as TUNEL, b-tubulin III, microtubule-associated protein-2 and neuron-specific enolase. 
 
5.3.2 The use of DREADDs to overcome technical issues 
One of the primary obstacles we encountered in Chapter 3 was mechanical damage and 
premature cannula removal resulting from the cannula implantation surgery, as the use of 
the AlstR system necessitated cannula implantation surgery for administration of the 
allatostatin peptide. In order to circumvent the problems associated with the cannula 
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implantation surgery method, we have already commenced preliminary experiments 
utilising an alternative method for conditional expression of transgenes known as 
“designer receptors exclusively activated by designer drugs” (DREADDs; Urban & Roth, 
2015). One of the key advantages of this technology is that it negates the need for cannula 
implantation surgery, facilitating temporary inactivation of a specific population of cells, 
in a much less invasive manner. Transgenic mice incorporating DREADD technology 
express receptors that can only be activated via administration of clozapine N-oxide 
(CNO; Urban & Roth, 2015). Thus, temporally-controlled inactivation of the target cell 
population can be achieved through a single intraperitoneal injection of CNO proximal to 
behavioural testing. Utilisation of DREADDs eliminates the possibility of secondary 
mechanical damage resulting from the cannula implantation surgery (see Appendix 
Figure 6.6A), as well as mitigating possible associated cognitive impairments resulting 
from the surgery (see Figure 3.6C). Furthermore, it will reduce the likelihood of animal 
exclusion resulting from premature cannula removal or improper infusion of the receptor 
ligand, a prominent obstacle we faced in our experiments which resulted in the removal 
of 34 animals from the final analysis (see Figure 3.6B and Appendix Table 6.10). 
 
5.3.3 Electrophysiology to provide evidence of the functional capability of injury-
induced newborn neurons 
Another future avenue of research would be to characterise the electrophysiological 
properties of the newly generated neurons we observed in the CA1 and CA3 and confirm 
their cell type identity and integration into the surrounding circuitry. Indeed, many of the 
early, and more recent studies, investigating injury-induced neurogenesis utilised 
electrophysiological methods as tools for determining functional integration of newly 
generated neurons into the existing circuitry (e.g., Hou et al., 2008; Villasana et al., 2015; 
Yamashita et al., 2006). Although adult-born neurons of the hippocampal DG possess 
increased excitability during the initial phases of post-mitotic maturation under 
physiological conditions (Gonçalves et al., 2016), they eventually become 
electrophysiologically indistinguishable from the surrounding pre-existing DG neurons 
(Laplagne et al., 2006). In concert with our aim to assess the functional contribution of 
newly generated neurons following injury to cognitive recovery, one of our original aims 
was also to assess the electrophysiological properties of these newly generated neurons. 
Chapter 5: General discussion and conclusions 
 
 
218 
Thus, a future avenue of investigation will be to determine whether the newly generated 
neurons we observed in our KA injury model possess similar electrophysiological 
properties to the surrounding CA1 and CA3 pyramidal neurons. 
 
5.3.4 A more comprehensive battery of cognitive tests is more likely to uncover 
effects of neurogenesis on cognitive recovery 
The experiments outlined in Chapter 3 represent a concerted attempt to examine the 
functional role of newly generated hippocampal neurons to learning and memory 
processes. Due to the various challenges associated with the investigation of this question 
(see section 3.4), we were only able to investigate one behavioural memory paradigm, 
long-term fear memory recall. Although the critical role of the hippocampus in learning 
and memory processes is well established, hippocampal contribution to specific forms of 
memory processes remains complex (Deng et al., 2010). Thus, investigating the 
functional contribution of the newly generated neurons to other forms of hippocampal-
dependent memory processes, including memory formation, consolidation and remote 
memory will be beneficial and provide a more comprehensive view of the ability of 
injury-induced neurogenesis to fully recover learning and memory processes. 
 
5.3.5 Use of alternative viral vectors may provide better results for investigating the 
origin of newly generated neurons following CNS injury 
Since their initial development, retroviruses have become a prevalent tool used in 
neurogenesis research for investigating cell lineage and morphology. A key feature of 
retroviral vectors is their propensity to only infect cells undergoing mitotic division, along 
with their ability to produce stable long-term integration of transfected DNA into the host 
cell’s genome (Barquinero et al., 2004). These two features made retroviral vectors an 
ideal tool for tracking cell lineage and tracing the origin of newly generated neurons 
following KA-induced injury. Nevertheless, the retrovirus we utilised in the present study 
appeared to produce differential expression of the GFP marker gene across different 
animals. In order to circumvent these problems in future studies, we have commenced 
investigations into alternative strategies for viral-mediated cell labelling. These include 
use of a retrovirus construct that has previously been used successfully in rodent studies 
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of adult neurogenesis (e.g.,  Zhao et al., 2006), or use of retroviral labelling in conjunction 
with rabies virus-mediated retrograde tracing, which facilitates retrograde tracing of 
neurons (Vivar et al., 2012) and will allow for investigations into network integration of 
the newly generated neurons following injury. 
 
5.3.6 Assessing the role of non-neuronal cells and gliogenesis following injury may 
provide further insights into the cellular and molecular mechanisms underlying 
injury-induced neurogenesis 
In addition to neurodegeneration, most forms of CNS injury, including KA-induced 
excitotoxicity, are known to be associated with an increase in neuroinflammation or 
reactive gliosis, and this likely contributes to the mechanism of recovery following injury 
(Burda & Sofroniew, 2014). The interplay between inflammation and adult neurogenesis 
remains complex, with evidence supporting both beneficial and detrimental roles of 
neuroinflammation in mediating the neurogenic response under both physiological and 
pathological conditions (Borsini et al., 2015; Dimou & Götz, 2014; Ekdahl et al., 2009; 
Ekdahl et al., 2003; Jakubs et al., 2008; Monje et al., 2003; Russo et al., 2011). 
Nevertheless, a large body of work is now beginning to untangle the role of 
neuroinflammation under pathological conditions, with its effect on neurogenesis 
appearing largely dependent on a composite of factors including mode of glial cell 
activation, duration of neuroinflammation and type of injury (i.e., acute versus chronic; 
Dimou & Götz, 2014; Russo et al., 2011). Furthermore, a growing body of evidence 
suggests that reactive gliosis, a term used to denote changes in glial cell populations in 
response to CNS injury (Burda & Sofroniew, 2014), may lead to acquisition of stem cell-
like properties in glial cell populations, and that distinct glial cell populations may 
differentially contribute to the post-injury milieu (Dimou & Götz, 2014). 
 
5.3.6.1 Astrocytes 
Astrocytes have previously been shown to play a key role in neurogenesis and cognitive 
recovery following CNS injury and indeed, much attention and focus has been directed 
at astrocytes as a potential mediator of injury-induced neurogenesis. Increased 
astrogliosis was observed proximal to lesion site following experimental TBI, while a 
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concomitant increase in DG neurogenesis was also observed, with both processes 
contributing to modelling of the cortical cellular architecture following injury (Kernie et 
al., 2001). Exogenous administration of S100B, a neurotrophic/ mitogenic protein 
secreted by astrocytes, was found to increase DG neurogenesis, an effect that was 
associated with improvements in spatial learning (Kleindienst et al., 2005). Further to this, 
ablation of reactive astrocytes following moderate experimental TBI exacerbated cortical 
degeneration and inflammation, suggesting an essential role of reactive astrocytes in 
preserving neural tissue and restricting inflammation following mild or moderate focal 
brain injury (Myer et al., 2006). More recently, Sierra and colleagues showed that severity 
of KA-induced neuronal hyperactivity differentially affects the astrocytic differentiation 
potential of radial neural stem cells (Sierra et al., 2015). Low levels of KA increased 
conversion of activated radial neural stem cells into astrocytes, while higher doses of KA 
facilitated division of activated neural stem cells into reactive astrocytes, and 
subsequently impairing hippocampal neurogenesis (Sierra et al., 2015). Together, these 
studies highlight the critical role of astrocytes in modulating the post-injury milieu, both 
for promoting cellular proliferation and enhancing survival of newly generated neurons. 
In recent years, the advent of trans-differentiation studies involving the reprogramming 
of non-neuronal cells into neurons has become the focus of potential therapeutic 
approaches following CNS injury as a novel approach towards brain repair strategies 
(Grande et al., 2013; Guo et al., 2014; Niu et al., 2013; Torper et al., 2013, 2015). These 
have involved viral-mediated approaches for induced expression of transcription factors 
such as NeuroD1 (Guo et al., 2014), Sox2 (Niu et al., 2013; Su et al., 2014), or Ascl1 
(Faiz et al., 2015; Liu et al., 2015) to reprogram astrocytes into neurons in vivo. 
Furthermore, evidence also shows that in the absence of exogenous reprogramming 
factors, astrocytes can still spontaneously reprogram into neurons following CNS injury. 
Downregulation of Notch signalling following experimental stroke in adult mice induced 
striatal astrocytes to express nestin, a marker of neural progenitor cells, and generate new 
neurons following injury (Magnusson et al., 2014). Using lentiviral-mediated approaches, 
another recent study found that expression of the transcription factor Sox2 was sufficient 
to induce conversion of NG2 glia into DCX+ neurons in the adult mouse cerebral cortex 
following stab wound injury in the CNS (Heinrich et al., 2014). Interestingly, in the 
absence of CNS injury, lentiviral-mediated expression of Sox2 failed to induce glial cell 
conversion to DCX+ neurons, suggesting activation of an endogenous cellular re-
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programming mechanism that may be specific to CNS injury. In the context of the present 
thesis, it would be beneficial to investigate whether spontaneous de-differentiation/ 
reprogramming of astrocytes is occurring in our KA model of injury-induced regeneration 
and whether this, in turn, may be contributing to the apparent neuron repopulation 
observed in our model. 
 
5.3.6.2 Microglia 
The role of microglia are increasingly being recognised as an important player in both 
cognition and CNS injury (Morris et al., 2013). Although microglia have been purported 
to serve a regulatory role in neurogenesis under physiological conditions (Battista et al., 
2006; Sierra et al., 2010; Walton et al., 2006; Ziv et al., 2006), recent evidence suggests 
that even under physiological conditions, microglia may be detrimental to cell 
proliferation in the absence of inflammation (Gebara et al., 2013). Furthermore, microglia 
appear to have dichotomous roles in their effect on injury-induced neurogenesis 
depending on the injury type and stage of neurogenesis affected (Carreira et al., 2015; 
Ekdahl et al., 2003). The release of nitric oxide by activated microglia following KA-
mediated seizure injury was associated with both increased neural stem cell proliferation 
and decreased survival of newly generated neurons in the DG (Carreira et al., 2015). 
Similarly, microglial activation following electrically induced seizure injury was 
associated with decreased survival of newly generated hippocampal neurons, whereby 
subsequent inhibition of microglial activation through minocycline administration was 
associated with recovery of seizure-induced hippocampal neurogenesis (Ekdahl et al., 
2003). Minocycline-induced inhibition of microglial activation following ischaemic 
injury was also associated with increased cell survival along with improved cognitive 
function (Liu et al., 2007). In contrast to these findings, inhibition of microglial activation 
had no effect on injury-induced neurogenesis in a model of experimental TBI (Ng et al., 
2012). Together, these findings suggest that microglial response and their effects on 
injury-induced neurogenesis may differ depending on injury type.  In the context of the 
present thesis, an in depth assessment of microglial activity and behaviour following 
varying severities of KA injury (such as the doses used in experiment 2.3.10) would be 
useful and may elucidate the reason why neuron repopulation appears to only occur at 
certain doses of KA. 
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5.3.6.3 Summary 
Although the molecular mechanisms underlying glial cell conversion under both 
physiological and pathological conditions are only just beginning to be elucidated, and 
further, the clinical relevance of this process remains yet to be determined (Bond et al., 
2015), it is clear that assessing the role of non-neuronal cells is critical to understanding 
the mechanisms underlying functional recovery following CNS injury and will facilitate 
a more comprehensive understanding of the mechanisms underlying this recovery, 
advancing research into its use as a potentially therapeutic tool.  
 
5.3.7 Assessing the magnitude and functional significance of injury-induced 
neurogenesis in a more clinically relevant model of acute CNS injury is crucial for 
understanding the therapeutic potential of endogenous injury-induced neurogenesis 
Although the KA model of neurodegeneration is a useful model for investigating the 
mechanisms underlying CNS neurodegeneration and injury-induced neurogenesis, and a 
reliable tool for modelling temporal lobe epilepsy (Lévesque & Avoli, 2013), we also 
acknowledge that it is not the most physiologically relevant tool for modelling acute CNS 
injury in humans. In many cases, promising treatments of neurological diseases in animal 
models fail to translate to the clinic, a result often attributed to poor modelling of the 
human disease state (Denayer et al., 2014; Fluri et al., 2015; Loane & Faden, 2010; Sorby-
Adams et al., 2018; van der Worp et al., 2010). Nevertheless, in spite of these 
shortcomings, animal models, and particularly small animal models (i.e., rodent models), 
remain one of the most widely used tools in both scientific and preclinical research, owing 
to their low costs, standardised outcomes and plethora of tools available for experimental 
manipulation of the organism (Xiong et al., 2013). Strategies to overcome this failure to 
translate include (among many others; for detailed reviews see Denayer et al., 2014; Fluri 
et al., 2015; Loane & Faden, 2010; van der Worp et al., 2010) inclusion of additional 
animal models that more accurately simulate the condition in humans, along with 
utilisation of CNS injury models which hold more clinical relevance in the context of 
inducing acute CNS injury and neurodegeneration.  
Currently, stroke and TBI are the most common forms of CNS injury affecting humans, 
accounting for a significant proportion of mortality and disability worldwide. Although 
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injury-induced neurogenesis has been widely investigated in animal models of both TBI 
and stroke, and indeed we highlighted many important findings emanating from this 
research (see sections 1.4.2 and 1.6), challenges still remain regarding the replicability of 
some findings, along with their clinical translation. Further, as previously stated in our 
introductory chapter, the functional relevance of the neurogenic response described in 
these studies remains to be conclusively demonstrated. It is clear that choice of injury 
model is an important determinate of the ultimate success and/ or failure of clinical 
translation (Xiong et al., 2013; Xu & Pan, 2013). Prior work by our group have utilised 
the MCAO model of stroke for investigating the mechanisms underlying 
neurodegeneration and strategies for neuroprotection (unpublished data). It would be 
useful to investigate the magnitude and functional relevance of the spontaneous 
neurogenic response in more clinically relevant models of acute CNS injury, such as the 
MCAO model of stroke, in order to better understand the breadth and specificity of the 
spontaneous injury-induced neurogenic response and further elucidate its potential as a 
therapeutic target. 
 
5.4 Conclusion 
The ultimate goal of enhancing endogenous neurogenesis is to facilitate functional 
recovery and improve clinical outcomes of patients affected by CNS injuries. Since the 
first discovery of adult neurogenesis almost a century ago, each advent of new technology 
has brought with it a renaissance of interest, ideas and investigations into adult 
neurogenesis. The advances in scientific technology, combined with increasing 
accessibility to these sophisticated tools for visualising the neurogenic process in vivo, 
will afford scientists a more comprehensive view and understanding of the neurogenic 
process following injury. While much work still remains to be done in regards to 
elucidating and understanding the functional role of injury-induced neurogenesis in 
cognitive recovery, the payoffs will be significant if this can be achieved. The results of 
this thesis provide preliminary evidence for the occurrence of spontaneous hippocampal 
neurogenesis in the CA1 and CA3 regions of the adult mammalian CNS following a 
controlled CNS injury, and provide an experimental framework with which to probe the 
functional relevance of this injury-induced neurogenic response to cognitive recovery in 
future studies. 
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6.1 Appendices for Chapter 2 
 
 
Appendix Figure 6.1. Supplementary data for experiment presented in section 2.3.9. (A-D) Representative images 
of the ipsilateral dorsal hippocampus in C57BL/6 mice following 1 mg/mL KA injury administered IHPC at 2 and 8 
weeks post-injury (wpi) as visualised by NeuN immunohistochemistry. The DG of mouse #132749 (A) and #137087 
(B) show evidence of DG hypertrophy while the DG of mouse #140828 (C) and #137453 (D) show no evidence of DG 
hypertrophy. Images (B) and (C) are the same images previously presented in Figure 2.10C and are provided here for 
comparison purposes. 
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Appendix Table 6.1: Raw data for experiment in section 2.3.1. 
  
      
22792 KA 2 1 43601.85 32528.36 n/a n/a 
22795 KA 2 1 41496.94 28246.68 n/a n/a 
22734 KA 2 1 32307.21 18072.23 n/a n/a 
22794 KA 2 1 45437.11 37022.83 n/a n/a 
22793 KA 2 1 40187.92 30834.72 n/a n/a 
19132 KA 4 3 14648.73 25883.09 57392.43 62725.36 
19346 KA 4 3 22724.25 25420.35 69912.03 48644.67 
17915 KA 4 2 31167.39 26190.09 66110.08 70580.16 
17928 KA 4 2 50750.05 29582.28 71499.15 57249.76 
19457 KA 4 3 36773.05 35195.33 90045.31 72165.81 
19411 KA 6 1 54705.74 40106.61 n/a n/a 
20109 KA 6 2 58187.77 41107.21 n/a n/a 
19420 KA 6 1 55678.26 18259.38 n/a n/a 
19396 KA 6 1 25868.23 12934.12 n/a n/a 
20184 KA 6 2 54691.26 48806.75 n/a n/a 
19045 KA 8 1 54663.64 44238.57 74954.01 62479 
19067 KA 8 1 73970.4 49728 76339.44 76976.66 
19097 KA 8 1 76726.45 43127.28 75415.53 51301.18 
19551 KA 8 2 52424.67 32453.37 n/a n/a 
19520 KA 8 2 77243.44 60565.88 88163.27 72530.67 
19549 KA 8 2 n/a n/a 105154.56 69285.89 
22758 PBS 2 1 76661.29 47772.62 n/a n/a 
22762 PBS 2 1 63466.56 66409.72 n/a n/a 
22768 PBS 2 1 77629.44 58490.88 n/a n/a 
22769 PBS 2 1 85929.05 67946.16 n/a n/a 
22756 PBS 2 1 81820.2 54377.4 n/a n/a 
19290 PBS 4 3 77665.59 51138.96 100688.08 73645.39 
19287 PBS 4 3 82132.65 58655.25 58298.48 46592.88 
19293 PBS 4 3 59031.51 49071.46 67148.35 66495.38 
17916 PBS 4 2 74865.37 61771.04 84665.65 59295.8 
17924 PBS 4 2 65175.33 58265.63 53901.83 48801.82 
19405 PBS 6 1 71820.00 52836.00 n/a n/a 
19453 PBS 6 1 73513.44 51236.64 n/a n/a 
19512 PBS 6 1 67001.09 50389.25 n/a n/a 
20124 PBS 6 2 68981.88 58801.34 n/a n/a 
19407 PBS 6 1 64541.09 56046.28 n/a n/a 
18960 PBS 8 1 86418.65 52811.4 68529.76 50952.32 
19153 PBS 8 1 79425.36 68246.98 74356.13 66244.55 
19644 PBS 8 2 70979.59 59112.35 69500.59 50277.02 
19556 PBS 8 2 79312.26 68180.72 83789.2 67311.82 
18956 PBS 8 1 91963.2 58423.68 85086.29 51871.88 
 
Appendix Table 6.2: Raw data for experiment in section 2.3.2. 
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47153 KA 2 4 1mg/mL Sigma SLBD1491V 58006.94 16206.28 
47154 KA 2 4 1mg/mL Sigma SLBD1491V 27382.96 6667.6 
48539 KA 2 4 1mg/mL Sigma SLBD1491V Not 
analysed 
Not 
analysed 
47158 KA 2 4 1mg/mL Sigma SLBD1491V Not 
analysed 
Not 
analysed 
47159 KA 2 4 1mg/mL Sigma SLBD1491V Not 
analysed 
Not 
analysed 
47160 KA 2 4 1mg/mL Sigma SLBD1491V Not 
analysed 
Not 
analysed 
46531 KA 2 1 1mg/mL Sigma unknown Premature 
mortality 
Premature 
mortality 
46551 KA 2 1 1mg/mL Sigma unknown Premature 
mortality 
Premature 
mortality 
48450 KA 2 1 1mg/mL Sigma unknown Premature 
mortality 
Premature 
mortality 
48451 KA 2 1 1mg/mL Sigma unknown Premature 
mortality 
Premature 
mortality 
48452 KA 2 1 1mg/mL Sigma unknown Premature 
mortality 
Premature 
mortality 
48453 KA 2 1 1mg/mL Sigma unknown Premature 
mortality 
Premature 
mortality 
48454 KA 2 1 1mg/mL Sigma unknown Premature 
mortality 
Premature 
mortality 
48487 KA 4 2 1mg/mL Sigma SLBD1491V 26241.86 12466.44 
484_ _ KA 4 2 1mg/mL Sigma SLBD1491V 75732.09 35515.35 
484_ _ KA 4 2 1mg/mL Sigma SLBD1491V 31994.45 15545.33 
484_ _ KA 4 2 1mg/mL Sigma SLBD1491V Not 
analysed 
Not 
analysed 
48478 KA 4 2 1mg/mL Sigma SLBD1491V Not 
analysed 
Not 
analysed 
48479 KA 4 2 1mg/mL Sigma SLBD1491V Not 
analysed 
Not 
analysed 
48486 KA 4 2 1mg/mL Sigma SLBD1491V Not 
analysed 
Not 
analysed 
47475 KA 8 3 1mg/mL Sigma SLBD1491V Not 
analysed 
Not 
analysed 
47484 KA 8 3 1mg/mL Sigma SLBD1491V Not 
analysed 
Not 
analysed 
48467 KA 8 3 1mg/mL Sigma SLBD1491V Not 
analysed 
Not 
analysed 
48468 KA 8 3 1mg/mL Sigma SLBD1491V Not 
analysed 
Not 
analysed 
48469 KA 8 3 1mg/mL Sigma SLBD1491V Not 
analysed 
Not 
analysed 
48470 KA 8 3 1mg/mL Sigma SLBD1491V Not 
analysed 
Not 
analysed 
48471 KA 8 3 1mg/mL Sigma SLBD1491V Not 
analysed 
Not 
analysed 
48445 PBS 2 1 n/a n/a n/a 42973.16 14838.5 
48458 PBS 2 1 n/a n/a n/a 62678.73 28490.33 
48459 PBS 2 1 n/a n/a n/a 74654.34 41105.97 
48447 PBS 2 1 n/a n/a n/a Not 
analysed 
Not 
analysed 
48446 PBS 2 1 n/a n/a n/a Premature 
mortality 
Premature 
mortality 
48 _ _ _ PBS 4 2 n/a n/a n/a 80989.98 59876.64 
48 _ _ _ PBS 4 2 n/a n/a n/a 78782.84 56161.05 
48 _ _ _ PBS 4 2 n/a n/a n/a 83793.53 51815.18 
48 _ _ _ PBS 4 2 n/a n/a n/a Not 
analysed 
Not 
analysed 
48533 PBS 4 2 n/a n/a n/a Not 
analysed 
Not 
analysed 
48540 PBS 8 3 n/a n/a n/a Not 
analysed 
Not 
analysed 
48543 PBS 8 3 n/a n/a n/a Not 
analysed 
Not 
analysed 
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48544 PBS 8 3 n/a n/a n/a Not 
analysed 
Not 
analysed 
48546 PBS 8 3 n/a n/a n/a Not 
analysed 
Not 
analysed 
48547 PBS 8 3 n/a n/a n/a Not 
analysed 
Not 
analysed 
 
Appendix Table 6.3: Raw data for experiment in section 2.3.3. 
  
   
 
 
  
54835 KA 2 1 0.5mg/mL Sigma MKBQ0979V 2 3 
54838 KA 2 1 0.5mg/mL Sigma MKBQ0979V 0 4 
54841 KA 2 1 0.5mg/mL Sigma MKBQ0979V 15 9 
54836 KA 2 1 0.5mg/mL Sigma MKBQ0979V Not 
analysed 
Not 
analysed 
54837 KA 2 1 0.5mg/mL Sigma MKBQ0979V Not 
analysed 
Not 
analysed 
54985 KA 2 1 0.75mg/mL Sigma MKBQ0979V 15 15 
54987 KA 2 1 0.75mg/mL Sigma MKBQ0979V 15 14 
54988 KA 2 1 0.75mg/mL Sigma MKBQ0979V 15 12 
54986 KA 2 1 0.75mg/mL Sigma MKBQ0979V Not 
analysed 
Not 
analysed 
54989 KA 2 1 0.75mg/mL Sigma MKBQ0979V Not 
analysed 
Not 
analysed 
54766 KA 2 1 1mg/mL Sigma MKBQ0979V 0 1 
54767 KA 2 1 1mg/mL Sigma MKBQ0979V 6 12 
54775 KA 2 1 1mg/mL Sigma MKBQ0979V 13 15 
54773 KA 2 1 1mg/mL Sigma MKBQ0979V Not 
analysed 
Not 
analysed 
54774 KA 2 1 1mg/mL Sigma MKBQ0979V Not 
analysed 
Not 
analysed 
53056 KA 8 2 0.5mg/mL Sigma MKBQ0979V 0 n/a 
53059 KA 8 2 0.5mg/mL Sigma MKBQ0979V 0 2 
53052 KA 8 2 0.5mg/mL Sigma MKBQ0979V 0 1 
53058 KA 8 2 0.5mg/mL Sigma MKBQ0979V Not 
analysed 
Not 
analysed 
53012 KA 8 2 0.5mg/mL Sigma MKBQ0979V Not 
analysed 
Not 
analysed 
53250 KA 8 2 0.75mg/mL Sigma MKBQ0979V 13 11 
52400 KA 8 2 0.75mg/mL Sigma MKBQ0979V 9 13 
53053 KA 8 2 0.75mg/mL Sigma MKBQ0979V 6 10 
53033 KA 8 2 0.75mg/mL Sigma MKBQ0979V Premature 
mortality 
Premature 
mortality 
53233 KA 8 2 0.75mg/mL Sigma MKBQ0979V Not 
analysed 
Not 
analysed 
52561 KA 8 2 1mg/mL Sigma MKBQ0979V 7 11 
54827 KA 8 1 1mg/mL Sigma MKBQ0979V 15 13 
54828 KA 8 1 1mg/mL Sigma MKBQ0979V 13 12 
52412 KA 8 2 1mg/mL Sigma MKBQ0979V Not 
analysed 
Not 
analysed 
52472 KA 8 2 1mg/mL Sigma MKBQ0979V Not 
analysed 
Not 
analysed 
54830 KA 8 1 1mg/mL Sigma MKBQ0979V Not 
analysed 
Not 
analysed 
53048 KA 8 2 1mg/mL Sigma MKBQ0979V Not 
analysed 
Not 
analysed 
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52341 KA 8 2 1mg/mL Sigma MKBQ0979V Premature 
mortality 
Premature 
mortality 
54993 PBS 2 1 n/a n/a n/a 0 2 
54995 PBS 2 1 n/a n/a n/a 0 1 
55003 PBS 2 1 n/a n/a n/a 0 0 
54990 PBS 2 1 n/a n/a n/a Not 
analysed 
Not 
analysed 
54994 PBS 2 1 n/a n/a n/a Not 
analysed 
Not 
analysed 
53044 PBS 8 2 n/a n/a n/a 0 3 
53045 PBS 8 2 n/a n/a n/a 0 1 
53051 PBS 8 2 n/a n/a n/a 0 0 
53040 PBS 8 2 n/a n/a n/a 0 0 
53046 PBS 8 2 n/a n/a n/a 0 0 
 
Appendix Table 6.4: Raw data for experiment in section 2.3.4. 
  
   
 
 
  
61892 KA 2 1 0.05mg/mL Sigma MKBR9848V 0 0 
61893 KA 2 1 0.05mg/mL Sigma MKBR9848V 0 1 
61894 KA 2 1 0.05mg/mL Sigma MKBR9848V 0 1 
61895 KA 2 1 0.05mg/mL Sigma MKBR9848V 0 1 
61902 KA 2 1 0.1mg/mL Sigma MKBR9848V 0 4 
61904 KA 2 1 0.1mg/mL Sigma MKBR9848V 0 2 
61905 KA 2 1 0.1mg/mL Sigma MKBR9848V 0 0 
61903 KA 2 1 0.1mg/mL Sigma MKBR9848V Tissue 
processing 
complications 
Tissue 
processing 
complications 
61906 KA 2 1 0.3mg/mL Sigma MKBR9848V 0 3 
61840 KA 2 1 0.3mg/mL Sigma MKBR9848V 9 4 
61841 KA 2 1 0.3mg/mL Sigma MKBR9848V 0 0 
61910 KA 2 1 0.3mg/mL Sigma MKBR9848V Premature 
mortality 
Premature 
mortality 
61842 KA 2 1 0.5mg/mL Sigma MKBR9848V 0 6 
61847 KA 2 1 0.5mg/mL Sigma MKBR9848V 3 11 
61877 KA 2 1 0.5mg/mL Sigma MKBR9848V 0 3 
61880 KA 2 1 0.5mg/mL Sigma MKBR9848V 0 8 
61912 KA 2 2 0.05mg/mL Sigma MKBQ0979V 0 0 
61913 KA 2 2 0.05mg/mL Sigma MKBQ0979V 0 0 
61914 KA 2 2 0.05mg/mL Sigma MKBQ0979V 0 4 
61925 KA 2 2 0.05mg/mL Sigma MKBQ0979V 0 3 
61928 KA 2 2 0.1mg/mL Sigma MKBQ0979V 0 2 
61929 KA 2 2 0.1mg/mL Sigma MKBQ0979V 0 3 
61932 KA 2 2 0.1mg/mL Sigma MKBQ0979V 0 4 
61911 KA 2 2 0.1mg/mL Sigma MKBQ0979V 0 0 
62143 KA 2 2 0.3mg/mL Sigma MKBQ0979V 0 5 
62143 KA 2 2 0.3mg/mL Sigma MKBQ0979V 0 2 
62143 KA 2 2 0.3mg/mL Sigma MKBQ0979V 2 1 
61891 KA 2 2 0.5mg/mL Sigma MKBQ0979V 0 8 
62133 KA 2 2 0.5mg/mL Sigma MKBQ0979V 0 7 
62134 KA 2 2 0.5mg/mL Sigma MKBQ0979V 0 8 
62135 KA 2 2 0.5mg/mL Sigma MKBQ0979V 15 15 
61886 PBS 2 1 n/a n/a n/a 0 4 
61888 PBS 2 1 n/a n/a n/a 0 2 
62111 PBS 2 2 n/a n/a n/a 0 0 
62112 PBS 2 2 n/a n/a n/a 0 0 
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Appendix Table 6.5: Raw data for experiment in section 2.3.5. 
  
   
 
 
  
  
673
72 
KA 2 2 0.5mg/
mL 
Tocris 65A/1424
07 
11 15 n/a n/a 
673
66 
KA 2 2 0.5mg/
mL 
Tocris 65A/1424
07 
0 2 n/a n/a 
673
85 
KA 2 2 0.5mg/
mL 
Tocris 65A/1424
07 
4 13 n/a n/a 
673
86 
KA 2 2 0.5mg/
mL 
Tocris 65A/1424
07 
0 4 n/a n/a 
673
92 
KA 2 2 0.5mg/
mL 
Tocris 65A/1424
07 
13 15 n/a n/a 
677
45 
KA 2 2 0.5mg/
mL 
Sigma MKBR984
8V 
0 1 n/a n/a 
677
46 
KA 2 2 0.5mg/
mL 
Sigma MKBR984
8V 
0 3 n/a n/a 
677
47 
KA 2 2 0.5mg/
mL 
Sigma MKBR984
8V 
0 4 n/a n/a 
677
48 
KA 2 2 0.5mg/
mL 
Sigma MKBR984
8V 
0 0 n/a n/a 
677
56 
KA 2 2 0.5mg/
mL 
Sigma MKBR984
8V 
0 2 n/a n/a 
677
57 
KA 2 2 0.5mg/
mL 
Abcam APN1305
8-1-1 
0 2 n/a n/a 
677
58 
KA 2 2 0.5mg/
mL 
Abcam APN1305
8-1-1 
0 2 n/a n/a 
677
59 
KA 2 2 0.5mg/
mL 
Abcam APN1305
8-1-1 
0 2 n/a n/a 
677
60 
KA 2 2 0.5mg/
mL 
Abcam APN1305
8-1-1 
0 8 n/a n/a 
677
61 
KA 2 2 0.5mg/
mL 
Abcam APN1305
8-1-1 
0 2 n/a n/a 
678
11 
KA 2 2 0.5mg/
mL 
calbioch
em 
D001604
59 
0 0 n/a n/a 
678
12 
KA 2 2 0.5mg/
mL 
calbioch
em 
D001604
59 
0 0 n/a n/a 
678
13 
KA 2 2 0.5mg/
mL 
calbioch
em 
D001604
59 
15 5 n/a n/a 
678
20 
KA 2 2 0.5mg/
mL 
calbioch
em 
D001604
59 
0 0 n/a n/a 
678
21 
KA 2 2 0.5mg/
mL 
calbioch
em 
D001604
59 
0 0 n/a n/a 
679
97 
PB
S 
2 2 n/a n/a n/a 0 0 n/a n/a 
679
98 
PB
S 
2 2 n/a n/a n/a 0 0 n/a n/a 
679
99 
PB
S 
2 2 n/a n/a n/a 1 6 n/a n/a 
680
36 
KA 8 4 0.5mg/
mL 
Tocris 65A/1424
07 
15 15 n/a n/a 
680
37 
KA 8 4 0.5mg/
mL 
Tocris 65A/1424
07 
0 3 n/a n/a 
680
38 
KA 8 4 0.5mg/
mL 
Tocris 65A/1424
07 
11 15 n/a n/a 
680
39 
KA 8 4 0.5mg/
mL 
Tocris 65A/1424
07 
0 0 n/a n/a 
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680
40 
KA 8 4 0.5mg/
mL 
Tocris 65A/1424
07 
13 15 n/a n/a 
681
40 
KA 8 4 0.5mg/
mL 
Sigma MKBR984
8V 
0 0 n/a n/a 
681
41 
KA 8 4 0.5mg/
mL 
Sigma MKBR984
8V 
0 0 n/a n/a 
681
42 
KA 8 4 0.5mg/
mL 
Sigma MKBR984
8V 
0 2 n/a n/a 
681
43 
KA 8 4 0.5mg/
mL 
Sigma MKBR984
8V 
0 1 n/a n/a 
681
44 
KA 8 4 0.5mg/
mL 
Sigma MKBR984
8V 
2 1 n/a n/a 
681
83 
KA 8 4 0.5mg/
mL 
Abcam APN1305
8-1-1 
0 2 n/a n/a 
681
89 
KA 8 4 0.5mg/
mL 
Abcam APN1305
8-1-1 
0 2 n/a n/a 
681
90 
KA 8 4 0.5mg/
mL 
Abcam APN1305
8-1-1 
0 2 n/a n/a 
681
91 
KA 8 4 0.5mg/
mL 
Abcam APN1305
8-1-1 
0 2 n/a n/a 
681
92 
KA 8 4 0.5mg/
mL 
Abcam APN1305
8-1-1 
0 4 n/a n/a 
682
47 
KA 8 4 0.5mg/
mL 
calbioch
em 
D001604
59 
0 1 n/a n/a 
682
48 
KA 8 4 0.5mg/
mL 
calbioch
em 
D001604
59 
0 1 n/a n/a 
682
49 
KA 8 4 0.5mg/
mL 
calbioch
em 
D001604
59 
0 1 n/a n/a 
682
50 
KA 8 4 0.5mg/
mL 
calbioch
em 
D001604
59 
0 5 n/a n/a 
682
52 
KA 8 4 0.5mg/
mL 
calbioch
em 
D001604
59 
0 3 n/a n/a 
680
00 
PB
S 
8 4 n/a n/a n/a 0 3 n/a n/a 
680
01 
PB
S 
8 4 n/a n/a n/a 0 0 n/a n/a 
682
03 
PB
S 
8 4 n/a n/a n/a 0 0 n/a n/a 
669
83 
KA 2 1 1mg/m
L 
Tocris 65A/1424
07 
10 15 n/a n/a 
670
02 
KA 2 1 1mg/m
L 
Tocris 65A/1424
07 
12 15 n/a n/a 
670
03 
KA 2 1 1mg/m
L 
Tocris 65A/1424
07 
13 15 n/a n/a 
670
47 
KA 2 1 1mg/m
L 
Tocris 65A/1424
07 
14 14 n/a n/a 
669
84 
KA 2 1 1mg/m
L 
Tocris 65A/1424
07 
Premat
ure 
mortalit
y 
Premat
ure 
mortalit
y 
Premat
ure 
mortalit
y 
Premat
ure 
mortalit
y 
670
48 
KA 2 1 1mg/m
L 
Sigma MKBR984
8V 
0 1 n/a n/a 
670
49 
KA 2 1 1mg/m
L 
Sigma MKBR984
8V 
3 11 n/a n/a 
670
51 
KA 2 1 1mg/m
L 
Sigma MKBR984
8V 
1 5 n/a n/a 
670
22 
KA 2 1 1mg/m
L 
Sigma MKBR984
8V 
0 1 n/a n/a 
670
23 
KA 2 1 1mg/m
L 
Sigma MKBR984
8V 
15 15 n/a n/a 
670
29 
KA 2 1 1mg/m
L 
Abcam APN1305
8-1-1 
15 9 n/a n/a 
670
30 
KA 2 1 1mg/m
L 
Abcam APN1305
8-1-1 
0 6 n/a n/a 
674
30 
KA 2 1 1mg/m
L 
Abcam APN1305
8-1-1 
1 11 n/a n/a 
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674
31 
KA 2 1 1mg/m
L 
Abcam APN1305
8-1-1 
13 13 n/a n/a 
674
32 
KA 2 1 1mg/m
L 
Abcam APN1305
8-1-1 
9 9 n/a n/a 
674
33 
KA 2 1 1mg/m
L 
calbioch
em 
D001604
59 
0 11 60272.7
6 
30001.4
8 
670
74 
KA 2 1 1mg/m
L 
calbioch
em 
D001604
59 
10 13 52985.6
4 
34429.4
9 
670
75 
KA 2 1 1mg/m
L 
calbioch
em 
D001604
59 
12 10 36772.4
5 
27991.8
5 
670
76 
KA 2 1 1mg/m
L 
calbioch
em 
D001604
59 
0 11 59027.9
5 
32251.7 
670
87 
KA 2 1 1mg/m
L 
calbioch
em 
D001604
59 
2 11 43857.9 22947.1
7 
673
65 
PB
S 
2 1 n/a n/a n/a 0 2 79057 46086 
673
70 
PB
S 
2 1 n/a n/a n/a 0 0 73047 49956 
673
71 
PB
S 
2 1 n/a n/a n/a 0 0 74716.9
9 
45731.9
5 
678
24 
KA 8 3 1mg/m
L 
Tocris 65A/1424
07 
11 13 n/a n/a 
678
25 
KA 8 3 1mg/m
L 
Tocris 65A/1424
07 
15 5 n/a n/a 
678
22 
KA 8 3 1mg/m
L 
Tocris 65A/1424
07 
Premat
ure 
mortalit
y 
Premat
ure 
mortalit
y 
Premat
ure 
mortalit
y 
Premat
ure 
mortalit
y 
678
23 
KA 8 3 1mg/m
L 
Tocris 65A/1424
07 
Premat
ure 
mortalit
y 
Premat
ure 
mortalit
y 
Premat
ure 
mortalit
y 
Premat
ure 
mortalit
y 
678
37 
KA 8 3 1mg/m
L 
Tocris 65A/1424
07 
Premat
ure 
mortalit
y 
Premat
ure 
mortalit
y 
Premat
ure 
mortalit
y 
Premat
ure 
mortalit
y 
680
12 
KA 8 3 1mg/m
L 
Sigma MKBR984
8V 
1 7 n/a n/a 
680
13 
KA 8 3 1mg/m
L 
Sigma MKBR984
8V 
0 3 n/a n/a 
680
14 
KA 8 3 1mg/m
L 
Sigma MKBR984
8V 
11 11 n/a n/a 
680
15 
KA 8 3 1mg/m
L 
Sigma MKBR984
8V 
0 4 n/a n/a 
680
35 
KA 8 3 1mg/m
L 
Sigma MKBR984
8V 
1 6 n/a n/a 
682
14 
KA 8 3 1mg/m
L 
Abcam APN1305
8-1-1 
1 7 n/a n/a 
682
15 
KA 8 3 1mg/m
L 
Abcam APN1305
8-1-1 
2 8 n/a n/a 
682
16 
KA 8 3 1mg/m
L 
Abcam APN1305
8-1-1 
0 1 n/a n/a 
682
20 
KA 8 3 1mg/m
L 
Abcam APN1305
8-1-1 
0 0 n/a n/a 
682
21 
KA 8 3 1mg/m
L 
Abcam APN1305
8-1-1 
7 11 n/a n/a 
683
05 
KA 8 3 1mg/m
L 
calbioch
em 
D001604
59 
3 3 70108.4
1 
46112.9
7 
683
10 
KA 8 3 1mg/m
L 
calbioch
em 
D001604
59 
0 6 83815.6
3 
45530.7
5 
683
11 
KA 8 3 1mg/m
L 
calbioch
em 
D001604
59 
5 7 56204.1
8 
30947.2
4 
683
12 
KA 8 3 1mg/m
L 
calbioch
em 
D001604
59 
4 6 49831.5
9 
29385.1
2 
683
13 
KA 8 3 1mg/m
L 
calbioch
em 
D001604
59 
0 5 78192.2
5 
39730.4
3 
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681
93 
PB
S 
8 3 n/a n/a n/a 0 0 89462 50387 
681
97 
PB
S 
8 3 n/a n/a n/a 0 0 74245 45567 
681
98 
PB
S 
8 3 n/a n/a n/a 0 0 85175 47544 
 
Appendix Table 6.6: Raw data for experiment in section 2.3.6. 
  
   
 
 
  
80301 KA 2 1 1mg/mL calbiochem D00160459 Tissue 
processing 
complications 
Tissue 
processing 
complications 
80303 KA 2 1 1mg/mL calbiochem D00160459 12 11 
80308 KA 2 1 1mg/mL calbiochem D00160459 0 10 
80309 KA 2 1 1mg/mL calbiochem D00160459 0 5 
80310 KA 2 1 1mg/mL calbiochem D00160459 1 7 
80088 KA 2 1 1mg/mL calbiochem D00160459 12 12 
80089 KA 2 1 1mg/mL calbiochem D00160459 15 15 
77893 PBS 2 1 n/a n/a n/a 0 0 
77894 PBS 2 1 n/a n/a n/a 0 0 
80090 KA 8 2 1mg/mL calbiochem D00160459 2 0 
80091 KA 8 2 1mg/mL calbiochem D00160459 14 15 
80111 KA 8 2 1mg/mL calbiochem D00160459 3 6 
80079 KA 8 2 1mg/mL calbiochem D00160459 7 10 
80080 KA 8 2 1mg/mL calbiochem D00160459 0 3 
80085 KA 8 2 1mg/mL calbiochem D00160459 Tissue 
processing 
complications 
Tissue 
processing 
complications 
80086 KA 8 2 1mg/mL calbiochem D00160459 9 10 
80087 PBS 8 2 n/a n/a n/a 0 0 
80379 PBS 8 2 n/a n/a n/a 0 0 
 
Appendix Table 6.7: Raw data for experiment in section 2.3.7. 
  
   
 
 
  
91744 KA 2 1 1mg/mL calbiochem D00160459 4 11 
91749 KA 2 1 1mg/mL calbiochem D00160459 9 13 
92023 KA 2 1 1mg/mL calbiochem D00160459 13 14 
92047 KA 2 1 1mg/mL calbiochem D00160459 1 11 
92063 KA 2 1 1mg/mL calbiochem D00160459 14 15 
91737 KA 2 1 1mg/mL calbiochem D00160459 3 13 
91748 PBS 2 1 n/a n/a n/a 4 4 
92052 PBS 2 1 n/a n/a n/a 3 8 
92053 PBS 2 1 n/a n/a n/a 7 8 
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91738 KA 8 2 1mg/mL calbiochem D00160459 5 8 
91740 KA 8 2 1mg/mL calbiochem D00160459 10 12 
91745 KA 8 2 1mg/mL calbiochem D00160459 9 12 
91746 KA 8 2 1mg/mL calbiochem D00160459 11 15 
91747 KA 8 2 1mg/mL calbiochem D00160459 13 15 
91739 KA 8 2 1mg/mL calbiochem D00160459 Premature 
mortality 
Premature 
mortality 
92054 PBS 8 2 n/a n/a n/a 0 0 
92062 PBS 8 2 n/a n/a n/a 0 0 
92043 PBS 8 2 n/a n/a n/a 0 0 
 
Appendix Table 6.8: Raw data for experiments in section 2.3.9. 
  
   
 
 
  
132204 KA 2 1 1mg/mL calbiochem 2748793 8457 8346 
132205 KA 2 1 1mg/mL calbiochem 2748793 10100 11024 
132748 KA 2 1 1mg/mL calbiochem 2748793 10290 8194 
132749 KA 2 1 1mg/mL calbiochem 2748793 5719 9722 
132830 KA 2 1 1mg/mL calbiochem 2748793 42684 31715 
132831 KA 2 1 1mg/mL calbiochem 2748793 n/a n/a 
132837 PBS 2 1 n/a n/a n/a 82642 51674 
132838 PBS 2 1 n/a n/a n/a 92071 49625 
132839 PBS 2 1 n/a n/a n/a 90285 54183 
137448 KA 8 2 1mg/mL calbiochem 2748793 n/a n/a 
137453 KA 8 2 1mg/mL calbiochem 2748793 n/a n/a 
137087 KA 8 2 1mg/mL calbiochem 2748793 n/a n/a 
137088 KA 8 2 1mg/mL calbiochem 2748793 n/a n/a 
137128 KA 8 2 1mg/mL calbiochem 2748793 n/a n/a 
137129 KA 8 2 1mg/mL calbiochem 2748793 n/a n/a 
137439 PBS 8 2 n/a n/a n/a n/a n/a 
137440 PBS 8 2 n/a n/a n/a n/a n/a 
137533 PBS 8 2 n/a n/a n/a n/a n/a 
140828 KA 2 3 1mg/mL calbiochem 2748793 4389 23059 
140829 KA 2 3 1mg/mL calbiochem 2748793 n/a n/a 
141315 KA 2 3 1mg/mL calbiochem 2748793 17836 24168 
141316 KA 2 3 1mg/mL calbiochem 2748793 6779 22742 
141321 KA 2 3 1mg/mL calbiochem 2748793 5367 8654 
141322 KA 2 3 1mg/mL calbiochem 2748793 7103 6333 
141166 PBS 2 3 n/a n/a n/a 71511 59831 
141167 PBS 2 3 n/a n/a n/a 86596 55561 
140752 PBS 2 3 n/a n/a n/a 79438 54903 
 
Appendix Table 6.9: Raw data for experiments in section 2.3.10. 
  
   
 
 
  
135695 KA 2 1 1mg/mL calbiochem 2748793 44486 33904 
135696 KA 2 1 1mg/mL calbiochem 2748793 77740 34313 
135793 KA 2 1 1mg/mL calbiochem 2748793 32392 23967 
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135797 KA 2 1 1mg/mL calbiochem 2748793 59841 34726 
135798 KA 2 1 1mg/mL calbiochem 2748793 64285 39113 
135799 KA 2 1 1mg/mL calbiochem 2748793 10307 14683 
135756 PBS 2 1 n/a n/a n/a 63806 49978 
135757 PBS 2 1 n/a n/a n/a 60219 36672 
135764 PBS 2 1 n/a n/a n/a Tissue 
processing 
complications 
Tissue 
processing 
complications 
142013 KA 2 2 1mg/mL calbiochem 2748793 14281 12241 
142014 KA 2 2 1mg/mL calbiochem 2748793 15312 20530 
142019 KA 2 2 1mg/mL calbiochem 2748793 79408 38360 
142020 KA 2 2 1mg/mL calbiochem 2748793 64780 42103 
141588 KA 2 2 1mg/mL calbiochem 2748793 64908 28701 
141589 KA 2 2 1mg/mL calbiochem 2748793 72218 33680 
141590 PBS 2 2 n/a n/a n/a 70797 57297 
141593 PBS 2 2 n/a n/a n/a 91303 56373 
141599 PBS 2 2 n/a n/a n/a 77190 67711 
143921 KA 2 8.2 1.2mg/mL calbiochem 2748793 n/a n/a 
143922 KA 2 8.2 1.2mg/mL calbiochem 2748793 100909 53069 
143923 KA 2 8.2 1.2mg/mL calbiochem 2748793 53161 27017 
143926 KA 2 8.2 1.2mg/mL calbiochem 2748793 68458 26928 
143857 KA 2 8.2 1.2mg/mL calbiochem 2748793 19475 16365 
143860 KA 2 8.2 1.2mg/mL calbiochem 2748793 65593 33844 
143861 PBS 2 8.2 n/a n/a n/a 93085 50202 
143868 PBS 2 8.2 n/a n/a n/a 78627 53420 
143869 PBS 2 8.2 n/a n/a n/a n/a n/a 
152552 KA 2 9.3 1.2mg/mL calbiochem 2748793 n/a n/a 
152553 KA 2 9.3 1.2mg/mL calbiochem 2748793 82213 53847 
152817 KA 2 9.3 1.2mg/mL calbiochem 2748793 57840 39841 
152818 KA 2 9.3 1.2mg/mL calbiochem 2748793 44673 18246 
152819 KA 2 9.3 1.2mg/mL calbiochem 2748793 36036 20050 
152820 KA 2 9.3 1.2mg/mL calbiochem 2748793 6252 8422 
152786 PBS 2 9.3 n/a n/a n/a 72818 45826 
152787 PBS 2 9.3 n/a n/a n/a Tissue 
processing 
complications 
Tissue 
processing 
complications 
152788 PBS 2 9.3 n/a n/a n/a 74152 45774 
143915 KA 2 8.3 1.5mg/mL calbiochem 2748793 49508 18319 
143916 KA 2 8.3 1.5mg/mL calbiochem 2748793 63463 23452 
143917 KA 2 8.3 1.5mg/mL calbiochem 2748793 n/a n/a 
143919 KA 2 8.3 1.5mg/mL calbiochem 2748793 67971 31802 
143775 KA 2 8.3 1.5mg/mL calbiochem 2748793 24457 15089 
143776 KA 2 8.3 1.5mg/mL calbiochem 2748793 10405 6954 
143914 PBS 2 8.3 n/a n/a n/a 76841 50462 
143920 PBS 2 8.3 n/a n/a n/a 71083 47666 
143931 PBS 2 8.3 n/a n/a n/a n/a n/a 
152908 KA 2 9.4 1.5mg/mL calbiochem 2748793 n/a n/a 
152909 KA 2 9.4 1.5mg/mL calbiochem 2748793 62878 39098 
152770 KA 2 9.4 1.5mg/mL calbiochem 2748793 19796 13168 
152771 KA 2 9.4 1.5mg/mL calbiochem 2748793 51525 12445 
153452 KA 2 9.4 1.5mg/mL calbiochem 2748793 12971 16630 
153453 KA 2 9.4 1.5mg/mL calbiochem 2748793 42125 28806 
153456 PBS 2 9.4 n/a n/a n/a 82517 53042 
153457 PBS 2 9.4 n/a n/a n/a 87510 52906 
153458 PBS 2 9.4 n/a n/a n/a 65286 47019 
190499 KA 8 10.1 1mg/mL calbiochem 2748793 80755 50000 
190512 KA 8 10.1 1mg/mL calbiochem 2748793 91387 45431 
190513 KA 8 10.1 1mg/mL calbiochem 2748793 74125 47017 
190526 KA 8 10.1 1mg/mL calbiochem 2748793 n/a n/a 
190505 KA 8 10.1 1mg/mL calbiochem 2748793 75984 43190 
190506 KA 8 10.1 1mg/mL calbiochem 2748793 79066 55620 
190507 PBS 8 10.1 n/a n/a n/a 96731 59794 
190520 PBS 8 10.1 n/a n/a n/a 65446 46524 
193359 KA 8 10.2 1mg/mL calbiochem 2748793 84079 43290 
193360 KA 8 10.2 1mg/mL calbiochem 2748793 Tissue 
processing 
complications 
Tissue 
processing 
complications 
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193361 KA 8 10.2 1mg/mL calbiochem 2748793 79775 37757 
193365 KA 8 10.2 1mg/mL calbiochem 2748793 77718 48920 
193486 KA 8 10.2 1mg/mL calbiochem 2748793 81751 40344 
193487 PBS 8 10.2 n/a n/a n/a 89750 55754 
193488 PBS 8 10.2 n/a n/a n/a 90258 53264 
193489 PBS 8 10.2 n/a n/a n/a 88561 49516 
154186 KA 8 9.1 1.2mg/mL calbiochem 2748793 67174 32635 
154187 KA 8 9.1 1.2mg/mL calbiochem 2748793 44619 19999 
154256 KA 8 9.1 1.2mg/mL calbiochem 2748793 76476 32684 
154265 KA 8 9.1 1.2mg/mL calbiochem 2748793 18938 12605 
154266 KA 8 9.1 1.2mg/mL calbiochem 2748793 8582 9109 
154267 KA 8 9.1 1.2mg/mL calbiochem 2748793 61517 35484 
154098 PBS 8 9.1 n/a n/a n/a 61506 40168 
154109 PBS 8 9.1 n/a n/a n/a 96488 46136 
154110 PBS 8 9.1 n/a n/a n/a 90704 52329 
154138 KA 8 9.5 1.2mg/mL calbiochem 2748793 30298 23159 
154285 KA 8 9.5 1.2mg/mL calbiochem 2748793 40366 14537 
154296 KA 8 9.5 1.2mg/mL calbiochem 2748793 57363 32100 
154297 KA 8 9.5 1.2mg/mL calbiochem 2748793 68323 30873 
154298 KA 8 9.5 1.2mg/mL calbiochem 2748793 53268 31760 
154299 KA 8 9.5 1.2mg/mL calbiochem 2748793 n/a n/a 
154237 PBS 8 9.5 n/a n/a n/a n/a n/a 
154238 PBS 8 9.5 n/a n/a n/a 79342 48917 
154239 PBS 8 9.5 n/a n/a n/a n/a n/a 
154025 KA 8 9.2 1.5mg/mL calbiochem 2748793 37407 19432 
154170 KA 8 9.2 1.5mg/mL calbiochem 2748793 12245 11840 
154171 KA 8 9.2 1.5mg/mL calbiochem 2748793 n/a n/a 
154172 KA 8 9.2 1.5mg/mL calbiochem 2748793 7960 9657 
154178 KA 8 9.2 1.5mg/mL calbiochem 2748793 64412 34378 
154193 KA 8 9.2 1.5mg/mL calbiochem 2748793 10661 11102 
154269 PBS 8 9.2 n/a n/a n/a 85299 49857 
154270 PBS 8 9.2 n/a n/a n/a 75459 47162 
154279 PBS 8 9.2 n/a n/a n/a 62862 46516 
154230 KA 8 9.6 1.5mg/mL calbiochem 2748793 18075 12805 
153955 KA 8 9.6 1.5mg/mL calbiochem 2748793 n/a n/a 
154249 KA 8 9.6 1.5mg/mL calbiochem 2748793 10465 7996 
154250 KA 8 9.6 1.5mg/mL calbiochem 2748793 37506 13229 
154253 KA 8 9.6 1.5mg/mL calbiochem 2748793 27567 20998 
154254 KA 8 9.6 1.5mg/mL calbiochem 2748793 72440 35701 
154202 PBS 8 9.6 n/a n/a n/a n/a n/a 
154209 PBS 8 9.6 n/a n/a n/a 74468 46270 
154210 PBS 8 9.6 n/a n/a n/a 78171 48404 
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6.2 Appendices for Chapter 3 
 
 
Appendix Figure 6.2. Recovery of fear memory in mice 8 weeks following KA injury. (A) Experimental protocol. 
(B) KA-injected mice exhibited deficits in contextual fear learning and memory at 2, 4 and 6 weeks post-injury (wpi) 
compared to PBS-injected animals. At 8 wpi, KA-injected mice exhibited significantly higher freezing when compared 
to mice injected with KA and 2 and 4 wpi, and this was not significantly different from PBS-injected animals at 8 wpi. 
All values represent the mean ± standard error of the mean (SEM). ***p < 0.001, #p < 0.01. n = 10-15 for PBS groups 
and n = 12-14 for KA groups. The data represented in this figure were generated by Lyndsey Konen. 
  
Chapter 6: Appendices and references 
 
 
238 
 
 
# Al i gned_sequences:  2
# 1:  Al st R- cr e+
# 2:  Cr e- ERT2
# Mat r i x:  EDNAFULL
# Gap_penal t y:  10. 0
# Ext end_penal t y:  0. 5
#
# Lengt h:  531
# I dent i t y:      446/ 531 ( 84. 0%)
# Si mi l ar i t y:    446/ 531 ( 84. 0%)
# Gaps:           85/ 531 ( 16. 0%)
# Scor e:  2177. 5
# 
#
#=======================================
Al st R- cr e+ 1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - GC- ACGAGTGATG     12
                                       | |  | | | | | | | | | |
Cr e- ERT2 1 GACCGTACACCAAAATTTGCCTGCATTACCGGTCGATGCAACGAGTGATG     50
Al st R- cr e+ 13 AGGTTCGCAAGAACCTGATGGACATGTTCAGGGATCGCCAGGCGTTTTTC     62
   | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  | | | | |
Cr e- ERT2 51 AGGTTCGCAAGAACCTGATGGACATGTTCAGGGATCGCCAGGCG- TTTTC     99
Al st R- cr e+  63 TGAGCATACCTGGAAAATGCTTCTGTCCGTTTGCCGGTCGTGGGCGGCAT    112
    | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Cr e- ERT2 100 TGAGCATACCTGGAAAATGCTTCTGTCCGTTTGCCGGTCGTGGGCGGCAT    149
Al st R- cr e+ 113 GGTGCAAGTTGAATAACCGGAAATGGTTTCCCGCAGAACCTGAAGATGTT    162
    | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Cr e- ERT2 150 GGTGCAAGTTGAATAACCGGAAATGGTTTCCCGCAGAACCTGAAGATGTT    199
Al st R- cr e+ 163 CGCGATTATCTTCTATATCTTCAGGCGCGCGGTCTGGCAGTAAAAACTAT    212
    | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Cr e- ERT2 200 CGCGATTATCTTCTATATCTTCAGGCGCGCGGTCTGGCAGTAAAAACTAT    249
Al st R- cr e+ 213 CCAGCAACATTTGGGCCAGCTAAACATGCTTCATCGTCGGTCCGGGCTGC    262
    | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Cr e- ERT2 250 CCAGCAACATTTGGGCCAGCTAAACATGCTTCATCGTCGGTCCGGGCTGC    299
Al st R- cr e+ 263 CACGACCAAGTGACAGCAATGCTGTTTCACTGGTTATGCGGCGGATCCGA    312
    | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Cr e- ERT2 300 CACGACCAAGTGACAGCAATGCTGTTTCACTGGTTATGCGGCGGATCCGA    349
Al st R- cr e+ 313 AAAGAAAACGTTGATGCCGGTGAACGTGCAAAACAGGCTCTAGCGTTCGA    362
    | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Cr e- ERT2 350 AAAGAAAACGTTGATGCCGGTGAACGTGCAAAACAGGCTCTAGCGTTCGA    399
Al st R- cr e+ 363 ACGCACTGATTTCGACCAGGTTCGTTCACTCATGGAAAATAGCGATCGCT    412
    | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Cr e- ERT2 400 ACGCACTGATTTCGACCAGGTTCGTTCACTCATGGAAAATAGCGATCGCT    449
Al st R- cr e+ 413 GCCAGGATATACGTAATCTGGCATT- - TGGGGAAAATATT- CTCNNNAAT    459
    | | | | | | | | | | | | | | | | | | | | | | | | |   | | | | |      | | |  | |        
Cr e- ERT2 450 GCCAGGATATACGTAATCTGGCATTTCTGGGG- - - - - ATTGCT- - - - - - -     487
Al st R- cr e+ 460 TTTCCCTGAGGGTGAACCGAAACACTGGTCG    490
                                                    
Cr e- ERT2 488 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -     487
A 
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# Al i gned_sequences:  2
# 1:  Al st R- cr e+
# 2:  Cr e- ERT2
# Mat r i x:  EDNAFULL
# Gap_penal t y:  10. 0
# Ext end_penal t y:  0. 5
#
# Lengt h:  524
# I dent i t y:      475/ 524 ( 90. 6%)
# Si mi l ar i t y:    475/ 524 ( 90. 6%)
# Gaps:           48/ 524 (  9. 2%)
# Scor e:  2351. 0
# 
#
#=======================================
Al st R- cr e+ 1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - GTTGATGCCGGTG- ACGTG     18
                                 | | | | | | | | | | | | |  | | | | |
Cr e- ERT2 1 ACTGGTTATGCGGCGGATCCGAAAAGAAAACGTTGATGCCGGTGAACGTG     50
Al st R- cr e+ 19 CAAAACAGGCTCTAGCGTTCGAACGCACTGATTTTCGACCAGGTTCGTTC     68
   | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  | | | | | | | | | | | | | | | | | |
Cr e- ERT2 51 CAAAACAGGCTCTAGCGTTCGAACGCACTGA- TTTCGACCAGGTTCGTTC     99
Al st R- cr e+  69 ACTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATCTGGCATTTC    118
    | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Cr e- ERT2 100 ACTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATCTGGCATTTC    149
Al st R- cr e+ 119 TGGGGATTGCTTATAACACCCTGTTACGTATAGCCGAAATTGCCAGGATC    168
    | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Cr e- ERT2 150 TGGGGATTGCTTATAACACCCTGTTACGTATAGCCGAAATTGCCAGGATC    199
Al st R- cr e+ 169 AGGGTTAAAGATATCTCACGTACTGACGGTGGGAGAATGTTAATCCATAT    218
    | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Cr e- ERT2 200 AGGGTTAAAGATATCTCACGTACTGACGGTGGGAGAATGTTAATCCATAT    249
Al st R- cr e+ 219 TGGCAGAACGAAAACGCTGGTTAGCACCGCAGGTGTAGAGAAGGCACTTA    268
    | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Cr e- ERT2 250 TGGCAGAACGAAAACGCTGGTTAGCACCGCAGGTGTAGAGAAGGCACTTA    299
Al st R- cr e+ 269 GCCTGGGGGTAACTAAACTGGTCGAGCGATGGATTTCCGTCTCTGGTGTA    318
    | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Cr e- ERT2 300 GCCTGGGGGTAACTAAACTGGTCGAGCGATGGATTTCCGTCTCTGGTGTA    349
Al st R- cr e+ 319 GCTGATGATCCGAATAACTACCTGTTTTGCCGGGTCAGAAAAAATGGTGT    368
    | | | | | | | | | | | | | | | | | | | . | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Cr e- ERT2 350 GCTGATGATCCGAATAACTTCCTGTTTTGCCGGGTCAGAAAAAATGGTGT    399
Al st R- cr e+ 369 TGCCGCGCCATCTGCCACCAGCCAGCTATCAACTCGCGCCCTGGAAGGGA    418
    | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Cr e- ERT2 400 TGCCGCGCCATCTGCCACCAGCCAGCTATCAACTCGCGCCCTGGAAGGGA    449
Al st R- cr e+ 419 TTTTTGAAGCAACTCATCGATTGATTTACGGCGCTAAGGATGACTCTGGT    468
    | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Cr e- ERT2 450 TTTTTGAAGCAACTCATCGATTGATTTACGGCGCTAAGGATGACTCTGGT    499
Al st R- cr e+ 469 CAGAGATAC- - - - - - - - - - - - - - -     477
    | | | | | | | | |                
Cr e- ERT2 500 CAGAGATACCTGGCCTGGTCTGGA    523
B 
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Appendix Figure 6.3. EMBOSS pairwise sequence alignment corresponding to sequencing results of AlstR-cre+ 
mice presented in Figure 3.9B. (A) PCR 1. (B) PCR 2. The data represented in this figure were generated by Lyndsey 
Konen. 
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# Al i gned_sequences:  2
# 1:  Al st R- cr e-
# 2:  Cr e- ERT2
# Mat r i x:  EDNAFULL
# Gap_penal t y:  10. 0
# Ext end_penal t y:  0. 5
#
# Lengt h:  517
# I dent i t y:      255/ 517 ( 49. 3%)
# Si mi l ar i t y:    362/ 517 ( 70. 0%)
# Gaps:           90/ 517 ( 17. 4%)
# Scor e:  872. 0
# 
#
#=======================================
Al st R- cr e- 1 - - - - - - - - - - - - AAATTTTTTMMMGAGGCTTTGCTTTTCASCTTGTT- - -      35
              | | | | | |          | |  . | | | . | | . | . . . | . | . |    
Cr e- ERT2 1 GACCGTACACCAAAATTT- - - - - - - - - GC- CTGCATTACCGGTCGATGCA     40
Al st R- cr e- 36 - TAWGTGATWA- - ATTGCATTTATWAATTYA- - - ATTTGTT- - GTTAWAT     77
    . . . | | | | |  |   . | . | | |    | . . | . . |  |    | . . | | | |   | . . | . . .
Cr e- ERT2 41 ACGAGTGATGAGGTTCGCA- - - AGAACCTGATGGACATGTTCAGGGATCG     87
Al st R- cr e- 78 CCTGGC- ATTTCTGGGGATWGCWMAAAM- - - - - - - - - - - - - - - - - - - - - -     104
   | | . | | |  . | | | | | | . | . | | . . | .  . | | .                       
Cr e- ERT2 88 CCAGGCGTTTTCTGAGCATACCTGGAAAATGCTTCTGTCCGTTTGCCGGT    137
Al st R- cr e- 105 - - - GNGCGGCCTSRCWGC- - GTKWTGGGAGCDCCGSAWGKGRYTWCCCAC    149
       |  | | | | | . | . .  . | |   | | .    | . | . .  | | | . | . . . | . . | . | | | . |
Cr e- ERT2 138 CGTGGGCGGCATGG- TGCAAGTT- - - GAATAACCGGAAATGGTTTCCCGC    183
Al st R- cr e- 150 AAARCCTSMMCATSTTCRCAATWAYMTKMKWTCATMWYMRGGYGM- NKST    198
    | . | . | | | . . . . | | . | | | . | . | | . | . . | . . . . |  | | . . . . . | | . | .   . . |
Cr e- ERT2 184 AGAACCTGAAGATGTTCGCGATTATCTTCTAT- ATCTTCAGGCGCGCGGT    232
Al st R- cr e- 199 MKRKYMRWRCMAAMWATCMRASAMCAWTWRGTMCRTSKRAAMRWRCYWCA    248
    . . . . . . . . . . . | | . . | | | . . . . | . | | . | . . | . . | . . . . . | | . . . . | . . | |
Cr e- ERT2 233 CTGGCAGTAAAAACTATCCAGCAACATTTGGGCCAGCTAAACATGCTTCA    282
Al st R- cr e- 249 WMTGT- TTTCCRRRMTRMMRMCAYMCMCTRWSMTCAATGMWGYYWMASYK    297
    . .  | |  . . | | | . . . . | . . . . . . | . . . . . | . . . . . | | | | | . . | . . . . | . . .
Cr e- ERT2 283 TC- GTCGGTCCGGGCTGCCACGACCAAGTGACAGCAATGCTGTTTCACTG    331
Al st R- cr e- 298 GTTRWSCGSMRRAGTCACGACAAAAAAMCATCGAGGMCATCTGWACATG-     346
    | | | . . . | | . . . . |  | |  | | | . | | . | | | . | . | . | | . | . |  . . | | . | | . | |  
Cr e- ERT2 332 GTTATGCGGCGGA- TC- CGAAAAGAAAACGTTGATGCC- GGTGAACGTGC    378
Al st R- cr e- 347 - - - - - - AGCTCATGGCAYTWCTGKKGATWGCTACTGATTTCGACCAGGTT    390
          . | | | |  | . | | . . |       | | .  | |  | | | | | | | | | | | | | | | | | |
Cr e- ERT2 379 AAAACAGGCTC- TAGCGTT- - - - - CGAACGC- ACTGATTTCGACCAGGTT    421
Al st R- cr e- 391 CGTTCACTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATCTGGC    440
    | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Cr e- ERT2 422 CGTTCACTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATCTGGC    471
Al st R- cr e- 441 ATTTCTGGGGATTGCTA    457
    | | | | | | | | | | | | | | | |  
Cr e- ERT2 472 ATTTCTGGGGATTGCT-     487
A 
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# Al i gned_sequences:  2
# 1:  Al st R- cr e-
# 2:  Cr e- ERT2
# Mat r i x:  EDNAFULL
# Gap_penal t y:  10. 0
# Ext end_penal t y:  0. 5
#
# Lengt h:  525
# I dent i t y:      467/ 525 ( 89. 0%)
# Si mi l ar i t y:    467/ 525 ( 89. 0%)
# Gaps:           57/ 525 ( 10. 9%)
# Scor e:  2311. 0
# 
#
#=======================================
Al st R- cr e- 1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -       0
                                                    
Cr e- ERT2 1 ACTGGTTATGCGGCGGATCCGAAAAGAAAACGTTGATGCCGGTGAACGTG     50
Al st R- cr e-  1 - - - - ACAGGCTCTAGCGTTCGAACGCACTGATTTC- ACCAGGTTCGTTCA     45
       | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  | | | | | | | | | | | | | |
Cr e- ERT2 51 CAAAACAGGCTCTAGCGTTCGAACGCACTGATTTCGACCAGGTTCGTTCA    100
Al st R- cr e-  46 CTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATCTGGCATTTCT     95
    | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Cr e- ERT2 101 CTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATCTGGCATTTCT    150
Al st R- cr e-  96 GGGGATTGCTTATAACACCCTGTTACGTATAGCCGAAATTGCCAGGATCA    145
    | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Cr e- ERT2 151 GGGGATTGCTTATAACACCCTGTTACGTATAGCCGAAATTGCCAGGATCA    200
Al st R- cr e- 146 GGGTTAAAGATATCTCACGTACTGACGGTGGGAGAATGTTAATCCATATT    195
    | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Cr e- ERT2 201 GGGTTAAAGATATCTCACGTACTGACGGTGGGAGAATGTTAATCCATATT    250
Al st R- cr e- 196 GGCAGAACGAAAACGCTGGTTAGCACCGCAGGTGTAGAGAAGGCACTTAG    245
    | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Cr e- ERT2 251 GGCAGAACGAAAACGCTGGTTAGCACCGCAGGTGTAGAGAAGGCACTTAG    300
Al st R- cr e- 246 CCTGGGGGTAACTAAACTGGTCGAGCGATGGATTTCCGTCTCTGGTGTAG    295
    | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Cr e- ERT2 301 CCTGGGGGTAACTAAACTGGTCGAGCGATGGATTTCCGTCTCTGGTGTAG    350
Al st R- cr e- 296 CTGATGATCCGAATAACTACCTGTTTTGCCGGGTCAGAAAAAATGGTGTT    345
    | | | | | | | | | | | | | | | | | | . | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Cr e- ERT2 351 CTGATGATCCGAATAACTTCCTGTTTTGCCGGGTCAGAAAAAATGGTGTT    400
Al st R- cr e- 346 GCCGCGCCATCTGCCACCAGCCAGCTATCAACTCGCGCCCTGGAAGGGAT    395
    | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Cr e- ERT2 401 GCCGCGCCATCTGCCACCAGCCAGCTATCAACTCGCGCCCTGGAAGGGAT    450
Al st R- cr e- 396 TTTTGAAGCAACTCATCGATTGATTTACGGCGCTAAGGATGACTCTGGTC    445
    | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Cr e- ERT2 451 TTTTGAAGCAACTCATCGATTGATTTACGGCGCTAAGGATGACTCTGGTC    500
Al st R- cr e- 446 AGAGATACCTGGCCTGGGTCTGGAA    470
    | | | | | | | | | | | | | | |  | | | | | | | |  
Cr e- ERT2 501 AGAGATACCTGGCCT- GGTCTGGA-     523
B 
Chapter 6: Appendices and references 
 
 
243 
Appendix Figure 6.4. EMBOSS pairwise sequence alignment corresponding to sequencing results of AlstR-cre- 
mice presented in Figure 3.9C. (A) PCR 1. (B) PCR 2. The data represented in this figure were generated by Lyndsey 
Konen. 
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Appendix Figure 6.5. Supplementary data for results presented in Figure 3.9. Results from real-time PCR melt 
curve analysis of DNA sample obtained from AlstR-cre- mouse used for the gene sequencing experiment described in 
section 3.3.7. The primer sequences utilised for genotyping were not detecting the spontaneously mutated Cre-ERT2 
gene sequence in our AlstR-cre- mice. Subsequent immunohistochemical analysis of eGFP expression showed positive 
eGFP expression in AlstR-cre- mice (see Figure 3.8) and gene sequencing analysis further confirmed the presence of a 
partial Cre-ERT2 sequence (see Figure 3.9). The data represented in this figure were generated by the Garvan Molecular 
Genetics Facility.  
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Appendix Figure 6.6. Supplementary data for experiments presented in sections 3.3.5 and 3.3.6. (A-B) 
Representative images of the dorsal hippocampus ipsilateral to PBS (A) or KA (B) injection in AlstR-cre+ mice 10 
weeks post-injury as visualised by NeuN immunohistochemistry and cresyl violet histology. (A) Evidence of 
mechanical damage likely resulting from cannula implantation surgery in PBS-injected mice. (B) Persistent 
hippocampal neurodegeneration in KA-injected mice. 
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Appendix Figure 6.7. Alst-cre- mice no longer possess the Cre-ERT2 gene sequence following back-cross to C57BL/6 wildtype background. (A-C) Assembly of sequencing results using 
FinchTV for DNA samples from C57BL/6 (A), AlstR-cre+ (B) and AlstR-cre- (C) mice following back-cross to C57BL/6 wildtype background. The data represented in this figure were generated 
by Lyndsey Konen. 
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Appendix Table 6.10: Raw data for experiment in section 3.3.5. 
  
  
 
  
 
 
582 AlstR-cre+ 1 KA yes AL 8.333333333 yes n/a 
583 AlstR-cre+ 1 KA yes AL 0 yes n/a 
584 AlstR-cre+ 1 KA yes n/a n/a no Premature 
mortality post-
cannula 
implantation 
590 AlstR-cre+ 1 KA n/a n/a n/a no Premature 
mortality post-KA 
591 AlstR-cre+ 1 KA yes AL 0 no Infusion 
complications 
597 AlstR-cre+ 1 KA yes n/a n/a no Premature 
mortality post-
cannula 
implantation 
599 AlstR-cre+ 1 KA n/a n/a n/a no Premature 
mortality post-KA 
600 AlstR-cre+ 1 KA yes AL 0 no Experienced 
spontaneous 
seizure during 
behavioural 
testing  
575 AlstR-cre+ 1 KA n/a n/a n/a no Premature 
mortality post-KA 
576 AlstR-cre+ 1 KA n/a n/a n/a no Premature 
mortality post-KA 
577 AlstR-cre+ 1 KA yes AL 10.41666667 yes n/a 
579 AlstR-cre+ 1 KA yes n/a n/a no Premature 
mortality post-
cannula 
implantation 
585 AlstR-cre- 1 KA yes AL 25 yes n/a 
586 AlstR-cre- 1 KA n/a n/a n/a no Premature 
mortality post-KA 
592 AlstR-cre- 1 KA yes AL 0 no Infusion 
complications 
598 AlstR-cre- 1 KA n/a n/a n/a no Premature 
mortality post-KA 
572 AlstR-cre- 1 KA yes AL 12.5 no Infusion 
complications 
573 AlstR-cre- 1 PBS yes AL 41.66666667 yes n/a 
574 AlstR-cre- 1 PBS yes AL 25 yes n/a 
569 AlstR-cre- 1 PBS yes AL 45.83333333 no Infusion 
complications 
578 AlstR-cre- 1 PBS yes AL 31.25 yes n/a 
706 AlstR-cre+ 2 KA yes AL 8.333333333 yes n/a 
707 AlstR-cre+ 2 KA yes saline 33.33333333 yes n/a 
747 AlstR-cre+ 2 KA yes AL 16.66666667 yes n/a 
748 AlstR-cre+ 2 KA yes n/a n/a no Premature 
cannula removal 
749 AlstR-cre+ 2 KA yes n/a n/a no Premature 
mortality post-
cannula 
implantation 
697/92 AlstR-cre+ 2 KA yes AL 14.58333333 yes n/a 
698 AlstR-cre+ 2 KA yes n/a n/a no Premature 
cannula removal 
716 AlstR-cre+ 2 KA yes saline 2.083333333 yes n/a 
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717 AlstR-cre+ 2 KA yes n/a  no Premature 
cannula removal 
719 AlstR-cre+ 2 KA yes saline 8.333333333 yes n/a 
106735 C57BL/6 2 KA yes saline 18.75 yes n/a 
106736 C57BL/6 2 KA yes n/a n/a no Premature 
cannula removal 
106737 C57BL/6 2 KA yes n/a n/a no Premature 
cannula removal 
106738 C57BL/6 2 KA yes n/a n/a no Premature 
mortality post-
cannula 
implantation 
106744 C57BL/6 2 KA yes saline 16.66666667 yes n/a 
106420 C57BL/6 2 KA yes saline 8.333333333 yes n/a 
739 AlstR-cre+ 2 PBS yes n/a n/a no Premature 
cannula removal 
755 AlstR-cre+ 2 PBS yes AL 31.25 yes n/a 
756 AlstR-cre+ 2 PBS yes AL 29.16666667 yes n/a 
710 AlstR-cre+ 2 PBS yes AL 27.08333333 yes n/a 
731 AlstR-cre+ 2 PBS yes AL 39.58333333 yes n/a 
106421 C57BL/6 2 PBS yes n/a n/a no Premature 
cannula removal 
106422 C57BL/6 2 PBS yes n/a n/a no Premature 
cannula removal 
106423 C57BL/6 2 PBS yes n/a n/a no Premature 
cannula removal 
106424 C57BL/6 2 PBS yes n/a n/a no Premature 
cannula removal 
106194 C57BL/6 2 PBS yes saline 41.66666667 yes n/a 
106195 C57BL/6 2 PBS yes saline 35.41666667 yes n/a 
826 AlstR-cre+ 3 KA yes n/a n/a no Premature 
cannula removal 
827 AlstR-cre+ 3 KA yes n/a n/a no Premature 
mortality post-
cannula 
implantation 
821 AlstR-cre+ 3 KA no n/a n/a no Premature 
mortality post-KA 
823 AlstR-cre+ 3 KA yes saline 0 yes n/a 
808 AlstR-cre+ 3 KA yes n/a n/a no Premature 
mortality post-
cannula 
implantation 
809 AlstR-cre+ 3 KA yes saline 8.888888889 no Infusion 
complications 
810 AlstR-cre+ 3 KA yes saline 8.888888889 no Infusion 
complications 
812 AlstR-cre+ 3 KA no n/a n/a no Premature 
mortality post-KA 
813 AlstR-cre+ 3 KA yes Alt 2.222222222 no Premature 
cannula removal 
818 AlstR-cre+ 3 KA yes Alt 8.888888889 yes n/a 
820 AlstR-cre+ 3 KA yes n/a n/a no Premature 
cannula removal 
779 AlstR-cre+ 3 KA yes Alt 2.222222222 no Premature 
cannula removal 
111266 C57BL/6 3 KA yes n/a n/a no Premature 
cannula removal 
111271 C57BL/6 3 KA yes n/a n/a no Premature 
mortality post-
cannula 
implantation 
111272 C57BL/6 3 KA no n/a n/a no Premature 
mortality post-KA 
111273 C57BL/6 3 KA yes n/a n/a no Premature 
cannula removal 
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111274 C57BL/6 3 KA yes n/a n/a no Premature 
cannula removal 
793 AlstR-cre+ 3 PBS yes Alt 20 yes n/a 
794 AlstR-cre+ 3 PBS yes Alt 11.11111111 yes n/a 
795 AlstR-cre+ 3 PBS yes n/a n/a no Premature 
cannula removal 
782 AlstR-cre+ 3 PBS yes n/a n/a no Premature 
cannula removal 
784 AlstR-cre+ 3 PBS yes n/a n/a no Premature 
cannula removal 
760 AlstR-cre+ 3 PBS yes Alt 20 no Infusion 
complications 
772 AlstR-cre+ 3 PBS yes n/a n/a no Premature 
cannula removal 
771 AlstR-cre+ 3 PBS yes Alt 44.44444444 yes n/a 
111279 C57BL/6 3 PBS yes n/a n/a no Premature 
cannula removal 
111280 C57BL/6 3 PBS yes n/a n/a no Premature 
cannula removal 
111281 C57BL/6 3 PBS yes n/a n/a no Premature 
cannula removal 
111282 C57BL/6 3 PBS yes n/a n/a no Premature 
cannula removal 
113580 C57BL/6 3 PBS yes n/a n/a no Premature 
cannula removal 
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6.3 Appendices for Chapter 4 
 
 
Appendix Figure 6.8. Supplementary data for experiment presented in section 4.3.1. Pooled behavioural data from 
long-term contextual fear memory test of 10-month-old wild-type and APPswe/PS1∆E9 mice. All values represent mean 
± standard error of the mean (SEM). n = 49 for wild-type and n = 48 for APPswe/PS1∆E9 mice. The data represented in 
this figure were generated by Dr Raphael Zinn. 
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Appendix Figure 6.9. Supplementary data for experiment presented in section 4.3.2. Representative images of 
Thioflavin S-stained cortical and hippocampal layer in wild-type and APPswe/PS1∆E9 mice aged 4, 6 and 10 months. 
Thioflavin S+ plaques are do not appear in the cortical layer of APPswe/PS1∆E9 mice until 6 months of age. 
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Appendix Table 6.11: Raw data for experiment in section 4.3.2. 
  
 
 
 
 
1086 Wild-type 4 0 0 0 
1034 Wild-type 4 0 0 0 
1035 Wild-type 4 0 0 0 
1087 Wild-type 4 0 0 0 
1050 Wild-type 4 0 0 0 
1081 APPswe/PS1∆E9 4 1 0 0.2 
1045 APPswe/PS1∆E9 4 0 0 0 
1046 APPswe/PS1∆E9 4 0 0 0 
1044 APPswe/PS1∆E9 4 0 0 0 
1043 APPswe/PS1∆E9 4 0 0 0 
594 Wild-type 6 0 0 0 
598 Wild-type 6 0 0 0 
591 Wild-type 6 0 0 0 
596 Wild-type 6 0 0 0 
614 APPswe/PS1∆E9 6 29 30 11.8 
621 APPswe/PS1∆E9 6 27 25 10.4 
629 APPswe/PS1∆E9 6 29 28 11.4 
595 APPswe/PS1∆E9 6 7 7 2.8 
592 APPswe/PS1∆E9 6 23 18 8.2 
151 Wild-type 10 1 0 0.2 
145 Wild-type 10 0 0 0 
162 Wild-type 10 0 0 0 
144 Wild-type 10 0 0 0 
171 Wild-type 10 4 1 1 
174 APPswe/PS1∆E9 10 145 119 52.8 
3 APPswe/PS1∆E9 10 124 137 52.2 
6 APPswe/PS1∆E9 10 175 175 70 
1 APPswe/PS1∆E9 10 137 182 63.8 
 
Appendix Table 6.12: Raw data for experiment in section 4.3.4. 
  
 
 
 
630 Wild-type 6 71803.86 43665.92 
594 Wild-type 6 74082.13 45497.55 
596 Wild-type 6 67087.61 47108.38 
598 Wild-type 6 67909.7 45819.91 
591 Wild-type 6 86441.43 48786.74 
592 APPswe/PS1∆E9 6 80495.61 52005.3 
621 APPswe/PS1∆E9 6 69420.72 48211.71 
629 APPswe/PS1∆E9 6 81265.7 43898.98 
595 APPswe/PS1∆E9 6 71984.47 44511.88 
614 APPswe/PS1∆E9 6 98461.02 60153.37 
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145 Wild-type 10 71589.12 53209.09 
162 Wild-type 10 100896.89 52135.8 
151 Wild-type 10 101319.5 59929.41 
144 Wild-type 10 77399.92 47769.18 
171 Wild-type 10 81977.05 56194.96 
174 APPswe/PS1∆E9 10 65510.18 52277.27 
6 APPswe/PS1∆E9 10 104012.9 54776.43 
1 APPswe/PS1∆E9 10 69678.26 48404.15 
170 APPswe/PS1∆E9 10 78577.58 49964.42 
3 APPswe/PS1∆E9 10 95262.77 78634.63 
 
Appendix Table 6.13: Raw data for experiment in section 4.3.5. 
  
 
 
 
630 Wild-type 6 8097.51 7223.22 
594 Wild-type 6 9315.81 8452.27 
596 Wild-type 6 9311.64 9005.5 
598 Wild-type 6 12246.63 10598.04 
591 Wild-type 6 9142.6 7877.1 
592 APPswe/PS1∆E9 6 10085.32 8648.22 
621 APPswe/PS1∆E9 6 9287.82 9133.46 
629 APPswe/PS1∆E9 6 9233.69 8528.83 
595 APPswe/PS1∆E9 6 8885.3 7438.27 
614 APPswe/PS1∆E9 6 7409.41 6170.29 
145 Wild-type 10 8995.26 7171.56 
162 Wild-type 10 13844.45 12087.67 
151 Wild-type 10 9537.37 8297.51 
144 Wild-type 10 10940.74 7301.96 
171 Wild-type 10 7655.75 7110.68 
174 APPswe/PS1∆E9 10 9005.85 5494 
6 APPswe/PS1∆E9 10 6243.48 5405.94 
1 APPswe/PS1∆E9 10 11197.67 10979.06 
170 APPswe/PS1∆E9 10 10015.16 7541.98 
3 APPswe/PS1∆E9 10 9018.76 5406.41 
 
Appendix Table 6.14: Raw data for experiment in section 4.3.6. 
  
 
 
 
630 Wild-type 6 4171.45 3436.48 
594 Wild-type 6 5773.96 5074.87 
596 Wild-type 6 5835.44 4154.45 
598 Wild-type 6 5564.82 4502.45 
591 Wild-type 6 5057.5 4135.69 
592 APPswe/PS1∆E9 6 5838.78 5092.85 
621 APPswe/PS1∆E9 6 4900.43 4290.7 
629 APPswe/PS1∆E9 6 4667.14 4016.43 
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595 APPswe/PS1∆E9 6 4764.06 4053.63 
614 APPswe/PS1∆E9 6 5284.87 4858.29 
145 Wild-type 10 5497.06 4724.03 
162 Wild-type 10 5312.03 5568.32 
151 Wild-type 10 4717.39 5266.51 
144 Wild-type 10 4542.22 3813.52 
171 Wild-type 10 5964.3 5076 
174 APPswe/PS1∆E9 10 5553.58 4852.9 
6 APPswe/PS1∆E9 10 5532.34 5102.89 
1 APPswe/PS1∆E9 10 5397.41 5221.68 
170 APPswe/PS1∆E9 10 4125.3 3869.07 
3 APPswe/PS1∆E9 10 5209.63 5209.63 
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